Hercules Capital (HTGC) 10-Q 30 Oct 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 24, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	814-00702
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	74-3113410
Entity Address, Address Line One	1 North B Street
Entity Address, Address Line Two	Suite 2000
Entity Address, City or Town	San Mateo
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94401
City Area Code	650
Local Phone Number	289-3060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		162,449,710
Entity Central Index Key	0001280784
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Common Stock Par Value $0.001 Per Share
Document Information [Line Items]
Title of 12(b) Security	Common Shares, par value $0.001 per share
Trading Symbol	HTGC
Security Exchange Name	NYSE
6.25% Notes Due 2033
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2033
Trading Symbol	HCXY
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF ASSE

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets
Investments, at fair value:	$ 3,560,513	$ 3,248,046
Cash and cash equivalents	38,904	98,899
Restricted cash (amounts related to a VIE $5,113 and $17,114, respectively)	5,113	17,114
Interest receivable	31,450	32,741
Right of use asset	17,249	4,787
Other assets	3,130	15,339
Total assets	3,656,359	3,416,926
Liabilities
Debt (net of debt issuance costs of $11,791 and $15,131, respectively; amounts related to a VIE $148,985 and $148,544, respectively)	1,739,209	1,554,869
Accounts payable and accrued liabilities	46,860	54,156
Operating lease liability	18,480	5,195
Total liabilities	1,804,549	1,614,220
Net assets consist of:
Common stock, par value	163	158
Capital in excess of par value	1,741,975	1,662,535
Total distributable earnings	109,672	140,013
Total net assets	1,851,810	1,802,706
Total liabilities and net assets	$ 3,656,359	$ 3,416,926
Shares of common stock outstanding ($0.001 par value and 200,000 authorized) (in shares)	162,505	157,758
Net asset value per share (in dollars per share)	$ 11.40	$ 11.43
Non-control/Non-affiliate investments
Assets
Investments, at fair value:	$ 3,447,416	$ 3,133,042
Control investments
Assets
Investments, at fair value:	$ 113,097	$ 115,004

CONSOLIDATED STATEMENTS OF AS_2

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investment cost	$ 3,609,986	$ 3,247,033
Restricted cash	5,113	17,114
Debt issuance costs	11,791	15,131
Debt amount related to VIE	$ 1,739,209	$ 1,554,869
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000	200,000
Non-control/Non-affiliate investments
Investment cost	$ 3,505,649	$ 3,143,851
Control investments
Investment cost	104,337	103,182
VIE
Investment cost	272,611	254,868
Restricted cash	5,113	17,114
Debt amount related to VIE	$ 148,985	$ 148,544

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investment income:
Total interest and dividend income	$ 119,050	$ 110,339	$ 352,358	$ 319,222
Total fee income	6,198	6,405	19,449	18,843
Total investment income	125,248	116,744	371,807	338,065
Operating expenses:
Interest	20,370	16,428	57,156	50,237
Loan fees	1,993	2,524	6,736	7,317
General and administrative	4,596	4,591	14,135	13,868
Tax expenses	1,986	1,882	4,451	5,249
Employee compensation:
Compensation and benefits	12,159	13,604	42,917	41,062
Stock-based compensation	3,194	3,337	9,671	9,848
Total employee compensation	15,353	16,941	52,588	50,910
Total gross operating expenses	44,298	42,366	135,066	127,581
Expenses allocated to the Adviser Subsidiary	(2,214)	(2,416)	(7,943)	(7,509)
Total net operating expenses	42,084	39,950	127,123	120,072
Net investment income	83,164	76,794	244,684	217,993
Net realized gain (loss):
Total net realized gain (loss)	(559)	(2,587)	1,825	5,590
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)	(13,894)	(46,240)	(44,982)	(6,277)
Total net realized gain (loss) and net change in unrealized appreciation (depreciation)	(14,453)	(48,827)	(43,157)	(687)
Net increase (decrease) in net assets resulting from operations	$ 68,711	$ 27,967	$ 201,527	$ 217,306
Net investment income before gains and losses per common share:
Basic (in dollars per share)	$ 0.51	$ 0.52	$ 1.52	$ 1.53
Change in net assets resulting from operations per common share:
Basic (in dollars per share)	0.42	0.19	1.25	1.52
Diluted (in dollars per share)	$ 0.42	$ 0.19	$ 1.24	$ 1.51
Weighted average shares outstanding:
Basic (in shares)	161,019	146,899	159,742	141,223
Diluted (in shares)	161,515	147,110	160,253	142,126
Distributions paid per common share:
Basic (in dollars per share)	$ 0.48	$ 0.48	$ 1.44	$ 1.42
Non-control/Non-affiliate investments
Investment income:
Total interest and dividend income	$ 115,563	$ 109,240	$ 342,457	$ 315,952
Total fee income	6,162	6,383	19,341	18,783
Net realized gain (loss):
Non-control/Non-affiliate investments	(559)	(2,587)	1,825	5,590
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)	(15,167)	(45,141)	(41,920)	(18,597)
Control investments
Investment income:
Total interest and dividend income	3,487	1,099	9,901	3,270
Total fee income	36	22	108	60
Total investment income			10,009	3,330
Net realized gain (loss):
Non-control/Non-affiliate investments	0	0	0	0
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)	$ 1,273	$ (1,099)	$ (3,062)	$ 12,320

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (unaudited) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended				12 Months Ended
	Sep. 30, 2024		Dec. 31, 2023	Sep. 30, 2023		Sep. 30, 2024		Sep. 30, 2023		Dec. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)						157,758,000
Beginning balance	$ 1,856,545		$ 1,652,057	$ 1,585,510		$ 1,802,706		$ 1,401,459		$ 1,401,459
Net increase (decrease) in net assets resulting from operations	68,711			27,967		$ 201,527		$ 217,306
Public offering, net of offering expenses (in shares)						3,700,000		16,200,000
Public offering, net of offering expenses	(88)			107,562		$ 66,284		$ 238,310
Issuance of common stock under equity-based award plans	75			163		2,976		378
Shares retired on vesting of equity-based awards	(1,165)			(675)		$ (5,371)		$ (12,503)
Distributions reinvested in common stock (in shares)						342,129		197,592
Distributions reinvested in common stock	2,445			1,057		$ 6,277		$ 2,936
Distributions	(77,943)			(72,534)		(231,868)		(204,687)		$ (278,301)
Stock-based compensation	$ 3,230	[1]		3,007	[2]	$ 9,279	[1]	8,858	[2]
Ending balance (in shares)	162,505,000		157,758,000			162,505,000				157,758,000
Ending balance	$ 1,851,810		$ 1,802,706	$ 1,652,057		$ 1,851,810		$ 1,652,057		$ 1,802,706
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	162,428,000		151,179,000	144,641,000		157,758,072		133,045,000		133,045,000
Beginning balance	$ 163		$ 152	$ 145		$ 158		$ 134		$ 134
Public offering, net of offering expenses (in shares)				6,500,000		3,725,000		16,221,000
Public offering, net of offering expenses				$ 7		$ 4		$ 16
Issuance of common stock under equity-based award plans (in shares)	10,000			21,000		1,032,000		1,923,000
Issuance of common stock under equity-based award plans						$ 1		$ 2
Shares retired on vesting of equity-based awards (in shares)	(69,000)			(48,000)		(351,000)		(208,000)
Distributions reinvested in common stock (in shares)	136,000			65,000		341,000		198,000
Distributions	$ (77,263)			$ (71,860)		$ (229,650)		$ (202,556)
Ending balance (in shares)	162,505,144		157,758,072	151,179,000		162,505,144		151,179,000		157,758,072
Ending balance	$ 163		$ 158	$ 152		$ 163		$ 152		$ 158
Capital in excess of par value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	1,737,478		1,579,377	1,468,270		1,662,535		1,341,416		1,341,416
Public offering, net of offering expenses	(88)			107,555		66,280		238,294
Issuance of common stock under equity-based award plans	75			163		2,975		376
Shares retired on vesting of equity-based awards	(1,165)			(675)		(5,371)		(12,503)
Distributions reinvested in common stock	2,445			1,057		6,277		2,936
Stock-based compensation	3,230	[1]		3,007	[2]	9,279	[1]	8,858	[2]
Ending balance	1,741,975		1,662,535	1,579,377		1,741,975		1,579,377		1,662,535
Distributable Earnings (loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	118,904		72,528	117,095		140,013		59,909		59,909
Net increase (decrease) in net assets resulting from operations	68,711			27,967		201,527		217,306
Distributions	(77,943)			(72,534)		(231,868)		(204,687)
Ending balance	$ 109,672		$ 140,013	$ 72,528		$ 109,672		$ 72,528		$ 140,013
[1]Stock-based compensation includes $36 thousand and $107 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2024, respectively[2] Stock-based compensation includes $31 thousand and $81 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2023, respectively.

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Restricted stock and option expense related to director compensation	$ 36	$ 31	$ 107	$ 81

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)		9 Months Ended
		Sep. 30, 2024		Sep. 30, 2023
Cash flows provided by (used in) operating activities:
Net increase (decrease) in net assets resulting from operations		$ 201,527,000		$ 217,306,000
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments		(1,180,071,000)	[1]	(1,291,627,000)
Fundings assigned to Adviser Funds		118,379,000	[1]	294,468,000
Principal and fee repayments received and proceeds from the sale of debt investments		721,944,000		685,103,000
Proceeds from the sale of equity and warrant investments		23,423,000		34,877,000
Net change in unrealized (appreciation) depreciation		44,982,000		6,277,000
Net realized (gain) loss		(1,825,000)		(5,590,000)
Payments of derivative instruments		(849,000)		0
Accretion of paid-in-kind interest		(37,870,000)		(17,999,000)
Accretion of loan discounts		(3,160,000)		(5,344,000)
Accretion of loan exit fees		(19,761,000)		(14,140,000)
Change in loan income, net of collections		14,899,000		15,349,000
Unearned fees related to unfunded commitments		(159,000)		(279,000)
Amortization of debt fees and issuance costs		5,229,000		5,227,000
Depreciation and amortization		373,000		167,000
Stock-based compensation and amortization of restricted stock grants	[2]	9,278,000		8,858,000
Change in operating assets and liabilities:
Interest receivable		1,191,000		(366,000)
Other assets		7,607,000		6,533,000
Accrued liabilities		6,019,000		(1,419,000)
Net cash (used in) operating activities		(88,844,000)		(62,599,000)
Cash flows provided by (used in) investing activities:
Purchases of capital equipment		(700,000)		(390,000)
Net cash (used in) investing activities		(700,000)		(390,000)
Cash flows provided by (used in) financing activities:
Issuance of common stock		67,275,000		243,609,000
Offering expenses		(991,000)		(5,299,000)
Retirement of employee shares, net		(2,395,000)		(12,125,000)
Distributions paid		(225,591,000)		(201,751,000)
Issuance of debt		939,000,000		533,000,000
Repayment of debt		(758,000,000)		(478,000,000)
Fees paid for credit facilities and debentures		(1,750,000)		(5,090,000)
Net cash provided by financing activities		17,548,000		74,344,000
Net increase (decrease) in cash, cash equivalents, and restricted cash		(71,996,000)		11,355,000
Cash, cash equivalents, and restricted cash at beginning of period		116,013,000		25,876,000
Cash, cash equivalents, and restricted cash at end of period		44,017,000		37,231,000
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid		64,221,000		57,410,000
Income tax, including excise tax, paid		5,185,000		5,205,000
Distributions reinvested		$ 6,277,000		$ 2,936,000
[1] Excluded from the amounts presented are certain investment funding allocations of $158.7 million, which were directly funded by the Adviser Funds during the nine month period ended September 30, 2024. Refer to Note 12 – Related Party Transaction for additional information.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Restricted stock and option expense related to director compensation	$ 36	$ 31	$ 107	$ 81
Cash and cash equivalents	38,904	31,979	38,904	31,979	$ 98,899
Restricted cash	5,113	5,252	5,113	5,252	17,114
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows	$ 44,017	$ 37,231	44,017	$ 37,231	$ 116,013	$ 25,876
Advisor Funds
Related Party Transaction [Line Items]
Investment fundings assigned to, directly originated or funded by the Adviser Funds			$ 158,700

CONSOLIDATED SCHEDULE OF INVEST

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands, $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2024 USD ($) shares		Dec. 31, 2023 USD ($) shares		Sep. 30, 2024 GBP (£) shares		Dec. 31, 2023 GBP (£) shares
Summary of Investment Holdings [Line Items]
Investment, basis spread, variable rate		8%		8.50%		8%		8.50%
Investment cost		$ 3,609,986		$ 3,247,033
Investments, at fair value:		3,560,513		$ 3,248,046
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Series Class A Units
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	238
Investments, at fair value:	[1]	$ 172
Investments owned acquisition date	[1],[3]	Dec. 27, 2022
Shares (in shares) | shares	[1]	69,239				69,239
Investment, Identifier [Axis]: Debt Investment Electronics & Computer Hardware (1.05%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			1.05%				1.05%
Investment cost	[5]			$ 18,348
Investments, at fair value:				$ 18,982
Investment, Identifier [Axis]: Debt Investment Electronics & Computer Hardware and Locus Robotics Corp., Senior Secured, June 2026, Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2026-06				2026-06
Investment, basis spread, variable rate	[6],[7]			4.50%				4.50%
Investment, interest rate, floor	[6],[7]			8%				8%
Investment exit fee	[6],[7]			4%				4%
Principal amount	[6]			$ 18,281
Investment cost	[5],[6]			18,348
Investments, at fair value:	[6]			$ 18,982
Investment, Identifier [Axis]: Debt Investment Manufacturing Technology (0.44%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.44%				0.44%
Investment cost	[5]			$ 8,064
Investments, at fair value:				$ 8,006
Investment, Identifier [Axis]: Debt Investment Medical Devices & Equipment (1.20%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			1.20%				1.20%
Investment cost	[5]			$ 21,572
Investments, at fair value:				$ 21,572
Investment, Identifier [Axis]: Debt Investment Biotechnology Tools (2.66%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			2.66%				2.66%
Investment cost	[5]			$ 47,010
Investments, at fair value:				$ 48,027
Investment, Identifier [Axis]: Debt Investment Biotechnology Tools and Alamar Biosciences, Inc., Senior Secured, June 2026, Prime + 3.00%, Floor rate 6.50%, PIK Interest 1.00%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9]			2026-06				2026-06
Investment, basis spread, variable rate	[7],[8],[9]			3%				3%
Investment, interest rate, floor	[7],[8],[9]			6.50%				6.50%
Investment, interest rate, paid in kind	[7],[8],[9]			1%				1%
Investment exit fee	[7],[8],[9]			5.95%				5.95%
Principal amount	[8],[9]			$ 15,049
Investment cost	[5],[8],[9]			15,069
Investments, at fair value:	[8],[9]			$ 15,508
Investment, Identifier [Axis]: Debt Investment Biotechnology Tools and PathAI, Inc., Senior Secured, January 2027, Prime + 2.15%, Floor rate 9.15%, 9.81% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10]			2027-01				2027-01
Investment, basis spread, variable rate	[7],[10]			2.15%				2.15%
Investment, interest rate, floor	[7],[10]			9.15%				9.15%
Investment exit fee	[7],[10]			9.81%				9.81%
Principal amount	[10]			$ 32,000
Investment cost	[5],[10]			31,941
Investments, at fair value:	[10]			$ 32,519
Investment, Identifier [Axis]: Debt Investment Communications & Networking and (1.62%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			1.62%				1.62%
Investment cost	[5]			$ 28,182
Investments, at fair value:				$ 29,272
Investment, Identifier [Axis]: Debt Investment Communications & Networking and Aryaka Networks, Inc., Senior Secured, July 2026, Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[8],[10]			2026-07				2026-07
Investment, basis spread, variable rate	[6],[7],[8],[10]			3.25%				3.25%
Investment, interest rate, floor	[6],[7],[8],[10]			6.75%				6.75%
Investment, interest rate, paid in kind	[6],[7],[8],[10]			1.05%				1.05%
Investment exit fee	[6],[7],[8],[10]			3.55%				3.55%
Principal amount	[6],[8],[10]			$ 25,153
Investment cost	[5],[6],[8],[10]			24,943
Investments, at fair value:	[6],[8],[10]			$ 26,000
Investment, Identifier [Axis]: Debt Investment Communications & Networking and Cytracom Holdings LLC, Senior Secured, February 2025, 3-month SOFR + 9.72%, Floor rate 10.62%
Summary of Investment Holdings [Line Items]
Maturity Date	[11],[12],[13]			2025-02				2025-02
Investment, basis spread, variable rate	[7],[11],[12],[13]			9.72%				9.72%
Investment, interest rate, floor	[7],[11],[12],[13]			10.62%				10.62%
Principal amount	[11],[12],[13]			$ 3,267
Investment cost	[5],[11],[12],[13]			3,239
Investments, at fair value:	[11],[12],[13]			$ 3,272
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services (28.24%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			28.24%				28.24%
Investment cost	[5]			$ 507,063
Investments, at fair value:				$ 509,053
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Altumint, Inc., Senior Secured, December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[14]			2027-12				2027-12
Investment, basis spread, variable rate	[7],[12],[14]			3.65%				3.65%
Investment, interest rate, floor	[7],[12],[14]			12.15%				12.15%
Investment exit fee	[7],[12],[14]			2.50%				2.50%
Principal amount	[12],[14]			$ 10,000
Investment cost	[5],[12],[14]			9,905
Investments, at fair value:	[12],[14]			$ 9,905
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and AppDirect, Inc., Senior Secured, April 2026, Prime + 5.50%, Floor rate 8.75%, 7.12% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10]			2026-04				2026-04
Investment, basis spread, variable rate	[7],[10]			5.50%				5.50%
Investment, interest rate, floor	[7],[10]			8.75%				8.75%
Investment exit fee	[7],[10]			7.12%				7.12%
Principal amount	[10]			$ 55,790
Investment cost	[5],[10]			57,653
Investments, at fair value:	[10]			$ 59,507
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Carwow LTD, Senior Secured, December 2024, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[15],[16]			2024-12				2024-12
Investment, basis spread, variable rate	[7],[8],[15],[16]			4.70%				4.70%
Investment, interest rate, floor	[7],[8],[15],[16]			7.95%				7.95%
Investment, interest rate, paid in kind	[7],[8],[15],[16]			1.45%				1.45%
Investment exit fee	[7],[8],[15],[16]			4.95%				4.95%
Principal amount | £	[8],[15],[16]							£ 19,146
Investment cost	[5],[8],[15],[16]			$ 26,834
Investments, at fair value:	[8],[15],[16]			$ 25,157
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Houzz, Inc., Convertible Debt, May 2028, PIK Interest 8.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[17]			2028-05				2028-05
Investment, interest rate, paid in kind	[7],[8],[17]			8.50%				8.50%
Principal amount	[8],[17]			$ 23,340
Investment cost	[5],[8],[17]			23,340
Investments, at fair value:	[8],[17]			$ 23,244
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Jobandtalent USA, Inc., Senior Secured, February 2025, 1-month SOFR + 8.86%, Floor rate 9.75%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2025-02				2025-02
Investment, basis spread, variable rate	[7],[15],[16]			8.86%				8.86%
Investment, interest rate, floor	[7],[15],[16]			9.75%				9.75%
Investment exit fee	[7],[15],[16]			3%				3%
Principal amount	[15],[16]			$ 14,000
Investment cost	[5],[15],[16]			14,095
Investments, at fair value:	[15],[16]			$ 14,259
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Plentific Ltd, Senior Secured, October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[15],[16]			2026-10				2026-10
Investment, basis spread, variable rate	[7],[12],[15],[16]			2.55%				2.55%
Investment, interest rate, floor	[7],[12],[15],[16]			11.05%				11.05%
Investment exit fee	[7],[12],[15],[16]			2.95%				2.95%
Principal amount	[12],[15],[16]			$ 875
Investment cost	[5],[12],[15],[16]			853
Investments, at fair value:	[12],[15],[16]			$ 853
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Provi, Senior Secured, December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2026-12				2026-12
Investment, basis spread, variable rate	[7],[14]			4.40%				4.40%
Investment, interest rate, floor	[7],[14]			10.65%				10.65%
Investment exit fee	[7],[14]			2.95%				2.95%
Principal amount	[14]			$ 15,000
Investment cost	[5],[14]			14,904
Investments, at fair value:	[14]			$ 15,046
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and RVShare, LLC, Senior Secured, December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9],[14]			2026-12				2026-12
Investment, basis spread, variable rate	[7],[8],[9],[14]			5.50%				5.50%
Investment, interest rate, floor	[7],[8],[9],[14]			6.50%				6.50%
Investment, interest rate, paid in kind	[7],[8],[9],[14]			4%				4%
Principal amount	[8],[9],[14]			$ 28,876
Investment cost	[5],[8],[9],[14]			28,404
Investments, at fair value:	[8],[9],[14]			$ 28,888
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Rhino Labs, Inc., Senior Secured, June 2024, Prime + 5.50%, Floor rate 8.75%, PIK Interest 2.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[14]			2024-06				2024-06
Investment, basis spread, variable rate	[7],[8],[14]			5.50%				5.50%
Investment, interest rate, floor	[7],[8],[14]			8.75%				8.75%
Investment, interest rate, paid in kind	[7],[8],[14]			2.25%				2.25%
Principal amount	[8],[14]			$ 4,710
Investment cost	[5],[8],[14]			4,704
Investments, at fair value:	[8],[14]			$ 4,704
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Riviera Partners LLC, Senior Secured, April 2027, 3-month SOFR + 8.26%, Floor rate 9.26%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2027-04				2027-04
Investment, basis spread, variable rate	[7],[12],[13]			8.26%				8.26%
Investment, interest rate, floor	[7],[12],[13]			9.26%				9.26%
Principal amount	[12],[13]			$ 36,868
Investment cost	[5],[12],[13]			36,339
Investments, at fair value:	[12],[13]			$ 34,659
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[18]			2026-07				2026-07
Investment, basis spread, variable rate	[7],[8],[10],[18]			2.50%				2.50%
Investment, interest rate, floor	[7],[8],[10],[18]			10.75%				10.75%
Investment, interest rate, paid in kind	[7],[8],[10],[18]			0.50%				0.50%
Investment exit fee	[7],[8],[10],[18]			3%				3%
Principal amount	[8],[10],[18]			$ 77,642
Investment cost	[5],[8],[10],[18]			77,170
Investments, at fair value:	[8],[10],[18]			$ 79,119
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[11],[18]			2026-05				2026-05
Investment, basis spread, variable rate	[7],[8],[11],[18]			7%				7%
Investment, interest rate, floor	[7],[8],[11],[18]			10.50%				10.50%
Investment, interest rate, paid in kind	[7],[8],[11],[18]			0.50%				0.50%
Investment exit fee	[7],[8],[11],[18]			4%				4%
Principal amount	[8],[11],[18]			$ 25,199
Investment cost	[5],[8],[11],[18]			25,126
Investments, at fair value:	[8],[11],[18]			$ 25,869
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Skyword, Inc., Senior Secured, November 2026, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9]			2026-11				2026-11
Investment, basis spread, variable rate	[7],[8],[9]			2.75%				2.75%
Investment, interest rate, floor	[7],[8],[9]			9.25%				9.25%
Investment, interest rate, paid in kind	[7],[8],[9]			1.75%				1.75%
Investment exit fee	[7],[8],[9]			3%				3%
Principal amount	[8],[9]			$ 9,169
Investment cost	[5],[8],[9]			9,189
Investments, at fair value:	[8],[9]			$ 9,311
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Tectura Corporation, Senior Secured, July 2024, FIXED 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[19]			2024-07				2024-07
Investment, interest rate, paid in cash	[7],[19]			8.25%				8.25%
Principal amount	[19]			$ 8,250
Investment cost	[5],[19]			8,250
Investments, at fair value:	[19]			$ 8,250
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Thumbtack, Inc., Senior Secured, April 2026, Prime + 4.95%, Floor rate 8.20%, PIK Interest 1.50%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[12]			2026-04				2026-04
Investment, basis spread, variable rate	[7],[8],[10],[12]			4.95%				4.95%
Investment, interest rate, floor	[7],[8],[10],[12]			8.20%				8.20%
Investment, interest rate, paid in kind	[7],[8],[10],[12]			1.50%				1.50%
Investment exit fee	[7],[8],[10],[12]			3.95%				3.95%
Principal amount	[8],[10],[12]			$ 10,258
Investment cost	[5],[8],[10],[12]			10,317
Investments, at fair value:	[8],[10],[12]			10,639
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Total SeatGeek, Inc
Summary of Investment Holdings [Line Items]
Principal amount				102,841
Investment cost	[5]			102,296
Investments, at fair value:				104,988
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Total Veem, Inc.,
Summary of Investment Holdings [Line Items]
Principal amount				10,217
Investment cost	[5]			10,365
Investments, at fair value:				10,516
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Total Worldremit Group Limited
Summary of Investment Holdings [Line Items]
Principal amount				94,500
Investment cost	[5]			95,626
Investments, at fair value:				$ 95,997
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Udacity, Inc., Senior Secured, September 2024, Prime + 4.50%, Floor rate 7.75%, PIK Interest 2.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10]			2024-09				2024-09
Investment, basis spread, variable rate	[7],[8],[10]			4.50%				4.50%
Investment, interest rate, floor	[7],[8],[10]			7.75%				7.75%
Investment, interest rate, paid in kind	[7],[8],[10]			2%				2%
Investment exit fee	[7],[8],[10]			3%				3%
Principal amount	[8],[10]			$ 53,000
Investment cost	[5],[8],[10]			53,989
Investments, at fair value:	[8],[10]			$ 53,130
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, March 2025, Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9]			2025-03				2025-03
Investment, basis spread, variable rate	[7],[8],[9]			4%				4%
Investment, interest rate, floor	[7],[8],[9]			7.25%				7.25%
Investment, interest rate, paid in kind	[7],[8],[9]			1.25%				1.25%
Investment exit fee	[7],[8],[9]			4.50%				4.50%
Principal amount	[8],[9]			$ 5,107
Investment cost	[5],[8],[9]			5,176
Investments, at fair value:	[8],[9]			$ 5,230
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, March 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10]			2025-03				2025-03
Investment, basis spread, variable rate	[7],[8],[10]			4.70%				4.70%
Investment, interest rate, floor	[7],[8],[10]			7.95%				7.95%
Investment, interest rate, paid in kind	[7],[8],[10]			1.50%				1.50%
Investment exit fee	[7],[8],[10]			4.50%				4.50%
Principal amount	[8],[10]			$ 5,110
Investment cost	[5],[8],[10]			5,189
Investments, at fair value:	[8],[10]			$ 5,286
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Worldremit Group Limited, Senior Secured, February 2025, 1-month SOFR + 9.35%, Floor rate 10.25%, 3.20% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[15],[16],[18]			2025-02				2025-02
Investment, basis spread, variable rate	[6],[7],[15],[16],[18]			9.35%				9.35%
Investment, interest rate, floor	[6],[7],[15],[16],[18]			10.25%				10.25%
Investment exit fee	[6],[7],[15],[16],[18]			3.20%				3.20%
Principal amount	[6],[15],[16],[18]			$ 6,250
Investment cost	[5],[6],[15],[16],[18]			6,308
Investments, at fair value:	[6],[15],[16],[18]			$ 6,344
Investment, Identifier [Axis]: Debt Investment Consumer & Business Services and Worldremit Group Limited, Senior Secured, February 2025, 3-month SOFR + 9.40%, Floor rate 10.25%, 3.20% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[10],[11],[15],[16],[18]			2025-02				2025-02
Investment, basis spread, variable rate	[6],[7],[10],[11],[15],[16],[18]			9.40%				9.40%
Investment, interest rate, floor	[6],[7],[10],[11],[15],[16],[18]			10.25%				10.25%
Investment exit fee	[6],[7],[10],[11],[15],[16],[18]			3.20%				3.20%
Principal amount	[6],[10],[11],[15],[16],[18]			$ 88,250
Investment cost	[5],[6],[10],[11],[15],[16],[18]			89,318
Investments, at fair value:	[6],[10],[11],[15],[16],[18]			$ 89,653
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services (3.17%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			3.17%				3.17%
Investment cost	[5]			$ 56,764
Investments, at fair value:				$ 57,096
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, September 2026, FIXED 11.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[19],[20]			2026-09				2026-09
Investment, interest rate, paid in cash	[7],[19],[20]			11.50%				11.50%
Principal amount	[19],[20]			$ 25,000
Investment cost	[5],[19],[20]			24,663
Investments, at fair value:	[19],[20]			$ 24,663
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, September 2026, FIXED 11.95%
Summary of Investment Holdings [Line Items]
Maturity Date	[19],[20]			2026-09				2026-09
Investment, interest rate, paid in cash	[7],[19],[20]			11.95%				11.95%
Principal amount	[19],[20]			$ 10,000
Investment cost	[5],[19],[20]			9,815
Investments, at fair value:	[19],[20]			$ 9,815
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services and Hercules Adviser LLC, Unsecured, June 2025, FIXED 5.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[19],[21]			2025-06				2025-06
Investment, interest rate, paid in cash	[7],[19],[21]			5%				5%
Principal amount	[19],[21]			$ 12,000
Investment cost	[5],[19],[21]			12,000
Investments, at fair value:	[19],[21]			$ 12,000
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services and Next Insurance, Inc., Senior Secured, February 2028, Prime - (1.50%), Floor rate 4.75%, PIK Interest 5.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[8],[12]			2028-02				2028-02
Investment, basis spread, variable rate	[6],[7],[8],[12]			(1.50%)				(1.50%)
Investment, interest rate, floor	[6],[7],[8],[12]			4.75%				4.75%
Investment, interest rate, paid in kind	[6],[7],[8],[12]			5.50%				5.50%
Principal amount	[6],[8],[12]			$ 10,469
Investment cost	[5],[6],[8],[12]			10,286
Investments, at fair value:	[6],[8],[12]			10,618
Investment, Identifier [Axis]: Debt Investment Diversified Financial Services and Total Gibraltar Acquisition, LLC
Summary of Investment Holdings [Line Items]
Principal amount				35,000
Investment cost	[5]			34,478
Investments, at fair value:				$ 34,478
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development (66.60%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			66.60%				66.60%
Investment cost	[5]			$ 1,184,022
Investments, at fair value:				$ 1,200,667
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and ATAI Life Sciences N.V., Senior Secured, August 2026, Prime + 4.55%, Floor rate 8.55%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2026-08				2026-08
Investment, basis spread, variable rate	[7],[15],[16]			4.55%				4.55%
Investment, interest rate, floor	[7],[15],[16]			8.55%				8.55%
Investment exit fee	[7],[15],[16]			6.95%				6.95%
Principal amount	[15],[16]			$ 10,500
Investment cost	[5],[15],[16]			10,695
Investments, at fair value:	[15],[16]			$ 10,904
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Akero Therapeutics, Inc., Senior Secured, January 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12],[16]			2027-01				2027-01
Investment, basis spread, variable rate	[7],[9],[12],[16]			3.65%				3.65%
Investment, interest rate, floor	[7],[9],[12],[16]			7.65%				7.65%
Investment exit fee	[7],[9],[12],[16]			5.85%				5.85%
Principal amount	[9],[12],[16]			$ 12,500
Investment cost	[5],[9],[12],[16]			12,525
Investments, at fair value:	[9],[12],[16]			$ 13,065
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Aldeyra Therapeutics, Inc., Senior Secured, October 2024, Prime + 3.10%, Floor rate 8.60%, 8.90% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[11]			2024-10				2024-10
Investment, basis spread, variable rate	[7],[11]			3.10%				3.10%
Investment, interest rate, floor	[7],[11]			8.60%				8.60%
Investment exit fee	[7],[11]			8.90%				8.90%
Principal amount	[11]			$ 15,000
Investment cost	[5],[11]			15,152
Investments, at fair value:	[11]			$ 15,152
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Alladapt Immunotherapeutics Inc., Senior Secured, September 2026, Prime + 3.65%, Floor rate 8.40%, Cap rate 10.90%, 5.30% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9]			2026-09				2026-09
Investment, basis spread, variable rate	[7],[9]			3.65%				3.65%
Investment, interest rate, floor	[7],[9]			8.40%				8.40%
Investment, interest rate, cap	[7],[9]			10.90%				10.90%
Investment exit fee	[7],[9]			5.30%				5.30%
Principal amount	[9]			$ 35,000
Investment cost	[5],[9]			35,173
Investments, at fair value:	[9]			$ 36,855
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2027-01				2027-01
Investment, basis spread, variable rate	[7],[14]			2.50%				2.50%
Investment, interest rate, floor	[7],[14]			9.50%				9.50%
Investment, interest rate, cap	[7],[14]			10.75%				10.75%
Investment exit fee	[7],[14]			5.85%				5.85%
Principal amount	[14]			$ 24,000
Investment cost	[5],[14]			24,120
Investments, at fair value:	[14]			$ 24,514
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Axsome Therapeutics, Inc., Senior Secured, January 2028, Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[11],[16],[18]			2028-01				2028-01
Investment, basis spread, variable rate	[7],[10],[11],[16],[18]			2.20%				2.20%
Investment, interest rate, floor	[7],[10],[11],[16],[18]			9.95%				9.95%
Investment, interest rate, cap	[7],[10],[11],[16],[18]			10.70%				10.70%
Investment exit fee	[7],[10],[11],[16],[18]			5.78%				5.78%
Principal amount	[10],[11],[16],[18]			$ 143,350
Investment cost	[5],[10],[11],[16],[18]			143,646
Investments, at fair value:	[10],[11],[16],[18]			$ 150,255
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Bicycle Therapeutics PLC, Senior Secured, July 2025, Prime + 4.55%, Floor rate 8.05%, Cap rate 9.05%, 5.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[11],[15],[16]			2025-07				2025-07
Investment, basis spread, variable rate	[7],[10],[11],[15],[16]			4.55%				4.55%
Investment, interest rate, floor	[7],[10],[11],[15],[16]			8.05%				8.05%
Investment, interest rate, cap	[7],[10],[11],[15],[16]			9.05%				9.05%
Investment exit fee	[7],[10],[11],[15],[16]			5%				5%
Principal amount	[10],[11],[15],[16]			$ 11,500
Investment cost	[5],[10],[11],[15],[16]			11,880
Investments, at fair value:	[10],[11],[15],[16]			$ 11,783
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and BiomX, INC, Senior Secured, September 2025, Prime + 5.70%, Floor rate 8.95%, 6.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[11],[15],[16]			2025-09				2025-09
Investment, basis spread, variable rate	[7],[11],[15],[16]			5.70%				5.70%
Investment, interest rate, floor	[7],[11],[15],[16]			8.95%				8.95%
Investment exit fee	[7],[11],[15],[16]			6.55%				6.55%
Principal amount	[11],[15],[16]			$ 6,448
Investment cost	[5],[11],[15],[16]			6,807
Investments, at fair value:	[11],[15],[16]			$ 6,790
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Braeburn, Inc., Senior Secured, October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8]			2028-10				2028-10
Investment, basis spread, variable rate	[7],[8]			2.45%				2.45%
Investment, interest rate, floor	[7],[8]			10.95%				10.95%
Investment, interest rate, paid in kind	[7],[8]			1.10%				1.10%
Investment exit fee	[7],[8]			5.45%				5.45%
Principal amount	[8]			$ 52,601
Investment cost	[5],[8]			52,185
Investments, at fair value:	[8]			$ 52,185
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and BridgeBio Pharma, Inc., Senior Secured, November 2026, FIXED 9.00%, 2.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9],[10]			2026-11				2026-11
Investment, interest rate, paid in cash	[7],[8],[9],[10]			9%				9%
Investment exit fee	[7],[8],[9],[10]			2%				2%
Principal amount	[8],[9],[10]			$ 38,167
Investment cost	[5],[8],[9],[10]			38,124
Investments, at fair value:	[8],[9],[10]			$ 35,498
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and COMPASS Pathways plc, Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[15],[16]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[8],[15],[16]			1.50%				1.50%
Investment, interest rate, floor	[7],[8],[15],[16]			9.75%				9.75%
Investment, interest rate, paid in kind	[7],[8],[15],[16]			1.40%				1.40%
Investment exit fee	[7],[8],[15],[16]			4.75%				4.75%
Principal amount	[8],[15],[16]			$ 24,144
Investment cost	[5],[8],[15],[16]			23,798
Investments, at fair value:	[8],[15],[16]			$ 24,601
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Cellarity, Inc., Senior Secured, June 2026, Prime + 5.70%, Floor rate 8.95%, 3.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[14]			2026-06				2026-06
Investment, basis spread, variable rate	[7],[9],[14]			5.70%				5.70%
Investment, interest rate, floor	[7],[9],[14]			8.95%				8.95%
Investment exit fee	[7],[9],[14]			3.75%				3.75%
Principal amount	[9],[14]			$ 29,193
Investment cost	[5],[9],[14]			29,482
Investments, at fair value:	[9],[14]			$ 30,051
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Corium, Inc., Senior Secured, September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[18]			2026-09				2026-09
Investment, basis spread, variable rate	[7],[9],[18]			5.70%				5.70%
Investment, interest rate, floor	[7],[9],[18]			8.95%				8.95%
Investment exit fee	[7],[9],[18]			7.75%				7.75%
Principal amount	[9],[18]			$ 105,225
Investment cost	[5],[9],[18]			107,667
Investments, at fair value:	[9],[18]			$ 108,545
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Curevo, Inc., Senior Secured, June 2027, Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2027-06				2027-06
Investment, basis spread, variable rate	[7],[14]			1.70%				1.70%
Investment, interest rate, floor	[7],[14]			9.70%				9.70%
Investment exit fee	[7],[14]			6.95%				6.95%
Principal amount	[14]			$ 10,000
Investment cost	[5],[14]			9,821
Investments, at fair value:	[14]			$ 10,076
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Eloxx Pharmaceuticals, Inc., Senior Secured, April 2025, Prime + 6.25%, Floor rate 9.50%, 6.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2025-04				2025-04
Investment, basis spread, variable rate	[7],[14]			6.25%				6.25%
Investment, interest rate, floor	[7],[14]			9.50%				9.50%
Investment exit fee	[7],[14]			6.55%				6.55%
Principal amount	[14]			$ 3,099
Investment cost	[5],[14]			3,789
Investments, at fair value:	[14]			$ 3,731
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and G1 Therapeutics, Inc., Senior Secured, November 2026, Prime + 5.65%, Floor rate 9.15%, 11.41% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[11],[14]			2026-11				2026-11
Investment, basis spread, variable rate	[7],[10],[11],[14]			5.65%				5.65%
Investment, interest rate, floor	[7],[10],[11],[14]			9.15%				9.15%
Investment exit fee	[7],[10],[11],[14]			11.41%				11.41%
Principal amount	[10],[11],[14]			$ 38,750
Investment cost	[5],[10],[11],[14]			39,679
Investments, at fair value:	[10],[11],[14]			$ 40,421
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Geron Corporation, Senior Secured, April 2025, Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[10],[16]			2025-04				2025-04
Investment, basis spread, variable rate	[7],[9],[10],[16]			4.50%				4.50%
Investment, interest rate, floor	[7],[9],[10],[16]			9%				9%
Investment exit fee	[7],[9],[10],[16]			6.55%				6.55%
Principal amount	[9],[10],[16]			$ 30,200
Investment cost	[5],[9],[10],[16]			31,005
Investments, at fair value:	[9],[10],[16]			$ 31,210
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Gritstone Bio, Inc., Senior Secured, July 2027, Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[8],[9]			3.15%				3.15%
Investment, interest rate, floor	[7],[8],[9]			7.15%				7.15%
Investment, interest rate, cap	[7],[8],[9]			8.65%				8.65%
Investment, interest rate, paid in kind	[7],[8],[9]			2%				2%
Investment exit fee	[7],[8],[9]			5.75%				5.75%
Principal amount	[8],[9]			$ 30,532
Investment cost	[5],[8],[9]			30,717
Investments, at fair value:	[8],[9]			$ 30,909
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Heron Therapeutics, Inc., Senior Secured, February 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12],[14]			2026-02				2026-02
Investment, basis spread, variable rate	[7],[8],[12],[14]			1.70%				1.70%
Investment, interest rate, floor	[7],[8],[12],[14]			9.95%				9.95%
Investment, interest rate, paid in kind	[7],[8],[12],[14]			1.50%				1.50%
Investment exit fee	[7],[8],[12],[14]			3%				3%
Principal amount	[8],[12],[14]			$ 20,095
Investment cost	[5],[8],[12],[14]			19,788
Investments, at fair value:	[8],[12],[14]			$ 19,788
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Hibercell, Inc., Senior Secured, May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[14]			2025-05				2025-05
Investment, basis spread, variable rate	[7],[9],[14]			5.40%				5.40%
Investment, interest rate, floor	[7],[9],[14]			8.65%				8.65%
Investment exit fee	[7],[9],[14]			4.95%				4.95%
Principal amount	[9],[14]			$ 12,535
Investment cost	[5],[9],[14]			13,117
Investments, at fair value:	[9],[14]			$ 13,181
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and HilleVax, Inc., Senior Secured, May 2027, Prime + 1.05%, Floor rate 4.55%, Cap rate 6.05%, PIK Interest 2.85%, 7.15% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[14]			2027-05				2027-05
Investment, basis spread, variable rate	[7],[8],[14]			1.05%				1.05%
Investment, interest rate, floor	[7],[8],[14]			4.55%				4.55%
Investment, interest rate, cap	[7],[8],[14]			6.05%				6.05%
Investment, interest rate, paid in kind	[7],[8],[14]			2.85%				2.85%
Investment exit fee	[7],[8],[14]			7.15%				7.15%
Principal amount	[8],[14]			$ 20,524
Investment cost	[5],[8],[14]			20,685
Investments, at fair value:	[8],[14]			$ 20,335
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Kura Oncology, Inc., Senior Secured, November 2027, Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[14],[16]			2027-11				2027-11
Investment, basis spread, variable rate	[7],[12],[14],[16]			2.40%				2.40%
Investment, interest rate, floor	[7],[12],[14],[16]			8.65%				8.65%
Investment exit fee	[7],[12],[14],[16]			15.13%				15.13%
Principal amount	[12],[14],[16]			$ 5,500
Investment cost	[5],[12],[14],[16]			5,532
Investments, at fair value:	[12],[14],[16]			$ 5,752
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Locus Biosciences, Inc., Senior Secured, July 2025, Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2025-07				2025-07
Investment, basis spread, variable rate	[7],[14]			6.10%				6.10%
Investment, interest rate, floor	[7],[14]			9.35%				9.35%
Investment exit fee	[7],[14]			4.95%				4.95%
Principal amount	[14]			$ 5,399
Investment cost	[5],[14]			5,651
Investments, at fair value:	[14]			$ 5,686
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Senior Secured, May 2026, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[16]			2026-05				2026-05
Investment, basis spread, variable rate	[7],[16]			2.45%				2.45%
Investment, interest rate, floor	[7],[16]			8.25%				8.25%
Investment exit fee	[7],[16]			5.35%				5.35%
Principal amount	[16]			$ 78,200
Investment cost	[5],[16]			78,728
Investments, at fair value:	[16]			$ 81,945
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, December 2027, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.15%, 7.29% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[12],[14],[16],[18],[22]			2027-12				2027-12
Investment, basis spread, variable rate	[7],[8],[10],[12],[14],[16],[18],[22]			1.35%				1.35%
Investment, interest rate, floor	[7],[8],[10],[12],[14],[16],[18],[22]			9.85%				9.85%
Investment, interest rate, paid in kind	[7],[8],[10],[12],[14],[16],[18],[22]			2.15%				2.15%
Investment exit fee	[7],[8],[10],[12],[14],[16],[18],[22]			7.29%				7.29%
Principal amount	[8],[10],[12],[14],[16],[18],[22]			$ 129,699
Investment cost	[5],[8],[10],[12],[14],[16],[18],[22]			130,934
Investments, at fair value:	[8],[10],[12],[14],[16],[18],[22]			$ 128,326
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Redshift Bioanalytics, Inc., Senior Secured, January 2026, Prime + 4.25%, Floor rate 7.50%, 3.80% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2026-01				2026-01
Investment, basis spread, variable rate	[7],[14]			4.25%				4.25%
Investment, interest rate, floor	[7],[14]			7.50%				7.50%
Investment exit fee	[7],[14]			3.80%				3.80%
Principal amount	[14]			$ 5,000
Investment cost	[5],[14]			5,047
Investments, at fair value:	[14]			$ 5,119
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Replimune Group, Inc., Senior Secured, October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[16]			2027-10				2027-10
Investment, basis spread, variable rate	[7],[8],[10],[16]			1.75%				1.75%
Investment, interest rate, floor	[7],[8],[10],[16]			7.25%				7.25%
Investment, interest rate, cap	[7],[8],[10],[16]			9%				9%
Investment, interest rate, paid in kind	[7],[8],[10],[16]			1.50%				1.50%
Investment exit fee	[7],[8],[10],[16]			4.95%				4.95%
Principal amount	[8],[10],[16]			$ 31,416
Investment cost	[5],[8],[10],[16]			31,450
Investments, at fair value:	[8],[10],[16]			$ 32,702
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and TG Therapeutics, Inc., Senior Secured, January 2026, Prime + 1.20%, Floor rate 8.95%, PIK Interest 2.25%, 5.69% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[11],[16]			2026-01				2026-01
Investment, basis spread, variable rate	[7],[8],[10],[11],[16]			1.20%				1.20%
Investment, interest rate, floor	[7],[8],[10],[11],[16]			8.95%				8.95%
Investment, interest rate, paid in kind	[7],[8],[10],[11],[16]			2.25%				2.25%
Investment exit fee	[7],[8],[10],[11],[16]			5.69%				5.69%
Principal amount	[8],[10],[11],[16]			$ 65,770
Investment cost	[5],[8],[10],[11],[16]			66,439
Investments, at fair value:	[8],[10],[11],[16]			$ 67,610
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Senior Secured, February 2027, Prime + 4.45%, Floor rate 8.45%, Cap rate 11.45%, 4.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12],[16]			2027-02				2027-02
Investment, basis spread, variable rate	[7],[9],[12],[16]			4.45%				4.45%
Investment, interest rate, floor	[7],[9],[12],[16]			8.45%				8.45%
Investment, interest rate, cap	[7],[9],[12],[16]			11.45%				11.45%
Investment exit fee	[7],[9],[12],[16]			4.75%				4.75%
Principal amount	[9],[12],[16]			$ 12,375
Investment cost	[5],[9],[12],[16]			12,488
Investments, at fair value:	[9],[12],[16]			$ 12,916
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Valo Health, LLC, Senior Secured, May 2024, Prime + 6.45%, Floor rate 9.70%, 3.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[11]			2024-05				2024-05
Investment, basis spread, variable rate	[7],[9],[11]			6.45%				6.45%
Investment, interest rate, floor	[7],[9],[11]			9.70%				9.70%
Investment exit fee	[7],[9],[11]			3.85%				3.85%
Principal amount	[9],[11]			$ 2,396
Investment cost	[5],[9],[11]			2,808
Investments, at fair value:	[9],[11]			$ 2,808
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Verona Pharma, Inc., Senior Secured, December 2028, 1-month SOFR + 5.85%, Floor rate 11.19%, Cap rate 13.19%, 3.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2028-12				2028-12
Investment, basis spread, variable rate	[7],[15],[16]			5.85%				5.85%
Investment, interest rate, floor	[7],[15],[16]			11.19%				11.19%
Investment, interest rate, cap	[7],[15],[16]			13.19%				13.19%
Investment exit fee	[7],[15],[16]			3.50%				3.50%
Principal amount	[15],[16]			$ 15,750
Investment cost	[5],[15],[16]			15,646
Investments, at fair value:	[15],[16]			$ 15,646
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and Viridian Therapeutics, Inc., Senior Secured, October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[16]			2026-10				2026-10
Investment, basis spread, variable rate	[7],[9],[16]			4.20%				4.20%
Investment, interest rate, floor	[7],[9],[16]			7.45%				7.45%
Investment, interest rate, cap	[7],[9],[16]			8.95%				8.95%
Investment exit fee	[7],[9],[16]			6%				6%
Principal amount	[9],[16]			$ 8,000
Investment cost	[5],[9],[16]			8,057
Investments, at fair value:	[9],[16]			$ 8,023
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and X4 Pharmaceuticals, Inc., Senior Secured, October 2026, Prime + 3.15%, Floor rate 10.15%, 3.80% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[10],[11]			2026-10				2026-10
Investment, basis spread, variable rate	[7],[9],[10],[11]			3.15%				3.15%
Investment, interest rate, floor	[7],[9],[10],[11]			10.15%				10.15%
Investment exit fee	[7],[9],[10],[11]			3.80%				3.80%
Principal amount	[9],[10],[11]			$ 55,000
Investment cost	[5],[9],[10],[11]			54,680
Investments, at fair value:	[9],[10],[11]			$ 55,417
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and enGene, Inc., Senior Secured, July 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2028-01				2028-01
Investment, basis spread, variable rate	[7],[15],[16]			0.75%				0.75%
Investment, interest rate, floor	[7],[15],[16]			9.25%				9.25%
Investment, interest rate, cap	[7],[15],[16]			9.75%				9.75%
Investment, interest rate, paid in kind	[7],[15],[16]			1.15%				1.15%
Investment exit fee	[7],[15],[16]			5.50%				5.50%
Principal amount	[15],[16]			$ 15,750
Investment cost	[5],[15],[16]			15,550
Investments, at fair value:	[15],[16]			$ 15,550
Investment, Identifier [Axis]: Debt Investment Drug Discovery & Development and uniQure B.V., Senior Secured, January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[11],[15],[16]			2027-01				2027-01
Investment, basis spread, variable rate	[7],[10],[11],[15],[16]			4.70%				4.70%
Investment, interest rate, floor	[7],[10],[11],[15],[16]			7.95%				7.95%
Investment exit fee	[7],[10],[11],[15],[16]			6.10%				6.10%
Principal amount	[10],[11],[15],[16]			$ 70,000
Investment cost	[5],[10],[11],[15],[16]			71,157
Investments, at fair value:	[10],[11],[15],[16]			$ 73,318
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other (16.56%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			16.56%				16.56%
Investment cost	[5]			$ 301,164
Investments, at fair value:				$ 298,523
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Better Therapeutics, Inc., Senior Secured, August 2025, Prime + 5.70%, Floor rate 8.95%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2025-08				2025-08
Investment, basis spread, variable rate	[7],[14]			5.70%				5.70%
Investment, interest rate, floor	[7],[14]			8.95%				8.95%
Investment exit fee	[7],[14]			5.95%				5.95%
Principal amount	[14]			$ 10,865
Investment cost	[5],[14]			11,285
Investments, at fair value:	[14]			$ 8,455
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Blue Sprig Pediatrics, Inc., Senior Secured, November 2026, 1-month SOFR + 5.11% , Floor rate 6.00%, PIK Interest 4.45%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9],[11]			2026-11				2026-11
Investment, basis spread, variable rate	[7]			5.11%				5.11%
Investment, interest rate, floor	[7],[8],[9],[11]			6%				6%
Investment, interest rate, paid in kind	[7],[8],[9],[11]			4.45%				4.45%
Principal amount	[8],[9],[11]			$ 69,032
Investment cost	[5],[8],[9],[11]			68,277
Investments, at fair value:	[8],[9],[11]			$ 68,393
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Carbon Health Technologies, Inc., Senior Secured, March 2025, Prime + 5.60%, Floor rate 8.85%, 4.61% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[11]			2025-03				2025-03
Investment, basis spread, variable rate	[7],[9],[11]			5.60%				5.60%
Investment, interest rate, floor	[7],[9],[11]			8.85%				8.85%
Investment exit fee	[7],[9],[11]			4.61%				4.61%
Principal amount	[9],[11]			$ 46,125
Investment cost	[5],[9],[11]			47,193
Investments, at fair value:	[9],[11]			$ 46,242
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Equality Health, LLC, Senior Secured, February 2026, Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[11]			2026-02				2026-02
Investment, basis spread, variable rate	[7],[8],[10],[11]			6.25%				6.25%
Investment, interest rate, floor	[7],[8],[10],[11]			9.50%				9.50%
Investment, interest rate, paid in kind	[7],[8],[10],[11]			1.55%				1.55%
Principal amount	[8],[10],[11]			$ 54,425
Investment cost	[5],[8],[10],[11]			54,142
Investments, at fair value:	[8],[10],[11]			$ 54,697
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Main Street Rural, Inc., Senior Secured, July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[14]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[12],[14]			1.95%				1.95%
Investment, interest rate, floor	[7],[12],[14]			9.95%				9.95%
Investment exit fee	[7],[12],[14]			6.85%				6.85%
Principal amount	[12],[14]			$ 24,500
Investment cost	[5],[12],[14]			24,476
Investments, at fair value:	[12],[14]			$ 24,929
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Modern Life, Inc., Senior Secured, February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12]			2027-02				2027-02
Investment, basis spread, variable rate	[7],[9],[12]			2.75%				2.75%
Investment, interest rate, floor	[7],[9],[12]			8.75%				8.75%
Investment exit fee	[7],[9],[12]			5%				5%
Principal amount	[9],[12]			$ 13,000
Investment cost	[5],[9],[12]			12,888
Investments, at fair value:	[9],[12]			$ 13,111
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Recover Together, Inc., Senior Secured, July 2027, Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date				2027-07				2027-07
Investment, basis spread, variable rate	[7]			1.90%				1.90%
Investment, interest rate, floor	[7]			10.15%				10.15%
Investment exit fee	[7]			7.50%				7.50%
Principal amount				$ 35,000
Investment cost	[5]			34,683
Investments, at fair value:				$ 34,683
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Strive Health Holdings, LLC, Senior Secured, September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[14]			2027-09				2027-09
Investment, basis spread, variable rate	[7],[14]			0.70%				0.70%
Investment, interest rate, floor	[7],[14]			9.20%				9.20%
Investment exit fee	[7],[14]			5.95%				5.95%
Principal amount	[14]			$ 12,000
Investment cost	[5],[14]			11,868
Investments, at fair value:	[14]			$ 11,868
Investment, Identifier [Axis]: Debt Investment Healthcare Services, Other and Vida Health, Inc., Senior Secured, March 2026, 9.20% + Lower of (Prime - 3.25%) or 1.00%, Floor rate 9.20%, Cap rate 10.20%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[11]			2026-03				2026-03
Investment, basis spread, variable rate	[7],[11]			3.25%				3.25%
Investment, interest rate, floor	[7],[11]			9.20%				9.20%
Investment, interest rate, cap	[7],[11]			10.20%				10.20%
Investment, interest rate, paid in kind	[7],[11]			1%				1%
Investment exit fee	[7],[11]			4.95%				4.95%
Principal amount	[11]			$ 36,500
Investment cost	[5],[11]			36,352
Investments, at fair value:	[11]			$ 36,145
Investment, Identifier [Axis]: Debt Investment Information Services (6.65%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			6.65%				6.65%
Investment cost	[5]			$ 117,099
Investments, at fair value:				$ 119,876
Investment, Identifier [Axis]: Debt Investment Information Services and Capella Space Corp., Senior Secured, November 2025, Prime + 5.00%, Floor rate 8.25%, PIK Interest 1.10%, 7.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[14]			2025-11				2025-11
Investment, basis spread, variable rate	[7],[8],[14]			5%				5%
Investment, interest rate, floor	[7],[8],[14]			8.25%				8.25%
Investment, interest rate, paid in kind	[7],[8],[14]			1.10%				1.10%
Investment exit fee	[7],[8],[14]			7%				7%
Principal amount	[8],[14]			$ 20,477
Investment cost	[5],[8],[14]			21,166
Investments, at fair value:	[8],[14]			$ 21,351
Investment, Identifier [Axis]: Debt Investment Information Services and Checkr Group, Inc., Senior Secured, August 2028, Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12]			2028-08				2028-08
Investment, basis spread, variable rate	[7],[8],[12]			1.45%				1.45%
Investment, interest rate, floor	[7],[8],[12]			8%				8%
Investment, interest rate, paid in kind	[7],[8],[12]			2%				2%
Investment exit fee	[7],[8],[12]			2.75%				2.75%
Principal amount	[8],[12]			$ 47,621
Investment cost	[5],[8],[12]			47,460
Investments, at fair value:	[8],[12]			$ 49,382
Investment, Identifier [Axis]: Debt Investment Information Services and Saama Technologies, LLC, Senior Secured, July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[8],[12]			0.70%				0.70%
Investment, interest rate, floor	[7],[8],[12]			8.95%				8.95%
Investment, interest rate, paid in kind	[7],[8],[12]			2%				2%
Investment exit fee	[7],[8],[12]			2.95%				2.95%
Principal amount	[8],[12]			$ 11,725
Investment cost	[5],[8],[12]			11,627
Investments, at fair value:	[8],[12]			$ 11,876
Investment, Identifier [Axis]: Debt Investment Information Services and Signal Media Limited, Senior Secured, June 2025, Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2025-06				2025-06
Investment, basis spread, variable rate	[7],[15],[16]			5.50%				5.50%
Investment, interest rate, floor	[7],[15],[16]			9%				9%
Investment, interest rate, cap	[7],[15],[16]			12%				12%
Investment exit fee	[7],[15],[16]			3.45%				3.45%
Principal amount	[15],[16]			$ 5,400
Investment cost	[5],[15],[16]			5,364
Investments, at fair value:	[15],[16]			$ 5,392
Investment, Identifier [Axis]: Debt Investment Information Services and Yipit, LLC, Senior Secured, September 2026, 1-month SOFR + 8.45%, Floor rate 9.35%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2026-09				2026-09
Investment, basis spread, variable rate	[7],[12],[13]			8.45%				8.45%
Investment, interest rate, floor	[7],[12],[13]			9.35%				9.35%
Principal amount	[12],[13]			$ 31,875
Investment cost	[5],[12],[13]			31,482
Investments, at fair value:	[12],[13]			$ 31,875
Investment, Identifier [Axis]: Debt Investment Manufacturing Technology and Bright Machines, Inc., Senior Secured, May 2025, Prime + 4.00%, Floor rate 9.50%, 5.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[9]			2025-05				2025-05
Investment, basis spread, variable rate	[7],[9]			4%				4%
Investment, interest rate, floor	[7],[9]			9.50%				9.50%
Investment exit fee	[7],[9]			5%				5%
Principal amount	[9]			$ 7,827
Investment cost	[5],[9]			8,064
Investments, at fair value:	[9]			$ 8,006
Investment, Identifier [Axis]: Debt Investment Media/Content/Info (0.69%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.69%				0.69%
Investment cost	[5]			$ 12,340
Investments, at fair value:				$ 12,469
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, December 2025, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2025-12				2025-12
Investment, basis spread, variable rate	[6],[7]			3.50%				3.50%
Investment, interest rate, floor	[6],[7]			9%				9%
Investment exit fee	[6],[7]			3%				3%
Principal amount	[6]			$ 1,333
Investment cost	[5],[6]			1,342
Investments, at fair value:	[6]			$ 1,351
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, June 2026, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2026-06				2026-06
Investment, basis spread, variable rate	[6],[7]			3.50%				3.50%
Investment, interest rate, floor	[6],[7]			9%				9%
Investment exit fee	[6],[7]			3%				3%
Principal amount	[6]			$ 1,667
Investment cost	[5],[6]			1,647
Investments, at fair value:	[6]			$ 1,653
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, March 2026, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2026-03				2026-03
Investment, basis spread, variable rate	[6],[7]			3.50%				3.50%
Investment, interest rate, floor	[6],[7]			9%				9%
Investment exit fee	[6],[7]			3%				3%
Principal amount	[6]			$ 1,500
Investment cost	[5],[6]			1,501
Investments, at fair value:	[6]			$ 1,509
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, September 2025, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2025-09				2025-09
Investment, basis spread, variable rate	[6],[7]			3.50%				3.50%
Investment, interest rate, floor	[6],[7]			9%				9%
Investment exit fee	[6],[7]			3%				3%
Principal amount	[6]			$ 1,167
Investment cost	[5],[6]			1,178
Investments, at fair value:	[6]			$ 1,188
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, September 2026, Prime + 3.50%, Floor rate 9.00%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2026-09				2026-09
Investment, basis spread, variable rate	[6],[7]			3.50%				3.50%
Investment, interest rate, floor	[6],[7]			9%				9%
Investment exit fee	[6],[7]			4%				4%
Principal amount	[6]			$ 6,667
Investment cost	[5],[6]			6,672
Investments, at fair value:	[6]			6,768
Investment, Identifier [Axis]: Debt Investment Media/Content/Info and Total Fever Labs, Inc.
Summary of Investment Holdings [Line Items]
Principal amount				12,334
Investment cost	[5]			12,340
Investments, at fair value:				$ 12,469
Investment, Identifier [Axis]: Debt Investment Medical Devices & Equipment and Senseonics Holdings, Inc., Senior Secured, September 2027, Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2027-09				2027-09
Investment, basis spread, variable rate	[7],[12]			1.40%				1.40%
Investment, interest rate, floor	[7],[12]			9.90%				9.90%
Investment exit fee	[7],[12]			6.95%				6.95%
Principal amount	[12]			$ 21,875
Investment cost	[5],[12]			21,572
Investments, at fair value:	[12]			$ 21,572
Investment, Identifier [Axis]: Debt Investment Software (40.39%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			40.39%				40.39%
Investment cost	[5]			$ 751,108
Investments, at fair value:				728,139
Investment, Identifier [Axis]: Debt Investment Software and Total Cybermaxx Intermediate Holdings, Inc.,
Summary of Investment Holdings [Line Items]
Principal amount				10,501
Investment cost	[5]			10,324
Investments, at fair value:				$ 10,334
Investment, Identifier [Axis]: Debt Investment Software and 3GTMS, LLC, Senior Secured, February 2025, 3-month SOFR + 6.88%, Floor rate 7.78%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2025-02				2025-02
Investment, basis spread, variable rate	[7],[12]			6.88%				6.88%
Investment, interest rate, floor	[7],[12],[13]			7.78%				7.78%
Principal amount	[12],[13]			$ 1,990
Investment cost	[5],[12],[13]			1,988
Investments, at fair value:	[12],[13]			$ 1,986
Investment, Identifier [Axis]: Debt Investment Software and 3GTMS, LLC, Senior Secured, February 2025, 3-month SOFR + 9.70%, Floor rate 10.60%
Summary of Investment Holdings [Line Items]
Maturity Date	[11],[12],[13]			2025-02				2025-02
Investment, basis spread, variable rate	[7],[11],[12],[13]			9.70%				9.70%
Investment, interest rate, floor	[7],[11],[12],[13]			10.60%				10.60%
Principal amount	[11],[12],[13]			$ 13,110
Investment cost	[5],[11],[12],[13]			13,029
Investments, at fair value:	[11],[12],[13]			$ 13,103
Investment, Identifier [Axis]: Debt Investment Software and Agilence, Inc., Senior Secured, October 2026, 1-month BSBY + 9.00%, Floor rate 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[12],[13]			2026-10				2026-10
Investment, basis spread, variable rate	[7],[10],[12],[13]			9%				9%
Investment, interest rate, floor	[7],[10],[12],[13]			10%				10%
Principal amount	[10],[12],[13]			$ 9,212
Investment cost	[5],[10],[12],[13]			9,040
Investments, at fair value:	[10],[12],[13]			$ 9,212
Investment, Identifier [Axis]: Debt Investment Software and Alchemer LLC, Senior Secured, May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12],[13]			2028-05				2028-05
Investment, basis spread, variable rate	[7],[9],[12],[13]			8.14%				8.14%
Investment, interest rate, floor	[7],[9],[12],[13]			9.14%				9.14%
Principal amount	[9],[12],[13]			$ 20,908
Investment cost	[5],[9],[12],[13]			20,508
Investments, at fair value:	[9],[12],[13]			$ 21,297
Investment, Identifier [Axis]: Debt Investment Software and Allvue Systems, LLC, Senior Secured, September 2029, 6-month SOFR + 7.25%, Floor rate 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2029-09				2029-09
Investment, basis spread, variable rate	[7],[12]			7.25%				7.25%
Investment, interest rate, floor	[7],[12]			8.25%				8.25%
Principal amount	[12]			$ 36,410
Investment cost	[5],[12]			35,530
Investments, at fair value:	[12]			$ 35,530
Investment, Identifier [Axis]: Debt Investment Software and Annex Cloud, Senior Secured, February 2027, 1-month BSBY + 9.41%, Floor rate 10.41%
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12]			2027-02				2027-02
Investment, basis spread, variable rate	[7],[9],[12]			9.41%				9.41%
Investment, interest rate, floor	[7],[9],[12]			10.41%				10.41%
Principal amount	[9],[12]			$ 9,823
Investment cost	[5],[9],[12]			9,649
Investments, at fair value:	[9],[12]			$ 9,761
Investment, Identifier [Axis]: Debt Investment Software and Automation Anywhere, Inc., Senior Secured, September 2027, Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[11],[12]			2027-09				2027-09
Investment, basis spread, variable rate	[6],[7],[11],[12]			4.25%				4.25%
Investment, interest rate, floor	[6],[7],[11],[12]			9%				9%
Investment exit fee	[6],[7],[11],[12]			4.50%				4.50%
Principal amount	[6],[11],[12]			$ 19,600
Investment cost	[5],[6],[11],[12]			19,345
Investments, at fair value:	[6],[11],[12]			$ 20,269
Investment, Identifier [Axis]: Debt Investment Software and Babel Street, Senior Secured, December 2027, 3-month SOFR + 7.89%, Floor rate 8.89%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13],[14]			2027-12				2027-12
Investment, basis spread, variable rate	[7],[12],[13],[14]			7.89%				7.89%
Investment, interest rate, floor	[7],[12],[13],[14]			8.89%				8.89%
Principal amount	[12],[13],[14]			$ 45,000
Investment cost	[5],[12],[13],[14]			43,983
Investments, at fair value:	[12],[13],[14]			$ 44,928
Investment, Identifier [Axis]: Debt Investment Software and Brain Corporation, Senior Secured, April 2026, Prime + 3.70%, Floor rate 9.20%, PIK Interest 1.00%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9],[12],[14]			2026-04				2026-04
Investment, basis spread, variable rate	[7],[8],[9],[12],[14]			3.70%				3.70%
Investment, interest rate, floor	[7],[8],[9],[12],[14]			9.20%				9.20%
Investment, interest rate, paid in kind	[7],[8],[9],[12],[14]			1%				1%
Investment exit fee	[7],[8],[9],[12],[14]			3.95%				3.95%
Principal amount	[8],[9],[12],[14]			$ 30,415
Investment cost	[5],[8],[9],[12],[14]			30,678
Investments, at fair value:	[8],[9],[12],[14]			$ 30,989
Investment, Identifier [Axis]: Debt Investment Software and Campaign Monitor Limited, Senior Secured, November 2025, 3-month SOFR + 9.05%, Floor rate 9.90%
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[9]			2025-11				2025-11
Investment, basis spread, variable rate	[6],[7],[9]			9.05%				9.05%
Investment, interest rate, floor	[6],[7],[9]			9.90%				9.90%
Principal amount	[6],[9]			$ 33,000
Investment cost	[5],[6],[9]			32,706
Investments, at fair value:	[6],[9]			$ 33,000
Investment, Identifier [Axis]: Debt Investment Software and Catchpoint Systems, Inc., Senior Secured, November 2025, 3-month SOFR + 9.41%, Floor rate 11.81%
Summary of Investment Holdings [Line Items]
Maturity Date	[13]			2025-11				2025-11
Investment, basis spread, variable rate	[7],[13]			9.41%				9.41%
Investment, interest rate, floor	[7],[13]			11.81%				11.81%
Principal amount	[13]			$ 10,073
Investment cost	[5],[13]			9,931
Investments, at fair value:	[13]			$ 9,940
Investment, Identifier [Axis]: Debt Investment Software and Ceros, Inc., Senior Secured, September 2026, 6-month SOFR + 8.99%, Floor rate 9.89%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2026-09				2026-09
Investment, basis spread, variable rate	[7]			8.99%				8.99%
Investment, interest rate, floor	[7],[12],[13]			9.89%				9.89%
Principal amount	[12],[13]			$ 22,867
Investment cost	[5],[12],[13]			22,498
Investments, at fair value:	[12],[13]			$ 23,075
Investment, Identifier [Axis]: Debt Investment Software and Constructor.io Corporation, Senior Secured, July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12],[13]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[9],[12],[13]			8.44%				8.44%
Investment, interest rate, floor	[7],[9],[12],[13]			9.44%				9.44%
Principal amount	[9],[12],[13]			$ 4,688
Investment cost	[5],[9],[12],[13]			4,592
Investments, at fair value:	[9],[12],[13]			$ 4,790
Investment, Identifier [Axis]: Debt Investment Software and Convoy, Inc., Senior Secured, March 2026, Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[8],[23]			2026-03				2026-03
Investment, basis spread, variable rate	[6],[7],[8],[23]			3.20%				3.20%
Investment, interest rate, floor	[6],[7],[8],[23]			6.45%				6.45%
Investment, interest rate, paid in kind	[6],[7],[8],[23]			1.95%				1.95%
Investment exit fee	[6],[7],[8],[23]			4.55%				4.55%
Principal amount	[6],[8],[23]			$ 31,049
Investment cost	[5],[6],[8],[23]			30,916
Investments, at fair value:	[6],[8],[23]			$ 0
Investment, Identifier [Axis]: Debt Investment Software and Copper CRM, Inc, Senior Secured, March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 3.96% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[11]			2025-03				2025-03
Investment, basis spread, variable rate	[7],[8],[11]			4.50%				4.50%
Investment, interest rate, floor	[7],[8],[11]			8.25%				8.25%
Investment, interest rate, cap	[7],[8],[11]			10.25%				10.25%
Investment, interest rate, paid in kind	[7],[8],[11]			1.95%				1.95%
Investment exit fee	[7],[8],[11]			3.96%				3.96%
Principal amount	[8],[11]			$ 9,141
Investment cost	[5],[8],[11]			9,307
Investments, at fair value:	[8],[11]			$ 9,153
Investment, Identifier [Axis]: Debt Investment Software and Cutover, Inc., Senior Secured, October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[10],[12],[15],[16]			2025-10				2025-10
Investment, basis spread, variable rate	[7],[10],[12],[15],[16]			5.20%				5.20%
Investment, interest rate, floor	[7],[10],[12],[15],[16]			9.95%				9.95%
Investment exit fee	[7],[10],[12],[15],[16]			4.95%				4.95%
Principal amount	[10],[12],[15],[16]			$ 5,500
Investment cost	[5],[10],[12],[15],[16]			5,544
Investments, at fair value:	[10],[12],[15],[16]			$ 5,715
Investment, Identifier [Axis]: Debt Investment Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, August 2026, 6-month SOFR + 12.36%, Floor rate 13.11%
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2026-08				2026-08
Investment, basis spread, variable rate	[7],[12]			12.36%				12.36%
Investment, interest rate, floor	[7],[12]			13.11%				13.11%
Principal amount	[12]			$ 2,546
Investment cost	[5],[12]			2,494
Investments, at fair value:	[12]			$ 2,556
Investment, Identifier [Axis]: Debt Investment Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, August 2026, 6-month SOFR + 8.63%, Floor rate 9.38%
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12]			2026-08				2026-08
Investment, basis spread, variable rate	[7],[9],[12]			8.63%				8.63%
Investment, interest rate, floor	[7],[9],[12]			9.38%				9.38%
Principal amount	[9],[12]			$ 7,955
Investment cost	[5],[9],[12]			7,830
Investments, at fair value:	[9],[12]			$ 7,778
Investment, Identifier [Axis]: Debt Investment Software and Dashlane, Inc., Senior Secured, December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 7.26% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[9],[11],[12]			2027-12				2027-12
Investment, basis spread, variable rate	[6],[7],[9],[11],[12]			3.05%				3.05%
Investment, interest rate, floor	[6],[7],[9],[11],[12]			11.55%				11.55%
Investment, interest rate, paid in kind	[6],[7],[9],[11],[12]			1.10%				1.10%
Investment exit fee	[6],[7],[9],[11],[12]			7.26%				7.26%
Principal amount	[6],[9],[11],[12]			$ 42,863
Investment cost	[5],[6],[9],[11],[12]			43,087
Investments, at fair value:	[6],[9],[11],[12]			$ 43,087
Investment, Identifier [Axis]: Debt Investment Software and Dispatch Technologies, Inc., Senior Secured, April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2028-04				2028-04
Investment, basis spread, variable rate	[7],[12],[13]			8.01%				8.01%
Investment, interest rate, floor	[7],[12],[13]			8.76%				8.76%
Principal amount	[12],[13]			$ 8,125
Investment cost	[5],[12],[13]			7,949
Investments, at fair value:	[12],[13]			$ 8,127
Investment, Identifier [Axis]: Debt Investment Software and DroneDeploy, Inc., Senior Secured, July 2026, Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2026-07				2026-07
Investment, basis spread, variable rate	[7],[12]			4.50%				4.50%
Investment, interest rate, floor	[7],[12]			8.75%				8.75%
Investment exit fee	[7],[12]			4%				4%
Principal amount	[12]			$ 6,250
Investment cost	[5],[12]			6,083
Investments, at fair value:	[12]			$ 6,153
Investment, Identifier [Axis]: Debt Investment Software and Eigen Technologies Ltd., Senior Secured, April 2025, Prime + 5.10%, Floor rate 8.35%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[15],[16]			2025-04				2025-04
Investment, basis spread, variable rate	[7],[15],[16]			5.10%				5.10%
Investment, interest rate, floor	[7],[15],[16]			8.35%				8.35%
Investment exit fee	[7],[15],[16]			2.95%				2.95%
Principal amount	[15],[16]			$ 3,750
Investment cost	[5],[15],[16]			3,801
Investments, at fair value:	[15],[16]			$ 3,730
Investment, Identifier [Axis]: Debt Investment Software and Elation Health, Inc., Senior Secured, March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[6],[8],[12]			2026-03				2026-03
Investment, basis spread, variable rate	[6],[7],[8],[12]			4.25%				4.25%
Investment, interest rate, floor	[6],[7],[8],[12]			9%				9%
Investment, interest rate, paid in kind	[6],[7],[8],[12]			1.95%				1.95%
Investment exit fee	[6],[7],[8],[12]			3.95%				3.95%
Principal amount	[6],[8],[12]			$ 12,629
Investment cost	[5],[6],[8],[12]			12,253
Investments, at fair value:	[6],[8],[12]			$ 12,692
Investment, Identifier [Axis]: Debt Investment Software and Enmark Systems, Inc., Senior Secured, September 2026, 3-month SOFR + 6.73%, Floor rate 7.73%, PIK Interest 2.13%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[11],[12],[13]			2026-09				2026-09
Investment, basis spread, variable rate	[7],[8],[11],[13]			6.73%				6.73%
Investment, interest rate, floor	[7],[8],[11],[12],[13]			7.73%				7.73%
Investment, interest rate, paid in kind	[7],[8],[11],[12],[13]			2.13%				2.13%
Principal amount	[8],[11],[12],[13]			$ 8,363
Investment cost	[5],[8],[11],[12],[13]			8,230
Investments, at fair value:	[8],[11],[12],[13]			$ 8,363
Investment, Identifier [Axis]: Debt Investment Software and Flight Schedule Pro, LLC, Senior Secured, October 2027, 1-month SOFR + 7.80%, Floor rate 8.70%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2027-10				2027-10
Investment, basis spread, variable rate	[7],[12],[13]			7.80%				7.80%
Investment, interest rate, floor	[7],[12],[13]			8.70%				8.70%
Principal amount	[12],[13]			$ 6,587
Investment cost	[5],[12],[13]			6,420
Investments, at fair value:	[12],[13]			$ 6,553
Investment, Identifier [Axis]: Debt Investment Software and Fortified Health Security, Senior Secured, December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%
Summary of Investment Holdings [Line Items]
Maturity Date	[11],[12],[13]			2027-12				2027-12
Investment, basis spread, variable rate	[7],[11],[12],[13]			7.64%				7.64%
Investment, interest rate, floor	[7],[11],[12],[13]			8.54%				8.54%
Principal amount	[11],[12],[13]			$ 7,000
Investment cost	[5],[11],[12],[13]			6,851
Investments, at fair value:	[11],[12],[13]			$ 6,910
Investment, Identifier [Axis]: Debt Investment Software and Ikon Science Limited, Senior Secured, October 2024, 3-month SOFR + 9.26%, Floor rate 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13],[15],[16]			2024-10				2024-10
Investment, basis spread, variable rate	[7],[12],[13],[15],[16]			9.26%				9.26%
Investment, interest rate, floor	[7],[12],[13],[15],[16]			10%				10%
Principal amount	[12],[13],[15],[16]			$ 6,213
Investment cost	[5],[12],[13],[15],[16]			6,148
Investments, at fair value:	[12],[13],[15],[16]			$ 6,148
Investment, Identifier [Axis]: Debt Investment Software and Khoros (p.k.a Lithium Technologies), Senior Secured, January 2025, 3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[8]			2025-01				2025-01
Investment, basis spread, variable rate	[7],[8]			4.50%				4.50%
Investment, interest rate, floor	[7],[8]			5.50%				5.50%
Investment, interest rate, paid in kind	[7],[8]			4.50%				4.50%
Principal amount	[8]			$ 57,770
Investment cost	[5],[8]			57,730
Investments, at fair value:	[8]			$ 56,293
Investment, Identifier [Axis]: Debt Investment Software and Leapwork ApS, Senior Secured, February 2026, Prime + 0.25%, Floor rate 7.25%, PIK Interest 1.95%, 2.70% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10],[12],[15],[16]			2026-02				2026-02
Investment, basis spread, variable rate	[7],[8],[10],[12],[15],[16]			0.25%				0.25%
Investment, interest rate, floor	[7],[8],[10],[12],[15],[16]			7.25%				7.25%
Investment, interest rate, paid in kind	[7],[8],[10],[12],[15],[16]			1.95%				1.95%
Investment exit fee	[7],[8],[10],[12],[15],[16]			2.70%				2.70%
Principal amount	[8],[10],[12],[15],[16]			$ 3,813
Investment cost	[5],[8],[10],[12],[15],[16]			3,810
Investments, at fair value:	[8],[10],[12],[15],[16]			$ 3,907
Investment, Identifier [Axis]: Debt Investment Software and LinenMaster, LLC, Senior Secured, August 2028, 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12]			2028-08				2028-08
Investment, basis spread, variable rate	[7],[8],[12]			6.25%				6.25%
Investment, interest rate, floor	[7],[8],[12]			7.25%				7.25%
Investment, interest rate, paid in kind	[7],[8],[12]			2.15%				2.15%
Principal amount	[8],[12]			$ 15,083
Investment cost	[5],[8],[12]			14,799
Investments, at fair value:	[8],[12]			$ 14,799
Investment, Identifier [Axis]: Debt Investment Software and Loftware, Inc., Senior Secured, March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2028-03				2028-03
Investment, basis spread, variable rate	[7],[12],[13]			7.88%				7.88%
Investment, interest rate, floor	[7],[12],[13]			8.88%				8.88%
Principal amount	[12],[13]			$ 26,469
Investment cost	[5],[12],[13]			25,897
Investments, at fair value:	[12],[13]			$ 26,566
Investment, Identifier [Axis]: Debt Investment Software and LogicSource, Senior Secured, July 2027, 3-month SOFR + 8.93%, Floor rate 9.93%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[12],[13]			8.93%				8.93%
Investment, interest rate, floor	[7],[12],[13]			9.93%				9.93%
Principal amount	[12],[13]			$ 13,300
Investment cost	[5],[12],[13]			13,074
Investments, at fair value:	[12],[13]			$ 13,493
Investment, Identifier [Axis]: Debt Investment Software and Mobile Solutions Services, Senior Secured, December 2025, 6-month SOFR + 9.31%, Floor rate 10.06%
Summary of Investment Holdings [Line Items]
Maturity Date	[13]			2025-12				2025-12
Investment, basis spread, variable rate	[7],[13]			9.31%				9.31%
Investment, interest rate, floor	[7],[13]			10.06%				10.06%
Principal amount	[13]			$ 18,366
Investment cost	[5],[13]			18,116
Investments, at fair value:	[13]			$ 18,176
Investment, Identifier [Axis]: Debt Investment Software and New Relic, Inc., Senior Secured, November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2030-11				2030-11
Investment, basis spread, variable rate	[7],[12]			6.75%				6.75%
Investment, interest rate, floor	[7],[12]			7.75%				7.75%
Principal amount	[12]			$ 20,890
Investment cost	[5],[12]			20,375
Investments, at fair value:	[12]			$ 20,375
Investment, Identifier [Axis]: Debt Investment Software and Omeda Holdings, LLC, Senior Secured, July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%
Summary of Investment Holdings [Line Items]
Maturity Date	[11],[12],[13]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[11],[12],[13]			8.05%				8.05%
Investment, interest rate, floor	[7],[11],[12],[13]			9.05%				9.05%
Principal amount	[11],[12],[13]			$ 7,706
Investment cost	[5],[11],[12],[13]			7,508
Investments, at fair value:	[11],[12],[13]			$ 7,702
Investment, Identifier [Axis]: Debt Investment Software and Onna Technologies, Inc., Senior Secured, March 2026, Prime + 1.35%, Floor rate 8.85%, PIK Interest 1.75%, 4.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8]			2026-03				2026-03
Investment, basis spread, variable rate	[7],[8]			1.35%				1.35%
Investment, interest rate, floor	[7],[8]			8.85%				8.85%
Investment, interest rate, paid in kind	[7],[8]			1.75%				1.75%
Investment exit fee	[7],[8]			4.45%				4.45%
Principal amount	[8]			$ 3,853
Investment cost	[5],[8]			3,814
Investments, at fair value:	[8]			$ 3,810
Investment, Identifier [Axis]: Debt Investment Software and Salary.com, LLC, Senior Secured, September 2027, 3-month SOFR + 8.00%, Floor rate 9.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[13]			2027-09				2027-09
Investment, basis spread, variable rate	[7],[13]			8%				8%
Investment, interest rate, floor	[7],[13]			9%				9%
Principal amount	[13]			$ 22,185
Investment cost	[5],[13]			21,814
Investments, at fair value:	[13]			$ 22,048
Investment, Identifier [Axis]: Debt Investment Software and ShadowDragon, LLC, Senior Secured, December 2026, 1-month SOFR + 9.01%, Floor rate 9.91%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2026-12				2026-12
Investment, basis spread, variable rate	[7],[12],[13]			9.01%				9.01%
Investment, interest rate, floor	[7],[12],[13]			9.91%				9.91%
Principal amount	[12],[13]			$ 6,000
Investment cost	[5],[12],[13]			5,883
Investments, at fair value:	[12],[13]			$ 5,921
Investment, Identifier [Axis]: Debt Investment Software and Simon Data, Inc., Senior Secured, March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.92% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[10]			2027-03				2027-03
Investment, basis spread, variable rate	[7],[8],[10]			1%				1%
Investment, interest rate, floor	[7],[8],[10]			8.75%				8.75%
Investment, interest rate, paid in kind	[7],[8],[10]			1.95%				1.95%
Investment exit fee	[7],[8],[10]			2.92%				2.92%
Principal amount	[8],[10]			$ 15,065
Investment cost	[5],[8],[10]			14,982
Investments, at fair value:	[8],[10]			$ 15,037
Investment, Identifier [Axis]: Debt Investment Software and Sisense Ltd., Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[15],[16]			2027-07				2027-07
Investment, basis spread, variable rate	[7],[8],[15],[16]			1.50%				1.50%
Investment, interest rate, floor	[7],[8],[15],[16]			9.50%				9.50%
Investment, interest rate, paid in kind	[7],[8],[15],[16]			1.95%				1.95%
Investment exit fee	[7],[8],[15],[16]			5.95%				5.95%
Principal amount	[8],[15],[16]			$ 34,830
Investment cost	[5],[8],[15],[16]			34,584
Investments, at fair value:	[8],[15],[16]			$ 34,881
Investment, Identifier [Axis]: Debt Investment Software and Streamline Healthcare Solutions, Senior Secured, March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2028-03				2028-03
Investment, basis spread, variable rate	[7],[12],[13]			7.25%				7.25%
Investment, interest rate, floor	[7],[12],[13]			8.25%				8.25%
Principal amount	[12],[13]			$ 13,200
Investment cost	[5],[12],[13]			12,953
Investments, at fair value:	[12],[13]			$ 13,327
Investment, Identifier [Axis]: Debt Investment Software and Sumo Logic, Inc., Senior Secured, May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[12]			2030-05				2030-05
Investment, basis spread, variable rate	[7],[12]			6.50%				6.50%
Investment, interest rate, floor	[7],[12]			7.50%				7.50%
Principal amount	[12]			$ 23,000
Investment cost	[5],[12]			22,460
Investments, at fair value:	[12]			$ 23,105
Investment, Identifier [Axis]: Debt Investment Software and Suzy, Inc., Senior Secured, August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12],[14]			2027-08				2027-08
Investment, basis spread, variable rate	[7],[8],[12],[14]			1.75%				1.75%
Investment, interest rate, floor	[7],[8],[12],[14]			10%				10%
Investment, interest rate, paid in kind	[7],[8],[12],[14]			1.95%				1.95%
Investment exit fee	[7],[8],[12],[14]			3.45%				3.45%
Principal amount	[8],[12],[14]			$ 12,064
Investment cost	[5],[8],[12],[14]			11,837
Investments, at fair value:	[8],[12],[14]			$ 11,837
Investment, Identifier [Axis]: Debt Investment Software and ThreatConnect, Inc., Senior Secured, May 2026, 6-month SOFR + 9.25%, Floor rate 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2026-05				2026-05
Investment, basis spread, variable rate	[7],[12],[13]			9.25%				9.25%
Investment, interest rate, floor	[7],[12],[13]			10%				10%
Principal amount	[12],[13]			$ 10,920
Investment cost	[5],[12],[13]			10,730
Investments, at fair value:	[12],[13]			$ 10,920
Investment, Identifier [Axis]: Debt Investment Software and Tipalti Solutions Ltd., Senior Secured, April 2027, Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[12],[15],[16]			2027-04				2027-04
Investment, basis spread, variable rate	[7],[8],[12],[15],[16]			0.45%				0.45%
Investment, interest rate, floor	[7],[8],[12],[15],[16]			7.95%				7.95%
Investment, interest rate, paid in kind	[7],[8],[12],[15],[16]			2%				2%
Investment exit fee	[7],[8],[12],[15],[16]			3.75%				3.75%
Principal amount	[8],[12],[15],[16]			$ 10,649
Investment cost	[5],[8],[12],[15],[16]			10,578
Investments, at fair value:	[8],[12],[15],[16]			10,835
Investment, Identifier [Axis]: Debt Investment Software and Total 3GTMS, LLC
Summary of Investment Holdings [Line Items]
Principal amount				15,100
Investment cost	[5]			15,017
Investments, at fair value:				$ 15,089
Investment, Identifier [Axis]: Debt Investment Software and Zappi, Inc., Senior Secured, December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%
Summary of Investment Holdings [Line Items]
Maturity Date	[9],[12],[13],[15],[16]			2027-12				2027-12
Investment, basis spread, variable rate	[7],[9],[12],[13],[15],[16]			8.03%				8.03%
Investment, interest rate, floor	[7],[9],[12],[13],[15],[16]			9.03%				9.03%
Principal amount	[9],[12],[13],[15],[16]			$ 9,000
Investment cost	[5],[9],[12],[13],[15],[16]			8,816
Investments, at fair value:	[9],[12],[13],[15],[16]			$ 8,967
Investment, Identifier [Axis]: Debt Investment Software and Zimperium, Inc., Senior Secured, May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%
Summary of Investment Holdings [Line Items]
Maturity Date	[12],[13]			2027-05				2027-05
Investment, basis spread, variable rate	[7],[12],[13]			8.31%				8.31%
Investment, interest rate, floor	[7],[12],[13]			9.31%				9.31%
Principal amount	[12],[13]			$ 16,313
Investment cost	[5],[12],[13]			16,057
Investments, at fair value:	[12],[13]			$ 16,394
Investment, Identifier [Axis]: Debt Investment Software and iGrafx, LLC, Senior Secured, May 2027, 1-month SOFR + 8.66%, Floor rate 9.56%
Summary of Investment Holdings [Line Items]
Maturity Date	[13]			2027-05				2027-05
Investment, basis spread, variable rate	[7],[13]			8.66%				8.66%
Investment, interest rate, floor	[7],[13]			9.56%				9.56%
Principal amount	[13]			$ 5,000
Investment cost	[5],[13]			4,901
Investments, at fair value:	[13]			$ 4,901
Investment, Identifier [Axis]: Debt Investment Sustainable and Renewable Technology (0.31%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.31%				0.31%
Investment cost	[5]			$ 5,634
Investments, at fair value:				$ 5,617
Investment, Identifier [Axis]: Debt Investment Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.78% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[8],[9]			2025-05				2025-05
Investment, basis spread, variable rate	[7],[8],[9]			4.70%				4.70%
Investment, interest rate, floor	[7],[8],[9]			7.95%				7.95%
Investment, interest rate, paid in kind	[7],[8],[9]			1.45%				1.45%
Investment exit fee	[7],[8],[9]			3.78%				3.78%
Principal amount	[8],[9]			$ 3,926
Investment cost	[5],[8],[9]			3,952
Investments, at fair value:	[8],[9]			$ 3,939
Investment, Identifier [Axis]: Debt Investment Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, June 2027, FIXED 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[6]			2027-06				2027-06
Investment, interest rate, paid in cash	[6],[7]			10%				10%
Principal amount	[6]			$ 1,682
Investment cost	[5],[6]			1,682
Investments, at fair value:	[6]			$ 1,678
Investment, Identifier [Axis]: Debt Investments (182.56%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	182.56%				182.56%
Investment cost	[2]	$ 3,415,799
Investments, at fair value:		$ 3,380,578
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools (1.81%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	1.81%				1.81%
Investment cost	[2]	$ 32,572
Investments, at fair value:		$ 33,600
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools and PathAI, Inc., Senior Secured, Maturity Date January 2027, Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[26]	2027-01				2027-01
Investment, basis spread, variable rate	[25],[26],[27]	2.15%				2.15%
Investment, interest rate, floor	[25],[26],[27]	9.15%				9.15%
Investment exit fee	[25],[26],[27]	7.85%				7.85%
Principal amount	[25],[26]	$ 32,000
Investment cost	[2],[25],[26]	32,572
Investments, at fair value:	[25],[26]	$ 33,600
Investment, Identifier [Axis]: Debt Investments Communications & Networking (1.42%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	1.42%				1.42%
Investment cost	[2]	$ 25,427
Investments, at fair value:		$ 26,373
Investment, Identifier [Axis]: Debt Investments Communications & Networking and Aryaka Networks, Inc. Senior Secured, Maturity Date July 2026, Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[28],[29]	2026-07				2026-07
Investment, basis spread, variable rate	[26],[27],[28],[29]	3.25%				3.25%
Investment, interest rate, floor	[26],[27],[28],[29]	6.75%				6.75%
Investment, interest rate, paid in kind	[26],[27],[28],[29]	1.05%				1.05%
Investment exit fee	[26],[27],[28],[29]	3.55%				3.55%
Principal amount	[26],[28],[29]	$ 25,351
Investment cost	[2],[26],[28],[29]	25,427
Investments, at fair value:	[26],[28],[29]	$ 26,373
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services (18.52%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	18.52%				18.52%
Investment cost	[2]	$ 340,435
Investments, at fair value:		$ 342,980
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Altumint, Inc. Senior Secured, Maturity Date December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2027-12				2027-12
Investment, basis spread, variable rate	[1],[27]	3.65%				3.65%
Investment, interest rate, floor	[1],[27]	12.15%				12.15%
Investment exit fee	[1],[27]	2.50%				2.50%
Principal amount	[1]	$ 10,000
Investment cost	[1],[2]	9,958
Investments, at fair value:	[1]	$ 10,107
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Carwow LTD Senior Secured, Maturity Date December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31]	2027-12				2027-12
Investment, basis spread, variable rate	[27],[29],[30],[31]	4.70%				4.70%
Investment, interest rate, floor	[27],[29],[30],[31]	11.45%				11.45%
Investment, interest rate, paid in kind	[27],[29],[30],[31]	1.45%				1.45%
Investment exit fee	[27],[29],[30],[31]	4.95%				4.95%
Principal amount | £	[29],[30],[31]					£ 20,287
Investment cost	[2],[29],[30],[31]	$ 27,650
Investments, at fair value:	[29],[30],[31]	$ 27,128
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Houzz, Inc. Convertible Debt, Maturity Date May 2028, PIK Interest 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[32]	2028-05				2028-05
Investment, interest rate, paid in kind	[27],[29],[32]	10%				10%
Principal amount	[29],[32]	$ 25,011
Investment cost	[2],[29],[32]	25,011
Investments, at fair value:	[29],[32]	$ 25,745
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Jobandtalent USA, Inc. Senior Secured, Maturity Date August 2025, 1-month SOFR + 8.86, Floor rate 9.75%, 2.87% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31]	2025-08				2025-08
Investment, basis spread, variable rate	[27],[30],[31]	8.86%				8.86%
Investment, interest rate, floor	[27],[30],[31]	9.75%				9.75%
Investment exit fee	[27],[30],[31]	2.87%				2.87%
Principal amount	[30],[31]	$ 13,123
Investment cost	[2],[30],[31]	13,345
Investments, at fair value:	[30],[31]	$ 13,345
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Plentific Ltd. Senior Secured, Maturity Date October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[30],[31]	2026-10				2026-10
Investment, basis spread, variable rate	[25],[27],[30],[31]	2.55%				2.55%
Investment, interest rate, floor	[25],[27],[30],[31]	11.05%				11.05%
Investment exit fee	[25],[27],[30],[31]	2.95%				2.95%
Principal amount	[25],[30],[31]	$ 3,325
Investment cost	[2],[25],[30],[31]	3,264
Investments, at fair value:	[25],[30],[31]	$ 3,324
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Provi, Senior Secured, Maturity Date December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2026-12				2026-12
Investment, basis spread, variable rate	[1],[27]	4.40%				4.40%
Investment, interest rate, floor	[1],[27]	10.65%				10.65%
Investment exit fee	[1],[27]	2.95%				2.95%
Principal amount	[1]	$ 15,000
Investment cost	[1],[2]	15,043
Investments, at fair value:	[1]	$ 15,229
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[25],[29]	2026-12				2026-12
Investment, basis spread, variable rate	[1],[25],[27],[29]	5.50%				5.50%
Investment, interest rate, floor	[1],[25],[27],[29]	6.50%				6.50%
Investment, interest rate, paid in kind	[1],[25],[27],[29]	4%				4%
Principal amount	[1],[25],[29]	$ 29,771
Investment cost	[1],[2],[25],[29]	29,442
Investments, at fair value:	[1],[25],[29]	$ 29,753
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Riviera Partners LLC. Senior Secured, Maturity Date April 2027, 1-month SOFR + 8.27%, Floor rate 9.27%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2027-04				2027-04
Investment, basis spread, variable rate	[27],[33],[34]	8.27%				8.27%
Investment, interest rate, floor	[27],[33],[34]	9.27%				9.27%
Principal amount	[33],[34]	$ 36,587
Investment cost	[2],[33],[34]	36,161
Investments, at fair value:	[33],[34]	$ 34,807
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc. Senior Secured, Maturity Date July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[35]	2026-07				2026-07
Investment, basis spread, variable rate	[26],[27],[29],[35]	2.50%				2.50%
Investment, interest rate, floor	[26],[27],[29],[35]	10.75%				10.75%
Investment, interest rate, paid in kind	[26],[27],[29],[35]	0.50%				0.50%
Investment exit fee	[26],[27],[29],[35]	3%				3%
Principal amount	[26],[29],[35]	$ 77,939
Investment cost	[2],[26],[29],[35]	77,594
Investments, at fair value:	[26],[29],[35]	$ 78,952
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[35],[36]	2026-05				2026-05
Investment, basis spread, variable rate	[27],[29],[35],[36]	7%				7%
Investment, interest rate, floor	[27],[29],[35],[36]	10.50%				10.50%
Investment, interest rate, paid in kind	[27],[29],[35],[36]	0.50%				0.50%
Investment exit fee	[27],[29],[35],[36]	4%				4%
Principal amount	[29],[35],[36]	$ 25,295
Investment cost	[2],[29],[35],[36]	25,313
Investments, at fair value:	[29],[35],[36]	$ 25,736
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Skyword, Inc. Senior Secured, Maturity Date November 2026, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[29]	2026-11				2026-11
Investment, basis spread, variable rate	[25],[27],[29]	2.75%				2.75%
Investment, interest rate, floor	[25],[27],[29]	9.25%				9.25%
Investment, interest rate, paid in kind	[25],[27],[29]	1.75%				1.75%
Investment exit fee	[25],[27],[29]	3%				3%
Principal amount	[25],[29]	$ 7,271
Investment cost	[2],[25],[29]	7,375
Investments, at fair value:	[25],[29]	$ 7,482
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date January 2027, FIXED 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[37]	2027-01				2027-01
Investment, interest rate, paid in cash	[27],[37]	8.25%				8.25%
Principal amount	[37]	$ 8,250
Investment cost	[2],[37]	8,250
Investments, at fair value:	[37]	$ 8,250
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Thumbtack, Inc. Senior Secured, Maturity Date March 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[33],[36]	2028-03				2028-03
Investment, basis spread, variable rate	[27],[29],[33],[36]	2.45%				2.45%
Investment, interest rate, floor	[27],[29],[33],[36]	10.95%				10.95%
Investment, interest rate, paid in kind	[27],[29],[33],[36]	1.50%				1.50%
Principal amount	[29],[33],[36]	$ 20,839
Investment cost	[2],[29],[33],[36]	20,460
Investments, at fair value:	[29],[33],[36]	21,069
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Total SeatGeek, Inc.
Summary of Investment Holdings [Line Items]
Principal amount		103,234
Investment cost	[2]	102,907
Investments, at fair value:		104,688
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Total Worldremit Group Limited
Summary of Investment Holdings [Line Items]
Principal amount		31,083
Investment cost	[2]	30,909
Investments, at fair value:		$ 31,393
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[29]	2025-03				2025-03
Investment, basis spread, variable rate	[25],[27],[29]	4%				4%
Investment, interest rate, floor	[25],[27],[29]	7.25%				7.25%
Investment, interest rate, paid in kind	[25],[27],[29]	1.25%				1.25%
Investment exit fee	[25],[27],[29]	4.50%				4.50%
Principal amount	[25],[29]	$ 5,156
Investment cost	[2],[25],[29]	5,322
Investments, at fair value:	[25],[29]	$ 5,322
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29]	2025-03				2025-03
Investment, basis spread, variable rate	[26],[27],[29]	4.70%				4.70%
Investment, interest rate, floor	[26],[27],[29]	7.95%				7.95%
Investment, interest rate, paid in kind	[26],[27],[29]	1.50%				1.50%
Investment exit fee	[26],[27],[29]	4.50%				4.50%
Principal amount	[26],[29]	$ 5,169
Investment cost	[2],[26],[29]	5,338
Investments, at fair value:	[26],[29]	$ 5,338
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2026, 1-month SOFR + 9.35%, Floor rate 10.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[30],[31]	2026-02				2026-02
Investment, basis spread, variable rate	[27],[28],[30],[31]	9.35%				9.35%
Investment, interest rate, floor	[27],[28],[30],[31]	10.25%				10.25%
Principal amount	[28],[30],[31]	$ 6,466
Investment cost	[2],[28],[30],[31]	6,424
Investments, at fair value:	[28],[30],[31]	$ 6,530
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2026, 3-month SOFR + 9.40%, Floor rate 10.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[28],[30],[31],[36]	2026-02				2026-02
Investment, basis spread, variable rate	[26],[27],[28],[30],[31],[36]	9.40%				9.40%
Investment, interest rate, floor	[26],[27],[28],[30],[31],[36]	10.25%				10.25%
Principal amount	[26],[28],[30],[31],[36]	$ 24,617
Investment cost	[2],[26],[28],[30],[31],[36]	24,485
Investments, at fair value:	[26],[28],[30],[31],[36]	24,863
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services, and Total Veem, Inc.
Summary of Investment Holdings [Line Items]
Principal amount		10,325
Investment cost	[2]	10,660
Investments, at fair value:		$ 10,660
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services (3.17%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	3.17%				3.17%
Investment cost	[2]	$ 58,390
Investments, at fair value:		$ 58,782
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, Maturity Date September 2026, FIXED 3.45%, PIK Interest 8.05%
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[37],[38]	2026-09				2026-09
Investment, interest rate, paid in kind	[27],[29],[37],[38]	8.05%				8.05%
Investment, interest rate, paid in cash	[27],[29],[37],[38]	3.45%				3.45%
Principal amount	[29],[37],[38]	$ 26,033
Investment cost	[2],[29],[37],[38]	25,774
Investments, at fair value:	[29],[37],[38]	$ 25,774
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, Maturity Date September 2026, Fixed 11.95%
Summary of Investment Holdings [Line Items]
Maturity Date	[37],[38]	2026-09				2026-09
Investment, interest rate, paid in cash	[27],[37],[38]	11.95%				11.95%
Principal amount	[37],[38]	$ 10,000
Investment cost	[2],[37],[38]	9,859
Investments, at fair value:	[37],[38]	$ 9,859
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Hercules Adviser LLC, Unsecured, Maturity Date June 2025, FIXED 5.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[37],[39]	2025-06				2025-06
Investment, interest rate, paid in cash	[27],[37],[39]	5%				5%
Principal amount	[37],[39]	$ 12,000
Investment cost	[2],[37],[39]	12,000
Investments, at fair value:	[37],[39]	$ 12,000
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Next Insurance, Inc, Senior Secured, Maturity Date February 2028, Prime -(1.50%), Floor rate 4.75%, PIK Interest 5.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[28],[29]	2028-02				2028-02
Investment, basis spread, variable rate	[25],[27],[28],[29]	(1.50%)				(1.50%)
Investment, interest rate, floor	[25],[27],[28],[29]	4.75%				4.75%
Investment, interest rate, paid in kind	[25],[27],[28],[29]	5.50%				5.50%
Principal amount	[25],[28],[29]	$ 10,918
Investment cost	[2],[25],[28],[29]	10,757
Investments, at fair value:	[25],[28],[29]	11,149
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Total Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)
Summary of Investment Holdings [Line Items]
Principal amount		36,033
Investment cost	[2]	35,633
Investments, at fair value:		$ 35,633
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development (57.90%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	57.90%				57.90%
Investment cost	[2]	$ 1,051,331
Investments, at fair value:		$ 1,072,243
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and ATAI Life Sciences N.V. Senior Secured, Maturity Date August 2026, Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31],[33]	2026-08				2026-08
Investment, basis spread, variable rate	[27],[30],[31],[33]	4.30%				4.30%
Investment, interest rate, floor	[27],[30],[31],[33]	9.05%				9.05%
Investment exit fee	[27],[30],[31],[33]	6.95%				6.95%
Principal amount	[30],[31],[33]	$ 14,000
Investment cost	[2],[30],[31],[33]	14,347
Investments, at fair value:	[30],[31],[33]	$ 14,253
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Adaptimmune Therapeutics plc. Senior Secured, Maturity Date June 2029, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31]	2029-06				2029-06
Investment, basis spread, variable rate	[27],[29],[30],[31]	1.15%				1.15%
Investment, interest rate, floor	[27],[29],[30],[31]	9.65%				9.65%
Investment, interest rate, paid in kind	[27],[29],[30],[31]	2%				2%
Investment exit fee	[27],[29],[30],[31]	5.85%				5.85%
Principal amount	[29],[30],[31]	$ 30,108
Investment cost	[2],[29],[30],[31]	29,878
Investments, at fair value:	[29],[30],[31]	$ 29,878
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Akero Therapeutics, Inc. Senior Secured, Maturity Date March 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[30],[33]	2027-03				2027-03
Investment, basis spread, variable rate	[25],[27],[30],[33]	3.65%				3.65%
Investment, interest rate, floor	[25],[27],[30],[33]	7.65%				7.65%
Investment exit fee	[25],[27],[30],[33]	5.85%				5.85%
Principal amount	[25],[30],[33]	$ 17,500
Investment cost	[2],[25],[30],[33]	17,603
Investments, at fair value:	[25],[30],[33]	$ 17,897
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc. Senior Secured, Maturity Date April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[36]	2026-04				2026-04
Investment, basis spread, variable rate	[27],[36]	3.10%				3.10%
Investment, interest rate, floor	[27],[36]	11.10%				11.10%
Investment exit fee	[27],[36]	8.90%				8.90%
Principal amount	[36]	$ 15,000
Investment cost	[2],[36]	15,292
Investments, at fair value:	[36]	$ 15,293
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, Maturity Date January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2027-01				2027-01
Investment, basis spread, variable rate	[1],[27]	2.50%				2.50%
Investment, interest rate, floor	[1],[27]	9.50%				9.50%
Investment, interest rate, cap	[1],[27]	10.75%				10.75%
Investment exit fee	[1],[27]	5.85%				5.85%
Principal amount	[1]	$ 24,000
Investment cost	[1],[2]	24,502
Investments, at fair value:	[1]	$ 24,891
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Arcus Biosciences, Inc., Senior Secured Maturity Date September 2029, Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[30],[33],[40]	2029-09				2029-09
Investment, basis spread, variable rate	[1],[27],[30],[33],[40]	1.95%				1.95%
Investment, interest rate, floor	[1],[27],[30],[33],[40]	10.45%				10.45%
Investment exit fee	[1],[27],[30],[33],[40]	7.75%				7.75%
Principal amount	[1],[30],[33],[40]	$ 37,500
Investment cost	[1],[2],[30],[33],[40]	37,248
Investments, at fair value:	[1],[30],[33],[40]	$ 37,248
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc. Senior Secured, Maturity Date January 2028 Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[30],[35],[36]	2028-01				2028-01
Investment, basis spread, variable rate	[26],[27],[30],[35],[36]	2.20%				2.20%
Investment, interest rate, floor	[26],[27],[30],[35],[36]	9.95%				9.95%
Investment, interest rate, cap	[26],[27],[30],[35],[36]	10.70%				10.70%
Investment exit fee	[26],[27],[30],[35],[36]	5.78%				5.78%
Principal amount	[26],[30],[35],[36]	$ 143,350
Investment cost	[2],[26],[30],[35],[36]	144,974
Investments, at fair value:	[26],[30],[35],[36]	$ 152,241
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Braeburn, Inc., Senior Secured, Maturity Date October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[33]	2028-10				2028-10
Investment, basis spread, variable rate	[27],[29],[33]	2.45%				2.45%
Investment, interest rate, floor	[27],[29],[33]	10.95%				10.95%
Investment, interest rate, paid in kind	[27],[29],[33]	1.10%				1.10%
Investment exit fee	[27],[29],[33]	5.45%				5.45%
Principal amount	[29],[33]	$ 53,045
Investment cost	[2],[29],[33]	53,079
Investments, at fair value:	[29],[33]	$ 54,450
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and COMPASS Pathways plc Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31]	2027-07				2027-07
Investment, basis spread, variable rate	[27],[29],[30],[31]	1.50%				1.50%
Investment, interest rate, floor	[27],[29],[30],[31]	9.75%				9.75%
Investment, interest rate, paid in kind	[27],[29],[30],[31]	1.40%				1.40%
Investment exit fee	[27],[29],[30],[31]	4.75%				4.75%
Principal amount	[29],[30],[31]	$ 24,404
Investment cost	[2],[29],[30],[31]	24,401
Investments, at fair value:	[29],[30],[31]	$ 25,280
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Corium, Inc. Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[35]	2026-09				2026-09
Investment, basis spread, variable rate	[25],[27],[35]	5.70%				5.70%
Investment, interest rate, floor	[25],[27],[35]	8.95%				8.95%
Investment exit fee	[25],[27],[35]	7.75%				7.75%
Principal amount	[25],[35]	$ 105,225
Investment cost	[2],[25],[35]	109,041
Investments, at fair value:	[25],[35]	$ 110,394
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Curevo, Inc. Senior Secured, Maturity Date June 2027, Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2027-06				2027-06
Investment, basis spread, variable rate	[1],[27]	1.70%				1.70%
Investment, interest rate, floor	[1],[27]	9.70%				9.70%
Investment exit fee	[1],[27]	6.95%				6.95%
Principal amount	[1]	$ 10,000
Investment cost	[1],[2]	10,039
Investments, at fair value:	[1]	$ 9,639
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Eloxx Pharmaceuticals, Inc. Senior Secured, Maturity Date April 2025, Prime + 6.25%, Floor rate 9.50%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2025-04				2025-04
Investment, basis spread, variable rate	[1],[27]	6.25%				6.25%
Investment, interest rate, floor	[1],[27]	9.50%				9.50%
Investment exit fee	[1],[27]	4%				4%
Principal amount	[1]	$ 489
Investment cost	[1],[2]	988
Investments, at fair value:	[1]	$ 988
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Geron Corporation, Senior Secured, Maturity Date October 2025, Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[26],[30],[33]	2025-10				2025-10
Investment, basis spread, variable rate	[25],[26],[27],[30],[33]	4.50%				4.50%
Investment, interest rate, floor	[25],[26],[27],[30],[33]	9%				9%
Investment exit fee	[25],[26],[27],[30],[33]	6.55%				6.55%
Principal amount	[25],[26],[30],[33]	$ 30,200
Investment cost	[2],[25],[26],[30],[33]	31,690
Investments, at fair value:	[25],[26],[30],[33]	$ 32,353
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Gritstone Bio, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[29]	2027-07				2027-07
Investment, basis spread, variable rate	[25],[27],[29]	3.15%				3.15%
Investment, interest rate, floor	[25],[27],[29]	7.15%				7.15%
Investment, interest rate, cap	[25],[27],[29]	8.65%				8.65%
Investment, interest rate, paid in kind	[25],[27],[29]	2%				2%
Investment exit fee	[25],[27],[29]	5.75%				5.75%
Principal amount	[25],[29]	$ 30,995
Investment cost	[2],[25],[29]	31,523
Investments, at fair value:	[25],[29]	$ 30,472
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Heron Therapeutics, Inc.. Senior Secured, Maturity Date February 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[29],[33]	2026-02				2026-02
Investment, basis spread, variable rate	[1],[27],[29],[33]	1.70%				1.70%
Investment, interest rate, floor	[1],[27],[29],[33]	9.95%				9.95%
Investment, interest rate, paid in kind	[1],[27],[29],[33]	1.50%				1.50%
Investment exit fee	[1],[27],[29],[33]	3%				3%
Principal amount	[1],[29],[33]	$ 20,327
Investment cost	[1],[2],[29],[33]	20,303
Investments, at fair value:	[1],[29],[33]	$ 20,761
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Hibercell, Inc. Senior Secured, Maturity Date May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[25]	2025-05				2025-05
Investment, basis spread, variable rate	[1],[25],[27]	5.40%				5.40%
Investment, interest rate, floor	[1],[25],[27]	8.65%				8.65%
Investment exit fee	[1],[25],[27]	4.95%				4.95%
Principal amount	[1],[25]	$ 6,233
Investment cost	[1],[2],[25]	6,980
Investments, at fair value:	[1],[25]	$ 6,980
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Kura Oncology, Inc. Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[30]	2027-11				2027-11
Investment, basis spread, variable rate	[1],[27],[30]	2.40%				2.40%
Investment, interest rate, floor	[1],[27],[30]	8.65%				8.65%
Investment exit fee	[1],[27],[30]	15.13%				15.13%
Principal amount	[1],[30]	$ 5,500
Investment cost	[1],[2],[30]	5,599
Investments, at fair value:	[1],[30]	$ 5,694
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Locus Biosciences, Inc. Senior Secured, Maturity Date July 2025, Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2025-07				2025-07
Investment, basis spread, variable rate	[1],[27]	6.10%				6.10%
Investment, interest rate, floor	[1],[27]	9.35%				9.35%
Investment exit fee	[1],[27]	4.95%				4.95%
Principal amount	[1]	$ 3,009
Investment cost	[1],[2]	3,343
Investments, at fair value:	[1]	$ 3,343
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc. Senior Secured, Maturity Date May 2027, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[30]	2027-05				2027-05
Investment, basis spread, variable rate	[25],[27],[30]	2.45%				2.45%
Investment, interest rate, floor	[25],[27],[30]	8.25%				8.25%
Investment exit fee	[25],[27],[30]	5.35%				5.35%
Principal amount	[25],[30]	$ 78,200
Investment cost	[2],[25],[30]	79,622
Investments, at fair value:	[25],[30]	$ 82,775
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and NorthSea Therapeutics, Convertible Debt, Maturity Date December 2025, FIXED 6.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31],[32]	2025-12				2025-12
Investment, interest rate, paid in cash	[27],[30],[31],[32]	6%				6%
Principal amount	[30],[31],[32]	$ 273
Investment cost	[2],[30],[31],[32]	273
Investments, at fair value:	[30],[31],[32]	$ 273
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc. Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 6.59% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[26],[29],[30],[33],[35],[41]	2027-12				2027-12
Investment, basis spread, variable rate	[1],[26],[27],[29],[30],[33],[35],[41]	1.35%				1.35%
Investment, interest rate, floor	[1],[26],[27],[29],[30],[33],[35],[41]	9.85%				9.85%
Investment, interest rate, cap	[1],[26],[27],[29],[30],[33],[35],[41]	10.35%				10.35%
Investment, interest rate, paid in kind	[1],[26],[27],[29],[30],[33],[35],[41]	2.15%				2.15%
Investment exit fee	[1],[26],[27],[29],[30],[33],[35],[41]	6.59%				6.59%
Principal amount	[1],[26],[29],[30],[33],[35],[41]	$ 153,201
Investment cost	[1],[2],[26],[29],[30],[33],[35],[41]	155,420
Investments, at fair value:	[1],[26],[29],[30],[33],[35],[41]	$ 158,117
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Replimune Group, Inc. Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[26],[29],[30]	2027-10				2027-10
Investment, basis spread, variable rate	[25],[26],[27],[29],[30]	1.75%				1.75%
Investment, interest rate, floor	[25],[26],[27],[29],[30]	7.25%				7.25%
Investment, interest rate, cap	[25],[26],[27],[29],[30]	9%				9%
Investment, interest rate, paid in kind	[25],[26],[27],[29],[30]	1.50%				1.50%
Investment exit fee	[25],[26],[27],[29],[30]	4.95%				4.95%
Principal amount	[25],[26],[29],[30]	$ 31,769
Investment cost	[2],[25],[26],[29],[30]	32,076
Investments, at fair value:	[25],[26],[29],[30]	$ 33,784
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and SynOx Therapeutics Limited Senior Secured, Maturity Date May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31]	2027-05				2027-05
Investment, basis spread, variable rate	[27],[30],[31]	1.40%				1.40%
Investment, interest rate, floor	[27],[30],[31]	9.90%				9.90%
Investment exit fee	[27],[30],[31]	7.25%				7.25%
Principal amount	[30],[31]	$ 4,500
Investment cost	[2],[30],[31]	4,431
Investments, at fair value:	[30],[31]	$ 4,431
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc. Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[30],[33]	2026-10				2026-10
Investment, basis spread, variable rate	[25],[27],[30],[33]	4.20%				4.20%
Investment, interest rate, floor	[25],[27],[30],[33]	7.45%				7.45%
Investment, interest rate, cap	[25],[27],[30],[33]	8.95%				8.95%
Investment exit fee	[25],[27],[30],[33]	6%				6%
Principal amount	[25],[30],[33]	$ 8,000
Investment cost	[2],[25],[30],[33]	8,191
Investments, at fair value:	[25],[30],[33]	$ 8,350
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[26],[36]	2027-07				2027-07
Investment, basis spread, variable rate	[25],[26],[27],[36]	3.15%				3.15%
Investment, interest rate, floor	[25],[26],[27],[36]	10.15%				10.15%
Investment exit fee	[25],[26],[27],[36]	3.72%				3.72%
Principal amount	[25],[26],[36]	$ 75,000
Investment cost	[2],[25],[26],[36]	75,292
Investments, at fair value:	[25],[26],[36]	$ 75,304
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and bluebird bio, Inc. Senior Secured, Maturity Date April 2029, Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29]	2029-04				2029-04
Investment, basis spread, variable rate	[27],[29]	1.45%				1.45%
Investment, interest rate, floor	[27],[29]	9.95%				9.95%
Investment, interest rate, paid in kind	[27],[29]	2.45%				2.45%
Investment exit fee	[27],[29]	6.45%				6.45%
Principal amount	[29]	$ 65,250
Investment cost	[2],[29]	63,337
Investments, at fair value:	[29]	$ 63,682
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and enGene, Inc. Senior Secured, Maturity Date January 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31],[33]	2028-01				2028-01
Investment, basis spread, variable rate	[27],[29],[30],[31],[33]	0.75%				0.75%
Investment, interest rate, floor	[27],[29],[30],[31],[33]	9.25%				9.25%
Investment, interest rate, cap	[27],[29],[30],[31],[33]	9.75%				9.75%
Investment, interest rate, paid in kind	[27],[29],[30],[31],[33]	1.15%				1.15%
Investment exit fee	[27],[29],[30],[31],[33]	5.50%				5.50%
Principal amount	[29],[30],[31],[33]	$ 15,878
Investment cost	[2],[29],[30],[31],[33]	15,897
Investments, at fair value:	[29],[30],[31],[33]	$ 16,337
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and uniQure B.V. Senior Secured, Maturity Date January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[30],[31],[36]	2027-01				2027-01
Investment, basis spread, variable rate	[26],[27],[30],[31],[36]	4.70%				4.70%
Investment, interest rate, floor	[26],[27],[30],[31],[36]	7.95%				7.95%
Investment exit fee	[26],[27],[30],[31],[36]	6.10%				6.10%
Principal amount	[26],[30],[31],[36]	$ 35,000
Investment cost	[2],[26],[30],[31],[36]	35,962
Investments, at fair value:	[26],[30],[31],[36]	$ 37,135
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware (5.13%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	5.13%				5.13%
Investment cost	[2]	$ 93,698
Investments, at fair value:		$ 94,978
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware and Locus Robotics Corp. Senior Secured, Maturity Date June 2026, Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[28]	2026-06				2026-06
Investment, basis spread, variable rate	[27],[28]	4.50%				4.50%
Investment, interest rate, floor	[27],[28]	8%				8%
Investment exit fee	[27],[28]	4%				4%
Principal amount	[28]	$ 18,281
Investment cost	[2],[28]	18,498
Investments, at fair value:	[28]	$ 18,846
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware and Shield AI, Inc. Senior Secured, Maturity Date February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[33]	2029-02				2029-02
Investment, basis spread, variable rate	[26],[27],[29],[33]	0.85%				0.85%
Investment, interest rate, floor	[26],[27],[29],[33]	6.85%				6.85%
Investment, interest rate, cap	[26],[27],[29],[33]	9.60%				9.60%
Investment, interest rate, paid in kind	[26],[27],[29],[33]	2.50%				2.50%
Investment exit fee	[26],[27],[29],[33]	2.50%				2.50%
Principal amount	[26],[29],[33]	$ 75,790
Investment cost	[2],[26],[29],[33]	75,200
Investments, at fair value:	[26],[29],[33]	$ 76,132
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other (30.59%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	30.59%				30.59%
Investment cost	[2]	$ 566,787
Investments, at fair value:		$ 566,384
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc. Senior Secured, Maturity Date November 2026, 1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[26],[29],[36]	2026-11				2026-11
Investment, basis spread, variable rate	[25],[26],[27],[29],[36]	5.11%				5.11%
Investment, interest rate, floor	[25],[26],[27],[29],[36]	6%				6%
Investment, interest rate, paid in kind	[25],[26],[27],[29],[36]	4.45%				4.45%
Principal amount	[25],[26],[29],[36]	$ 71,414
Investment cost	[2],[25],[26],[29],[36]	70,813
Investments, at fair value:	[25],[26],[29],[36]	$ 70,397
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc. Convertible Debt, Maturity Date December 2025, FIXED 12.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[32]	2025-12				2025-12
Investment, interest rate, paid in cash	[27],[32]	12%				12%
Principal amount	[32]	$ 202
Investment cost	[2],[32]	202
Investments, at fair value:	[32]	$ 202
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc. Senior Secured, Maturity Date June 2026, Prime - (1.50%), Floor rate 7.00%, PIK Interest 7.00%, 5.64% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[29],[36]	2026-06				2026-06
Investment, basis spread, variable rate	[25],[27],[29],[36]	(1.50%)				(1.50%)
Investment, interest rate, floor	[25],[27],[29],[36]	7%				7%
Investment, interest rate, paid in kind	[25],[27],[29],[36]	7%				7%
Investment exit fee	[25],[27],[29],[36]	5.64%				5.64%
Principal amount	[25],[29],[36]	$ 49,524
Investment cost	[2],[25],[29],[36]	51,125
Investments, at fair value:	[25],[29],[36]	$ 49,393
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Curana Health Holdings, LLC Senior Secured, Maturity Date January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[28],[33]	2028-01				2028-01
Investment, basis spread, variable rate	[25],[27],[28],[33]	1.45%				1.45%
Investment, interest rate, floor	[25],[27],[28],[33]	9.20%				9.20%
Investment exit fee	[25],[27],[28],[33]	4.95%				4.95%
Principal amount	[25],[28],[33]	$ 27,500
Investment cost	[2],[25],[28],[33]	27,630
Investments, at fair value:	[25],[28],[33]	$ 28,053
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2026, Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[36]	2026-02				2026-02
Investment, basis spread, variable rate	[26],[27],[29],[36]	6.25%				6.25%
Investment, interest rate, floor	[26],[27],[29],[36]	9.50%				9.50%
Investment, interest rate, paid in kind	[26],[27],[29],[36]	1.55%				1.55%
Principal amount	[26],[29],[36]	$ 70,402
Investment cost	[2],[26],[29],[36]	70,084
Investments, at fair value:	[26],[29],[36]	$ 70,078
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Main Street Rural, Inc. Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[25],[33]	2027-07				2027-07
Investment, basis spread, variable rate	[1],[25],[27],[33]	1.95%				1.95%
Investment, interest rate, floor	[1],[25],[27],[33]	9.95%				9.95%
Investment exit fee	[1],[25],[27],[33]	6.85%				6.85%
Principal amount	[1],[25],[33]	$ 38,500
Investment cost	[1],[2],[25],[33]	38,859
Investments, at fair value:	[1],[25],[33]	$ 39,132
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Marathon Health, LLC Senior Secured, Maturity Date February 2029, Prime - (0.90%), Floor rate 7.10%, PIK Interest 4.00%, 3.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[33],[35]	2029-02				2029-02
Investment, basis spread, variable rate	[27],[29],[33],[35]	(0.90%)				(0.90%)
Investment, interest rate, floor	[27],[29],[33],[35]	7.10%				7.10%
Investment, interest rate, paid in kind	[27],[29],[33],[35]	4%				4%
Investment exit fee	[27],[29],[33],[35]	3%				3%
Principal amount	[29],[33],[35]	$ 157,577
Investment cost	[2],[29],[33],[35]	156,581
Investments, at fair value:	[29],[33],[35]	$ 157,857
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Modern Life, Inc. Senior Secured, Maturity Date February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25]	2027-02				2027-02
Investment, basis spread, variable rate	[25],[27]	2.75%				2.75%
Investment, interest rate, floor	[25],[27]	8.75%				8.75%
Investment exit fee	[25],[27]	5%				5%
Principal amount	[25]	$ 18,200
Investment cost	[2],[25]	18,208
Investments, at fair value:	[25]	$ 18,393
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and NeueHealth, Inc. Senior Secured, Maturity Date June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date		2028-06				2028-06
Investment, basis spread, variable rate	[27]	1.15%				1.15%
Investment, interest rate, floor	[27]	9.65%				9.65%
Investment, interest rate, paid in kind	[27]	2.50%				2.50%
Investment exit fee	[27]	2.50%				2.50%
Principal amount		$ 24,874
Investment cost	[2]	23,990
Investments, at fair value:		$ 24,141
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Recover Together, Inc. Senior Secured, Maturity Date July 2027 Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date		2027-07				2027-07
Investment, basis spread, variable rate	[27]	1.90%				1.90%
Investment, interest rate, floor	[27]	10.15%				10.15%
Investment exit fee	[27]	7.50%				7.50%
Principal amount		$ 40,000
Investment cost	[2]	40,257
Investments, at fair value:		$ 40,110
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Strive Health Holdings, LLC Senior Secured, Maturity Date September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1]	2027-09				2027-09
Investment, basis spread, variable rate	[1],[27]	0.70%				0.70%
Investment, interest rate, floor	[1],[27]	9.20%				9.20%
Investment exit fee	[1],[27]	5.95%				5.95%
Principal amount	[1]	$ 12,000
Investment cost	[1],[2]	12,015
Investments, at fair value:	[1]	12,359
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Total Carbon Health Technologies, Inc.
Summary of Investment Holdings [Line Items]
Principal amount		49,726
Investment cost	[2]	51,327
Investments, at fair value:		$ 49,595
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Vida Health, Inc. Senior Secured, Maturity Date July 2026, FIXED 8.50%, PIK Interest 2.05%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[36]	2026-07				2026-07
Investment, interest rate, paid in kind	[27],[29],[36]	2.05%				2.05%
Investment, interest rate, paid in cash	[27],[29],[36]	8.50%				8.50%
Investment exit fee	[27],[29],[36]	4.95%				4.95%
Principal amount	[29],[36]	$ 36,571
Investment cost	[2],[29],[36]	37,000
Investments, at fair value:	[29],[36]	$ 36,636
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and WellBe Senior Medical, LLC Senior Secured, Maturity Date May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[29],[33]	2029-05				2029-05
Investment, basis spread, variable rate	[1],[27],[29],[33]	0.75%				0.75%
Investment, interest rate, floor	[1],[27],[29],[33]	7.75%				7.75%
Investment, interest rate, paid in kind	[1],[27],[29],[33]	2.65%				2.65%
Investment exit fee	[1],[27],[29],[33]	6.75%				6.75%
Principal amount	[1],[29],[33]	$ 20,148
Investment cost	[1],[2],[29],[33]	20,023
Investments, at fair value:	[1],[29],[33]	$ 19,633
Investment, Identifier [Axis]: Debt Investments Information Services (4.18%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	4.18%				4.18%
Investment cost	[2]	$ 74,182
Investments, at fair value:		$ 77,344
Investment, Identifier [Axis]: Debt Investments Information Services and Checkr Group, Inc. Senior Secured, Maturity Date August 2028, Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[33]	2028-08				2028-08
Investment, basis spread, variable rate	[26],[27],[29],[33]	1.45%				1.45%
Investment, interest rate, floor	[26],[27],[29],[33]	8%				8%
Investment, interest rate, paid in kind	[26],[27],[29],[33]	2%				2%
Investment exit fee	[26],[27],[29],[33]	2.75%				2.75%
Principal amount	[26],[29],[33]	$ 48,354
Investment cost	[2],[26],[29],[33]	48,371
Investments, at fair value:	[26],[29],[33]	$ 50,620
Investment, Identifier [Axis]: Debt Investments Information Services and Saama Technologies, LLC Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[33]	2027-07				2027-07
Investment, basis spread, variable rate	[26],[27],[29],[33]	0.70%				0.70%
Investment, interest rate, floor	[26],[27],[29],[33]	8.95%				8.95%
Investment, interest rate, paid in kind	[26],[27],[29],[33]	2%				2%
Investment exit fee	[26],[27],[29],[33]	2.95%				2.95%
Principal amount	[26],[29],[33]	$ 19,679
Investment cost	[2],[26],[29],[33]	19,591
Investments, at fair value:	[26],[29],[33]	$ 20,300
Investment, Identifier [Axis]: Debt Investments Information Services and Signal Media Limited, Senior Secured, Maturity Date June 2025, Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31]	2025-06				2025-06
Investment, basis spread, variable rate	[27],[30],[31]	5.50%				5.50%
Investment, interest rate, floor	[27],[30],[31]	9%				9%
Investment, interest rate, cap	[27],[30],[31]	12%				12%
Investment exit fee	[27],[30],[31]	3.45%				3.45%
Principal amount	[30],[31]	$ 6,150
Investment cost	[2],[30],[31]	6,220
Investments, at fair value:	[30],[31]	$ 6,424
Investment, Identifier [Axis]: Debt Investments Medical Devices & Equipment (2.99%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	2.99%				2.99%
Investment cost	[2]	$ 54,923
Investments, at fair value:		$ 55,413
Investment, Identifier [Axis]: Debt Investments Medical Devices & Equipment and Senseonics Holdings, Inc. Senior Secured, Maturity Date September 2027 Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[36]	2027-09				2027-09
Investment, basis spread, variable rate	[27],[36]	1.40%				1.40%
Investment, interest rate, floor	[27],[36]	9.90%				9.90%
Investment exit fee	[27],[36]	6.95%				6.95%
Principal amount	[36]	$ 30,625
Investment cost	[2],[36]	30,650
Investments, at fair value:	[36]	$ 31,136
Investment, Identifier [Axis]: Debt Investments Medical Devices & Equipment and Sight Sciences, Inc. Senior Secured, Maturity Date July 2028 Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2028-07				2028-07
Investment, basis spread, variable rate	[27],[33]	2.35%				2.35%
Investment, interest rate, floor	[27],[33]	10.35%				10.35%
Investment exit fee	[27],[33]	5.95%				5.95%
Principal amount	[33]	$ 24,500
Investment cost	[2],[33]	24,273
Investments, at fair value:	[33]	$ 24,277
Investment, Identifier [Axis]: Debt Investments Software (53.06%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	53.06%				53.06%
Investment cost	[2]	$ 1,048,267
Investments, at fair value:		$ 982,622
Investment, Identifier [Axis]: Debt Investments Software and Reveleer, Senior Secured, Maturity Date February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[29]	2027-02				2027-02
Investment, basis spread, variable rate	[1],[27],[29]	0.65%				0.65%
Investment, interest rate, floor	[1],[27],[29]	9.15%				9.15%
Investment, interest rate, paid in kind	[1],[27],[29]	2%				2%
Investment exit fee	[1],[27],[29]	5.05%				5.05%
Principal amount	[1],[29]	$ 36,191
Investment cost	[1],[2],[29]	36,071
Investments, at fair value:	[1],[29]	$ 36,095
Investment, Identifier [Axis]: Debt Investments Software and 3GMTS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 7.25%, Floor rate 8.15%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2025-02				2025-02
Investment, basis spread, variable rate	[27],[33],[34]	7.25%				7.25%
Investment, interest rate, floor	[27],[33],[34]	8.15%				8.15%
Principal amount	[33],[34]	$ 6,209
Investment cost	[2],[33],[34]	6,184
Investments, at fair value:	[33],[34]	$ 6,184
Investment, Identifier [Axis]: Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 10.40%, Floor rate 11.30%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34],[36]	2025-02				2025-02
Investment, basis spread, variable rate	[27],[33],[34],[36]	10.40%				10.40%
Investment, interest rate, floor	[27],[33],[34],[36]	11.30%				11.30%
Principal amount	[33],[34],[36]	$ 13,042
Investment cost	[2],[33],[34],[36]	13,013
Investments, at fair value:	[33],[34],[36]	$ 13,013
Investment, Identifier [Axis]: Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[34]	2028-05				2028-05
Investment, basis spread, variable rate	[25],[27],[34]	8.14%				8.14%
Investment, interest rate, floor	[25],[27],[34]	9.14%				9.14%
Principal amount	[25],[34]	$ 21,302
Investment cost	[2],[25],[34]	20,955
Investments, at fair value:	[25],[34]	$ 21,302
Investment, Identifier [Axis]: Debt Investments Software and Allvue Systems, LLC, Senior Secured, Maturity Date September 2029, 3-month SOFR + 7.25%, Floor rate 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2029-09				2029-09
Investment, basis spread, variable rate	[27],[33]	7.25%				7.25%
Investment, interest rate, floor	[27],[33]	8.25%				8.25%
Principal amount	[33]	$ 36,410
Investment cost	[2],[33]	35,612
Investments, at fair value:	[33]	$ 36,651
Investment, Identifier [Axis]: Debt Investments Software and AlphaSense, Inc. Senior Secured, Maturity Date June 2029, 1-month SOFR + 6.25%, Floor rate 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2029-06				2029-06
Investment, basis spread, variable rate	[27],[33]	6.25%				6.25%
Investment, interest rate, floor	[27],[33]	8.25%				8.25%
Principal amount	[33]	$ 20,000
Investment cost	[2],[33]	19,808
Investments, at fair value:	[33]	$ 19,808
Investment, Identifier [Axis]: Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 1-month BSBY + 10.00%, Floor rate 11.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[25]	2027-02				2027-02
Investment, basis spread, variable rate	[25],[27]	10%				10%
Investment, interest rate, floor	[25],[27]	11%				11%
Principal amount	[25]	$ 11,408
Investment cost	[2],[25]	11,260
Investments, at fair value:	[25]	$ 11,016
Investment, Identifier [Axis]: Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[33]	2028-03				2028-03
Investment, basis spread, variable rate	[26],[27],[29],[33]	0%				0%
Investment, interest rate, floor	[26],[27],[29],[33]	7.50%				7.50%
Investment, interest rate, paid in kind	[26],[27],[29],[33]	2%				2%
Investment exit fee	[26],[27],[29],[33]	2.25%				2.25%
Principal amount	[26],[29],[33]	$ 50,477
Investment cost	[2],[26],[29],[33]	50,154
Investments, at fair value:	[26],[29],[33]	$ 50,974
Investment, Identifier [Axis]: Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[33]	2028-03				2028-03
Investment, basis spread, variable rate	[27],[29],[33]	1.25%				1.25%
Investment, interest rate, floor	[27],[29],[33]	7.50%				7.50%
Investment, interest rate, paid in kind	[27],[29],[33]	2%				2%
Investment exit fee	[27],[29],[33]	2.25%				2.25%
Principal amount	[29],[33]	$ 25,031
Investment cost	[2],[29],[33]	24,802
Investments, at fair value:	[29],[33]	$ 24,880
Investment, Identifier [Axis]: Debt Investments Software and Automation Anywhere, Inc. Senior Secured, Maturity Date September 2027, Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[36]	2027-09				2027-09
Investment, basis spread, variable rate	[27],[28],[36]	4.25%				4.25%
Investment, interest rate, floor	[27],[28],[36]	9%				9%
Investment exit fee	[27],[28],[36]	4.50%				4.50%
Principal amount	[28],[36]	$ 19,600
Investment cost	[2],[28],[36]	19,587
Investments, at fair value:	[28],[36]	$ 20,354
Investment, Identifier [Axis]: Debt Investments Software and Babel Street, Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.01%, Floor rate 9.01%
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[33],[34]	2027-12				2027-12
Investment, basis spread, variable rate	[1],[27],[33],[34]	8.01%				8.01%
Investment, interest rate, floor	[1],[27],[33],[34]	9.01%				9.01%
Principal amount	[1],[33],[34]	$ 65,500
Investment cost	[1],[2],[33],[34]	64,138
Investments, at fair value:	[1],[33],[34]	$ 64,956
Investment, Identifier [Axis]: Debt Investments Software and Behavox Limited, Senior Secured, Maturity Date September 2027, Prime - (0.55%), Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31],[33]	2027-09				2027-09
Investment, basis spread, variable rate	[27],[30],[31],[33]	(0.55%)				(0.55%)
Investment, interest rate, floor	[27],[30],[31],[33]	7.45%				7.45%
Investment, interest rate, paid in kind	[27],[30],[31],[33]	3%				3%
Investment exit fee	[27],[30],[31],[33]	4.95%				4.95%
Principal amount	[30],[31],[33]	$ 7,000
Investment cost	[2],[30],[31],[33]	6,972
Investments, at fair value:	[30],[31],[33]	$ 6,972
Investment, Identifier [Axis]: Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25]	2028-09				2028-09
Investment, basis spread, variable rate	[25],[27]	1.35%				1.35%
Investment, interest rate, floor	[25],[27]	9.85%				9.85%
Investment, interest rate, paid in kind	[25],[27]	2.50%				2.50%
Investment exit fee	[25],[27]	3.95%				3.95%
Principal amount	[25]	$ 31,849
Investment cost	[2],[25]	31,468
Investments, at fair value:	[25]	$ 31,614
Investment, Identifier [Axis]: Debt Investments Software and Catchpoint Systems, Inc., Senior Secured, Maturity Date November 2025, 1-month SOFR + 9.41%, Floor rate 11.81%
Summary of Investment Holdings [Line Items]
Maturity Date	[34]	2025-11				2025-11
Investment, basis spread, variable rate	[27],[34]	9.41%				9.41%
Investment, interest rate, floor	[27],[34]	11.81%				11.81%
Principal amount	[34]	$ 9,996
Investment cost	[2],[34]	9,905
Investments, at fair value:	[34]	$ 9,985
Investment, Identifier [Axis]: Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 3-month SOFR+ 8.99%, Floor rate 9.89%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2026-09				2026-09
Investment, basis spread, variable rate	[27],[33],[34]	8.99%				8.99%
Investment, interest rate, floor	[27],[33],[34]	9.89%				9.89%
Principal amount	[33],[34]	$ 22,762
Investment cost	[2],[33],[34]	22,483
Investments, at fair value:	[33],[34]	$ 22,261
Investment, Identifier [Axis]: Debt Investments Software and Constructor io Corporation, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[33],[34]	2027-07				2027-07
Investment, basis spread, variable rate	[25],[27],[33],[34]	8.44%				8.44%
Investment, interest rate, floor	[25],[27],[33],[34]	9.44%				9.44%
Principal amount	[25],[33],[34]	$ 4,688
Investment cost	[2],[25],[33],[34]	4,608
Investments, at fair value:	[25],[33],[34]	$ 4,687
Investment, Identifier [Axis]: Debt Investments Software and Convoy, Inc., Senior Secured, Maturity Date March 2026, Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[29],[42]	2026-03				2026-03
Investment, basis spread, variable rate	[27],[28],[29],[42]	3.20%				3.20%
Investment, interest rate, floor	[27],[28],[29],[42]	6.45%				6.45%
Investment, interest rate, paid in kind	[27],[28],[29],[42]	1.95%				1.95%
Investment exit fee	[27],[28],[29],[42]	4.55%				4.55%
Principal amount	[28],[29],[42]	$ 31,049
Investment cost	[2],[28],[29],[42]	30,916
Investments, at fair value:	[28],[29],[42]	$ 0
Investment, Identifier [Axis]: Debt Investments Software and Copper CRM, Inc, Senior Secured, Maturity Date March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[36]	2025-03				2025-03
Investment, basis spread, variable rate	[27],[29],[36]	4.50%				4.50%
Investment, interest rate, floor	[27],[29],[36]	8.25%				8.25%
Investment, interest rate, cap	[27],[29],[36]	10.25%				10.25%
Investment, interest rate, paid in kind	[27],[29],[36]	1.95%				1.95%
Investment exit fee	[27],[29],[36]	4.50%				4.50%
Principal amount	[29],[36]	$ 8,669
Investment cost	[2],[29],[36]	8,954
Investments, at fair value:	[29],[36]	$ 8,954
Investment, Identifier [Axis]: Debt Investments Software and Coronet Cyber Security Ltd., Senior Secured, Maturity Date October 2028, Prime - (2.95%), Floor rate 3.55%, PIK Interest 5.85%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2028-10				2028-10
Investment, basis spread, variable rate	[27],[33]	(2.95%)				(2.95%)
Investment, interest rate, floor	[27],[33]	3.55%				3.55%
Investment, interest rate, paid in kind	[27],[33]	5.85%				5.85%
Principal amount	[33]	$ 8,500
Investment cost	[2],[33]	8,348
Investments, at fair value:	[33]	$ 8,348
Investment, Identifier [Axis]: Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee1
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[30],[31]	2025-10				2025-10
Investment, basis spread, variable rate	[26],[27],[30],[31]	5.20%				5.20%
Investment, interest rate, floor	[26],[27],[30],[31]	9.95%				9.95%
Investment exit fee	[26],[27],[30],[31]	4.95%				4.95%
Principal amount	[26],[30],[31]	$ 5,500
Investment cost	[2],[26],[30],[31]	5,634
Investments, at fair value:	[26],[30],[31]	$ 5,757
Investment, Identifier [Axis]: Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee2
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31]	2025-10				2025-10
Investment, basis spread, variable rate	[27],[30],[31]	5.20%				5.20%
Investment, interest rate, floor	[27],[30],[31]	9.95%				9.95%
Investment exit fee	[27],[30],[31]	4.95%				4.95%
Principal amount | £	[30],[31]					£ 1,250
Investment cost	[2],[30],[31]	$ 1,597
Investments, at fair value:	[30],[31]	$ 1,774
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 12.36%, Floor rate 13.11%, 0.58% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[33],[34]	2026-08				2026-08
Investment, basis spread, variable rate	[25],[27],[33],[34]	12.36%				12.36%
Investment, interest rate, floor	[25],[27],[33],[34]	13.11%				13.11%
Investment exit fee	[25],[27],[33],[34]	0.58%				0.58%
Principal amount	[25],[33],[34]	$ 2,527
Investment cost	[2],[25],[33],[34]	2,489
Investments, at fair value:	[25],[33],[34]	$ 2,581
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 8.63%, Floor rate 9.38%, 0.58% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[33],[34]	2026-08				2026-08
Investment, basis spread, variable rate	[25],[27],[33],[34]	8.63%				8.63%
Investment, interest rate, floor	[25],[27],[33],[34]	9.38%				9.38%
Investment exit fee	[25],[27],[33],[34]	0.58%				0.58%
Principal amount	[25],[33],[34]	$ 8,207
Investment cost	[2],[25],[33],[34]	8,120
Investments, at fair value:	[25],[33],[34]	$ 8,071
Investment, Identifier [Axis]: Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[28],[29],[36]	2027-12				2027-12
Investment, basis spread, variable rate	[25],[27],[28],[29],[36]	3.05%				3.05%
Investment, interest rate, floor	[25],[27],[28],[29],[36]	11.55%				11.55%
Investment, interest rate, paid in kind	[25],[27],[28],[29],[36]	1.10%				1.10%
Investment exit fee	[25],[27],[28],[29],[36]	6.28%				6.28%
Principal amount	[25],[28],[29],[36]	$ 45,350
Investment cost	[2],[25],[28],[29],[36]	46,088
Investments, at fair value:	[25],[28],[29],[36]	$ 47,370
Investment, Identifier [Axis]: Debt Investments Software and Dispatch Technologies, Inc., Senior Secured, Maturity Date April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2028-04				2028-04
Investment, basis spread, variable rate	[27],[33],[34]	8.01%				8.01%
Investment, interest rate, floor	[27],[33],[34]	8.76%				8.76%
Principal amount	[33],[34]	$ 8,792
Investment cost	[2],[33],[34]	8,643
Investments, at fair value:	[33],[34]	$ 8,533
Investment, Identifier [Axis]: Debt Investments Software and Dragos, Inc., Senior Secured, Maturity Date July 2027, Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 1.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2027-07				2027-07
Investment, basis spread, variable rate	[27],[33]	2%				2%
Investment, interest rate, floor	[27],[33]	8.75%				8.75%
Investment, interest rate, paid in kind	[27],[33]	2%				2%
Investment exit fee	[27],[33]	1%				1%
Principal amount	[33]	$ 6,500
Investment cost	[2],[33]	6,162
Investments, at fair value:	[33]	$ 6,163
Investment, Identifier [Axis]: Debt Investments Software and DroneDeploy, Inc., Senior Secured, Maturity Date July 2026, Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[33]	2026-07				2026-07
Investment, basis spread, variable rate	[25],[27],[33]	4.50%				4.50%
Investment, interest rate, floor	[25],[27],[33]	8.75%				8.75%
Investment exit fee	[25],[27],[33]	4%				4%
Principal amount	[25],[33]	$ 9,375
Investment cost	[2],[25],[33]	9,271
Investments, at fair value:	[25],[33]	$ 9,457
Investment, Identifier [Axis]: Debt Investments Software and Earnix, Inc., Senior Secured, Maturity Date June 2029, Prime - (1.15%), Floor rate 5.35%, PIK Interest 4.45%
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[33]	2029-06				2029-06
Investment, basis spread, variable rate	[27],[29],[33]	(1.15%)				(1.15%)
Investment, interest rate, floor	[27],[29],[33]	5.35%				5.35%
Investment, interest rate, paid in kind	[27],[29],[33]	4.45%				4.45%
Principal amount	[29],[33]	$ 18,952
Investment cost	[2],[29],[33]	18,631
Investments, at fair value:	[29],[33]	$ 18,631
Investment, Identifier [Axis]: Debt Investments Software and Elation Health, Inc., Senior Secured, Maturity Date March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[29],[33]	2026-03				2026-03
Investment, basis spread, variable rate	[27],[28],[29],[33]	4.25%				4.25%
Investment, interest rate, floor	[27],[28],[29],[33]	9%				9%
Investment, interest rate, paid in kind	[27],[28],[29],[33]	1.95%				1.95%
Investment exit fee	[27],[28],[29],[33]	3.95%				3.95%
Principal amount	[28],[29],[33]	$ 12,815
Investment cost	[2],[28],[29],[33]	12,699
Investments, at fair value:	[28],[29],[33]	$ 13,074
Investment, Identifier [Axis]: Debt Investments Software and Flight Schedule Pro, LLC, Senior Secured, Maturity Date October 2027, 1-month SOFR + 7.80%, Floor rate 8.70%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2027-10				2027-10
Investment, basis spread, variable rate	[27],[33],[34]	7.80%				7.80%
Investment, interest rate, floor	[27],[33],[34]	8.70%				8.70%
Principal amount	[33],[34]	$ 6,907
Investment cost	[2],[33],[34]	6,758
Investments, at fair value:	[33],[34]	$ 6,955
Investment, Identifier [Axis]: Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34],[36]	2027-12				2027-12
Investment, basis spread, variable rate	[27],[33],[34],[36]	7.64%				7.64%
Investment, interest rate, floor	[27],[33],[34],[36]	8.54%				8.54%
Principal amount	[33],[34],[36]	$ 7,000
Investment cost	[2],[33],[34],[36]	6,873
Investments, at fair value:	[33],[34],[36]	$ 7,037
Investment, Identifier [Axis]: Debt Investments Software and Harness, Inc., Senior Secured, Maturity Date March 2029, Prime - (2.25%), Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[29],[33]	2029-03				2029-03
Investment, basis spread, variable rate	[27],[28],[29],[33]	(2.25%)				(2.25%)
Investment, interest rate, floor	[27],[28],[29],[33]	5.25%				5.25%
Investment, interest rate, cap	[27],[28],[29],[33]	6.50%				6.50%
Investment, interest rate, paid in kind	[27],[28],[29],[33]	6.25%				6.25%
Investment exit fee	[27],[28],[29],[33]	1%				1%
Principal amount	[28],[29],[33]	$ 17,849
Investment cost	[2],[28],[29],[33]	17,650
Investments, at fair value:	[28],[29],[33]	$ 17,887
Investment, Identifier [Axis]: Debt Investments Software and Ikon Science Limited, Senior Secured, Maturity Date October 2024, 3-month SOFR + 9.26%, Floor rate 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[30],[31],[33],[34]	2024-10				2024-10
Investment, basis spread, variable rate	[27],[30],[31],[33],[34]	9.26%				9.26%
Investment, interest rate, floor	[27],[30],[31],[33],[34]	10%				10%
Principal amount	[30],[31],[33],[34]	$ 5,950
Investment cost	[2],[30],[31],[33],[34]	5,947
Investments, at fair value:	[30],[31],[33],[34]	$ 5,947
Investment, Identifier [Axis]: Debt Investments Software and Khoros (p.k.a Lithium Technologies), Senior Secured, Maturity Date January 2025, PIK 3-month SOFR + 4.50%, Floor rate 5.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[42]	2025-01				2025-01
Investment, basis spread, variable rate	[27],[29],[42]	4.50%				4.50%
Investment, interest rate, floor	[27],[29],[42]	5.50%				5.50%
Principal amount	[29],[42]	$ 61,341
Investment cost	[2],[29],[42]	61,317
Investments, at fair value:	[29],[42]	$ 20,723
Investment, Identifier [Axis]: Debt Investments Software and Leapwork ApS., Senior Secured, Maturity Date February 2026, Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[30],[31],[33]	2026-02				2026-02
Investment, basis spread, variable rate	[26],[27],[29],[30],[31],[33]	0.25%				0.25%
Investment, interest rate, floor	[26],[27],[29],[30],[31],[33]	7%				7%
Investment, interest rate, paid in kind	[26],[27],[29],[30],[31],[33]	1.95%				1.95%
Investment exit fee	[26],[27],[29],[30],[31],[33]	2.70%				2.70%
Principal amount	[26],[29],[30],[31],[33]	$ 3,871
Investment cost	[2],[26],[29],[30],[31],[33]	3,901
Investments, at fair value:	[26],[29],[30],[31],[33]	$ 3,999
Investment, Identifier [Axis]: Debt Investments Software and LinenMaster, LLC., Senior Secured, Maturity Date August 2028 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29],[33]	2028-08				2028-08
Investment, basis spread, variable rate	[26],[27],[29],[33]	6.25%				6.25%
Investment, interest rate, floor	[26],[27],[29],[33]	7.25%				7.25%
Investment, interest rate, paid in kind	[26],[27],[29],[33]	2.15%				2.15%
Principal amount	[26],[29],[33]	$ 15,342
Investment cost	[2],[26],[29],[33]	15,090
Investments, at fair value:	[26],[29],[33]	$ 15,495
Investment, Identifier [Axis]: Debt Investments Software and Loftware, Inc., Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2028-03				2028-03
Investment, basis spread, variable rate	[27],[33],[34]	7.88%				7.88%
Investment, interest rate, floor	[27],[33],[34]	8.88%				8.88%
Principal amount	[33],[34]	$ 27,206
Investment cost	[2],[33],[34]	26,696
Investments, at fair value:	[33],[34]	$ 27,646
Investment, Identifier [Axis]: Debt Investments Software and LogRhythm, Inc., Senior Secured, Maturity Date July 2029, 3-month SOFR + 7.50%, Floor rate 8.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2029-07				2029-07
Investment, basis spread, variable rate	[27],[33]	7.50%				7.50%
Investment, interest rate, floor	[27],[33]	8.50%				8.50%
Principal amount	[33]	$ 25,000
Investment cost	[2],[33]	24,277
Investments, at fair value:	[33]	$ 24,277
Investment, Identifier [Axis]: Debt Investments Software and LogicSource, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.93%, Floor rate 9.93%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2027-07				2027-07
Investment, basis spread, variable rate	[27],[33],[34]	8.93%				8.93%
Investment, interest rate, floor	[27],[33],[34]	9.93%				9.93%
Principal amount	[33],[34]	$ 13,178
Investment cost	[2],[33],[34]	12,993
Investments, at fair value:	[33],[34]	$ 13,178
Investment, Identifier [Axis]: Debt Investments Software and Marigold Group, Inc. (p.k.a. Campaign Monitor Limited), Senior Secured, Maturity Date November 2026, PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[28],[29]	2026-11				2026-11
Investment, basis spread, variable rate	[25],[28],[29]	10.55%				10.55%
Investment, interest rate, floor	[25],[27],[28],[29]	11.55%				11.55%
Principal amount	[25],[28],[29]	$ 37,413
Investment cost	[2],[25],[28],[29]	36,875
Investments, at fair value:	[25],[28],[29]	$ 31,863
Investment, Identifier [Axis]: Debt Investments Software and Mobile Solutions Services, Senior Secured, Maturity Date December 2025, 6-month SOFR + 9.31%, Floor rate 10.06%
Summary of Investment Holdings [Line Items]
Maturity Date	[34]	2025-12				2025-12
Investment, basis spread, variable rate	[27],[34]	9.31%				9.31%
Investment, interest rate, floor	[27],[34]	10.06%				10.06%
Principal amount	[34]	$ 18,366
Investment cost	[2],[34]	18,205
Investments, at fair value:	[34]	$ 17,609
Investment, Identifier [Axis]: Debt Investments Software and New Relic, Inc., Senior Secured, Maturity Date November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2030-11				2030-11
Investment, basis spread, variable rate	[27],[33]	6.75%				6.75%
Investment, interest rate, floor	[27],[33]	7.75%				7.75%
Principal amount	[33]	$ 20,890
Investment cost	[2],[33]	20,412
Investments, at fair value:	[33]	$ 20,291
Investment, Identifier [Axis]: Debt Investments Software and Omeda Holdings, LLC, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34],[36]	2027-07				2027-07
Investment, basis spread, variable rate	[27],[33],[34],[36]	8.05%				8.05%
Investment, interest rate, floor	[27],[33],[34],[36]	9.05%				9.05%
Principal amount	[33],[34],[36]	$ 7,688
Investment cost	[2],[33],[34],[36]	7,524
Investments, at fair value:	[33],[34],[36]	$ 7,687
Investment, Identifier [Axis]: Debt Investments Software and Pindrop Security, Inc., Senior Secured, Maturity Date June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[33]	2029-06				2029-06
Investment, basis spread, variable rate	[1],[27],[33]	3.50%				3.50%
Investment, interest rate, floor	[1],[27],[33]	10%				10%
Investment exit fee	[1],[27],[33]	2%				2%
Principal amount	[1],[33]	$ 31,000
Investment cost	[1],[2],[33]	30,521
Investments, at fair value:	[1],[33]	$ 30,521
Investment, Identifier [Axis]: Debt Investments Software and Semperis Technologies Inc., Senior Secured, Maturity Date April 2028, Prime - (1.75%), Floor rate 6.75%, PIK Interest 3.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[28],[29],[33]	2028-04				2028-04
Investment, basis spread, variable rate	[27],[28],[29],[33]	(1.75%)				(1.75%)
Investment, interest rate, floor	[27],[28],[29],[33]	6.75%				6.75%
Investment, interest rate, paid in kind	[27],[28],[29],[33]	3.25%				3.25%
Principal amount	[28],[29],[33]	$ 15,124
Investment cost	[2],[28],[29],[33]	15,016
Investments, at fair value:	[28],[29],[33]	$ 15,016
Investment, Identifier [Axis]: Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 8.92%, Floor rate 9.82%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2026-12				2026-12
Investment, basis spread, variable rate	[27],[33],[34]	8.92%				8.92%
Investment, interest rate, floor	[27],[33],[34]	9.82%				9.82%
Principal amount	[33],[34]	$ 6,000
Investment cost	[2],[33],[34]	5,909
Investments, at fair value:	[33],[34]	$ 5,977
Investment, Identifier [Axis]: Debt Investments Software and Simon Data, Inc., Senior Secured, Maturity Date March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[26],[29]	2027-03				2027-03
Investment, basis spread, variable rate	[26],[27],[29]	1%				1%
Investment, interest rate, floor	[26],[27],[29]	8.75%				8.75%
Investment, interest rate, paid in kind	[26],[27],[29]	1.95%				1.95%
Investment exit fee	[26],[27],[29]	2.95%				2.95%
Principal amount	[26],[29]	$ 13,022
Investment cost	[2],[26],[29]	13,051
Investments, at fair value:	[26],[29]	$ 13,125
Investment, Identifier [Axis]: Debt Investments Software and Sisense Ltd., Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31]	2027-07				2027-07
Investment, basis spread, variable rate	[27],[29],[30],[31]	1.50%				1.50%
Investment, interest rate, floor	[27],[29],[30],[31]	9.50%				9.50%
Investment, interest rate, paid in kind	[27],[29],[30],[31]	1.95%				1.95%
Investment exit fee	[27],[29],[30],[31]	5.95%				5.95%
Principal amount	[29],[30],[31]	$ 33,894
Investment cost	[2],[29],[30],[31]	34,126
Investments, at fair value:	[29],[30],[31]	$ 34,298
Investment, Identifier [Axis]: Debt Investments Software and Streamline Healthcare Solutions, Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[33],[34],[36]	2028-03				2028-03
Investment, basis spread, variable rate	[25],[27],[33],[34],[36]	7.25%				7.25%
Investment, interest rate, floor	[25],[27],[33],[34],[36]	8.25%				8.25%
Principal amount	[25],[33],[34],[36]	$ 17,600
Investment cost	[2],[25],[33],[34],[36]	17,306
Investments, at fair value:	[25],[33],[34],[36]	$ 17,763
Investment, Identifier [Axis]: Debt Investments Software and Sumo Logic, Inc., Senior Secured, Maturity Date May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%
Summary of Investment Holdings [Line Items]
Maturity Date	[33]	2030-05				2030-05
Investment, basis spread, variable rate	[27],[33]	6.50%				6.50%
Investment, interest rate, floor	[27],[33]	7.50%				7.50%
Principal amount	[33]	$ 23,000
Investment cost	[2],[33]	22,504
Investments, at fair value:	[33]	$ 23,212
Investment, Identifier [Axis]: Debt Investments Software and Suzy, Inc.., Senior Secured, Maturity Date August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[29],[33]	2027-08				2027-08
Investment, basis spread, variable rate	[1],[27],[29],[33]	1.75%				1.75%
Investment, interest rate, floor	[1],[27],[29],[33]	10%				10%
Investment, interest rate, paid in kind	[1],[27],[29],[33]	1.95%				1.95%
Investment exit fee	[1],[27],[29],[33]	3.45%				3.45%
Principal amount	[1],[29],[33]	$ 16,264
Investment cost	[1],[2],[29],[33]	16,071
Investments, at fair value:	[1],[29],[33]	$ 16,605
Investment, Identifier [Axis]: Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 3-month SOFR + 9.15%, Floor rate 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2026-05				2026-05
Investment, basis spread, variable rate	[27],[33],[34]	9.15%				9.15%
Investment, interest rate, floor	[27],[33],[34]	10%				10%
Principal amount	[33],[34]	$ 10,794
Investment cost	[2],[33],[34]	10,658
Investments, at fair value:	[33],[34]	$ 10,794
Investment, Identifier [Axis]: Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2027, Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[29],[30],[31]	2027-04				2027-04
Investment, basis spread, variable rate	[27],[29],[30],[31]	0.45%				0.45%
Investment, interest rate, floor	[27],[29],[30],[31]	7.95%				7.95%
Investment, interest rate, paid in kind	[27],[29],[30],[31]	2%				2%
Investment exit fee	[27],[29],[30],[31]	3.75%				3.75%
Principal amount	[29],[30],[31]	$ 42,455
Investment cost	[2],[29],[30],[31]	41,989
Investments, at fair value:	[29],[30],[31]	43,092
Investment, Identifier [Axis]: Debt Investments Software and Total 3GTMS, LLC
Summary of Investment Holdings [Line Items]
Principal amount		19,251
Investment cost	[2]	19,197
Investments, at fair value:		19,197
Investment, Identifier [Axis]: Debt Investments Software and Total Armis, Inc.
Summary of Investment Holdings [Line Items]
Principal amount		75,508
Investment cost	[2]	74,956
Investments, at fair value:		75,854
Investment, Identifier [Axis]: Debt Investments Software and Total Cutover, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[2]	7,231
Investments, at fair value:		7,531
Investment, Identifier [Axis]: Debt Investments Software and Total Cybermaxx Intermediate Holdings, Inc.
Summary of Investment Holdings [Line Items]
Principal amount		10,734
Investment cost	[2]	10,609
Investments, at fair value:		$ 10,652
Investment, Identifier [Axis]: Debt Investments Software and Zappi, Inc., Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[30],[31],[33],[34]	2027-12				2027-12
Investment, basis spread, variable rate	[25],[27],[30],[31],[33],[34]	8.03%				8.03%
Investment, interest rate, floor	[25],[27],[30],[31],[33],[34]	9.03%				9.03%
Principal amount	[25],[30],[31],[33],[34]	$ 12,761
Investment cost	[2],[25],[30],[31],[33],[34]	12,540
Investments, at fair value:	[25],[30],[31],[33],[34]	$ 12,786
Investment, Identifier [Axis]: Debt Investments Software and Zimperium, Inc., Senior Secured, Maturity Date May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%
Summary of Investment Holdings [Line Items]
Maturity Date	[33],[34]	2027-05				2027-05
Investment, basis spread, variable rate	[27],[33],[34]	8.31%				8.31%
Investment, interest rate, floor	[27],[33],[34]	9.31%				9.31%
Principal amount	[33],[34]	$ 14,790
Investment cost	[2],[33],[34]	14,602
Investments, at fair value:	[33],[34]	$ 14,459
Investment, Identifier [Axis]: Debt Investments Software and iGrafx, LLC, Senior Secured, Maturity Date May 2027, 1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[34]	2027-05				2027-05
Investment, basis spread, variable rate	[27],[34]	8.61%				8.61%
Investment, interest rate, floor	[27],[34]	9.51%				9.51%
Investment exit fee	[27]	0.47%				0.47%
Principal amount	[34]	$ 4,962
Investment cost	[2],[34]	4,884
Investments, at fair value:	[34]	$ 4,915
Investment, Identifier [Axis]: Debt Investments Space Technologies (2.42%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	2.42%				2.42%
Investment cost	[2]	$ 44,839
Investments, at fair value:		$ 44,839
Investment, Identifier [Axis]: Debt Investments Space Technologies and Voyager Space Holdings, Inc., Senior Secured, Maturity Date July 2028, Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[29]	2028-07				2028-07
Investment, basis spread, variable rate	[1],[27],[29]	1.25%				1.25%
Investment, interest rate, floor	[1],[27],[29]	9.75%				9.75%
Investment, interest rate, paid in kind	[1],[27],[29]	2.50%				2.50%
Investment exit fee	[1],[27],[29]	5.50%				5.50%
Principal amount	[1],[29]	$ 45,153
Investment cost	[1],[2],[29]	44,839
Investments, at fair value:	[1],[29]	$ 44,839
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology (1.35%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	1.35%				1.35%
Investment cost	[2]	$ 24,948
Investments, at fair value:		$ 25,020
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, Maturity Date May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[25],[29]	2025-05				2025-05
Investment, basis spread, variable rate	[25],[27],[29]	4.70%				4.70%
Investment, interest rate, floor	[25],[27],[29]	7.95%				7.95%
Investment, interest rate, paid in kind	[25],[27],[29]	1.45%				1.45%
Investment exit fee	[25],[27],[29]	3.95%				3.95%
Principal amount	[25],[29]	$ 3,970
Investment cost	[2],[25],[29]	4,063
Investments, at fair value:	[25],[29]	$ 4,063
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee
Summary of Investment Holdings [Line Items]
Maturity Date	[1],[28],[29]	2028-05				2028-05
Investment, basis spread, variable rate	[1],[27],[28],[29]	2.25%				2.25%
Investment, interest rate, floor	[1],[27],[28],[29]	10.75%				10.75%
Investment, interest rate, paid in kind	[1],[27],[28],[29]	1.25%				1.25%
Investment exit fee	[1],[27],[28],[29]	4.89%				4.89%
Principal amount	[1],[28],[29]	$ 20,069
Investment cost	[1],[2],[28],[29]	19,514
Investments, at fair value:	[1],[28],[29]	$ 19,610
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, Maturity Date June 2027, FIXED 10.00%
Summary of Investment Holdings [Line Items]
Maturity Date	[28]	2027-06				2027-06
Investment, interest rate, paid in cash	[27],[28]	10%				10%
Principal amount	[28]	$ 1,371
Investment cost	[2],[28]	1,371
Investments, at fair value:	[28]	$ 1,347
Investment, Identifier [Axis]: Equity Investments (7.72%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	7.72%				7.72%
Investment cost	[2]	$ 159,203
Investments, at fair value:		$ 143,035
Investment, Identifier [Axis]: Equity Investments (8.44%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			8.44%				8.44%
Investment cost	[5]			$ 155,226
Investments, at fair value:				$ 152,170
Investment, Identifier [Axis]: Equity Investments Biotechnology Tools (0.08%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.08%				0.08%
Investment cost	[2]	$ 1,500
Investments, at fair value:		1,492
Investment, Identifier [Axis]: Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[2]	1,500
Investments, at fair value:		$ 1,492
Investments owned acquisition date	[3]	Feb. 21, 2024
Shares (in shares) | shares		503,778				503,778
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products (0.04%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.04%				0.04%
Investment cost	[2]	$ 1,675
Investments, at fair value:		821
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products (0.13%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.13%				0.13%
Investment cost	[5]			$ 1,764
Investments, at fair value:				2,264
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost	[5]			1,101
Investments, at fair value:				$ 700
Investments owned acquisition date	[43]			Jul. 16, 2013
Shares (in shares) | shares				130,191				130,191
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		128	[2]	$ 128	[5]
Investments, at fair value:		$ 43		$ 96
Investments owned acquisition date		Apr. 30, 2010	[3]	Apr. 30, 2010	[43]
Shares (in shares) | shares		42,989		42,989		42,989		42,989
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 7/16/2013, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 1,101
Investments, at fair value:		$ 279
Investments owned acquisition date	[3]	Jul. 16, 2013
Shares (in shares) | shares		130,191				130,191
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 433
Investments, at fair value:	[3]	$ 17
Investments owned acquisition date	[3]	Apr. 30, 2021
Shares (in shares) | shares	[3]	12,260				12,260
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Equity, Acquisition Date 4/30/2021, Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 433
Investments, at fair value:	[43]			$ 21
Investments owned acquisition date	[43]			Apr. 30, 2021
Shares (in shares) | shares	[43]			12,260				12,260
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 13
Investments, at fair value:		$ 482
Investments owned acquisition date	[3]	Apr. 30, 2010
Shares (in shares) | shares		172,328				172,328
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Equity, Acquisition Date 4/30/2010, Class A Units
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 13
Investments, at fair value:				$ 863
Investments owned acquisition date	[43]			Apr. 30, 2010
Shares (in shares) | shares				172,328				172,328
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and TFG Holding, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 89
Investments, at fair value:				$ 584
Investments owned acquisition date	[43]			Apr. 30, 2010
Shares (in shares) | shares				173,180				173,180
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Total Fabletics, Inc.
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,229	[2]	$ 1,229	[5]
Investments, at fair value:		$ 322		$ 796
Shares (in shares) | shares		173,180		173,180		173,180		173,180
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services (0.39%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.39%				0.39%
Investment cost	[2]	$ 26,128
Investments, at fair value:		7,224
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services (0.70%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.70%				0.70%
Investment cost	[5]			$ 26,145
Investments, at fair value:				12,703
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-4
Summary of Investment Holdings [Line Items]
Investment cost		1,151	[2],[30],[31]	1,151	[5],[15],[16]
Investments, at fair value:		$ 647	[30],[31]	$ 679	[15],[16]
Investments owned acquisition date		Dec. 15, 2021	[3],[30],[31]	Dec. 15, 2021	[15],[16],[43]
Shares (in shares) | shares		214,869	[30],[31]	199,742	[15],[16]	214,869	[30],[31]	199,742	[15],[16]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and DoorDash, Inc., Equity, Acquisition Date 12/20/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 657
Investments, at fair value:	[43]			$ 5,636
Investments owned acquisition date	[43]			Dec. 20, 2018
Shares (in shares) | shares	[43]			56,996				56,996
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 5,263	[2],[3]	$ 5,263	[5],[43]
Investments, at fair value:		$ 1,284	[3]	$ 1,510	[43]
Investments owned acquisition date		Dec. 26, 2018	[3]	Dec. 26, 2018	[43]
Shares (in shares) | shares		100,738	[3]	100,738	[43]	100,738	[3]	100,738	[43]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2],[3]	$ 1,000	[5],[43]
Investments, at fair value:		$ 98	[3]	$ 343	[43]
Investments owned acquisition date		Sep. 17, 2021	[3]	Sep. 17, 2021	[43]
Shares (in shares) | shares		100,000	[3]	100,000	[43]	100,000	[3]	100,000	[43]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,663	[2]	$ 1,663	[5]
Investments, at fair value:		$ 439		$ 377
Investments owned acquisition date		Oct. 25, 2016	[3]	Oct. 25, 2016	[43]
Shares (in shares) | shares		286,080		286,080		286,080		286,080
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-1
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 632
Investments, at fair value:		$ 167
Investments owned acquisition date	[3]	Oct. 25, 2016
Shares (in shares) | shares		108,710				108,710
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 577	[2],[3]	$ 577	[5],[43]
Investments, at fair value:		$ 136	[3]	$ 189	[43]
Investments owned acquisition date		Jun. 28, 2013	[3]	Jun. 28, 2013	[43]
Shares (in shares) | shares		48,365	[3]	48,365	[43]	48,365	[3]	48,365	[43]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 40
Investments, at fair value:		$ 0
Investments owned acquisition date	[3]	Jul. 31, 2020
Shares (in shares) | shares		3,095				3,095
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2]	$ 1,000	[5]
Investments, at fair value:		$ 0		$ 559
Investments owned acquisition date		Jan. 24, 2022	[3]	Jan. 24, 2022	[43]
Shares (in shares) | shares		7,063		7,063		7,063		7,063
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 39
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			Jul. 31, 2020
Shares (in shares) | shares				3,095				3,095
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 13,263	[2],[37]	$ 13,263	[5],[19]
Investments, at fair value:		$ 3,772	[37]	$ 3,251	[19]
Investments owned acquisition date		Dec. 29, 2023	[3],[37]	Dec. 29, 2023	[19],[43]
Shares (in shares) | shares		3,235,298	[37]	3,235,298	[19]	3,235,298	[37]	3,235,298	[19]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 900	[2],[37]	$ 900	[5],[19]
Investments, at fair value:		$ 6	[37]	$ 4	[19]
Investments owned acquisition date		May 23, 2018	[3],[37]	May 23, 2018	[19],[43]
Shares (in shares) | shares		414,994,863	[37]	414,994,863	[19]	414,994,863	[37]	414,994,863	[19]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB
Summary of Investment Holdings [Line Items]
Investment cost		$ 0	[2],[37]	$ 0	[5],[19]
Investments, at fair value:		$ 15	[37]	$ 12	[19]
Investments owned acquisition date		Jun. 06, 2016	[3],[37]	Jun. 06, 2016	[19],[43]
Shares (in shares) | shares		1,000,000	[37]	1,000,000	[19]	1,000,000	[37]	1,000,000	[19]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Total OfferUp, Inc.
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,295	[2]	$ 2,295	[5]
Investments, at fair value:		$ 606		$ 520
Shares (in shares) | shares		394,790		394,790		394,790		394,790
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Total Tectura Corporation
Summary of Investment Holdings [Line Items]
Investment cost		$ 14,163	[2]	$ 14,163	[5]
Investments, at fair value:		$ 3,793		$ 3,267
Shares (in shares) | shares		419,230,161		419,230,161		419,230,161		419,230,161
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 639
Investments, at fair value:	[30],[31]	$ 660
Investments owned acquisition date	[3],[30],[31]	Jun. 24, 2024
Shares (in shares) | shares	[30],[31]	6,641				6,641
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services (2.89%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	2.89%				2.89%
Investment cost	[2]	$ 34,444
Investments, at fair value:		53,429
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services (3.17%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			3.17%				3.17%
Investment cost	[5]			$ 34,444
Investments, at fair value:				57,072
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units
Summary of Investment Holdings [Line Items]
Investment cost		34,006	[2],[37],[38]	34,006	[5],[19],[20]
Investments, at fair value:		$ 21,669	[37],[38]	$ 28,034	[19],[20]
Investments owned acquisition date		Mar. 01, 2018	[3],[37],[38]	Mar. 01, 2018	[19],[20],[43]
Shares (in shares) | shares		1	[37],[38]	1	[19],[20]	1	[37],[38]	1	[19],[20]
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units
Summary of Investment Holdings [Line Items]
Investment cost		$ 35	[2],[37],[39]	$ 35	[5],[19],[21]
Investments, at fair value:		$ 31,433	[37],[39]	$ 28,713	[19],[21]
Investments owned acquisition date		Mar. 26, 2021	[3],[37],[39]	Mar. 26, 2021	[19],[21],[43]
Shares (in shares) | shares		1	[37],[39]	1	[19],[21]	1	[37],[39]	1	[19],[21]
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-2
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 403
Investments, at fair value:		$ 327
Investments owned acquisition date	[3]	Sep. 30, 2021
Shares (in shares) | shares		210,282				210,282
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-2
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 403
Investments, at fair value:				$ 325
Investments owned acquisition date	[43]			Sep. 30, 2021
Shares (in shares) | shares				210,282				210,282
Investment, Identifier [Axis]: Equity Investments Drug Delivery (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets		0%	[24]	0%	[4]	0%	[24]	0%	[4]
Investment cost		$ 3,638	[2]	$ 3,638	[5]
Investments, at fair value:		19		21
Investment, Identifier [Axis]: Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		1,500	[2],[3]	1,500	[5],[43]
Investments, at fair value:		$ 2	[3]	$ 2	[43]
Investments owned acquisition date		Mar. 28, 2014	[3]	Mar. 28, 2014	[43]
Shares (in shares) | shares		680	[3]	680	[43]	680	[3]	680	[43]
Investment, Identifier [Axis]: Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 500	[2]	$ 500	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Dec. 08, 2015	[3]	Dec. 08, 2015	[43]
Shares (in shares) | shares		165,000		165,000		165,000		165,000
Investment, Identifier [Axis]: Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 309	[2],[3]	$ 309	[5],[43]
Investments, at fair value:		$ 9	[3]	$ 12	[43]
Investments owned acquisition date		Apr. 06, 2015	[3]	Apr. 06, 2015	[43]
Shares (in shares) | shares		2,498	[3]	2,498	[43]	2,498	[3]	2,498	[43]
Investment, Identifier [Axis]: Equity Investments Drug Delivery and Talphera, Inc, Equity, Acquisition Date 12/10/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 1,329
Investments, at fair value:	[3]	$ 8
Investments owned acquisition date	[3]	Dec. 10, 2018
Shares (in shares) | shares	[3]	8,836				8,836
Investment, Identifier [Axis]: Equity Investments Drug Delivery and Talphera, Inc. (p.k.a. AcelRx Pharmaceuticals, Inc.), Equity, Acquisition Date 12/10/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 1,329
Investments, at fair value:	[43]			$ 7
Investments owned acquisition date	[43]			Dec. 10, 2018
Shares (in shares) | shares	[43]			8,836				8,836
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development (2.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	2.03%				2.03%
Investment cost	[2]	$ 38,616
Investments, at fair value:		37,538
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development (2.47%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			2.47%				2.47%
Investment cost	[5]			$ 40,735
Investments, at fair value:				44,500
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[30]	1,000
Investments, at fair value:	[3],[30]	$ 989
Investments owned acquisition date	[3],[30]	Mar. 08, 2024
Shares (in shares) | shares	[3],[30]	34,483				34,483
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2],[3]	1,000	[5],[43]
Investments, at fair value:		$ 0	[3]	$ 0	[43]
Investments owned acquisition date		Aug. 19, 2014	[3]	Aug. 19, 2014	[43]
Shares (in shares) | shares		42	[3]	42	[43]	42	[3]	42	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[30],[35]	$ 4,165
Investments, at fair value:	[3],[30],[35]	$ 11,415
Investments owned acquisition date	[3],[30],[35]	May 09, 2022
Shares (in shares) | shares	[3],[30],[35]	127,021				127,021
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc.., Equity, Acquisition Date 5/9/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[16],[18],[43]			$ 4,165
Investments, at fair value:	[16],[18],[43]			$ 10,110
Investments owned acquisition date	[16],[18],[43]			May 09, 2022
Shares (in shares) | shares	[16],[18],[43]			127,021				127,021
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16],[43]			$ 1,871
Investments, at fair value:	[15],[16],[43]			$ 1,774
Investments owned acquisition date	[15],[16],[43]			Oct. 05, 2020
Shares (in shares) | shares	[15],[16],[43]			98,100				98,100
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[30],[31]	$ 1,871
Investments, at fair value:	[3],[30],[31]	$ 2,220
Investments owned acquisition date	[3],[30],[31]	Oct. 05, 2020
Shares (in shares) | shares	[3],[30],[31]	98,100				98,100
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,255	[2],[3]	$ 2,255	[5],[43]
Investments, at fair value:		$ 5,890	[3]	$ 9,339	[43]
Investments owned acquisition date		Jun. 21, 2018	[3]	Jun. 21, 2018	[43]
Shares (in shares) | shares		231,329	[3]	231,329	[43]	231,329	[3]	231,329	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc. (p.k.a. Applied Molecular Transport)., Equity, Acquisition Date 4/06/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[16],[43]			$ 42
Investments, at fair value:	[16],[43]			$ 0
Investments owned acquisition date	[16],[43]			Apr. 06, 2021
Shares (in shares) | shares	[16],[43]			134				134
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc., Equity, Acquisition Date 4/6/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[30]	$ 42
Investments, at fair value:	[3],[30]	$ 0
Investments owned acquisition date	[3],[30]	Apr. 06, 2021
Shares (in shares) | shares	[3],[30]	134				134
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 1,000
Investments, at fair value:	[3]	$ 4
Investments owned acquisition date	[3]	Jan. 08, 2015
Shares (in shares) | shares	[3]	1,129				1,129
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 1,000
Investments, at fair value:	[43]			$ 4
Investments owned acquisition date	[43]			Jan. 08, 2015
Shares (in shares) | shares	[43]			13,550				13,550
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 550	[2],[3],[30]	$ 550	[5],[16],[43]
Investments, at fair value:		$ 223	[3],[30]	$ 280	[16],[43]
Investments owned acquisition date		Jul. 22, 2015	[3],[30]	Jul. 22, 2015	[16],[43]
Shares (in shares) | shares		20,000	[3],[30]	20,000	[16],[43]	20,000	[3],[30]	20,000	[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2],[3]	$ 1,000	[5],[43]
Investments, at fair value:		$ 257	[3]	$ 903	[43]
Investments owned acquisition date		Oct. 26, 2022	[3]	Oct. 26, 2022	[43]
Shares (in shares) | shares		442,477	[3]	442,477	[43]	442,477	[3]	442,477	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 500	[2],[3]	$ 500	[5],[43]
Investments, at fair value:		$ 726	[3]	$ 620	[43]
Investments owned acquisition date		Jul. 25, 2023	[3]	Jul. 25, 2023	[43]
Shares (in shares) | shares		364,963	[3]	364,963	[43]	364,963	[3]	364,963	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 4,250	[1],[2]	$ 4,250	[5],[14]
Investments, at fair value:		$ 253	[1]	$ 1,834	[14]
Investments owned acquisition date		May 07, 2021	[1],[3]	May 07, 2021	[14],[43]
Shares (in shares) | shares		3,466,840	[1]	3,466,840	[14]	3,466,840	[1]	3,466,840	[14]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 4,000
Investments, at fair value:	[3]	$ 414
Investments owned acquisition date	[3]	May 03, 2022
Shares (in shares) | shares	[3]	235,295				235,295
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and HilleVax, Inc., Equity, Acquisition Date 5/3/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 4,000
Investments, at fair value:	[43]			$ 3,777
Investments owned acquisition date	[43]			May 03, 2022
Shares (in shares) | shares	[43]			235,295				235,295
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Humanigen, Inc., Equity, Acquisition Date 3/31/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[16],[43]			$ 800
Investments, at fair value:	[16],[43]			$ 0
Investments owned acquisition date	[16],[43]			Mar. 31, 2021
Shares (in shares) | shares	[16],[43]			43,243				43,243
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 550	[2],[3],[30]	$ 550	[5],[16],[43]
Investments, at fair value:		$ 935	[3],[30]	$ 688	[16],[43]
Investments owned acquisition date		Jun. 16, 2023	[3],[30]	Jun. 16, 2023	[16],[43]
Shares (in shares) | shares		47,826	[3],[30]	47,826	[16],[43]	47,826	[3],[30]	47,826	[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 773	[2],[3],[30]	$ 773	[5],[16],[43]
Investments, at fair value:		$ 1,082	[3],[30]	$ 1,180	[16],[43]
Investments owned acquisition date		Sep. 29, 2023	[3],[30]	Sep. 29, 2023	[16],[43]
Shares (in shares) | shares		5,100	[3],[30]	5,100	[16],[43]	5,100	[3],[30]	5,100	[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,000	[2],[30],[31]	$ 2,000	[5],[15],[16]
Investments, at fair value:		$ 1,334	[30],[31]	$ 1,427	[15],[16]
Investments owned acquisition date		Dec. 15, 2021	[30],[31]	Dec. 15, 2021	[15],[16],[43]
Shares (in shares) | shares		983	[30],[31]	983	[15],[16]	983	[30],[31]	983	[15],[16]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,730	[2],[3],[30],[35]	$ 1,730	[5],[16],[18],[43]
Investments, at fair value:		$ 2,662	[3],[30],[35]	$ 1,344	[16],[18],[43]
Investments owned acquisition date		Jun. 09, 2023	[3],[30],[35]	Jun. 09, 2023	[16],[18],[43]
Shares (in shares) | shares		147,233	[3],[30],[35]	147,233	[16],[18],[43]	147,233	[3],[30],[35]	147,233	[16],[18],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,500	[2],[3]	$ 1,500	[5],[43]
Investments, at fair value:		$ 18	[3]	$ 28	[43]
Investments owned acquisition date		Aug. 22, 2007	[3]	Aug. 22, 2007	[43]
Shares (in shares) | shares		944	[3]	944	[43]	944	[3]	944	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 203	[2],[3]	$ 203	[5],[43]
Investments, at fair value:		$ 47	[3]	$ 52	[43]
Investments owned acquisition date		Aug. 11, 2015	[3]	Aug. 11, 2015	[43]
Shares (in shares) | shares		11,119	[3]	11,119	[43]	11,119	[3]	11,119	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Sio Gene Therapies, Inc., Equity, Acquisition Date 2/2/2017, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 1,269
Investments, at fair value:	[43]			$ 6
Investments owned acquisition date	[43]			Feb. 02, 2017
Shares (in shares) | shares	[43]			16,228				16,228
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,050	[2],[3],[30]	$ 2,100	[5],[16],[43]
Investments, at fair value:		$ 2,558	[3],[30]	$ 3,150	[16],[43]
Investments owned acquisition date		May 05, 2022	[3],[30]	May 05, 2022	[16],[43]
Shares (in shares) | shares		77,778	[3],[30]	155,555	[16],[43]	77,778	[3],[30]	155,555	[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Total Valo Health, LLC
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 4,000
Investments, at fair value:				$ 4,098
Shares (in shares) | shares				680,410				680,410
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2]	$ 1,000	[5]
Investments, at fair value:		$ 1,029		$ 1,187
Investments owned acquisition date		Oct. 31, 2022	[3]	Oct. 31, 2022	[43]
Shares (in shares) | shares		170,102		170,102		170,102		170,102
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 3,000	[2]	$ 3,000	[5]
Investments, at fair value:		$ 2,126		$ 2,911
Investments owned acquisition date		Dec. 11, 2020	[3]	Dec. 11, 2020	[43]
Shares (in shares) | shares		510,308		510,308		510,308		510,308
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,500	[2]	$ 1,500	[5]
Investments, at fair value:		$ 1,488		$ 1,753
Investments owned acquisition date		Sep. 06, 2023	[3]	Sep. 06, 2023	[43]
Shares (in shares) | shares		208,588		208,588		208,588		208,588
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 400	[2],[3],[30]	$ 400	[5],[16],[43]
Investments, at fair value:		$ 735	[3],[30]	$ 704	[16],[43]
Investments owned acquisition date		Nov. 06, 2023	[3],[30]	Nov. 06, 2023	[16],[43]
Shares (in shares) | shares		32,310	[3],[30]	32,310	[16],[43]	32,310	[3],[30]	32,310	[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,945	[2],[3]	$ 2,945	[5],[43]
Investments, at fair value:		$ 1,048	[3]	$ 1,313	[43]
Investments owned acquisition date		Nov. 26, 2019	[3]	Nov. 26, 2019	[43]
Shares (in shares) | shares		1,566,064	[3]	1,566,064	[43]	1,566,064	[3]	1,566,064	[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 332	[2],[3],[30],[31]	$ 332	[5],[15],[16],[43]
Investments, at fair value:		$ 85	[3],[30],[31]	$ 116	[15],[16],[43]
Investments owned acquisition date		Jan. 31, 2019	[3],[30],[31]	Jan. 31, 2019	[15],[16],[43]
Shares (in shares) | shares		17,175	[3],[30],[31]	17,175	[15],[16],[43]	17,175	[3],[30],[31]	17,175	[15],[16],[43]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development, Total Valo Health LLC
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 4,000
Investments, at fair value:		$ 3,155
Shares (in shares) | shares		680,410				680,410
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware (0.05%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets		0.05%	[24]	0.05%	[4]	0.05%	[24]	0.05%	[4]
Investment cost		$ 2,150	[2]	$ 2,150	[5]
Investments, at fair value:		843		951
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F
Summary of Investment Holdings [Line Items]
Investment cost		650	[2]	650	[5]
Investments, at fair value:		$ 277		$ 407
Investments owned acquisition date		Nov. 17, 2022	[3]	Nov. 17, 2022	[43]
Shares (in shares) | shares		15,116		15,116		15,116		15,116
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,500	[2]	$ 1,500	[5]
Investments, at fair value:		$ 566		$ 544
Investments owned acquisition date		Mar. 08, 2022	[3]	Mar. 08, 2022	[43]
Shares (in shares) | shares		248,900		248,900		248,900		248,900
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other (0.05%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.05%				0.05%
Investment cost	[5]			$ 6,782
Investments, at fair value:				960
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other (0.36%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.36%				0.36%
Investment cost	[2]	$ 12,543
Investments, at fair value:		6,650
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		5,094	[2],[3]	5,094	[5],[43]
Investments, at fair value:		$ 287	[3]	$ 754	[43]
Investments owned acquisition date		Mar. 11, 2019	[3]	Mar. 11, 2019	[43]
Shares (in shares) | shares		825,732	[3]	825,732	[43]	825,732	[3]	825,732	[43]
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,687	[2]	$ 1,688	[5]
Investments, at fair value:		$ 6		$ 206
Investments owned acquisition date		Mar. 30, 2021	[3]	Mar. 30, 2021	[43]
Shares (in shares) | shares		217,880		217,880		217,880		217,880
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 1,662
Investments, at fair value:	[1]	$ 1,800
Investments owned acquisition date	[1],[3]	May 20, 2024
Shares (in shares) | shares	[1]	560,000				560,000
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 2,500
Investments, at fair value:		$ 2,837
Investments owned acquisition date	[3]	May 13, 2024
Shares (in shares) | shares		1,114,380				1,114,380
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 1,600
Investments, at fair value:		$ 1,720
Investments owned acquisition date	[3]	Jun. 10, 2024
Shares (in shares) | shares		181,163				181,163
Investment, Identifier [Axis]: Equity Investments Information Services (0.21%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.21%				0.21%
Investment cost	[2]	$ 3,825
Investments, at fair value:		3,907
Investment, Identifier [Axis]: Equity Investments Information Services (0.35%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.35%				0.35%
Investment cost	[5]			$ 4,440
Investments, at fair value:				6,243
Investment, Identifier [Axis]: Equity Investments Information Services and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			615
Investments, at fair value:	[43]			$ 1,353
Investments owned acquisition date	[43]			Jun. 21, 2019
Shares (in shares) | shares	[43]			547,880				547,880
Investment, Identifier [Axis]: Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		3,825	[2]	$ 3,825	[5]
Investments, at fair value:		$ 3,907		$ 4,890
Investments owned acquisition date		Dec. 30, 2021	[3]	Dec. 30, 2021	[43]
Shares (in shares) | shares		41,021		41,021		41,021		41,021
Investment, Identifier [Axis]: Equity Investments Manufacturing Technology (0.05%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.05%				0.05%
Investment cost	[2]	$ 47
Investments, at fair value:		958
Investment, Identifier [Axis]: Equity Investments Manufacturing Technology and Xometry, Inc., Equity, Acquisition Date 5/9/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	47
Investments, at fair value:	[3]	$ 958
Investments owned acquisition date	[3]	May 09, 2018
Shares (in shares) | shares	[3]	52,126				52,126
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.01%				0.01%
Investment cost	[5]			$ 250
Investments, at fair value:				262
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.02%				0.02%
Investment cost	[2]	$ 250
Investments, at fair value:		319
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost		0	[2],[37]	0	[5],[19]
Investments, at fair value:		$ 1	[37]	$ 2	[19]
Investments owned acquisition date		Oct. 15, 2021	[3],[37]	Oct. 15, 2021	[19],[43]
Shares (in shares) | shares		180,000	[37]	180,000	[19]	180,000	[37]	180,000	[19]
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-2
Summary of Investment Holdings [Line Items]
Investment cost	[2],[37]	$ 250
Investments, at fair value:	[37]	$ 318
Investments owned acquisition date	[3],[37]	Oct. 15, 2021
Shares (in shares) | shares	[37]	5,000,000				5,000,000
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment, Coronado Aesthetics, LLC
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 250
Investments, at fair value:				$ 262
Shares (in shares) | shares				5,180,000				5,180,000
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment, Total Coronado Aesthetics, LLC
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 250
Investments, at fair value:		$ 319
Shares (in shares) | shares		5,180,000				5,180,000
Investment, Identifier [Axis]: Equity Investments Semiconductors (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.01%				0.01%
Investment cost	[2]	$ 160
Investments, at fair value:		194
Investment, Identifier [Axis]: Equity Investments Semiconductors (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.02%				0.02%
Investment cost	[5]			$ 160
Investments, at fair value:				394
Investment, Identifier [Axis]: Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		160	[2]	160	[5]
Investments, at fair value:		$ 194		$ 394
Investments owned acquisition date		Jul. 01, 2011	[3]	Jul. 01, 2011	[43]
Shares (in shares) | shares		277,995		277,995		277,995		277,995
Investment, Identifier [Axis]: Equity Investments Software (1.27%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			1.27%				1.27%
Investment cost	[5]			$ 23,210
Investments, at fair value:				22,919
Investment, Identifier [Axis]: Equity Investments Software (1.40%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	1.40%				1.40%
Investment cost	[2]	$ 23,357
Investments, at fair value:		25,995
Investment, Identifier [Axis]: Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		1,000	[2]	1,000	[5]
Investments, at fair value:		$ 745		$ 863
Investments owned acquisition date		Aug. 09, 2021	[3]	Aug. 09, 2021	[43]
Shares (in shares) | shares		1,000,000		1,000,000		1,000,000		1,000,000
Investment, Identifier [Axis]: Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,406	[2],[44]	$ 2,406	[5],[45]
Investments, at fair value:		$ 2,406	[44]	$ 2,406	[45]
Investments owned acquisition date		Mar. 24, 2021	[3],[44]	Mar. 24, 2021	[43],[45]
Shares (in shares) | shares		3	[44]	3	[45]	3	[44]	3	[45]
Investment, Identifier [Axis]: Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-3
Summary of Investment Holdings [Line Items]
Investment cost		$ 51	[2]	$ 51	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Oct. 26, 2012	[3]	Oct. 26, 2012	[43]
Shares (in shares) | shares		53,614		53,614		53,614		53,614
Investment, Identifier [Axis]: Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 500	[2],[30],[31]	$ 500	[5],[15],[16]
Investments, at fair value:		$ 895	[30],[31]	$ 842	[15],[16]
Investments owned acquisition date		Nov. 20, 2018	[3],[30],[31]	Nov. 20, 2018	[15],[16],[43]
Shares (in shares) | shares		108,500	[30],[31]	108,500	[15],[16]	108,500	[30],[31]	108,500	[15],[16]
Investment, Identifier [Axis]: Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 138	[2],[30],[31]	$ 138	[5],[15],[16]
Investments, at fair value:		$ 323	[30],[31]	$ 303	[15],[16]
Investments owned acquisition date		Dec. 22, 2020	[3],[30],[31]	Dec. 22, 2020	[15],[16],[43]
Shares (in shares) | shares		41,000	[30],[31]	41,000	[15],[16]	41,000	[30],[31]	41,000	[15],[16]
Investment, Identifier [Axis]: Equity Investments Software and DNAnexus, Inc, Equity, Acquisition Date 3/21/2014, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 97
Investments, at fair value:		$ 5
Investments owned acquisition date	[3]	Mar. 21, 2014
Shares (in shares) | shares		51,948				51,948
Investment, Identifier [Axis]: Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 4,284	[2]	$ 4,284	[5]
Investments, at fair value:		$ 210		$ 636
Investments owned acquisition date		Nov. 29, 2018	[3]	Nov. 29, 2018	[43]
Shares (in shares) | shares		20,000		20,000		20,000		20,000
Investment, Identifier [Axis]: Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 2
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,000	[2]	$ 1,000	[5]
Investments, at fair value:		$ 2,617		$ 2,752
Investments owned acquisition date		Oct. 22, 2015	[3]	Oct. 22, 2015	[43]
Shares (in shares) | shares		458,841		458,841		458,841		458,841
Investment, Identifier [Axis]: Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 3
Summary of Investment Holdings [Line Items]
Investment cost		$ 300	[2]	$ 300	[5]
Investments, at fair value:		$ 560		$ 587
Investments owned acquisition date		Aug. 24, 2017	[3]	Aug. 24, 2017	[43]
Shares (in shares) | shares		93,620		93,620		93,620		93,620
Investment, Identifier [Axis]: Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 307	[2]	$ 307	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Jan. 18, 2013	[3]	Jan. 18, 2013	[43]
Shares (in shares) | shares		190		190		190		190
Investment, Identifier [Axis]: Equity Investments Software and Leapwork ApS, Equity, Acquisition Date 8/25/2023, Preferred Series B2
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16]			$ 250
Investments, at fair value:	[15],[16]			$ 231
Investments owned acquisition date	[15],[16],[43]			Aug. 25, 2023
Shares (in shares) | shares	[15],[16]			183,073				183,073
Investment, Identifier [Axis]: Equity Investments Software and Leapwork ApS., Equity, Acquisition Date 8/25/2023, Series Preferred Series B2
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 250
Investments, at fair value:	[30],[31]	$ 155
Investments owned acquisition date	[3],[30],[31]	Aug. 25, 2023
Shares (in shares) | shares	[30],[31]	183,073				183,073
Investment, Identifier [Axis]: Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 265	[2]	$ 265	[5]
Investments, at fair value:		$ 25		$ 23
Investments owned acquisition date		Dec. 04, 2020	[3]	Dec. 04, 2020	[43]
Shares (in shares) | shares		38,461		38,461		38,461		38,461
Investment, Identifier [Axis]: Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 4,854	[2],[3]	$ 4,854	[5],[43]
Investments, at fair value:		$ 2,528	[3]	$ 1,927	[43]
Investments owned acquisition date		Aug. 01, 2018	[3]	Aug. 01, 2018	[43]
Shares (in shares) | shares		1,019,255	[3]	1,019,255	[43]	1,019,255	[3]	1,019,255	[43]
Investment, Identifier [Axis]: Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,834	[2],[3]	$ 3,474	[5],[43]
Investments, at fair value:		$ 11,160	[3]	$ 9,758	[43]
Investments owned acquisition date		Sep. 23, 2020	[3]	Sep. 23, 2020	[43]
Shares (in shares) | shares		300,000	[3]	568,337	[43]	300,000	[3]	568,337	[43]
Investment, Identifier [Axis]: Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,000	[2]	$ 2,000	[5]
Investments, at fair value:		$ 1,842		$ 1,721
Investments owned acquisition date		Nov. 25, 2020	[3]	Nov. 25, 2020	[43]
Shares (in shares) | shares		580,983		580,983		580,983		580,983
Investment, Identifier [Axis]: Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F
Summary of Investment Holdings [Line Items]
Investment cost		$ 280	[2]	$ 280	[5]
Investments, at fair value:		$ 207		$ 196
Investments owned acquisition date		Aug. 12, 2021	[3]	Aug. 12, 2021	[43]
Shares (in shares) | shares		52,956		52,956		52,956		52,956
Investment, Identifier [Axis]: Equity Investments Software and Sirion Labs, Inc., Equity, Acquisition Date 6/30/2024, Series Preferred Series F1
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 1,791
Investments, at fair value:	[30],[31]	$ 1,999
Investments owned acquisition date	[3],[30],[31]	Jun. 30, 2024
Shares (in shares) | shares	[30],[31]	152,250				152,250
Investment, Identifier [Axis]: Equity Investments Software and Total Contentful Global, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 638
Investments, at fair value:				$ 1,145
Shares (in shares) | shares				149,500				149,500
Investment, Identifier [Axis]: Equity Investments Software and Total Druva Holdings, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 1,300
Investments, at fair value:				$ 3,339
Shares (in shares) | shares				552,461				552,461
Investment, Identifier [Axis]: Equity Investments Software and Total SingleStore, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 2,280
Investments, at fair value:				$ 1,917
Shares (in shares) | shares				633,939				633,939
Investment, Identifier [Axis]: Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		$ 2,000	[2]	$ 2,000	[5]
Investments, at fair value:		$ 318		$ 422
Investments owned acquisition date		Jul. 08, 2021	[3]	Jul. 08, 2021	[43]
Shares (in shares) | shares		952,562		952,562		952,562		952,562
Investment, Identifier [Axis]: Equity Investments Software and ZeroFox, Inc., Equity, Acquisition Date 5/7/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 101
Investments, at fair value:	[43]			$ 252
Investments owned acquisition date	[43]			May 07, 2020
Shares (in shares) | shares	[43]			289,992				289,992
Investment, Identifier [Axis]: Equity Investments Software, Total Contentful Global, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 638
Investments, at fair value:		$ 1,218
Shares (in shares) | shares		149,500				149,500
Investment, Identifier [Axis]: Equity Investments Software, Total Druva Holdings, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 1,300
Investments, at fair value:		$ 3,177
Shares (in shares) | shares		552,461				552,461
Investment, Identifier [Axis]: Equity Investments Software, Total SingleStore, Inc.
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 2,280
Investments, at fair value:		$ 2,049
Shares (in shares) | shares		633,939				633,939
Investment, Identifier [Axis]: Equity Investments Space Technologies (0.07%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.07%				0.07%
Investment cost	[2]	$ 615
Investments, at fair value:		1,222
Investment, Identifier [Axis]: Equity Investments Space Technologies and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	615
Investments, at fair value:	[3]	$ 1,222
Investments owned acquisition date	[3]	Jun. 21, 2019
Shares (in shares) | shares	[3]	547,880				547,880
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology (0.13%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.13%				0.13%
Investment cost	[2]	$ 10,255
Investments, at fair value:		2,424
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology (0.22%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.22%				0.22%
Investment cost	[5]			$ 11,508
Investments, at fair value:				3,881
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Fulcrum Bioenergy, Inc., Equity, Acquisition Date 9/13/2012, Series Preferred Series C-1
Summary of Investment Holdings [Line Items]
Investment cost	[5]			711
Investments, at fair value:				$ 529
Investments owned acquisition date	[43]			Sep. 13, 2012
Shares (in shares) | shares				187,265				187,265
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-1
Summary of Investment Holdings [Line Items]
Investment cost		2,000	[2]	$ 2,000	[5]
Investments, at fair value:		$ 112		$ 479
Investments owned acquisition date		May 10, 2019	[3]	May 10, 2019	[43]
Shares (in shares) | shares		188,611		188,611		188,611		188,611
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 500	[2]	$ 500	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Jun. 01, 2015	[3]	Jun. 01, 2015	[43]
Shares (in shares) | shares		1,035		1,035		1,035		1,035
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost		$ 102	[2]	$ 102	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Aug. 31, 2013	[3]	Aug. 31, 2013	[43]
Shares (in shares) | shares		59,665		59,665		59,665		59,665
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 3,153	[2],[3]	$ 3,153	[5],[43]
Investments, at fair value:		$ 3	[3]	$ 180	[43]
Investments owned acquisition date		Dec. 10, 2020	[3]	Dec. 10, 2020	[43]
Shares (in shares) | shares		20,299	[3]	304,487	[43]	20,299	[3]	304,487	[43]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 4,500	[2]	$ 4,500	[5]
Investments, at fair value:		$ 2,309		$ 2,684
Investments owned acquisition date		Jun. 28, 2021	[3]	Jun. 28, 2021	[43]
Shares (in shares) | shares		593,080		593,080		593,080		593,080
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Proterra, Inc., Equity, Acquisition Date 5/28/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 542
Investments, at fair value:	[43]			$ 9
Investments owned acquisition date	[43]			May 28, 2015
Shares (in shares) | shares	[43]			457,841				457,841
Investment, Identifier [Axis]: Equity Investments and Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-2
Summary of Investment Holdings [Line Items]
Investment cost	[5],[19]			$ 250
Investments, at fair value:	[19]			$ 260
Investments owned acquisition date	[19],[43]			Oct. 15, 2021
Shares (in shares) | shares	[19]			5,000,000				5,000,000
Investment, Identifier [Axis]: Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date10/25/2016, Series Preferred Series A-1
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 632
Investments, at fair value:				$ 143
Investments owned acquisition date	[43]			Oct. 25, 2016
Shares (in shares) | shares				108,710				108,710
Investment, Identifier [Axis]: Investment Fund After Cash & Cash Equivalents (183.28%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets				183.28%				183.28%
Investment cost	[5]			$ 3,303,033
Investments, at fair value:				3,304,046
Investment, Identifier [Axis]: Investment Fund Cash & Cash Equivalent and GS Financial Square Government Fund, Series FGTXX/38141W273
Summary of Investment Holdings [Line Items]
Investment cost	[5]			56,000
Investments, at fair value:				$ 56,000
Investment, Identifier [Axis]: Investment Fund In Cash & Cash Equivalents (3.11%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets				3.11%				3.11%
Investment cost	[5]			$ 56,000
Investments, at fair value:				$ 56,000
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments (0.26%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.26%				0.26%
Investment cost	[5]			$ 4,483
Investments, at fair value:				$ 4,608
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments (0.37%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.37%				0.37%
Investment cost	[2]	$ 4,264
Investments, at fair value:		$ 6,877
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development (0.23%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.23%				0.23%
Investment cost	[5]			$ 4,102
Investments, at fair value:				4,230
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development (0.35%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.35%				0.35%
Investment cost	[2]	$ 3,883
Investments, at fair value:		6,481
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/2020
Summary of Investment Holdings [Line Items]
Investment cost		2,847	[2],[30],[31],[33]	3,783	[5],[12],[15],[16]
Investments, at fair value:		$ 5,123	[30],[31],[33]	$ 3,619	[12],[15],[16]
Investments owned acquisition date		Nov. 16, 2020	[3],[30],[31],[33]	Nov. 16, 2020	[12],[15],[16],[43]
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/2022
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,036	[2],[30],[31],[33]	$ 319	[5],[12],[15],[16]
Investments, at fair value:		$ 1,358	[30],[31],[33]	$ 611	[12],[15],[16]
Investments owned acquisition date		Jun. 23, 2022	[3],[30],[31],[33]	Jun. 23, 2022	[12],[15],[16],[43]
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Software (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets		0.02%	[24]	0.02%	[4]	0.02%	[24]	0.02%	[4]
Investment cost		$ 381	[2]	$ 381	[5]
Investments, at fair value:		396		$ 378
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/2022
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	381
Investments, at fair value:	[30],[31]	$ 396
Investments owned acquisition date	[3],[30],[31]	Jul. 21, 2022
Investment, Identifier [Axis]: Investments (180.18%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			180.18%				180.18%
Investment cost	[5]			$ 3,247,033
Investments, at fair value:				$ 3,248,046
Investment, Identifier [Axis]: Investments (192.27%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	192.27%				192.27%
Investment cost	[2]	$ 3,609,986
Investments, at fair value:		$ 3,560,513
Investment, Identifier [Axis]: Investments in Securities (179.92%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			179.92%				179.92%
Investment cost	[5]			$ 3,242,550
Investments, at fair value:				$ 3,243,438
Investment, Identifier [Axis]: Investments in Securities (191.90%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	191.90%				191.90%
Investment cost	[2]	$ 3,605,722
Investments, at fair value:		$ 3,553,636
Investment, Identifier [Axis]: Total Debt Investments (169.59%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			169.59%				169.59%
Investment cost	[5]			$ 3,058,370
Investments, at fair value:				$ 3,057,299
Investment, Identifier [Axis]: Total Warrant Investments (1.88%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			1.88%				1.88%
Investment cost	[5]			$ 28,954
Investments, at fair value:				$ 33,969
Investment, Identifier [Axis]: Warrant Diversified Financial Services (0.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets				0.03%				0.03%
Investment cost				$ 214
Investments, at fair value:				$ 554
Investment, Identifier [Axis]: Warrant Investments (1.62%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	1.62%				1.62%
Investment cost	[2]	$ 30,720
Investments, at fair value:		$ 30,023
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.01%				0.01%
Investment cost	[2]	$ 496
Investments, at fair value:		219
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.02%				0.02%
Investment cost	[5]			$ 496
Investments, at fair value:				354
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost	[5]			36
Investments, at fair value:				$ 20
Investments owned acquisition date	[43]			Jun. 21, 2022
Shares (in shares) | shares				46,197				46,197
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[2]	36
Investments, at fair value:		$ 124
Investments owned acquisition date	[3]	Jun. 21, 2022
Shares (in shares) | shares		75,567				75,567
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 460	[2],[26]	$ 460	[5],[10]
Investments, at fair value:		$ 95	[26]	$ 334	[10]
Investments owned acquisition date		Dec. 23, 2022	[3],[26]	Dec. 23, 2022	[10],[43]
Shares (in shares) | shares		53,418	[26]	53,418	[10]	53,418	[26]	53,418	[10]
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0%				0%
Investment cost	[2]	$ 123
Investments, at fair value:		92
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.01%				0.01%
Investment cost	[5]			$ 123
Investments, at fair value:				128
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		123	[2],[26]	123	[5],[10]
Investments, at fair value:		$ 92	[26]	$ 128	[10]
Investments owned acquisition date		Jun. 28, 2022	[3],[26]	Jun. 28, 2022	[10],[43]
Shares (in shares) | shares		229,611	[26]	229,611	[10]	229,611	[26]	229,611	[10]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.02%				0.02%
Investment cost	[5]			$ 611
Investments, at fair value:				325
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products (0.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.03%				0.03%
Investment cost	[2]	$ 245
Investments, at fair value:		464
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		228	[2]	228	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Jun. 03, 2014	[3]	Jun. 03, 2014	[43]
Shares (in shares) | shares		1,662,441		1,662,441		1,662,441		1,662,441
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and The Neat Company, Warrant, Acquisition Date 8/13/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 365
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			Aug. 13, 2014
Shares (in shares) | shares				54,054				54,054
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost		$ 17	[2]	$ 18	[5]
Investments, at fair value:		$ 464		$ 325
Investments owned acquisition date		Jun. 27, 2018	[3]	Jun. 27, 2018	[43]
Shares (in shares) | shares		686,270		686,270		686,270		686,270
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services (0.23%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.23%				0.23%
Investment cost	[5]			$ 4,208
Investments, at fair value:				4,217
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services (0.30%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.30%				0.30%
Investment cost	[2]	$ 4,163
Investments, at fair value:		5,627
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services , Total Carwow LTD
Summary of Investment Holdings [Line Items]
Investment cost	[2]	184
Investments, at fair value:		$ 65
Shares (in shares) | shares		283,420				283,420
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 164	[2],[30],[31]	164	[5],[15],[16]
Investments, at fair value:		$ 54	[30],[31]	$ 75	[15],[16]
Investments owned acquisition date		Dec. 14, 2021	[3],[30],[31]	Dec. 14, 2021	[15],[16],[43]
Shares (in shares) | shares		174,163	[30],[31]	174,163	[15],[16]	174,163	[30],[31]	174,163	[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-4
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 20
Investments, at fair value:	[30],[31]	$ 11
Investments owned acquisition date	[3],[30],[31]	Feb. 13, 2024
Shares (in shares) | shares	[30],[31]	109,257				109,257
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 20	[2]	$ 20	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Oct. 29, 2019	[3]	Oct. 29, 2019	[43]
Shares (in shares) | shares		529,661		529,661		529,661		529,661
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 116	[1],[2]	$ 116	[5],[14]
Investments, at fair value:		$ 140	[1]	$ 298	[14]
Investments owned acquisition date		Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[14],[43]
Shares (in shares) | shares		11,806	[1]	11,806	[14]	11,806	[1]	11,806	[14]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 39	[2]	$ 39	[5]
Investments, at fair value:		$ 22		$ 33
Investments owned acquisition date		Mar. 29, 2019	[3]	Mar. 29, 2019	[43]
Shares (in shares) | shares		127,032		127,032		127,032		127,032
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 60
Investments, at fair value:	[30],[31]	$ 38
Investments owned acquisition date	[3],[30],[31]	Oct. 03, 2023
Shares (in shares) | shares	[30],[31]	27,298				27,298
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary shares
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16]			$ 48
Investments, at fair value:	[15],[16]			$ 51
Investments owned acquisition date	[15],[16],[43]			Oct. 03, 2023
Shares (in shares) | shares	[15],[16]			19,499				19,499
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 166
Investments, at fair value:	[1]	$ 65
Investments owned acquisition date	[1],[3]	Dec. 22, 2022
Shares (in shares) | shares	[1]	117,042				117,042
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[14]			$ 166
Investments, at fair value:	[14]			$ 74
Investments owned acquisition date	[14],[43]			Dec. 22, 2022
Shares (in shares) | shares	[14]			117,042				117,042
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 470	[1],[2]	$ 470	[5],[14]
Investments, at fair value:		$ 0	[1]	$ 4	[14]
Investments owned acquisition date		Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[14],[43]
Shares (in shares) | shares		13,106	[1]	13,106	[14]	13,106	[1]	13,106	[14]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 842	[2],[35]	$ 842	[5],[18]
Investments, at fair value:		$ 4,464	[35]	$ 3,065	[18]
Investments owned acquisition date		Jun. 12, 2019	[3],[35]	Jun. 12, 2019	[18],[43]
Shares (in shares) | shares		1,379,761	[35]	1,379,761	[18]	1,379,761	[35]	1,379,761	[18]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 57	[2]	$ 57	[5]
Investments, at fair value:		$ 13		$ 58
Investments owned acquisition date		Nov. 14, 2022	[3]	Nov. 14, 2022	[43]
Shares (in shares) | shares		1,607,143		1,607,143		1,607,143		1,607,143
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 83	[2]	$ 83	[5]
Investments, at fair value:		$ 1		$ 5
Investments owned acquisition date		Aug. 23, 2019	[3]	Aug. 23, 2019	[43]
Shares (in shares) | shares		444,444		444,444		444,444		444,444
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 16	[2]	$ 16	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Apr. 20, 2020	[3]	Apr. 20, 2020	[43]
Shares (in shares) | shares		600,000		600,000		600,000		600,000
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A
Summary of Investment Holdings [Line Items]
Investment cost		$ 782	[2]	$ 782	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Jun. 30, 2016	[3]	Jun. 30, 2016	[43]
Shares (in shares) | shares		1,800,000		1,800,000		1,800,000		1,800,000
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 62	[2]	$ 62	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Aug. 01, 2018	[3]	Aug. 01, 2018	[43]
Shares (in shares) | shares		1,211,537		1,211,537		1,211,537		1,211,537
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 985	[2]	$ 844	[5],[10]
Investments, at fair value:		$ 741		$ 515	[10]
Investments owned acquisition date		May 01, 2018	[3]	May 01, 2018	[10],[43]
Shares (in shares) | shares		343,497		267,225	[10]	343,497		267,225	[10]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Total Skyword, Inc.
Summary of Investment Holdings [Line Items]
Investment cost		$ 140	[2]	$ 140	[5]
Investments, at fair value:		$ 14		$ 63
Shares (in shares) | shares		2,051,587		2,051,587		2,051,587		2,051,587
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.
Summary of Investment Holdings [Line Items]
Investment cost		$ 860	[2]	$ 860	[5]
Investments, at fair value:		$ 0		$ 0
Shares (in shares) | shares		3,611,537		3,611,537		3,611,537		3,611,537
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited
Summary of Investment Holdings [Line Items]
Investment cost		$ 155	[2]	$ 155	[5]
Investments, at fair value:		$ 69		$ 23
Shares (in shares) | shares		79,083		79,083		79,083		79,083
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Udacity, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[10]			$ 218
Investments, at fair value:	[10]			$ 0
Investments owned acquisition date	[10],[43]			Sep. 25, 2020
Shares (in shares) | shares	[10]			486,359				486,359
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 126	[2],[26]	$ 126	[5],[10]
Investments, at fair value:		$ 9	[26]	$ 16	[10]
Investments owned acquisition date		Mar. 31, 2022	[3],[26]	Mar. 31, 2022	[10],[43]
Shares (in shares) | shares		98,428	[26]	98,428	[10]	98,428	[26]	98,428	[10]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 129	[2],[26],[30],[31]	$ 129	[5],[10],[15],[16],[18]
Investments, at fair value:		$ 69	[26],[30],[31]	$ 23	[10],[15],[16],[18]
Investments owned acquisition date		Feb. 11, 2021	[3],[26],[30],[31]	Feb. 11, 2021	[10],[15],[16],[18],[43]
Shares (in shares) | shares		77,215	[26],[30],[31]	77,215	[10],[15],[16],[18]	77,215	[26],[30],[31]	77,215	[10],[15],[16],[18]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		$ 26	[2],[30],[31]	$ 26	[5],[15],[16],[18]
Investments, at fair value:		$ 0	[30],[31]	$ 0	[15],[16],[18]
Investments owned acquisition date		Aug. 27, 2021	[3],[30],[31]	Aug. 27, 2021	[15],[16],[18],[43]
Shares (in shares) | shares		1,868	[30],[31]	1,868	[15],[16],[18]	1,868	[30],[31]	1,868	[15],[16],[18]
Investment, Identifier [Axis]: Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost				$ 214
Investments, at fair value:				$ 554
Investments owned acquisition date				Feb. 03, 2023
Shares (in shares) | shares				522,930				522,930
Investment, Identifier [Axis]: Warrant Investments and Diversified Financial Services (0.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.03%				0.03%
Investment cost	[2]	$ 214
Investments, at fair value:		498
Investment, Identifier [Axis]: Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	214
Investments, at fair value:		$ 498
Investments owned acquisition date	[3]	Feb. 03, 2023
Shares (in shares) | shares		522,930				522,930
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets		0%	[24]	0%	[4]	0%	[24]	0%	[4]
Investment cost		$ 1	[2]	$ 392	[5]
Investments, at fair value:		0		0
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and Aerami Therapeutics Holdings, Inc., Warrant, Acquisition Date 6/1/2016, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			0
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			Jun. 01, 2016
Shares (in shares) | shares				67,069				67,069
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		1	[2]	$ 2	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		Oct. 27, 2014	[3]	Oct. 27, 2014	[43]
Shares (in shares) | shares		459,183		459,183		459,183		459,183
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and PDS Biotechnology Corporation, Warrant, Acquisition Date 8/28/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 390
Investments, at fair value:	[43]			$ 0
Investments owned acquisition date	[43]			Aug. 28, 2014
Shares (in shares) | shares	[43]			3,929				3,929
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development (0.46%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.46%				0.46%
Investment cost	[5]			$ 7,517
Investments, at fair value:				8,302
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development (0.51%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.51%				0.51%
Investment cost	[2]	$ 9,068
Investments, at fair value:		9,355
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and ADMA Biologics, Inc.., Warrant, Acquisition Date 2/24/2014 Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[43]			166
Investments, at fair value:	[43]			$ 11
Investments owned acquisition date	[43]			Feb. 24, 2014
Shares (in shares) | shares	[43]			58,000				58,000
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		330	[2],[3],[30]	$ 175	[16],[43]
Investments, at fair value:		$ 547	[3],[30]	$ 335	[16],[43]
Investments owned acquisition date		Jun. 15, 2022	[3],[30]	Jun. 15, 2022	[16],[43]
Shares (in shares) | shares		32,128	[3],[30]	22,949	[16],[43]	32,128	[3],[30]	22,949	[16],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and AmplifyBio, Warrant, Acquisition Date 12/27/2022, Series Class A Units
Summary of Investment Holdings [Line Items]
Investment cost	[14]			$ 237
Investments, at fair value:	[14]			$ 184
Investments owned acquisition date	[14],[43]			Dec. 27, 2022
Shares (in shares) | shares	[14]			69,239				69,239
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,290	[2],[3],[26],[30],[35]	$ 1,290	[10],[16],[18],[43]
Investments, at fair value:		$ 1,813	[3],[26],[30],[35]	$ 1,657	[10],[16],[18],[43]
Investments owned acquisition date		Sep. 25, 2020	[3],[26],[30],[35]	Sep. 25, 2020	[10],[16],[18],[43]
Shares (in shares) | shares		61,004	[3],[26],[30],[35]	61,004	[10],[16],[18],[43]	61,004	[3],[26],[30],[35]	61,004	[10],[16],[18],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost		$ 278	[2],[3],[30],[31]	$ 278	[15],[16],[43]
Investments, at fair value:		$ 136	[3],[30],[31]	$ 285	[15],[16],[43]
Investments owned acquisition date		Jun. 30, 2023	[3],[30],[31]	Jun. 30, 2023	[15],[16],[43]
Shares (in shares) | shares		75,376	[3],[30],[31]	75,376	[15],[16],[43]	75,376	[3],[30],[31]	75,376	[15],[16],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 287	[1],[2]	$ 287	[14]
Investments, at fair value:		$ 64	[1]	$ 201	[14]
Investments owned acquisition date		Dec. 08, 2021	[1],[3]	Dec. 08, 2021	[14],[43]
Shares (in shares) | shares		100,000	[1]	100,000	[14]	100,000	[1]	100,000	[14]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 37	[2],[3]	$ 37	[43]
Investments, at fair value:		$ 0	[3]	$ 1	[43]
Investments owned acquisition date		Sep. 14, 2020	[3]	Sep. 14, 2020	[43]
Shares (in shares) | shares		16,112	[3]	16,112	[43]	16,112	[3]	16,112	[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[14]			$ 233
Investments, at fair value:	[14]			$ 251
Investments owned acquisition date	[14],[43]			Jun. 09, 2023
Shares (in shares) | shares	[14]			95,221				95,221
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 233
Investments, at fair value:	[1]	$ 149
Investments owned acquisition date	[1],[3]	Jun. 09, 2023
Shares (in shares) | shares	[1]	95,221				95,221
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 101	[2],[30],[31]	$ 101	[16]
Investments, at fair value:		$ 0	[30],[31]	$ 7	[16]
Investments owned acquisition date		May 31, 2019	[3],[30],[31]	May 31, 2019	[16],[43]
Shares (in shares) | shares		223,642	[30],[31]	223,642	[16]	223,642	[30],[31]	223,642	[16]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Evofem Biosciences, Inc., Warrant, Acquisition Date 6/11/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[43]			$ 266
Investments, at fair value:	[43]			$ 0
Investments owned acquisition date	[43]			Jun. 11, 2014
Shares (in shares) | shares	[43]			3				3
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.), Warrant, Acquisition Date 2/18/2016, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[43]			$ 119
Investments, at fair value:	[43]			$ 0
Investments owned acquisition date	[43]			Feb. 18, 2016
Shares (in shares) | shares	[43]			201				201
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc., Warrant, Acquisition Date 2/18/2016, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 119
Investments, at fair value:	[3]	$ 0
Investments owned acquisition date	[3]	Feb. 18, 2016
Shares (in shares) | shares	[3]	201				201
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 228	[1],[2],[3]	$ 228	[14],[43]
Investments, at fair value:		$ 233	[1],[3]	$ 223	[14],[43]
Investments owned acquisition date		Aug. 09, 2023	[1],[3]	Aug. 09, 2023	[14],[43]
Shares (in shares) | shares		238,095	[1],[3]	238,095	[14],[43]	238,095	[1],[3]	238,095	[14],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 110	[2],[3]	$ 110	[43]
Investments, at fair value:		$ 0	[3]	$ 0	[43]
Investments owned acquisition date		Dec. 20, 2019	[3]	Dec. 20, 2019	[43]
Shares (in shares) | shares		2,202	[3]	2,202	[43]	2,202	[3]	2,202	[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 88	[1],[2],[3],[30]	$ 88	[14],[16],[43]
Investments, at fair value:		$ 92	[1],[3],[30]	$ 63	[14],[16],[43]
Investments owned acquisition date		Nov. 02, 2022	[1],[3],[30]	Nov. 02, 2022	[14],[16],[43]
Shares (in shares) | shares		14,342	[1],[3],[30]	14,342	[14],[16],[43]	14,342	[1],[3],[30]	14,342	[14],[16],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 570	[2],[3],[30]	$ 570	[16],[43]
Investments, at fair value:		$ 1,539	[3],[30]	$ 1,842	[16],[43]
Investments owned acquisition date		May 09, 2022	[3],[30]	May 09, 2022	[16],[43]
Shares (in shares) | shares		13,229	[3],[30]	13,229	[16],[43]	13,229	[3],[30]	13,229	[16],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 848	[1],[2],[3],[26],[30],[35]	$ 848	[10],[14],[16],[18],[43]
Investments, at fair value:		$ 128	[1],[3],[26],[30],[35]	$ 68	[10],[14],[16],[18],[43]
Investments owned acquisition date		Sep. 17, 2021	[1],[3],[26],[30],[35]	Sep. 17, 2021	[10],[14],[16],[18],[43]
Shares (in shares) | shares		64,687	[1],[3],[26],[30],[35]	64,687	[10],[14],[16],[18],[43]	64,687	[1],[3],[26],[30],[35]	64,687	[10],[14],[16],[18],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost		$ 20	[1],[2]	$ 20	[14]
Investments, at fair value:		$ 23	[1]	$ 6	[14]
Investments owned acquisition date		Mar. 23, 2022	[1],[3]	Mar. 23, 2022	[14],[43]
Shares (in shares) | shares		475,510	[1]	475,510	[14]	475,510	[1]	475,510	[14]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 296	[2],[3]	$ 296	[43]
Investments, at fair value:		$ 4	[3]	$ 28	[43]
Investments owned acquisition date		May 14, 2021	[3]	May 14, 2021	[43]
Shares (in shares) | shares		106,035	[3]	106,035	[43]	106,035	[3]	106,035	[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 83
Investments, at fair value:	[30],[31]	$ 83
Investments owned acquisition date	[3],[30],[31]	Apr. 18, 2024
Shares (in shares) | shares	[30],[31]	251,195				251,195
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,284	[2],[3],[30]	$ 1,284	[10],[16],[43]
Investments, at fair value:		$ 3,514	[3],[30]	$ 2,583	[10],[16],[43]
Investments owned acquisition date		Feb. 28, 2019	[3],[30]	Feb. 28, 2019	[10],[16],[43]
Shares (in shares) | shares		264,226	[3],[30]	264,226	[10],[16],[43]	264,226	[3],[30]	264,226	[10],[16],[43]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost				$ 256
Investments, at fair value:				$ 153
Investments owned acquisition date	[43]			Jun. 15, 2020
Shares (in shares) | shares				102,216				102,216
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 256
Investments, at fair value:		$ 102
Investments owned acquisition date	[3]	Jun. 15, 2020
Shares (in shares) | shares		102,216				102,216
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 510
Investments, at fair value:	[3]	$ 137
Investments owned acquisition date	[3]	Mar. 18, 2019
Shares (in shares) | shares	[3]	1,392,787				1,392,787
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/218/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[43]			$ 510
Investments, at fair value:	[43]			$ 225
Investments owned acquisition date	[43]			Mar. 18, 2019
Shares (in shares) | shares	[43]			1,392,787				1,392,787
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and blubird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 1,744
Investments, at fair value:	[3]	$ 514
Investments owned acquisition date	[3]	Mar. 15, 2024
Shares (in shares) | shares	[3]	2,224,137				2,224,137
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[15],[16],[43]			$ 118
Investments, at fair value:	[15],[16],[43]			$ 179
Investments owned acquisition date	[15],[16],[43]			Dec. 22, 2023
Shares (in shares) | shares	[15],[16],[43]			43,689				43,689
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[30],[31]	$ 118
Investments, at fair value:	[3],[30],[31]	$ 105
Investments owned acquisition date	[3],[30],[31]	Dec. 22, 2023
Shares (in shares) | shares	[3],[30],[31]	43,689				43,689
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets		0.02%	[24]	0.02%	[4]	0.02%	[24]	0.02%	[4]
Investment cost		$ 692	[2]	$ 692	[5]
Investments, at fair value:		304		391
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		101	[2],[3]	101	[5],[43]
Investments, at fair value:		$ 9	[3]	$ 175	[43]
Investments owned acquisition date		Mar. 15, 2017	[3]	Mar. 15, 2017	[43]
Shares (in shares) | shares		49,078	[3]	49,078	[43]	49,078	[3]	49,078	[43]
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 34	[2]	$ 34	[5]
Investments, at fair value:		$ 51		$ 102
Investments owned acquisition date		Jun. 21, 2022	[3]	Jun. 21, 2022	[43]
Shares (in shares) | shares		8,503		8,503		8,503		8,503
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 557	[2]	$ 557	[5]
Investments, at fair value:		$ 244		$ 114
Investments owned acquisition date		Nov. 08, 2021	[3]	Nov. 08, 2021	[43]
Shares (in shares) | shares		622,255		622,255		622,255		622,255
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other (0.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.03%				0.03%
Investment cost	[5]			$ 750
Investments, at fair value:				596
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other (0.09%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.09%				0.09%
Investment cost	[2]	$ 1,668
Investments, at fair value:		1,716
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC., Warrant, Acquisition Date 1/4/2024, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[2]	156
Investments, at fair value:		$ 562
Investments owned acquisition date	[3]	Jan. 04, 2024
Shares (in shares) | shares		447,410				447,410
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			164
Investments, at fair value:				$ 165
Investments owned acquisition date	[43]			Mar. 30, 2023
Shares (in shares) | shares				37,618				37,618
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 210
Investments, at fair value:		$ 113
Investments owned acquisition date	[3]	Mar. 30, 2023
Shares (in shares) | shares		52,665				52,665
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3],[26]	$ 716
Investments, at fair value:	[3],[26]	$ 726
Investments owned acquisition date	[3],[26]	Jun. 21, 2024
Shares (in shares) | shares	[3],[26]	185,625				185,625
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Recover Together, Inc., , Warrant, Acquisition Date 7/3/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 382
Investments, at fair value:				$ 327
Investments owned acquisition date	[43]			Jul. 03, 2023
Shares (in shares) | shares				194,830				194,830
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Recover Together, Inc.., Warrant, Acquisition Date 7/3/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 382
Investments, at fair value:		$ 193
Investments owned acquisition date	[3]	Jul. 03, 2023
Shares (in shares) | shares		194,830				194,830
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Warrant, Acquisition Date 9/28/2023, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[5],[14]			$ 83
Investments, at fair value:	[14]			$ 95
Investments owned acquisition date	[14],[43]			Sep. 28, 2023
Shares (in shares) | shares	[14]			51,760				51,760
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC., Warrant, Acquisition Date 9/28/2023, Series Common Units
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 83
Investments, at fair value:	[1]	$ 121
Investments owned acquisition date	[1],[3]	Sep. 28, 2023
Shares (in shares) | shares	[1]	51,760				51,760
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 121
Investments, at fair value:		$ 1
Investments owned acquisition date	[3]	Mar. 28, 2022
Shares (in shares) | shares		192,431				192,431
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Warrant, Acquisition Date 3/28/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 121
Investments, at fair value:				$ 9
Investments owned acquisition date	[43]			Mar. 28, 2022
Shares (in shares) | shares				192,431				192,431
Investment, Identifier [Axis]: Warrant Investments and Information Services (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0%				0%
Investment cost	[2]	$ 495
Investments, at fair value:		15
Investment, Identifier [Axis]: Warrant Investments and Information Services (0.03%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.03%				0.03%
Investment cost	[5]			$ 694
Investments, at fair value:				486
Investment, Identifier [Axis]: Warrant Investments and Information Services and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[14]			207
Investments, at fair value:	[14]			$ 33
Investments owned acquisition date	[14],[43]			Oct. 21, 2021
Shares (in shares) | shares	[14]			176,200				176,200
Investment, Identifier [Axis]: Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		82	[2],[30],[31]	$ 82	[5],[15],[16]
Investments, at fair value:		$ 0	[30],[31]	$ 0	[15],[16]
Investments owned acquisition date		Nov. 19, 2014	[3],[30],[31]	Nov. 19, 2014	[15],[16],[43]
Shares (in shares) | shares		149,165	[30],[31]	65,587	[15],[16]	149,165	[30],[31]	65,587	[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Information Services and NetBase Quid, Inc. (p.k.a NetBase Solutions), Warrant, Acquisition Date 8/22/2017, Series Preferred Series 1
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 356
Investments, at fair value:		$ 0
Investments owned acquisition date	[3]	Aug. 22, 2017
Shares (in shares) | shares		60,000				60,000
Investment, Identifier [Axis]: Warrant Investments and Information Services and NetBase Solutions, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 1
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 356
Investments, at fair value:				$ 362
Investments owned acquisition date	[43]			Aug. 22, 2017
Shares (in shares) | shares				60,000				60,000
Investment, Identifier [Axis]: Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 57	[2],[30],[31]	$ 49	[5],[15],[16]
Investments, at fair value:		$ 15	[30],[31]	$ 91	[15],[16]
Investments owned acquisition date		Jun. 29, 2022	[3],[30],[31]	Jun. 29, 2022	[15],[16],[43]
Shares (in shares) | shares		129,638	[30],[31]	113,828	[15],[16]	129,638	[30],[31]	113,828	[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology (0.06%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.06%				0.06%
Investment cost	[2]	$ 1,065
Investments, at fair value:		1,138
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology (0.17%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.17%				0.17%
Investment cost	[5]			$ 1,112
Investments, at fair value:				3,000
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		537	[2]	537	[5]
Investments, at fair value:		$ 1,006		$ 279
Investments owned acquisition date		Mar. 31, 2022	[3]	Mar. 31, 2022	[43]
Shares (in shares) | shares		392,308		392,308		392,308		392,308
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 528	[2]	$ 528	[5]
Investments, at fair value:		$ 132		$ 677
Investments owned acquisition date		Mar. 23, 2022	[3]	Mar. 23, 2022	[43]
Shares (in shares) | shares		1,111,111		1,111,111		1,111,111		1,111,111
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and Xometry, Inc., Warrant, Acquisition Date 5/9/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 47
Investments, at fair value:	[43]			$ 2,044
Investments owned acquisition date	[43]			May 09, 2018
Shares (in shares) | shares	[43]			87,784				87,784
Investment, Identifier [Axis]: Warrant Investments and Media/Content/Info (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0%				0%
Investment cost	[2]	$ 67
Investments, at fair value:		55
Investment, Identifier [Axis]: Warrant Investments and Media/Content/Info (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.01%				0.01%
Investment cost	[5]			$ 67
Investments, at fair value:				235
Investment, Identifier [Axis]: Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-1
Summary of Investment Holdings [Line Items]
Investment cost		67	[2]	67	[5]
Investments, at fair value:		$ 55		$ 235
Investments owned acquisition date		Dec. 30, 2022	[3]	Dec. 30, 2022	[43]
Shares (in shares) | shares		369,370		369,370		369,370		369,370
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment (0.01%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.01%				0.01%
Investment cost	[5]			$ 956
Investments, at fair value:				262
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.02%				0.02%
Investment cost	[2]	$ 1,066
Investments, at fair value:		421
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Intuity Medical, Inc., Warrant, Acquisition Date 12/29/2017, Series Preferred Series B-1
Summary of Investment Holdings [Line Items]
Investment cost	[5]			294
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			Dec. 29, 2017
Shares (in shares) | shares				3,076,323				3,076,323
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Outset Medical Inc, Warrant, Acquisition Date 9/27/2013, Series Common stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 401
Investments, at fair value:	[43]			$ 78
Investments owned acquisition date	[43]			Sep. 27, 2013
Shares (in shares) | shares	[43]			62,794				62,794
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	401
Investments, at fair value:	[3]	$ 2
Investments owned acquisition date	[3]	Sep. 27, 2013
Shares (in shares) | shares	[3]	62,794				62,794
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			$ 200
Investments, at fair value:	[43]			$ 184
Investments owned acquisition date	[43]			Sep. 08, 2023
Shares (in shares) | shares	[43]			728,317				728,317
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc., Warrant, Acquisition Date 9/8/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 277
Investments, at fair value:	[3]	$ 88
Investments owned acquisition date	[3]	Sep. 08, 2023
Shares (in shares) | shares	[3]	1,032,718				1,032,718
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2],[3]	$ 327
Investments, at fair value:	[3]	$ 331
Investments owned acquisition date	[3]	Jan. 22, 2024
Shares (in shares) | shares	[3]	94,980				94,980
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 61	[2],[3]	$ 61	[5],[43]
Investments, at fair value:		$ 0	[3]	$ 0	[43]
Investments owned acquisition date		Mar. 31, 2017	[3]	Mar. 31, 2017	[43]
Shares (in shares) | shares		15,712	[3]	15,712	[43]	15,712	[3]	15,712	[43]
Investment, Identifier [Axis]: Warrant Investments and Semiconductors (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.02%				0.02%
Investment cost	[2]	$ 99
Investments, at fair value:		461
Investment, Identifier [Axis]: Warrant Investments and Semiconductors (0.04%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.04%				0.04%
Investment cost	[5]			$ 99
Investments, at fair value:				811
Investment, Identifier [Axis]: Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-2
Summary of Investment Holdings [Line Items]
Investment cost		99	[2]	99	[5]
Investments, at fair value:		$ 461		$ 811
Investments owned acquisition date		Jun. 26, 2015	[3]	Jun. 26, 2015	[43]
Shares (in shares) | shares		750,000		750,000		750,000		750,000
Investment, Identifier [Axis]: Warrant Investments and Software (0.50%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.50%				0.50%
Investment cost	[2]	$ 10,429
Investments, at fair value:		9,223
Investment, Identifier [Axis]: Warrant Investments and Software (0.75%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.75%				0.75%
Investment cost	[5]			$ 10,445
Investments, at fair value:				13,549
Investment, Identifier [Axis]: Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G
Summary of Investment Holdings [Line Items]
Investment cost		74	[2]	74	[5]
Investments, at fair value:		$ 0		$ 0
Investments owned acquisition date		May 22, 2015	[3]	May 22, 2015	[43]
Shares (in shares) | shares		231,535		231,535		231,535		231,535
Investment, Identifier [Axis]: Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 449	[2]	$ 448	[5]
Investments, at fair value:		$ 338		$ 430
Investments owned acquisition date		Sep. 23, 2022	[3]	Sep. 23, 2022	[43]
Shares (in shares) | shares		254,778		254,778		254,778		254,778
Investment, Identifier [Axis]: Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 284	[2]	$ 284	[5]
Investments, at fair value:		$ 417		$ 666
Investments owned acquisition date		Nov. 18, 2020	[3]	Nov. 18, 2020	[43]
Shares (in shares) | shares		29,691		29,691		29,691		29,691
Investment, Identifier [Axis]: Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 215	[2]	$ 165	[5],[14]
Investments, at fair value:		$ 90		$ 47	[14]
Investments owned acquisition date		Oct. 04, 2021	[3]	Oct. 04, 2021	[14],[43]
Shares (in shares) | shares		435,396		194,629	[14]	435,396		194,629	[14]
Investment, Identifier [Axis]: Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 117	[2]	$ 117	[5]
Investments, at fair value:		$ 0		$ 12
Investments owned acquisition date		Sep. 30, 2020	[3]	Sep. 30, 2020	[43]
Shares (in shares) | shares		211,342		211,342		211,342		211,342
Investment, Identifier [Axis]: Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 71	[2]	$ 71	[5]
Investments, at fair value:		$ 0		$ 29
Investments owned acquisition date		Nov. 06, 2018	[3]	Nov. 06, 2018	[43]
Shares (in shares) | shares		477,454		477,454		477,454		477,454
Investment, Identifier [Axis]: Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 54	[2],[30],[31]	$ 54	[5],[15],[16]
Investments, at fair value:		$ 665	[30],[31]	$ 844	[15],[16]
Investments owned acquisition date		Apr. 10, 2018	[3],[30],[31]	Apr. 10, 2018	[15],[16],[43]
Shares (in shares) | shares		6,763	[30],[31]	6,763	[15],[16]	6,763	[30],[31]	6,763	[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 254
Investments, at fair value:		$ 254
Investments owned acquisition date	[3]	Sep. 26, 2024
Shares (in shares) | shares		39,183				39,183
Investment, Identifier [Axis]: Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 462	[2],[3]	$ 462	[5],[43]
Investments, at fair value:		$ 728	[3]	$ 1,225	[43]
Investments owned acquisition date		Apr. 25, 2019	[3]	Apr. 25, 2019	[43]
Shares (in shares) | shares		105,350	[3]	105,350	[43]	105,350	[3]	105,350	[43]
Investment, Identifier [Axis]: Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 26	[2],[26],[30],[31]	$ 26	[5],[10],[15],[16]
Investments, at fair value:		$ 44	[26],[30],[31]	$ 62	[10],[15],[16]
Investments owned acquisition date		Sep. 21, 2022	[3],[26],[30],[31]	Sep. 21, 2022	[10],[15],[16],[43]
Shares (in shares) | shares		102,898	[26],[30],[31]	102,898	[10],[15],[16]	102,898	[26],[30],[31]	102,898	[10],[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Software and DNAnexus, Inc., Warrant, Acquisition Date 3/21/2014, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 97
Investments, at fair value:				$ 47
Investments owned acquisition date	[43]			Mar. 21, 2014
Shares (in shares) | shares				909,091				909,091
Investment, Identifier [Axis]: Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 461	[2]	$ 461	[5]
Investments, at fair value:		$ 1,077		$ 258
Investments owned acquisition date		Mar. 11, 2019	[3]	Mar. 11, 2019	[43]
Shares (in shares) | shares		770,838		770,838		770,838		770,838
Investment, Identifier [Axis]: Warrant Investments and Software and Delphix Corp., Warrant, Acquisition Date 10/8/2019, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 1,594
Investments, at fair value:				$ 3,801
Investments owned acquisition date	[43]			Oct. 08, 2019
Shares (in shares) | shares				718,898				718,898
Investment, Identifier [Axis]: Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 545	[2]	$ 545	[5]
Investments, at fair value:		$ 135		$ 396
Investments owned acquisition date		Aug. 02, 2021	[3]	Aug. 02, 2021	[43]
Shares (in shares) | shares		727,047		727,047		727,047		727,047
Investment, Identifier [Axis]: Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,576	[2]	$ 1,452	[5]
Investments, at fair value:		$ 867		$ 1,207
Investments owned acquisition date		Jun. 28, 2023	[3]	Jun. 28, 2023	[43]
Shares (in shares) | shares		57,528		49,309		57,528		49,309
Investment, Identifier [Axis]: Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 278	[2]	$ 278	[5]
Investments, at fair value:		$ 295		$ 413
Investments owned acquisition date		Jun. 30, 2022	[3]	Jun. 30, 2022	[43]
Shares (in shares) | shares		95,911		95,911		95,911		95,911
Investment, Identifier [Axis]: Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 220
Investments, at fair value:		$ 295
Investments owned acquisition date	[3]	Jun. 06, 2024
Shares (in shares) | shares		20,762				20,762
Investment, Identifier [Axis]: Warrant Investments and Software and Eigen Technologies Ltd., Warrant, Acquisition Date 4/13/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16]			$ 8
Investments, at fair value:	[15],[16]			$ 4
Investments owned acquisition date	[15],[16],[43]			Apr. 13, 2022
Shares (in shares) | shares	[15],[16]			522				522
Investment, Identifier [Axis]: Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 583	[2]	$ 583	[5]
Investments, at fair value:		$ 226		$ 188
Investments owned acquisition date		Sep. 12, 2022	[3]	Sep. 12, 2022	[43]
Shares (in shares) | shares		362,837		362,837		362,837		362,837
Investment, Identifier [Axis]: Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost		$ 96	[2]	$ 96	[5]
Investments, at fair value:		$ 24		$ 77
Investments owned acquisition date		May 10, 2018	[3]	May 10, 2018	[43]
Shares (in shares) | shares		75,917		75,917		75,917		75,917
Investment, Identifier [Axis]: Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 325	[2]	$ 325	[5]
Investments, at fair value:		$ 255		$ 456
Investments owned acquisition date		Jul. 29, 2022	[3]	Jul. 29, 2022	[43]
Shares (in shares) | shares		84,995		84,995		84,995		84,995
Investment, Identifier [Axis]: Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 534
Investments, at fair value:		$ 554
Investments owned acquisition date	[3]	Mar. 12, 2024
Shares (in shares) | shares		193,618				193,618
Investment, Identifier [Axis]: Warrant Investments and Software and Kore, ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 208
Investments, at fair value:				$ 243
Investments owned acquisition date	[43]			Mar. 31, 2023
Shares (in shares) | shares				64,293				64,293
Investment, Identifier [Axis]: Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 208
Investments, at fair value:		$ 196
Investments owned acquisition date	[3]	Mar. 31, 2023
Shares (in shares) | shares		64,293				64,293
Investment, Identifier [Axis]: Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 16	[2],[26],[30],[31]	$ 16	[5],[10],[15],[16]
Investments, at fair value:		$ 22	[26],[30],[31]	$ 35	[10],[15],[16]
Investments owned acquisition date		Jan. 23, 2023	[3],[26],[30],[31]	Jan. 23, 2023	[10],[15],[16],[43]
Shares (in shares) | shares		39,948	[26],[30],[31]	39,948	[10],[15],[16]	39,948	[26],[30],[31]	39,948	[10],[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 131
Investments, at fair value:				$ 49
Investments owned acquisition date	[43]			Feb. 14, 2018
Shares (in shares) | shares				89,685				89,685
Investment, Identifier [Axis]: Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-2
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 131
Investments, at fair value:		$ 24
Investments owned acquisition date	[3]	Feb. 14, 2018
Shares (in shares) | shares		86,984				86,984
Investment, Identifier [Axis]: Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 252	[2]	$ 252	[5]
Investments, at fair value:		$ 231		$ 306
Investments owned acquisition date		Sep. 30, 2020	[3]	Sep. 30, 2020	[43]
Shares (in shares) | shares		82,362		82,362		82,362		82,362
Investment, Identifier [Axis]: Warrant Investments and Software and Onna TechnologiesInc, Warrant, Acquisition Date 7/5/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 60
Investments, at fair value:				$ 39
Investments owned acquisition date	[43]			Jul. 05, 2023
Shares (in shares) | shares				172,867				172,867
Investment, Identifier [Axis]: Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 494
Investments, at fair value:	[1]	$ 427
Investments owned acquisition date	[1],[3]	Jun. 26, 2024
Shares (in shares) | shares	[1]	134,542				134,542
Investment, Identifier [Axis]: Warrant Investments and Software and Poplicus, Inc., Warrant, Acquisition Date 5/28/2014, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 0
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			May 28, 2014
Shares (in shares) | shares				132,168				132,168
Investment, Identifier [Axis]: Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 215	[2]	$ 215	[5]
Investments, at fair value:		$ 595		$ 447
Investments owned acquisition date		Jun. 30, 2020	[3]	Jun. 30, 2020	[43]
Shares (in shares) | shares		69,120		69,120		69,120		69,120
Investment, Identifier [Axis]: Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 115
Investments, at fair value:		$ 161
Investments owned acquisition date	[3]	Apr. 23, 2024
Shares (in shares) | shares		72,122				72,122
Investment, Identifier [Axis]: Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 96	[2],[26]	$ 96	[5],[10]
Investments, at fair value:		$ 63	[26]	$ 76	[10]
Investments owned acquisition date		Mar. 22, 2023	[3],[26]	Mar. 22, 2023	[10],[43]
Shares (in shares) | shares		77,934	[26]	77,934	[10]	77,934	[26]	77,934	[10]
Investment, Identifier [Axis]: Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D
Summary of Investment Holdings [Line Items]
Investment cost		$ 103	[2]	$ 103	[5]
Investments, at fair value:		$ 430		$ 386
Investments owned acquisition date		Apr. 28, 2020	[3]	Apr. 28, 2020	[43]
Shares (in shares) | shares		312,596		312,596		312,596		312,596
Investment, Identifier [Axis]: Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Series Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost	[2],[30],[31]	$ 174
Investments, at fair value:	[30],[31]	$ 54
Investments owned acquisition date	[3],[30],[31]	Jun. 08, 2023
Shares (in shares) | shares	[30],[31]	321,956				321,956
Investment, Identifier [Axis]: Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16]			$ 174
Investments, at fair value:	[15],[16]			$ 128
Investments owned acquisition date	[15],[16],[43]			Jun. 08, 2023
Shares (in shares) | shares	[15],[16]			321,956				321,956
Investment, Identifier [Axis]: Warrant Investments and Software and Suzy Inc, Warrant, Acquisition Date 8/24/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[14]			$ 367
Investments, at fair value:	[14]			$ 354
Investments owned acquisition date	[14],[43]			Aug. 24, 2023
Shares (in shares) | shares	[14]			292,936				292,936
Investment, Identifier [Axis]: Warrant Investments and Software and Suzy, Inc. Warrant, Acquisition Date 8/24/2023, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 367
Investments, at fair value:	[1]	$ 230
Investments owned acquisition date	[1],[3]	Aug. 24, 2023
Shares (in shares) | shares	[1]	292,936				292,936
Investment, Identifier [Axis]: Warrant Investments and Software and The Faction Group LLC, Warrant, Acquisition Date 11/3/2014, Series Preferred Series AA
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 234
Investments, at fair value:				$ 904
Investments owned acquisition date	[43]			Nov. 03, 2014
Shares (in shares) | shares				8,076				8,076
Investment, Identifier [Axis]: Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares
Summary of Investment Holdings [Line Items]
Investment cost		$ 359	[2],[30],[31]	$ 174	[5],[15],[16]
Investments, at fair value:		$ 323	[30],[31]	$ 234	[15],[16]
Investments owned acquisition date		Mar. 22, 2023	[3],[30],[31]	Mar. 22, 2023	[15],[16],[43]
Shares (in shares) | shares		509,753	[30],[31]	254,877	[15],[16]	509,753	[30],[31]	254,877	[15],[16]
Investment, Identifier [Axis]: Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		$ 1,275	[1],[2]	$ 1,275	[5],[14]
Investments, at fair value:		$ 203	[1]	$ 186	[14]
Investments owned acquisition date		Jan. 21, 2022	[1],[3]	Jan. 21, 2022	[14],[43]
Shares (in shares) | shares		152,048	[1]	152,048	[14]	152,048	[1]	152,048	[14]
Investment, Identifier [Axis]: Warrant Investments and Space Technologies (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0%				0%
Investment cost	[2]	$ 207
Investments, at fair value:		21
Investment, Identifier [Axis]: Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	207
Investments, at fair value:	[1]	$ 21
Investments owned acquisition date	[1],[3]	Oct. 21, 2021
Shares (in shares) | shares	[1]	176,200				176,200
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices (0.04%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0.04%				0.04%
Investment cost	[5]			$ 39
Investments, at fair value:				676
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices and TransMedics Group, Inc., Warrant, Acquisition Date 9/11/2015, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost	[5],[43]			39
Investments, at fair value:	[43]			$ 676
Investments owned acquisition date	[43]			Sep. 11, 2015
Shares (in shares) | shares	[43]			14,440				14,440
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology (0.00%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[4]			0%				0%
Investment cost	[5]			$ 539
Investments, at fair value:				83
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology (0.02%)
Summary of Investment Holdings [Line Items]
Investment owned, percent of net assets	[24]	0.02%				0.02%
Investment cost	[2]	$ 622
Investments, at fair value:		414
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock
Summary of Investment Holdings [Line Items]
Investment cost		52	[2]	52	[5]
Investments, at fair value:		$ 51		$ 36
Investments owned acquisition date		Apr. 15, 2022	[3]	Apr. 15, 2022	[43]
Shares (in shares) | shares		18,472		18,472		18,472		18,472
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common stock
Summary of Investment Holdings [Line Items]
Investment cost	[1],[2]	$ 507
Investments, at fair value:	[1]	$ 363
Investments owned acquisition date	[1],[3]	Mar. 27, 2024
Shares (in shares) | shares	[1]	246,618				246,618
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/22/2014, Series Preferred Series A
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 155
Investments, at fair value:				$ 36
Investments owned acquisition date	[43]			Apr. 22, 2014
Shares (in shares) | shares				325,000				325,000
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Common stock
Summary of Investment Holdings [Line Items]
Investment cost	[2]	$ 63
Investments, at fair value:		$ 0
Investments owned acquisition date	[3]	Apr. 07, 2015
Shares (in shares) | shares		144,914				144,914
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Preferred Series B
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 63
Investments, at fair value:				$ 11
Investments owned acquisition date	[43]			Apr. 07, 2015
Shares (in shares) | shares				131,883				131,883
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Total Halio, Inc.,
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 218
Investments, at fair value:				$ 47
Shares (in shares) | shares				456,883				456,883
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Warrant, Polyera Corporation Acquisition Date 3/24/2015, Series Preferred Series C
Summary of Investment Holdings [Line Items]
Investment cost	[5]			$ 269
Investments, at fair value:				$ 0
Investments owned acquisition date	[43]			Mar. 24, 2015
Shares (in shares) | shares				150,036				150,036
Investment, Identifier [Axis]: nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/2022
Summary of Investment Holdings [Line Items]
Investment cost	[5],[15],[16]			$ 381
Investments, at fair value:	[15],[16]			$ 378
Investments owned acquisition date	[15],[16],[43]			Jul. 21, 2022
[1] Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company. Except for warrants in 22 publicly traded companies and common stock in 33 publicly traded companies, all investments are restricted as of September 30, 2024 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”). Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Denotes second lien senior secured debt. Prime represents 8.50% as of December 31, 2023. 1-month SOFR, 3-month SOFR, and 6-month SOFR represent 5.34%, 5.36%, and 5.35%, respectively, as of December 31, 2023. Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”). Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”). Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2023 (Refer to “Note 11 — Commitments and Contingencies”). Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition. Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company. Non-U.S. company or the company’s principal place of business is outside the United States. Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2023. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure. Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $12.0 million and $9.4 million, respectively. Debt is on non-accrual status as of December 31, 2023, and is therefore considered non-income producing. Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”). Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”). Prime represents 8.00% as of September 30, 2024. 1-month SOFR, 3-month SOFR and 6-month SOFR represent 4.85%, 4.59%, and 4.25%, respectively, as of September 30, 2024. Denotes second lien senior secured debt. Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets. Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of September 30, 2024 (Refer to “Note 11 - Commitments and Contingencies”). Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition. Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of September 30, 2024. Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure. Denotes that all or a portion of the investment in this portfolio company is held by Hercules SBIC V, L.P., the Company’s wholly owned small business investment company. Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $12.0 million and $10.9 million, respectively. Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of September 30, 2024, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million. Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of December 31, 2023, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million.

CONSOLIDATED SCHEDULE OF INVE_2

CONSOLIDATED SCHEDULE OF INVESTMENTS - Forward Foreign Currency Exchange Contracts £ in Thousands, $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2024 GBP (£)	Dec. 31, 2023 GBP (£)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Open Forward Foreign Currency Contract, Identifier [Axis]: Foreign Currency Exchange Contracts Counterparty Goldman Sachs Bank USA Settlement Date 6/3/2025
Schedule Of Investments [Line Items]
Settlement Date		Jun. 03, 2025
Derivative asset, notional amount				$ 26,178
Derivative liability, notional amount | £		£ 20,511
Cumulative unrealized gain loss on derivatives				$ (1,168)
Open Forward Foreign Currency Contract, Identifier [Axis]: Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/2024
Schedule Of Investments [Line Items]
Settlement Date			Jun. 03, 2024
Derivative asset, notional amount					$ 23,810
Derivative liability, notional amount | £			£ 19,288
Cumulative unrealized gain loss on derivatives					$ (766)
Open Forward Foreign Currency Contract, Identifier [Axis]: Total Foreign Currency Forward ((0.04%))
Schedule Of Investments [Line Items]
Investment owned, percent of net assets			(0.04%)		(0.04%)
Derivative asset, notional amount					$ 23,810
Cumulative unrealized gain loss on derivatives					$ (766)
Open Forward Foreign Currency Contract, Identifier [Axis]: Total Foreign Currency Forward ((0.06%))
Schedule Of Investments [Line Items]
Investment owned, percent of net assets	[1]	(0.06%)		(0.06%)
Derivative asset, notional amount				$ 26,178
Cumulative unrealized gain loss on derivatives				$ (1,168)
[1] Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

CONSOLIDATED SCHEDULE OF INVE_3

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical) $ in Thousands	Sep. 30, 2024 USD ($) Firm	Dec. 31, 2023 USD ($) Firm
Investment Holding [Line Items]
Investment, basis spread, variable rate	8%	8.50%
Aggregate Gross Unrealized Appreciation	$ 121,300	$ 118,300
Aggregate Gross Unrealized Depreciation	169,900	115,900
Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes	(48,600)	2,400
Aggregate cost of securities for U.S. federal income tax purposes (in billions)	3,600,000	3,200,000
Investment cost	3,609,986	3,247,033
Investments, at fair value:	$ 3,560,513	$ 3,248,046
1-month SOFR
Investment Holding [Line Items]
Interest rate	4.85%	5.34%
3-month SOFR
Investment Holding [Line Items]
Interest rate	4.59%	5.36%
6-month SOFR
Investment Holding [Line Items]
Interest rate	4.25%	5.35%
Common Stock | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment Holding [Line Items]
Number of publicly traded companies | Firm	33	36
Warrants | Significant Other Observable Inputs (Level 2)
Investment Holding [Line Items]
Number of publicly traded companies | Firm	22	24
Black Crow AI, Inc. affiliates | Promissory Note
Investment Holding [Line Items]
Principal amount	$ 2,400	$ 2,400
Phathom Pharmaceuticals, Inc. | Royalty Contract
Investment Holding [Line Items]
Investment cost	12,000	12,000
Investments, at fair value:	$ 10,900	$ 9,400

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The Company sources its investments through its principal office located in San Mateo, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, Denver, CO, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003. The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Code (see “Note 6 - Income Taxes”). The Company is not registered with the Commodity Futures Trading Commission. The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA. Hercules Capital IV, L.P. (“HC IV”) is our wholly owned Delaware limited partnership that was formed in December 2010. HC IV received a license to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020. In September 2023, the Company formed Hercules SBIC V, L.P. (“SBIC V”) which received its SBIC license on July 9, 2024. SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC, is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV and SBIC V. The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Certain of the subsidiaries are taxable and not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions. Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit. Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company. Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. As of September 30, 2024, approximately 97.4% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company provides financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in technology-related industries including drug discovery and development, software, consumer & business services, and other healthcare services at all stages of development. Given the nature of investing in these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company principally invests in debt securities with a particular emphasis on Structured Debt. The Company uses the term “Structured Debt” to refer to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred stock. Given the nature of lending to venture capital-backed and institutional-backed companies in technology-related industries, substantially all of the Company’s debt investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recording warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate Net Asset Value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820. Derivative Instruments The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. The net cash flows realized on settlement of derivatives are included in realized (gain) loss in the Consolidated Statements of Cash Flows. Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2024, the Company held $102 thousand (Cost basis $102 thousand) of foreign cash. As of December 31, 2023, the Company held $804 thousand (Cost basis $842 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”). Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables. Escrow Receivables Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”. Investment Income Recognition The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID. The OID received upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term. The Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal. Realized Gains or Losses Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries. Secured Borrowings The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value. Equity Offering Expenses The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities. Debt The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”. Debt Issuance Costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2024 and December 31, 2023. (in thousands) Balance as of Quoted Prices in Significant Significant Description Other assets and liabilities Escrow and Other Investment Receivables $ 158 $ — $ — $ 158 Accounts Payable and Accrued Liabilities (1,770) — — (1,770) Investments Senior Secured Debt $ 3,306,724 $ — $ — $ 3,306,724 Unsecured Debt 73,854 — — 73,854 Preferred Stock 47,342 — — 47,342 Common Stock (2) 95,693 49,018 — 46,675 Warrants 30,023 — 10,647 19,376 $ 3,553,636 $ 49,018 $ 10,647 $ 3,493,971 Investment Funds & Vehicles measured at Net Asset Value (3) 6,877 Total Investments, at fair value $ 3,560,513 Derivative Instruments (4) (1,168) Total Investments, at fair value including derivative instruments $ 3,559,345 (in thousands) Balance as of Quoted Prices in Significant Significant Description Cash and cash equivalents Money Market Fund (1) $ 56,000 $ 56,000 $ — $ — Other assets Escrow and Other Investment Receivables $ 10,888 $ — $ — $ 10,888 Investments Senior Secured Debt $ 2,987,577 $ — $ — $ 2,987,577 Unsecured Debt 69,722 — — 69,722 Preferred Stock 53,038 — — 53,038 Common Stock (2) 99,132 57,342 — 41,790 Warrants 33,969 — 11,881 22,088 $ 3,243,438 $ 57,342 $ 11,881 $ 3,174,215 Investment Funds & Vehicles measured at Net Asset Value (3) 4,608 Total Investments, at fair value $ 3,248,046 Derivative Instruments (4) (766) Total Investments including cash and cash equivalents and derivative instruments $ 3,303,280 (1) This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities. (2) Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock. (3) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities. (4) Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy. The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024 and 2023. (in thousands) Balance as of Net Realized Gains (Losses) (1) Net Change in Unrealized Appreciation (Depreciation) (2) Purchases (5) Sales Repayments (6) Gross Transfers into Level 3 (3)* Gross Transfers out of Level 3 (3)* Balance as of Investments Senior Secured Debt $ 2,987,577 $ (9,120) $ (34,978) $ 1,099,563 $ — $ (732,225) $ — $ (4,093) $ 3,306,724 Unsecured Debt 69,722 — 828 3,304 — — — — 73,854 Preferred Stock 53,038 (711) (9,013) 1,597 — — 2,431 — 47,342 Common Stock 41,790 (1,351) 474 4,100 — — 1,662 — 46,675 Warrants 22,088 (464) (2,367) 2,948 (2,829) — — — 19,376 Other Assets and Liabilities Escrow and Other Investment Receivables 10,888 85 5,869 43 (18,497) — — 1,770 158 Accounts Payable and Accrued Liabilities — — — — — — (1,770) — (1,770) Total $ 3,185,103 $ (11,561) $ (39,187) $ 1,111,555 $ (21,326) $ (732,225) $ 2,323 $ (2,323) $ 3,492,359 (in thousands) Balance as of Net Realized Gains (Losses) (1) Net Change in Unrealized Appreciation (Depreciation) (2) Purchases (5) Sales Repayments (6) Gross Transfers into Level 3 (4)* Gross Transfers out of Level 3 (4)* Balance as of Investments Senior Secured Debt $ 2,741,388 $ (5,400) $ (22,135) $ 1,003,953 $ — $ (695,856) $ — $ — $ 3,021,950 Unsecured Debt 54,056 — 4,958 10,916 — — — — 69,930 Preferred Stock 41,488 (3,441) 1,392 2,851 — — — — 42,290 Common Stock 25,059 — 10,684 4,500 (594) — — — 39,649 Warrants 19,419 (3,443) 1,539 3,711 (1,108) — — — 20,118 Other Assets Escrow Receivable 875 80 — — (207) — — — 748 Total $ 2,882,285 $ (12,204) $ (3,562) $ 1,025,931 $ (1,909) $ (695,856) $ — $ — $ 3,194,685 * The Company recognizes transfers as of the transaction date. (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations. (3) Transfers out of Level 3 during the nine months ended September 30, 2024 related to the conversion of the Company's Level 3 debt investments in Better Therapeutics, Inc. and Eigen Technologies Ltd. into common stock and preferred stock Level 3 investments in acquiring companies. (4) There were no transfers into or out of Level 3 during the nine months ended September 30, 2023. (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock, and warrant Level 3 investments relating to assets still held at the reporting date. (in millions) Nine Months Ended September 30, 2024 2023 Debt Investments $ (32.3) $ (16.9) Preferred Stock (9.2) (2.0) Common Stock (0.3) 10.7 Warrant Investments (0.8) (0.9) The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2024 and December 31, 2023. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted Average (2) Pharmaceuticals $ 990,349 Market Comparable Companies Hypothetical Market Yield 9.90% - 16.55% 12.74% Premium/(Discount) (2.00)% - 4.00% 0.08% Technology 1,202,375 Market Comparable Companies Hypothetical Market Yield 10.08% - 19.19% 13.26% Premium/(Discount) (0.75)% - 3.00% 0.33% 25,745 Convertible Note Analysis Probability weighting of alternative outcomes 1.00% - 70.00% 50.64% 52,586 Liquidation (3) Probability weighting of alternative outcomes 5.00% - 100.00% 57.86% Sustainable and Renewable Technology 20,957 Market Comparable Companies Hypothetical Market Yield 12.13% - 15.66% 15.43% Premium/(Discount) 0.25% - 3.00% 0.43% Medical Devices 55,413 Market Comparable Companies Hypothetical Market Yield 12.23% - 13.19% 12.65% Premium/(Discount) 0.00% - 0.50% 0.28% Lower Middle Market 601,995 Market Comparable Companies Hypothetical Market Yield 8.66% - 19.68% 14.61% Premium/(Discount) (0.25)% - 3.25% 0.84% Debt Investments for which Cost Approximates Fair Value 240,443 Debt Investments originated within 6 months 70,171 Imminent Payoffs (4) 72,911 Debt Investments Maturing in Less than One Year 47,633 Debt Investments in Wholly-Owned Subsidiaries $ 3,380,578 Total Level 3 Debt Investments Accounts Payable and Accrued Liabilities (1,770) Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 38.97% $ 3,378,808 Total Level Three Debt Investments and Other Investment Receivables (Payables) (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, and “Software” industries. • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes. (4) Imminent Payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Debt Investments Fair Value as of Valuation Techniques/ Methodologies Unobservable Input (1) Range Weighted Average (2) Pharmaceuticals $ 971,775 Market Comparable Companies Hypothetical Market Yield 10.91% - 21.43% 13.46% Premium/(Discount) (1.00)% - 3.50% 0.04% 8,455 Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 41.83% Technology 1,181,823 Market Comparable Companies Hypothetical Market Yield 11.30% - 20.74% 15.03% Premium/(Discount) (1.00)% - 5.00% 0.47% 23,244 Convertible Note Analysis Probability weighting of alternative outcomes 1.00% - 50.00% 39.32% — Liquidation (3) Probability weighting of alternative outcomes 100.00% - 100.00% 100.00% Sustainable and Renewable Technology 1,678 Market Comparable Companies Hypothetical Market Yield 10.75% - 10.75% 10.75% Premium/(Discount) 0.75% - 0.75% 0.75% Lower Middle Market 322,162 Market Comparable Companies Hypothetical Market Yield 12.54% - 20.15% 14.13% Premium/(Discount) (0.75)% - 2.25% 0.56% Debt Investments for which Cost Approximates Fair Value 431,512 Debt Investments originated within 6 months 54,430 Imminent Payoffs (4) 62,220 Debt Investments Maturing in Less than One Year $ 3,057,299 Total Level 3 Debt Investments Other Investment Receivables 9,648 Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 41.83% $ 3,066,947 Total Level Three Debt Investments and Other Investment Receivables (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries. • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 43,990 Market Comparable Companies Revenue Multiple (2) 0.4x - 14.8x 13.4x Tangible Book Value Multiple (2) 1.6x - 1.6x 1.6x Discount for Lack of Marketability (3) 13.48% - 92.82% 36.18% 13,781 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (83.75)% - 30.35% (8.48)% 33,234 Discounted Cash Flow Discount Rate (7) 11.52% - 33.40% 31.14% 3,012 Other (6) Warrant Investments 15,466 Market Comparable Companies Revenue Multiple (2) 0.9x - 11.9x 4.1x Discount for Lack of Marketability (3) 12.93% - 33.96% 24.63% 3,910 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (62.04)% - 30.35% (1.40)% Total Level 3 Equity and Warrant Investments $ 113,393 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 52,094 Market Comparable Companies EBITDA Multiple (2) 12.3x - 12.3x 12.3x Revenue Multiple (2) 0.3x - 20.1x 7.2x Tangible Book Value Multiple (2) 1.8x - 1.8x 1.8x Discount for Lack of Marketability (3) 7.11% - 92.72% 31.57% 11,096 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (86.14)% - 32.69% 7.47% 28,713 Discounted Cash Flow Discount Rate (7) 19.88% - 31.97% 30.51% 2,925 Other (6) Warrant Investments 19,014 Market Comparable Companies EBITDA Multiple (2) 12.3x -12.3x 12.3x Revenue Multiple (2) 0.9x - 10.2x 4.2x Discount for Lack of Marketability (3) 6.21% - 33.12% 21.70% 3,074 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (70.67)% - 34.86% 13.17% — Other (6) Total Level 3 Equity and Warrant Investments $ 116,916 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument. As of September 30, 2024 and December 31, 2023, the 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $25.63 and $25.25 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit. Based on market quotations on or around September 30, 2024 and December 31, 2023, the 2031 Asset-Backed Notes were quoted for 0.970 and 0.950. The fair values of the SBA debentures, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of September 30, 2024 and December 31, 2023. The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 Description Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs SBA Debentures $ 170,763 $ 155,728 $ — $ — $ 155,728 February 2025 Notes 49,952 49,902 — — 49,902 June 2025 Notes 69,879 69,890 — — 69,890 June 2025 3-Year Notes 49,887 50,560 — — 50,560 March 2026 A Notes 49,866 48,691 — — 48,691 March 2026 B Notes 49,854 48,726 — — 48,726 September 2026 Notes 323,075 301,311 — — 301,311 January 2027 Notes 346,932 327,712 — — 327,712 2031 Asset-Backed Notes 148,985 145,500 — 145,500 — 2033 Notes 39,016 41,008 — 41,008 — MUFG Bank Facility 240,000 240,000 — — 240,000 SMBC Facility 201,000 201,000 — — 201,000 Total $ 1,739,209 $ 1,680,028 $ — $ 186,508 $ 1,493,520 (in thousands) December 31, 2023 Description Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs SBA Debentures $ 170,323 $ 142,011 $ — $ — $ 142,011 July 2024 Notes 104,828 105,755 — — 105,755 February 2025 Notes 49,866 49,144 — — 49,144 June 2025 Notes 69,757 67,198 — — 67,198 June 2025 3-Year Notes 49,771 48,983 — — 48,983 March 2026 A Notes 49,795 47,702 — — 47,702 March 2026 B Notes 49,776 47,759 — — 47,759 September 2026 Notes 322,339 288,711 — — 288,711 January 2027 Notes 345,935 315,832 — — 315,832 2031 Asset-Backed Notes 148,544 142,500 — 142,500 — 2033 Notes 38,935 40,400 — 40,400 — MUFG Bank Facility 61,000 61,000 — — 61,000 SMBC Facility 94,000 94,000 — — 94,000 Total $ 1,554,869 $ 1,450,995 $ — $ 182,900 $ 1,268,095

Investments

Investments	9 Months Ended
	Sep. 30, 2024
Schedule of Investments [Abstract]
Investments	Investments Control and Affiliate Investments As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds. The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2024 and 2023. (in thousands) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Portfolio Company (1) Type Fair Value as of September 30, 2024 Interest & Dividend Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest & Dividend Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 319 $ — $ — $ 133 $ — $ — $ — $ 57 $ — Gibraltar Acquisition LLC (2) Control 57,302 1,359 36 (74) — 3,926 108 (6,365) — Hercules Adviser LLC (3) Control 43,433 1,954 — 705 — 5,457 — 2,720 — Tectura Corporation Control 12,043 174 — 509 — 518 — 526 — Total Control Investments $ 113,097 $ 3,487 $ 36 $ 1,273 $ — $ 9,901 $ 108 $ (3,062) $ — (in thousands) Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Portfolio Company (1) Type Fair Value as of September 30, 2023 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 247 $ — $ — $ (50) $ — $ — $ — $ (72) $ — Gibraltar Acquisition, LLC (2) Control 55,992 772 22 (1,726) — 2,299 60 4,676 — Hercules Adviser LLC (3) Control 40,668 153 — 1,507 — 455 — 9,515 — Tectura Corporation Control 6,243 174 — (830) — 516 — (1,799) — Total Control Investments $ 103,150 $ 1,099 $ 22 $ (1,099) $ — $ 3,270 $ 60 $ 12,320 $ — (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2024 and September 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (3) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure. Portfolio Composition The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 3,306,724 92.9 % $ 2,987,577 92.0 % Unsecured Debt 73,854 2.1 % 69,722 2.2 % Preferred Stock 47,342 1.3 % 53,038 1.6 % Common Stock 95,693 2.7 % 99,132 3.1 % Warrants 30,023 0.8 % 33,969 1.0 % Investment Funds & Vehicles 6,877 0.2 % 4,608 0.1 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2024 and December 31, 2023 is shown as follows: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of United States $ 3,219,874 90.4 % $ 2,861,615 88.1 % United Kingdom 174,566 4.9 % 222,136 6.9 % Israel 77,767 2.2 % 52,868 1.6 % Netherlands 59,562 1.7 % 89,995 2.8 % Canada 16,441 0.5 % 15,730 0.5 % Ireland 4,513 0.1 % — 0.0 % Denmark 4,176 0.1 % 4,173 0.1 % Singapore 1,999 0.1 % — 0.0 % Germany 1,219 0.0 % 1,144 0.0 % Other 396 0.0 % 385 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,125,617 31.6 % $ 1,257,699 38.7 % Software 1,018,236 28.6 % 764,985 23.6 % Healthcare Services, Other 574,750 16.1 % 300,079 9.3 % Consumer & Business Services 355,831 10.0 % 525,973 16.2 % Diversified Financial Services 112,709 3.2 % 114,722 3.5 % Electronics & Computer Hardware 96,125 2.7 % 20,324 0.6 % Information Services 81,266 2.3 % 126,605 3.9 % Medical Devices & Equipment 56,153 1.6 % 22,096 0.7 % Space Technologies 46,082 1.3 % — 0.0 % Biotechnology Tools 35,311 1.0 % 48,381 1.5 % Sustainable and Renewable Technology 27,858 0.8 % 9,581 0.3 % Communications & Networking 26,465 0.7 % 29,400 0.9 % Manufacturing Technology 2,096 0.1 % 11,006 0.3 % Consumer & Business Products 1,285 0.0 % 2,589 0.1 % Semiconductors 655 0.0 % 1,205 0.0 % Media/Content/Info 55 0.0 % 12,704 0.4 % Drug Delivery 19 0.0 % 21 0.0 % Surgical Devices — 0.0 % 676 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of September 30, 2024 or December 31, 2023. Concentrations of Credit Risk As of September 30, 2024, the Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development”, “Software”, “Healthcare Services, Other”, “Consumer & Business Services”, and “Diversified Financial Services” sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated among several portfolio companies. As of September 30, 2024 and December 31, 2023, the Company’s ten largest portfolio companies represented approximately 30.6% and 29.7% of the total fair value of the Company’s investments in portfolio companies, respectively. As of September 30, 2024 and December 31, 2023, the Company had five and five portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of September 30, 2024 and December 31, 2023, the Company had four and five equity investments, respectively, that represented 5% or more of the total fair value of the Company’s equity investments. These equity investments represented approximately 52.9% and 56.5% of the total fair value of the Company’s equity investments as of September 30, 2024 and December 31, 2023, respectively. Investment Collateral In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of September 30, 2024 and December 31, 2023: Percentage of debt investments (at fair value), as of September 30, 2024 December 31, 2023 Senior Secured First Lien All assets including intellectual property 63.1 % 52.3 % All assets with negative pledge on intellectual property 16.1 % 24.0 % “Last-out” with security interest in all of the assets 10.3 % 12.5 % Total senior secured first lien position 89.5 % 88.8 % Second lien 8.3 % 8.9 % Unsecured 2.2 % 2.3 % Total debt investments at fair value 100.0 % 100.0 % Derivative Instruments The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of September 30, 2024 and December 31, 2023: (in thousands) Fair Value Derivative Instrument Statement Location September 30, 2024 December 31, 2023 Foreign currency forward contract Other assets $ — $ — Foreign currency forward contract Accounts payable and accrued liabilities 1,168 766 Total $ 1,168 $ 766 Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and nine months ended September 30, 2024 and 2023 are in the following locations in the Consolidated Statements of Operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Statement Location 2024 2023 2024 2023 Foreign currency forward contract Net realized gain (loss) - Non-control / Non-affiliate investments $ — $ — $ (849) $ — Foreign currency forward contract Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments (1,356) 784 (402) 230 Total $ (1,356) $ 784 $ (1,251) $ 230 Investment Income The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Contractual interest income $ 90,288 $ 89,747 $ 268,441 $ 258,685 Exit fee interest income 12,047 10,904 34,519 34,340 PIK interest income 12,706 6,652 37,870 17,999 Dividend income 2,100 — 5,800 — Other investment income (1) 1,909 3,036 5,728 8,198 Total interest and dividend income $ 119,050 $ 110,339 $ 352,358 $ 319,222 (1) Other investment income includes OID interest income and interest recorded on other assets. (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Recurring fee income $ 2,423 $ 2,243 $ 7,081 $ 6,418 Fee income - expired commitments 413 300 1,790 651 Accelerated fee income - early repayments 3,362 3,862 10,578 11,774 Total fee income $ 6,198 $ 6,405 $ 19,449 $ 18,843 As of September 30, 2024 and December 31, 2023, unamortized capitalized fee income was recorded as follows: (in millions) September 30, December 31, Offset against debt investment cost $ 36.7 $ 32.9 Deferred obligation contingent on funding or other milestone 9.7 9.4 Total Unamortized Fee Income $ 46.4 $ 42.3 As of September 30, 2024 and December 31, 2023, loan exit fees receivable were recorded as follows: (in millions) September 30, December 31, Included within debt investment cost $ 37.0 $ 35.9 Deferred receivable related to expired commitments 3.4 4.3 Total Exit Fees Receivable $ 40.4 $ 40.2

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt As of September 30, 2024 and December 31, 2023, the Company had the following available and outstanding debt: (in thousands) September 30, 2024 December 31, 2023 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures (2)(4) $ 350,000 $ 175,000 $ 170,763 $ 175,000 $ 175,000 $ 170,323 July 2024 Notes — — — 105,000 105,000 104,828 February 2025 Notes 50,000 50,000 49,952 50,000 50,000 49,866 June 2025 Notes 70,000 70,000 69,879 70,000 70,000 69,757 June 2025 3-Year Notes 50,000 50,000 49,887 50,000 50,000 49,771 March 2026 A Notes 50,000 50,000 49,866 50,000 50,000 49,795 March 2026 B Notes 50,000 50,000 49,854 50,000 50,000 49,776 September 2026 Notes 325,000 325,000 323,075 325,000 325,000 322,339 January 2027 Notes 350,000 350,000 346,932 350,000 350,000 345,935 2031 Asset-Backed Notes 150,000 150,000 148,985 150,000 150,000 148,544 2033 Notes 40,000 40,000 39,016 40,000 40,000 38,935 MUFG Bank Facility (2) 400,000 240,000 240,000 400,000 61,000 61,000 SMBC Facility (2)(3) 400,000 201,000 201,000 400,000 94,000 94,000 Total $ 2,285,000 $ 1,751,000 $ 1,739,209 $ 2,215,000 $ 1,570,000 $ 1,554,869 (1) Except for the SMBC Facility and MUFG Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) “Total Available” includes $175.0 million of available commitment through the letter of credit facility as of September 30, 2024 and December 31, 2023. (4) As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV. Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 SBA Debentures $ 4,237 $ 4,677 July 2024 Notes — 172 February 2025 Notes 48 134 June 2025 Notes 121 243 June 2025 3-Year Notes 113 229 March 2026 A Notes 134 205 March 2026 B Notes 146 224 September 2026 Notes 1,925 2,661 January 2027 Notes 3,068 4,065 2031 Asset-Backed Notes 1,015 1,456 2033 Notes 984 1,065 MUFG Bank Facility (1) 2,220 3,540 SMBC Facility (1) 1,235 1,775 Total $ 15,246 $ 20,446 (1) The MUFG Bank Facility and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30. For the three and nine months ended September 30, 2024, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,149 $ 147 $ — $ 1,296 $ 2,300 $ 3,424 $ 439 $ — $ 3,863 $ 4,575 July 2024 Notes 202 24 — 226 2,504 2,706 172 — 2,878 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 755 40 — 795 — 2,263 121 — 2,384 1,508 June 2025 3-Year Notes 750 38 — 788 — 2,250 116 — 2,366 1,500 March 2026 A Notes 563 24 — 587 1,125 1,688 71 — 1,759 2,250 March 2026 B Notes 568 25 — 593 1,138 1,706 77 — 1,783 2,276 September 2026 Notes 2,174 205 — 2,379 4,266 6,523 612 — 7,135 8,531 January 2027 Notes 3,080 208 — 3,288 5,906 9,236 622 — 9,858 11,812 2031 Asset-Backed Notes 1,903 100 — 2,003 1,856 5,710 300 — 6,010 5,568 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 MUFG Bank Facility 4,105 443 329 4,877 3,875 8,181 1,328 1,572 11,081 7,596 SMBC Facility 3,961 180 174 4,315 4,020 9,989 540 599 11,128 9,582 Total $ 20,370 $ 1,490 $ 503 $ 22,363 $ 28,685 $ 57,156 $ 4,565 $ 2,171 $ 63,892 $ 64,221 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2024 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2024 of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the three and nine months ended September 30, 2023, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,150 $ 146 $ — $ 1,296 $ 2,300 $ 3,412 $ 436 $ — $ 3,848 $ 4,562 July 2024 Notes 1,252 74 — 1,326 2,505 3,756 222 — 3,978 5,009 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 June 2025 3-Year Notes 750 39 — 789 — 2,250 117 — 2,367 1,500 March 2026 A Notes 563 24 — 587 1,125 1,688 71 — 1,759 2,250 March 2026 B Notes 569 26 — 595 1,138 1,706 78 — 1,784 2,275 September 2026 Notes 2,174 203 — 2,377 4,266 6,523 611 — 7,134 8,532 January 2027 Notes 3,079 207 — 3,286 5,906 9,236 621 — 9,857 11,812 2031 Asset-Backed Notes 1,902 101 — 2,003 1,857 5,709 301 — 6,010 5,570 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 MUFG Bank Facility 1,247 443 709 2,399 1,240 4,323 1,327 2,017 7,667 4,673 SMBC Facility 1,828 180 276 2,284 1,715 5,891 513 715 7,119 5,703 Total $ 16,428 $ 1,539 $ 985 $ 18,952 $ 23,747 $ 50,237 $ 4,585 $ 2,732 $ 57,554 $ 57,410 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2023 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2023, of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. The overall weighted average cost of debt for the Company was approximately 5.1% and 4.8% for the three months ended September 30, 2024 and 2023, respectively and 5.0% and 4.8% for the nine months ended September 30, 2024 and 2023, respectively. The weighted average cost of debt includes interest and fees on the Company's debt but excludes the impact of fee accelerations due to the extinguishment of debt, as applicable. As of September 30, 2024 and December 31, 2023, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company’s debt. SBA Debentures The Company held the following SBA debentures outstanding principal balances as of September 30, 2024 and December 31, 2023: (in thousands) Maturity Date Interest Rate (1) September 30, 2024 December 31, 2023 March 26, 2021 September 1, 2031 1.58% $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58% 16,200 16,200 July 28, 2021 September 1, 2031 1.58% 5,400 5,400 August 20, 2021 September 1, 2031 1.58% 5,400 5,400 October 21, 2021 March 1, 2032 3.21% 14,000 14,000 November 1, 2021 March 1, 2032 3.21% 21,000 21,000 November 15, 2021 March 1, 2032 3.21% 5,200 5,200 November 30, 2021 March 1, 2032 3.21% 20,800 20,800 December 20, 2021 March 1, 2032 3.21% 10,000 10,000 December 23, 2021 March 1, 2032 3.21% 10,000 10,000 December 28, 2021 March 1, 2032 3.21% 5,000 5,000 January 14, 2022 March 1, 2032 3.21% 4,500 4,500 January 21, 2022 March 1, 2032 3.21% 20,000 20,000 Total SBA Debentures $ 175,000 $ 175,000 (1) Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges. SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs compliance with SBA regulations. Our SBIC was in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of September 30, 2024 and December 31, 2023. HC IV received its license to operate as an SBIC on October 27, 2020. The license has a 10-year term. Through the license, HC IV has access to $175.0 million of capital through the SBA debenture program, subject to maintaining certain conditions. As of September 30, 2024 and December 31, 2023, HC IV has issued a total of $175.0 million in SBA guaranteed debentures. On July 9, 2024, SBIC V received its license to operate as an SBIC. This is Hercules' fourth SBIC license, through which the Company has access to $175.0 million of SBA debentures, subject to meeting certain conditions. The license has a 10-year term and SBA debentures bear fixed interest based on the treasury rate plus a spread applicable for the period the debentures are drawn. As of the latest debenture pooling date in September 2024, SBA debentures were issued with an interest rate of approximately 4.509%. The actual rates may vary depending on the timing of drawdown and pooling period. The following table summarizes information related to our SBICs as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description HC IV SBIC V HC IV SBIC V Number of investments held 28 1 25 — Fair value of investments (in millions) $ 352.4 $ 11.2 $ 331.5 $ — Percentage of fair value of investments based on the Company's total investment portfolio 9.9 % 0.3 % 10.2 % 0.0 % Tangible assets (in millions) $ 369.7 $ 13.3 $ 341.8 $ — Percentage of tangible assets based on the Company's total assets 10.1 % 0.4 % 10.0 % 0.0 % 2024 Notes On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the July 2024 Notes is due semiannually. The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On July 16, 2024, the Company fully repaid the aggregate outstanding $105.0 million principal and $2.5 million of accrued interest pursuant to the terms of the July 2024 Notes. February 2025 Notes On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is due semiannually. The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 Notes On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 3-Year Notes On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.00% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes is due semiannually. The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 A Notes On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.50% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes is due semiannually. The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 B Notes On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. Interest on the March 2026 B Notes is due semiannually. The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. September 2026 Notes On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year. The September 2026 Notes are general unsecured obligations and rank pari passu , or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. January 2027 Notes On January 20, 2022, the Company issued $350.0 million in aggregate principal amount of 3.375% interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Notes”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year. The January 2027 Notes are general unsecured obligations and rank pari passu , or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture. 2031 Asset-Backed Notes On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $150.0 million in aggregate principal amount of 4.95% interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available. Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of September 30, 2024 and December 31, 2023, there was approximately $5.1 million and $17.1 million, respectively, of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. The reinvestment period for 2031 Asset-Backed Notes ended on July 20, 2024, and as a result all principal payments received from portfolio companies will no longer be eligible for reinvestment and will be utilized to pay down the outstanding principal amount. 2033 Notes On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu , or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023. Credit Facilities As of September 30, 2024 and December 31, 2023, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the nine months ended September 30, 2024 and year ended December 31, 2023, the weighted average interest rate was 7.79% and 7.41%, respectively, and the average debt outstanding under the Credit Facilities was $311.0 million and $192.3 million, respectively. MUFG Bank Facility On January 13, 2023, the Company entered into a third amended credit facility agreement, which amends the agreement dated as of June 10, 2022. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time. Under the MUFG Bank Facility, the lenders have made commitments of $400.0 million, which may be further increased via an accordion feature up to an aggregate $600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. Debt under the MUFG Bank Facility generally bears interest at a rate per annum equal to SOFR The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy. SMBC Facility On June 14, 2022, the Company entered into a second amendment to a revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of September 30, 2024, the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $225.0 million, from which the Company may access subject to certain conditions. The SMBC Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $500.0 million, funded by existing or additional lenders and with the agreement of SMBC Bank and subject to other customary conditions. Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026. Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder. Additionally in January 2023, the Company entered into a Letter of Credit Facility Agreement (the “SMBC LC Facility”) with Sumitomo Mitsui Banking Corporation that provides for a letter of credit facility with a final maturity date ending on January 13, 2026 and a commitment amount of $175.0 million as amended. Further, the SMBC LC Facility includes an accordion provision to increase the commitment up to $400.0 million, subject to certain conditions. The Company’s obligations under the SMBC LC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and is primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and any subsidiary guarantors thereunder. Interest under the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CORRA, or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 0.875% to 2.0% per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility. The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The determination of taxable income pursuant to U.S. federal income tax regulations differs from U.S. GAAP. As a result, permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. During the year ended December 31, 2023, the Company reclassified $0.8 million from accumulated net realized gains (losses) to additional paid-in capital for book purposes primarily related to net realized gains from portfolio companies which are held in taxable subsidiaries and are not consolidated with the Company for income tax purposes. Taxable income and taxable net realized gains (losses) for the three and nine months ended September 30, 2024 and 2023 appears as follows: (in millions, except per share data) Three Months Ended September 30, Nine Months Ended September 30, Description 2024 2023 2024 2023 Taxable income $ 75.8 $ 72.7 $ 230.0 $ 197.7 Taxable income per share $ 0.47 $ 0.50 $ 1.44 $ 1.40 Taxable net realized gains (losses) $ 8.7 $ 6.8 $ 18.1 $ 34.2 Taxable net realized gains (losses) per share $ 0.05 $ 0.04 $ 0.11 $ 0.24 Weighted average shares outstanding 161.0 146.9 159.7 141.2 The aggregate gross unrealized appreciation of the Company’s investments over cost for U.S. federal income tax purposes appears as follows: (in millions) September 30, 2024 December 31, 2023 Aggregate Gross Unrealized Appreciation $ 121.3 $ 118.3 Aggregate Gross Unrealized Depreciation 169.9 115.9 Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes (48.6) 2.4 Aggregate cost of securities for U.S. federal income tax purposes (in billions) 3.6 3.2 For the three and nine months ended September 30, 2024, the Company paid zero and $5.2 million of income tax, including excise tax, and had $5.3 million of accrued, but unpaid tax expense as of September 30, 2024. For the three and nine months ended September 30, 2023, the Company paid approximately $0.1 million and $5.2 million of income tax, including excise tax, and had $5.3 million of accrued, but unpaid tax expense as of September 30, 2023. Additionally, the Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal U.S. federal tax rates based on its taxable income. In accordance with ASC 740, the Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes. Based on an analysis of the Company’s tax position, there are no uncertain tax positions that met the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2020 - 2023 federal tax years for the Company remain subject to examination by the Internal Revenue Service. The 2019 – 2023 state tax years for the Company remain subject to examination by the state taxing authorities.

Stockholders' Equity and Distri

Stockholders' Equity and Distributions	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity and Distributions	Stockholders’ Equity and Distributions The Company has issued and outstanding 162,505,144 and 157,758,072 shares of common stock as of September 30, 2024 and December 31, 2023, respectively. The Company currently sell shares through its equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jefferies”) (the “2023 Equity Distribution Agreement”) entered into on May 5, 2023. The 2023 Equity Distribution Agreement provides that the Company may offer and sell up to 25.0 million shares of its common stock from time to time through JMP or Jefferies, as the Company's sales agents. Sales of the Company's common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. Additionally, on August 7, 2023, the Company sold 6.5 million shares of common stock through an upsized public offering pursuant to an underwriting agreement with Morgan Stanley & Co. LLC, UBS Securities, and Wells Fargo Securities, LLC as joint book-running managers to sell. The Company issued and sold the following shares of common stock during the nine months ended September 30, 2024 and 2023: (in millions, except per share data) Nine Months Ended September 30, Number of Shares Issued Gross Proceeds Underwriting Fees/Offering Expenses Net Proceeds Average Price/Share 2024 3.7 $ 67.3 $ 1.0 $ 66.3 $ 17.83 2023 16.2 $ 243.6 $ 5.3 $ 238.3 $ 14.69 The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of September 30, 2024, approximately 13.6 million shares remain available for issuance and sale under the current equity distribution agreement. The Company currently pays quarterly distributions to its stockholders. The following table summarizes the Company’s distributions declared during the nine months ended September 30, 2024 and year ended December 31, 2023: (in thousands, except per share data) Distribution Type Declared Date Record Date Payment Date Per Share Amount Total Amount Base February 9, 2023 March 2, 2023 March 9, 2023 $ 0.39 $ 53,749 Supplemental February 9, 2023 March 2, 2023 March 9, 2023 $ 0.08 $ 11,025 Base April 27, 2023 May 16, 2023 May 23, 2023 $ 0.39 $ 55,910 Supplemental April 27, 2023 May 16, 2023 May 23, 2023 $ 0.08 $ 11,469 Base July 28, 2023 August 18, 2023 August 25, 2023 $ 0.40 $ 60,445 Supplemental July 28, 2023 August 18, 2023 August 25, 2023 $ 0.08 $ 12,089 Base October 26, 2023 November 15, 2023 November 22, 2023 $ 0.40 $ 61,345 Supplemental October 26, 2023 November 15, 2023 November 22, 2023 $ 0.08 $ 12,269 Total distributions declared during the year ended December 31, 2023 $ 1.90 $ 278,301 Base February 8, 2024 February 28, 2024 March 6, 2024 $ 0.40 $ 63,359 Supplemental February 8, 2024 February 28, 2024 March 6, 2024 $ 0.08 $ 12,672 Base April 25, 2024 May 14, 2024 May 21, 2024 $ 0.40 $ 64,912 Supplemental April 25, 2024 May 14, 2024 May 21, 2024 $ 0.08 $ 12,982 Base July 25, 2024 August 13, 2024 August 20, 2024 $ 0.40 $ 64,953 Supplemental July 25, 2024 August 13, 2024 August 20, 2024 $ 0.08 $ 12,990 Total distributions declared during the nine months ended September 30, 2024 $ 1.44 $ 231,868 During the nine months ended September 30, 2024, for income tax purposes, the distributions paid of $1.44 per share were comprised of ordinary income. As of September 30, 2024, the Company estimates that it has generated undistributed taxable earnings “spillover” of $0.94 per share. The undistributed taxable earnings spillover will be carried forward toward distributions to be paid in accordance with RIC requirements. The Company has a distribution reinvestment plan, whereby the Company may buy shares of its common stock in the open market or issue new shares in order to satisfy dividend reinvestment requests. When the Company issues new shares in connection with the dividend reinvestment plan, the issue price is equal to the closing price of its common stock on the dividend record date. During the nine months ended September 30, 2024 and 2023, the Company issued 342,129 and 197,592 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018 and, unless earlier terminated by the Board, terminate on May 12, 2028. Subject to certain adjustments and permitted reversions of shares, the maximum aggregate number of shares that may be authorized for issuance under awards granted under the 2018 Plan and Director Plan is 9,261,229 shares and 300,000 shares, respectively. In connection with the issuance of shares under the 2018 Plan and Director Plan, the Company has registered, in aggregate, 18.7 million and 300,000 shares of common stock, respectively. Outstanding awards issued under plans that precede the 2018 Plan and Director Plan remain outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with their terms. The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock. The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended September 30, 2024, and 2023, the Company recognized $3.2 million and $3.3 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. For the nine months ended September 30, 2024, and 2023, the company recognized $9.7 million and $9.8 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. As of September 30, 2024, and 2023, approximately $20.0 million and $21.3 million of total unrecognized compensation costs expected to be recognized over the next 2.3 and 2.8 years, respectively. Service-Vesting Awards The Company grants equity-based awards which have service conditions, which generally begin to vest one-third after one year after the date of grant and ratably over the succeeding 2 years in accordance with the individual award terms. Certain awards have service conditions of longer duration and may begin to vest up to seven years after the date of grant. These equity-based awards which vest upon achievement of service conditions are collectively referred to as the “Service Vesting Awards”. The grant date fair value of Service Vesting Awards granted during the nine months ended September 30, 2024, and 2023, were approximately $14.7 million, and $18.3 million, respectively. The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the nine months ended September 30, 2024, and 2023, are summarized below: Nine Months Ended September 30, 2024 2023 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 1,880,409 $ 14.52 958,985 $ 16.35 Granted 835,481 $ 17.48 1,314,268 $ 13.83 Vested (687,360) $ 14.46 (526,292) $ 16.18 Forfeited (38,128) $ 15.45 (11,572) $ 15.42 Unvested Shares End of Period 1,990,402 $ 12.70 1,735,389 $ 14.50 In addition to the restricted stock equity-based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the nine months ended September 30, 2024 and 2023, was approximately $134,000 and $134,000, respectively. During the nine months ended September 30, 2024 and 2023, approximately $98,000, and $73,000, of share-based cost due to stock option grants was expensed, respectively. Performance-Vesting Awards The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date using a Monte-Carlo simulation multiplied by the target payout level and is recognized over the service period. For certain Performance Awards, distribution equivalent units (“Performance DEUs”) will accrue in the form of additional shares, but will not be paid unless the Performance Awards to which such Performance DEUs relate actually vest. During the nine months ended September 30, 2024 and 2023, no Performance Awards were granted or vested. During the nine months ended September 30, 2024, no shares of Performance DEUs were issued or vested. During the nine months ended September 30, 2023, 54,858 Performance DEUs were issued with a grant date fair value of $0.7 million. As of September 30, 2024 and 2023, there were no unvested Performance Awards. Liability Classified Awards The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). As of September 30, 2024, all Liability Awards have vested and have been settled. Generally, if the performance conditions of these types of awards are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The Company records Liability Awards as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statements of Assets and Liabilities. Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. The Company accrues for Liability Awards based on the expected probability that the performance conditions would be met, this assumption is re-evaluated each period, and may be adjusted to reflect changes in this assumption. Generally, the other Liability Awards vest over a three-year service term. For the nine months ended September 30, 2024, there was approximately $0.5 million of compensation expense related to the Liability Awards recognized in the Consolidated Statements of Operations and no amounts remain outstanding. During the nine months ended September 30, 2024 and 2023, $3.1 million and no Liability Awards vested, respectively.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator Net increase (decrease) in net assets resulting from operations $ 68,711 $ 27,967 $ 201,527 $ 217,306 Less: Total distributions declared (77,943) (72,534) (231,868) (204,687) Total Earnings (loss), net of total distributions (9,232) (44,567) (30,341) 12,619 Earnings (loss), net of distributions attributable to common shares (9,232) (44,567) (30,341) 12,486 Add: Distributions declared attributable to common shares 77,263 71,860 229,650 202,556 Numerator for basic and diluted change in net assets per common share $ 68,031 $ 27,293 $ 199,309 $ 215,042 Denominator Basic weighted average common shares outstanding 161,019 146,899 159,742 141,223 Common shares issuable 496 211 511 903 Weighted average common shares outstanding assuming dilution 161,515 147,110 160,253 142,126 Change in net assets per common share: Basic $ 0.42 $ 0.19 $ 1.25 $ 1.52 Diluted $ 0.42 $ 0.19 $ 1.24 $ 1.51 In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share. The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2024, and 2023, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three Months Ended September 30, Nine Months Ended September 30, Anti-dilutive Securities 2024 2023 2024 2023 Unvested common stock options 832 347 1,212 1,782 Restricted stock units — — — 5,810 Unvested restricted stock awards 152 395 398 40,034 As of September 30, 2024 and December 31, 2023, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote. On October 28, 2024, the Company filed Articles of Amendment (the “Charter Amendment”) with the Secretary of State of the State of Maryland. The Charter Amendment amended the Company’s Articles of Incorporation to increase the number of authorized shares of Company stock from 200.0 million shares to 300.0 million shares, as approved by the Company’s Board. The Charter Amendment is effective as of October 28, 2024.

Financial Highlights

Financial Highlights	9 Months Ended
	Sep. 30, 2024
Investment Company, Financial Highlights [Abstract]
Financial Highlights	Financial Highlights Following is a schedule of financial highlights for the nine months ended September 30, 2024 and 2023: (in thousands, except per share data and ratios) Nine Months Ended September 30, 2024 2023 Per share data: (1) Net asset value at beginning of period $ 11.43 $ 10.53 Net investment income 1.53 1.54 Net realized gain (loss) 0.01 0.04 Net unrealized appreciation (depreciation) (0.28) (0.04) Total from investment operations 1.26 1.54 Net increase (decrease) in net assets from capital share transactions (1) 0.10 0.25 Distributions of net investment income (6) (1.45) (1.45) Stock-based compensation expense included in net investment income and other movements (2) 0.06 0.06 Net asset value at end of period $ 11.40 $ 10.93 Ratios and supplemental data: Per share market value at end of period $ 19.64 $ 16.42 Total return (3) 26.84 % 36.09 % Shares outstanding at end of period 162,505 151,179 Weighted average number of common shares outstanding 159,742 141,223 Net assets at end of period $ 1,851,810 $ 1,652,057 Ratio of total expense to average net assets (4) 9.18 % 10.38 % Ratio of net investment income before investment gains and losses to average net assets (4) 17.67 % 18.85 % Portfolio turnover rate (5) 20.06 % 22.20 % Weighted average debt outstanding $ 1,696,442 $ 1,601,552 Weighted average debt per common share $ 10.62 $ 11.34 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, the expense is offset by a corresponding increase in paid-in capital. Additionally, adjusts for other items attributed to the difference between certain per share data based on the weighted-average basic shares outstanding and those calculated using the shares outstanding as of a period end or transaction date. (3) The total return for the nine months ended September 30, 2024, and 2023 equals to the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the nine months ended September 30, 2024, and 2023 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of September 30, 2024, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones. As of September 30, 2024, and December 31, 2023, the Company had approximately $489.0 million and $335.3 million, respectively, of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The amounts disclosed exclude unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements. As of September 30, 2024, and December 31, 2023, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2024 December 31, 2023 Debt Investments: Earnix Ltd. $ 41,250 $ — Arcus Biosciences, Inc. 37,500 — Shield AI, Inc. 37,500 — Thumbtack, Inc. 30,000 40,000 Armis, Inc. 25,000 — Checkr Group, Inc. 23,625 23,625 Skydio, Inc. 22,500 22,500 Pindrop Security, Inc. 19,375 — Braeburn Pharmaceuticals 17,500 — Coronet Cyber Security Ltd. 17,000 — Phathom Pharmaceuticals, Inc. 15,300 6,120 Akero Therapeutics, Inc. 15,000 15,000 Main Street Rural, Inc. 14,000 10,500 Harness, Inc. 11,550 — Marathon Health, LLC 10,000 — Viridian Therapeutics 10,000 — Suzy, Inc. 8,000 12,000 WellBe Senior Medical, LLC 8,000 — Geron Corporation 7,800 — Semperis Technologies Inc. 7,500 — Elation Health, Inc. 7,500 7,500 Curana Health Holdings, LLC 7,500 — ATAI Life Sciences N.V. 7,000 — Behavox Limited 7,000 — Dragos 6,500 13,000 Leapwork ApS 6,345 3,900 enGene, Inc. 5,250 — Babel Street 4,367 3,375 Heron Therapeutics, Inc. 4,000 4,000 AlphaSense Inc. 4,000 — Saama Technologies, LLC 3,875 3,875 Allvue Systems, LLC 3,590 3,590 Sight Sciences, Inc. 3,500 — LogRhythm, Inc. 3,142 — Recover Together, Inc. 2,500 — Dronedeploy, Inc. 3,125 6,250 Riviera Partners LLC 3,000 3,000 Zappi, Inc. 2,571 2,571 Loftware, Inc. 2,277 2,277 (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2024 December 31, 2023 Debt Investments: Streamline Healthcare Solutions $ 2,200 $ 2,200 New Relic, Inc. 2,176 2,176 Sumo Logic, Inc. 2,000 2,000 Ceros, Inc. 1,707 1,707 ThreatConnect, Inc. 1,600 1,600 LogicSource 1,209 1,209 3GTMS, LLC 1,155 1,182 Zimperium, Inc. 1,088 3,727 Flight Schedule Pro, LLC 1,080 639 Ikon Science Limited 1,050 1,050 LinenMaster, LLC 1,000 1,000 Fortified Health Security 840 840 Omeda Holdings, LLC 731 731 Dispatch Technologies, Inc. 688 625 Constructor.io Corporation 625 625 ShadowDragon, LLC 333 333 Cybermaxx Intermediate Holdings, Inc. 12 390 Automation Anywhere, Inc. — 29,400 Tarsus Pharmaceuticals, Inc. — 20,625 Kura Oncology, Inc. — 19,250 Tipalti Solutions Ltd. — 10,500 Next Insurance, Inc. — 10,000 Senseonics Holdings, Inc. — 8,750 Modern Life, Inc. — 6,500 Brain Corporation — 5,000 Cutover, Inc. — 2,650 Plentific Ltd — 2,625 Altumint, Inc. — 2,500 Yipit, LLC — 2,250 Dashlane, Inc. — 2,137 Annex Cloud — 1,750 Agilence, Inc. — 800 Enmark Systems, Inc. — 457 Alchemer LLC — 445 Cytracom Holdings LLC — 72 Total Unfunded Debt Commitments: 484,936 330,828 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 1,757 1,757 Forbion Growth Opportunities Fund II C.V. 2,277 2,748 Total Unfunded Commitments in Investment Funds & Vehicles: 4,034 4,505 Total Unfunded Commitments $ 488,970 $ 335,333 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $152.2 million and $127.7 million of unfunded commitments as of September 30, 2024, and December 31, 2023, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds. The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) September 30, 2024 December 31, 2023 Expiring during: 2024 $ 162,870 $ 291,896 2025 236,470 3,004 2026 32,202 7,537 2027 15,071 14,078 2028 6,164 6,547 2029 27,983 3,590 2030 4,176 4,176 Total Unfunded Debt Commitments 484,936 330,828 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 1,757 1,757 2032 2,277 2,748 Total Unfunded Commitments in Investment Funds & Vehicles 4,034 4,505 Total Unfunded Commitments $ 488,970 $ 335,333 The following tables provide the Company’s contractual obligations as of September 30, 2024 and December 31, 2023: As of September 30, 2024: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,751,000 $ 170,000 $ 1,216,000 $ — $ 365,000 Lease and License Obligations (4) 24,528 3,206 6,551 5,560 9,211 Total $ 1,775,528 $ 173,206 $ 1,222,551 $ 5,560 $ 374,211 As of December 31, 2023: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,570,000 $ 105,000 $ 689,000 $ 411,000 $ 365,000 Lease and License Obligations (4) 26,741 2,539 6,629 6,248 11,325 Total $ 1,596,741 $ 107,539 $ 695,629 $ 417,248 $ 376,325 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $175.0 million in principal outstanding under the SBA Debentures, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of September 30, 2024. There was also $201.0 million outstanding under the SMBC Facility and $240.0 million outstanding under the MUFG Bank Facility as of September 30, 2024. (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $175.0 million in principal outstanding under the SBA Debentures, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of December 31, 2023. There was also $94.0 million outstanding under the SMBC Facility and $61.0 million outstanding under the MUFG Bank Facility as of December 31, 2023. Certain premises are leased or licensed under agreements which expire at various dates through July 2034. For the three months ended September 30, 2024 and 2023, total rent expense, including short-term leases, amounted to approximately $0.8 million and $0.9 million in each period, respectively. For the nine months ended September 30, 2024 and 2023, total rent expense, including short-term leases, amounted to approximately $2.7 million and $2.5 million in each period, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset. The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2024, and 2023: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Total operating lease cost $ 762 $ 691 $ 2,091 $ 1,995 Cash paid for amounts included in the measurement of lease liabilities $ 371 $ 495 $ 1,268 $ 2,231 As of September 30, 2024 As of December 31, 2023 Weighted-average remaining lease term (in years) 8.06 8.68 Weighted-average discount rate 6.85 % 6.79 % The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2024: (in thousands) As of September 30, 2024 2024 $ 598 2025 3,088 2026 3,179 2027 3,452 Thereafter 14,090 Total lease payments 24,407 Less: imputed interest & other items (5,927) Total operating lease liability $ 18,480

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions As disclosed in “Note 1 - Description of Business”, the Adviser Subsidiary is the Company's wholly owned registered investment advisor business, composed of the collectively held and presented entities Hercules Adviser LLC, Hercules Capital Management, LLC, and Hercules Partner Holdings, LLC entities. The Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. The Adviser Subsidiary has entered into investment management agreements with its privately offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds. In addition, the general partner interests (the “GP Interests”) held by Hercules Partner Holdings, LLC may receive incentive fees based on the performance of the Adviser Funds. Both the Adviser Subsidiary and Hercules Partner Holdings, LLC are owned by Hercules Capital Management LLC. During the three and nine months ended September 30, 2024, the Adviser Subsidiary declared and paid dividend distributions to the Company of $1.8 million and $5.0 million, respectively. No dividend distributions were made during the three and nine months ended September 30, 2023. Refer to “Note 4 – Investments” for information related to income, gains and losses recognized related to the Company’s investment. The Company has a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary has access to the Company's human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology). Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended September 30, 2024 and 2023, are net of expenses allocated to the Adviser Subsidiary of $2.2 million and $2.4 million, respectively. The Company's total expenses for the nine months ended September 30, 2024 and 2023, are net of expenses allocated to the Adviser Subsidiary of $7.9 million and $7.5 million, respectively. As of September 30, 2024 and December 31, 2023, there was less than $0.1 million and approximately $0.1 million receivable, respectively, from the Adviser Subsidiary. In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. The assigned investment activities for the nine months ended September 30, 2024 and 2023, are summarized below: (in millions) Nine Months Ended September 30, 2024 2023 Investment commitments assigned to or directly committed by the Adviser Funds $ 422.1 $ 491.4 Investment fundings assigned to, directly originated or funded by the Adviser Funds $ 277.1 $ 294.4 Amounts received by the Company from the Adviser Funds relating to assigned investments $ 6.0 $ 12.1

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Dividend Distribution Declaration On October 24, 2024, the Board declared a cash distribution of $0.40 per share to be paid on November 20, 2024 to stockholders of record as of November 13, 2024. In addition to the cash distribution, and as part of the supplemental cash distribution of $0.32 per share to be paid in four quarterly distributions of $0.08 per share, the Board declared a supplemental cash distribution of $0.08 per share to be paid on November 20, 2024 to stockholders of record as of November 13, 2024. Including the $0.08 per share supplemental cash distributions paid to stockholders of record as of March 6, 2024, May 14, 2024 and August 13, 2024, the Board has declared the full $0.32 per share of supplemental cash distribution declared on February 8, 2024. Authorized shares of Company stock On October 28, 2024, the Company filed Charter Amendment with the Secretary of State of the State of Maryland. The Charter Amendment amended the Company’s Articles of Incorporation to increase the number of authorized shares of Company stock from 200.0 million shares to 300.0 million shares, as approved by the Company’s Board. The Charter Amendment is effective as of October 28, 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net increase (decrease) in net assets resulting from operations	$ 68,711	$ 27,967	$ 201,527	$ 217,306

Insider Trading Arrangements

Insider Trading Arrangements - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Scott Bluestein [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement			On June 27, 2024, Scott Bluestein, chief executive officer and director, adopted a written plan for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan covered the sale of up to 100,000 shares of the Company’s common stock over a period commencing after the later of (1) 91 days from the adoption date or (2) the earlier of (a) the third business day following the public disclosure of the Company’s financial results on Form 10-Q for the quarter ended June 30, 2024 or (b) 121 days after the adoption date, and terminated on December 15, 2024 or upon the earlier completion of all authorized transactions under the plan. On September 26, 2024, all authorized transactions were completed under the plan and the plan terminated.
Name		Scott Bluestein
Title		chief executive officer and director
Rule 10b5-1 Arrangement Adopted		true
Adoption Date		June 27, 2024
Expiration Date		December 15, 2024
Arrangement Duration		171 days
Aggregate Available		100,000

N-2

N-2 - $ / shares	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cover [Abstract]
Entity Central Index Key	0001280784
Amendment Flag	false
Securities Act File Number	814-00702
Document Type	10-Q
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Address, Address Line One	1 North B Street
Entity Address, Address Line Two	Suite 2000
Entity Address, City or Town	San Mateo
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94401
City Area Code	650
Local Phone Number	289-3060
Entity Emerging Growth Company	false
General Description of Registrant [Abstract]
Risk Factors [Table Text Block]	ITEM 1A. RISK FACTORS In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 15, 2024 (the “Annual Report”). Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of September 30, 2024 that represent greater than 5% of our net assets: (in thousands) September 30, 2024 Fair Value Percentage of Net Assets Axsome Therapeutics, Inc. $ 165,469 8.9 % Phathom Pharmaceuticals, Inc. $ 160,907 8.7 % Marathon Health, LLC $ 157,857 8.5 % Corium, Inc. $ 110,394 6.0 % SeatGeek, Inc. $ 109,152 5.9 % • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Marathon Health, LLC is a provider of employer-sponsored healthcare platform intended to provide convenient and unhurried patient-centered care services. • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events. Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.
Share Price	$ 19.64		$ 16.42
NAV Per Share	$ 11.40	$ 11.43	$ 10.93	$ 10.53
Significant Portfolio Investment [Member]
General Description of Registrant [Abstract]
Risk [Text Block]	Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of September 30, 2024 that represent greater than 5% of our net assets: (in thousands) September 30, 2024 Fair Value Percentage of Net Assets Axsome Therapeutics, Inc. $ 165,469 8.9 % Phathom Pharmaceuticals, Inc. $ 160,907 8.7 % Marathon Health, LLC $ 157,857 8.5 % Corium, Inc. $ 110,394 6.0 % SeatGeek, Inc. $ 109,152 5.9 % • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Marathon Health, LLC is a provider of employer-sponsored healthcare platform intended to provide convenient and unhurried patient-centered care services. • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events. Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.
Fair Value Measurements	Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.
Valuation of Investments	Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. As of September 30, 2024, approximately 97.4% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company provides financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in technology-related industries including drug discovery and development, software, consumer & business services, and other healthcare services at all stages of development. Given the nature of investing in these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company principally invests in debt securities with a particular emphasis on Structured Debt. The Company uses the term “Structured Debt” to refer to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred stock. Given the nature of lending to venture capital-backed and institutional-backed companies in technology-related industries, substantially all of the Company’s debt investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recording warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate Net Asset Value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.
Derivative Instruments	Derivative Instruments The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. The net cash flows realized on settlement of derivatives are included in realized (gain) loss in the Consolidated Statements of Cash Flows.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2024, the Company held $102 thousand (Cost basis $102 thousand) of foreign cash. As of December 31, 2023, the Company held $804 thousand (Cost basis $842 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).
Other Assets	Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables.
Escrow Receivables	Escrow Receivables
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.
Investment Income Recognition	Investment Income Recognition The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID. The OID received upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term. The Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
Realized Gains or Losses	Realized Gains or Losses Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries.
Secured Borrowings	Secured Borrowings The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value.
Equity Offering Expenses	Equity Offering Expenses
Debt	Debt
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest , debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.
Stock-Based Compensation	Stock-Based Compensation The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock-based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes. The Company has elected to be treated as a RIC under Subchapter M of the Code. To qualify as a RIC, the Company is required to meet certain income and asset tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. See “Certain United States Federal Income Tax Considerations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 15, 2024 for additional information. As a RIC, the Company is subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains). The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company's earnings fall below the amount of the dividend distributions declared, however, a portion of the total amount of the Company's distributions for the fiscal year may be deemed a return of capital.
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.
Comprehensive Income	Comprehensive Income
Distributions	Distributions
Segments	Segments

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Investments Measured at Fair Value on Recurring Basis	Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2024 and December 31, 2023. (in thousands) Balance as of Quoted Prices in Significant Significant Description Other assets and liabilities Escrow and Other Investment Receivables $ 158 $ — $ — $ 158 Accounts Payable and Accrued Liabilities (1,770) — — (1,770) Investments Senior Secured Debt $ 3,306,724 $ — $ — $ 3,306,724 Unsecured Debt 73,854 — — 73,854 Preferred Stock 47,342 — — 47,342 Common Stock (2) 95,693 49,018 — 46,675 Warrants 30,023 — 10,647 19,376 $ 3,553,636 $ 49,018 $ 10,647 $ 3,493,971 Investment Funds & Vehicles measured at Net Asset Value (3) 6,877 Total Investments, at fair value $ 3,560,513 Derivative Instruments (4) (1,168) Total Investments, at fair value including derivative instruments $ 3,559,345 (in thousands) Balance as of Quoted Prices in Significant Significant Description Cash and cash equivalents Money Market Fund (1) $ 56,000 $ 56,000 $ — $ — Other assets Escrow and Other Investment Receivables $ 10,888 $ — $ — $ 10,888 Investments Senior Secured Debt $ 2,987,577 $ — $ — $ 2,987,577 Unsecured Debt 69,722 — — 69,722 Preferred Stock 53,038 — — 53,038 Common Stock (2) 99,132 57,342 — 41,790 Warrants 33,969 — 11,881 22,088 $ 3,243,438 $ 57,342 $ 11,881 $ 3,174,215 Investment Funds & Vehicles measured at Net Asset Value (3) 4,608 Total Investments, at fair value $ 3,248,046 Derivative Instruments (4) (766) Total Investments including cash and cash equivalents and derivative instruments $ 3,303,280 (1) This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities. (2) Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock. (3) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities. (4) Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy.
Schedule of Reconciliation Changes for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024 and 2023. (in thousands) Balance as of Net Realized Gains (Losses) (1) Net Change in Unrealized Appreciation (Depreciation) (2) Purchases (5) Sales Repayments (6) Gross Transfers into Level 3 (3)* Gross Transfers out of Level 3 (3)* Balance as of Investments Senior Secured Debt $ 2,987,577 $ (9,120) $ (34,978) $ 1,099,563 $ — $ (732,225) $ — $ (4,093) $ 3,306,724 Unsecured Debt 69,722 — 828 3,304 — — — — 73,854 Preferred Stock 53,038 (711) (9,013) 1,597 — — 2,431 — 47,342 Common Stock 41,790 (1,351) 474 4,100 — — 1,662 — 46,675 Warrants 22,088 (464) (2,367) 2,948 (2,829) — — — 19,376 Other Assets and Liabilities Escrow and Other Investment Receivables 10,888 85 5,869 43 (18,497) — — 1,770 158 Accounts Payable and Accrued Liabilities — — — — — — (1,770) — (1,770) Total $ 3,185,103 $ (11,561) $ (39,187) $ 1,111,555 $ (21,326) $ (732,225) $ 2,323 $ (2,323) $ 3,492,359 (in thousands) Balance as of Net Realized Gains (Losses) (1) Net Change in Unrealized Appreciation (Depreciation) (2) Purchases (5) Sales Repayments (6) Gross Transfers into Level 3 (4)* Gross Transfers out of Level 3 (4)* Balance as of Investments Senior Secured Debt $ 2,741,388 $ (5,400) $ (22,135) $ 1,003,953 $ — $ (695,856) $ — $ — $ 3,021,950 Unsecured Debt 54,056 — 4,958 10,916 — — — — 69,930 Preferred Stock 41,488 (3,441) 1,392 2,851 — — — — 42,290 Common Stock 25,059 — 10,684 4,500 (594) — — — 39,649 Warrants 19,419 (3,443) 1,539 3,711 (1,108) — — — 20,118 Other Assets Escrow Receivable 875 80 — — (207) — — — 748 Total $ 2,882,285 $ (12,204) $ (3,562) $ 1,025,931 $ (1,909) $ (695,856) $ — $ — $ 3,194,685 * The Company recognizes transfers as of the transaction date. (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations. (3) Transfers out of Level 3 during the nine months ended September 30, 2024 related to the conversion of the Company's Level 3 debt investments in Better Therapeutics, Inc. and Eigen Technologies Ltd. into common stock and preferred stock Level 3 investments in acquiring companies. (4) There were no transfers into or out of Level 3 during the nine months ended September 30, 2023. (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
Schedule of Unrealized Gain (Loss) on Investments	The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock, and warrant Level 3 investments relating to assets still held at the reporting date. (in millions) Nine Months Ended September 30, 2024 2023 Debt Investments $ (32.3) $ (16.9) Preferred Stock (9.2) (2.0) Common Stock (0.3) 10.7 Warrant Investments (0.8) (0.9)
Schedule of Quantitative Information of Fair Value Measurements	The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2024 and December 31, 2023. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted Average (2) Pharmaceuticals $ 990,349 Market Comparable Companies Hypothetical Market Yield 9.90% - 16.55% 12.74% Premium/(Discount) (2.00)% - 4.00% 0.08% Technology 1,202,375 Market Comparable Companies Hypothetical Market Yield 10.08% - 19.19% 13.26% Premium/(Discount) (0.75)% - 3.00% 0.33% 25,745 Convertible Note Analysis Probability weighting of alternative outcomes 1.00% - 70.00% 50.64% 52,586 Liquidation (3) Probability weighting of alternative outcomes 5.00% - 100.00% 57.86% Sustainable and Renewable Technology 20,957 Market Comparable Companies Hypothetical Market Yield 12.13% - 15.66% 15.43% Premium/(Discount) 0.25% - 3.00% 0.43% Medical Devices 55,413 Market Comparable Companies Hypothetical Market Yield 12.23% - 13.19% 12.65% Premium/(Discount) 0.00% - 0.50% 0.28% Lower Middle Market 601,995 Market Comparable Companies Hypothetical Market Yield 8.66% - 19.68% 14.61% Premium/(Discount) (0.25)% - 3.25% 0.84% Debt Investments for which Cost Approximates Fair Value 240,443 Debt Investments originated within 6 months 70,171 Imminent Payoffs (4) 72,911 Debt Investments Maturing in Less than One Year 47,633 Debt Investments in Wholly-Owned Subsidiaries $ 3,380,578 Total Level 3 Debt Investments Accounts Payable and Accrued Liabilities (1,770) Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 38.97% $ 3,378,808 Total Level Three Debt Investments and Other Investment Receivables (Payables) (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, and “Software” industries. • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes. (4) Imminent Payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Debt Investments Fair Value as of Valuation Techniques/ Methodologies Unobservable Input (1) Range Weighted Average (2) Pharmaceuticals $ 971,775 Market Comparable Companies Hypothetical Market Yield 10.91% - 21.43% 13.46% Premium/(Discount) (1.00)% - 3.50% 0.04% 8,455 Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 41.83% Technology 1,181,823 Market Comparable Companies Hypothetical Market Yield 11.30% - 20.74% 15.03% Premium/(Discount) (1.00)% - 5.00% 0.47% 23,244 Convertible Note Analysis Probability weighting of alternative outcomes 1.00% - 50.00% 39.32% — Liquidation (3) Probability weighting of alternative outcomes 100.00% - 100.00% 100.00% Sustainable and Renewable Technology 1,678 Market Comparable Companies Hypothetical Market Yield 10.75% - 10.75% 10.75% Premium/(Discount) 0.75% - 0.75% 0.75% Lower Middle Market 322,162 Market Comparable Companies Hypothetical Market Yield 12.54% - 20.15% 14.13% Premium/(Discount) (0.75)% - 2.25% 0.56% Debt Investments for which Cost Approximates Fair Value 431,512 Debt Investments originated within 6 months 54,430 Imminent Payoffs (4) 62,220 Debt Investments Maturing in Less than One Year $ 3,057,299 Total Level 3 Debt Investments Other Investment Receivables 9,648 Liquidation (3) Probability weighting of alternative outcomes 10.00% - 50.00% 41.83% $ 3,066,947 Total Level Three Debt Investments and Other Investment Receivables (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries. • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 43,990 Market Comparable Companies Revenue Multiple (2) 0.4x - 14.8x 13.4x Tangible Book Value Multiple (2) 1.6x - 1.6x 1.6x Discount for Lack of Marketability (3) 13.48% - 92.82% 36.18% 13,781 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (83.75)% - 30.35% (8.48)% 33,234 Discounted Cash Flow Discount Rate (7) 11.52% - 33.40% 31.14% 3,012 Other (6) Warrant Investments 15,466 Market Comparable Companies Revenue Multiple (2) 0.9x - 11.9x 4.1x Discount for Lack of Marketability (3) 12.93% - 33.96% 24.63% 3,910 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (62.04)% - 30.35% (1.40)% Total Level 3 Equity and Warrant Investments $ 113,393 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 52,094 Market Comparable Companies EBITDA Multiple (2) 12.3x - 12.3x 12.3x Revenue Multiple (2) 0.3x - 20.1x 7.2x Tangible Book Value Multiple (2) 1.8x - 1.8x 1.8x Discount for Lack of Marketability (3) 7.11% - 92.72% 31.57% 11,096 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (86.14)% - 32.69% 7.47% 28,713 Discounted Cash Flow Discount Rate (7) 19.88% - 31.97% 30.51% 2,925 Other (6) Warrant Investments 19,014 Market Comparable Companies EBITDA Multiple (2) 12.3x -12.3x 12.3x Revenue Multiple (2) 0.9x - 10.2x 4.2x Discount for Lack of Marketability (3) 6.21% - 33.12% 21.70% 3,074 Market Adjusted OPM Backsolve Market Equity Adjustment (4) (70.67)% - 34.86% 13.17% — Other (6) Total Level 3 Equity and Warrant Investments $ 116,916 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Schedule of Fair Value Hierarchy of Outstanding Borrowings	The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 Description Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs SBA Debentures $ 170,763 $ 155,728 $ — $ — $ 155,728 February 2025 Notes 49,952 49,902 — — 49,902 June 2025 Notes 69,879 69,890 — — 69,890 June 2025 3-Year Notes 49,887 50,560 — — 50,560 March 2026 A Notes 49,866 48,691 — — 48,691 March 2026 B Notes 49,854 48,726 — — 48,726 September 2026 Notes 323,075 301,311 — — 301,311 January 2027 Notes 346,932 327,712 — — 327,712 2031 Asset-Backed Notes 148,985 145,500 — 145,500 — 2033 Notes 39,016 41,008 — 41,008 — MUFG Bank Facility 240,000 240,000 — — 240,000 SMBC Facility 201,000 201,000 — — 201,000 Total $ 1,739,209 $ 1,680,028 $ — $ 186,508 $ 1,493,520 (in thousands) December 31, 2023 Description Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs SBA Debentures $ 170,323 $ 142,011 $ — $ — $ 142,011 July 2024 Notes 104,828 105,755 — — 105,755 February 2025 Notes 49,866 49,144 — — 49,144 June 2025 Notes 69,757 67,198 — — 67,198 June 2025 3-Year Notes 49,771 48,983 — — 48,983 March 2026 A Notes 49,795 47,702 — — 47,702 March 2026 B Notes 49,776 47,759 — — 47,759 September 2026 Notes 322,339 288,711 — — 288,711 January 2027 Notes 345,935 315,832 — — 315,832 2031 Asset-Backed Notes 148,544 142,500 — 142,500 — 2033 Notes 38,935 40,400 — 40,400 — MUFG Bank Facility 61,000 61,000 — — 61,000 SMBC Facility 94,000 94,000 — — 94,000 Total $ 1,554,869 $ 1,450,995 $ — $ 182,900 $ 1,268,095

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Schedule of Investments [Abstract]
Schedule of Investments in and Advances to Affiliates	The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2024 and 2023. (in thousands) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Portfolio Company (1) Type Fair Value as of September 30, 2024 Interest & Dividend Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest & Dividend Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 319 $ — $ — $ 133 $ — $ — $ — $ 57 $ — Gibraltar Acquisition LLC (2) Control 57,302 1,359 36 (74) — 3,926 108 (6,365) — Hercules Adviser LLC (3) Control 43,433 1,954 — 705 — 5,457 — 2,720 — Tectura Corporation Control 12,043 174 — 509 — 518 — 526 — Total Control Investments $ 113,097 $ 3,487 $ 36 $ 1,273 $ — $ 9,901 $ 108 $ (3,062) $ — (in thousands) Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Portfolio Company (1) Type Fair Value as of September 30, 2023 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 247 $ — $ — $ (50) $ — $ — $ — $ (72) $ — Gibraltar Acquisition, LLC (2) Control 55,992 772 22 (1,726) — 2,299 60 4,676 — Hercules Adviser LLC (3) Control 40,668 153 — 1,507 — 455 — 9,515 — Tectura Corporation Control 6,243 174 — (830) — 516 — (1,799) — Total Control Investments $ 103,150 $ 1,099 $ 22 $ (1,099) $ — $ 3,270 $ 60 $ 12,320 $ — (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2024 and September 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (3) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure.
Schedule of Investments Portfolio	The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 3,306,724 92.9 % $ 2,987,577 92.0 % Unsecured Debt 73,854 2.1 % 69,722 2.2 % Preferred Stock 47,342 1.3 % 53,038 1.6 % Common Stock 95,693 2.7 % 99,132 3.1 % Warrants 30,023 0.8 % 33,969 1.0 % Investment Funds & Vehicles 6,877 0.2 % 4,608 0.1 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2024 and December 31, 2023 is shown as follows: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of United States $ 3,219,874 90.4 % $ 2,861,615 88.1 % United Kingdom 174,566 4.9 % 222,136 6.9 % Israel 77,767 2.2 % 52,868 1.6 % Netherlands 59,562 1.7 % 89,995 2.8 % Canada 16,441 0.5 % 15,730 0.5 % Ireland 4,513 0.1 % — 0.0 % Denmark 4,176 0.1 % 4,173 0.1 % Singapore 1,999 0.1 % — 0.0 % Germany 1,219 0.0 % 1,144 0.0 % Other 396 0.0 % 385 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,125,617 31.6 % $ 1,257,699 38.7 % Software 1,018,236 28.6 % 764,985 23.6 % Healthcare Services, Other 574,750 16.1 % 300,079 9.3 % Consumer & Business Services 355,831 10.0 % 525,973 16.2 % Diversified Financial Services 112,709 3.2 % 114,722 3.5 % Electronics & Computer Hardware 96,125 2.7 % 20,324 0.6 % Information Services 81,266 2.3 % 126,605 3.9 % Medical Devices & Equipment 56,153 1.6 % 22,096 0.7 % Space Technologies 46,082 1.3 % — 0.0 % Biotechnology Tools 35,311 1.0 % 48,381 1.5 % Sustainable and Renewable Technology 27,858 0.8 % 9,581 0.3 % Communications & Networking 26,465 0.7 % 29,400 0.9 % Manufacturing Technology 2,096 0.1 % 11,006 0.3 % Consumer & Business Products 1,285 0.0 % 2,589 0.1 % Semiconductors 655 0.0 % 1,205 0.0 % Media/Content/Info 55 0.0 % 12,704 0.4 % Drug Delivery 19 0.0 % 21 0.0 % Surgical Devices — 0.0 % 676 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % The following table summarizes information related to our SBICs as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description HC IV SBIC V HC IV SBIC V Number of investments held 28 1 25 — Fair value of investments (in millions) $ 352.4 $ 11.2 $ 331.5 $ — Percentage of fair value of investments based on the Company's total investment portfolio 9.9 % 0.3 % 10.2 % 0.0 % Tangible assets (in millions) $ 369.7 $ 13.3 $ 341.8 $ — Percentage of tangible assets based on the Company's total assets 10.1 % 0.4 % 10.0 % 0.0 %
Schedule of Investment Collateral	The Company's investments were collateralized as follows as of September 30, 2024 and December 31, 2023: Percentage of debt investments (at fair value), as of September 30, 2024 December 31, 2023 Senior Secured First Lien All assets including intellectual property 63.1 % 52.3 % All assets with negative pledge on intellectual property 16.1 % 24.0 % “Last-out” with security interest in all of the assets 10.3 % 12.5 % Total senior secured first lien position 89.5 % 88.8 % Second lien 8.3 % 8.9 % Unsecured 2.2 % 2.3 % Total debt investments at fair value 100.0 % 100.0 %
Summary of Fair Value and Location of the Company's Derivative Instruments	The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of September 30, 2024 and December 31, 2023: (in thousands) Fair Value Derivative Instrument Statement Location September 30, 2024 December 31, 2023 Foreign currency forward contract Other assets $ — $ — Foreign currency forward contract Accounts payable and accrued liabilities 1,168 766 Total $ 1,168 $ 766
Summary of Net Realized and Unrealized Gains and Losses	Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and nine months ended September 30, 2024 and 2023 are in the following locations in the Consolidated Statements of Operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Statement Location 2024 2023 2024 2023 Foreign currency forward contract Net realized gain (loss) - Non-control / Non-affiliate investments $ — $ — $ (849) $ — Foreign currency forward contract Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments (1,356) 784 (402) 230 Total $ (1,356) $ 784 $ (1,251) $ 230
Schedule of Investment Interest Income and Fee Income	The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Contractual interest income $ 90,288 $ 89,747 $ 268,441 $ 258,685 Exit fee interest income 12,047 10,904 34,519 34,340 PIK interest income 12,706 6,652 37,870 17,999 Dividend income 2,100 — 5,800 — Other investment income (1) 1,909 3,036 5,728 8,198 Total interest and dividend income $ 119,050 $ 110,339 $ 352,358 $ 319,222 (1) Other investment income includes OID interest income and interest recorded on other assets. (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Recurring fee income $ 2,423 $ 2,243 $ 7,081 $ 6,418 Fee income - expired commitments 413 300 1,790 651 Accelerated fee income - early repayments 3,362 3,862 10,578 11,774 Total fee income $ 6,198 $ 6,405 $ 19,449 $ 18,843
Schedule of Unamortized Capitalized Fee Income	As of September 30, 2024 and December 31, 2023, unamortized capitalized fee income was recorded as follows: (in millions) September 30, December 31, Offset against debt investment cost $ 36.7 $ 32.9 Deferred obligation contingent on funding or other milestone 9.7 9.4 Total Unamortized Fee Income $ 46.4 $ 42.3
Schedule of Loan Exit Fees Receivable	As of September 30, 2024 and December 31, 2023, loan exit fees receivable were recorded as follows: (in millions) September 30, December 31, Included within debt investment cost $ 37.0 $ 35.9 Deferred receivable related to expired commitments 3.4 4.3 Total Exit Fees Receivable $ 40.4 $ 40.2

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Available and Outstanding Debt	As of September 30, 2024 and December 31, 2023, the Company had the following available and outstanding debt: (in thousands) September 30, 2024 December 31, 2023 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures (2)(4) $ 350,000 $ 175,000 $ 170,763 $ 175,000 $ 175,000 $ 170,323 July 2024 Notes — — — 105,000 105,000 104,828 February 2025 Notes 50,000 50,000 49,952 50,000 50,000 49,866 June 2025 Notes 70,000 70,000 69,879 70,000 70,000 69,757 June 2025 3-Year Notes 50,000 50,000 49,887 50,000 50,000 49,771 March 2026 A Notes 50,000 50,000 49,866 50,000 50,000 49,795 March 2026 B Notes 50,000 50,000 49,854 50,000 50,000 49,776 September 2026 Notes 325,000 325,000 323,075 325,000 325,000 322,339 January 2027 Notes 350,000 350,000 346,932 350,000 350,000 345,935 2031 Asset-Backed Notes 150,000 150,000 148,985 150,000 150,000 148,544 2033 Notes 40,000 40,000 39,016 40,000 40,000 38,935 MUFG Bank Facility (2) 400,000 240,000 240,000 400,000 61,000 61,000 SMBC Facility (2)(3) 400,000 201,000 201,000 400,000 94,000 94,000 Total $ 2,285,000 $ 1,751,000 $ 1,739,209 $ 2,215,000 $ 1,570,000 $ 1,554,869 (1) Except for the SMBC Facility and MUFG Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) “Total Available” includes $175.0 million of available commitment through the letter of credit facility as of September 30, 2024 and December 31, 2023. (4) As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV. The Company held the following SBA debentures outstanding principal balances as of September 30, 2024 and December 31, 2023: (in thousands) Maturity Date Interest Rate (1) September 30, 2024 December 31, 2023 March 26, 2021 September 1, 2031 1.58% $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58% 16,200 16,200 July 28, 2021 September 1, 2031 1.58% 5,400 5,400 August 20, 2021 September 1, 2031 1.58% 5,400 5,400 October 21, 2021 March 1, 2032 3.21% 14,000 14,000 November 1, 2021 March 1, 2032 3.21% 21,000 21,000 November 15, 2021 March 1, 2032 3.21% 5,200 5,200 November 30, 2021 March 1, 2032 3.21% 20,800 20,800 December 20, 2021 March 1, 2032 3.21% 10,000 10,000 December 23, 2021 March 1, 2032 3.21% 10,000 10,000 December 28, 2021 March 1, 2032 3.21% 5,000 5,000 January 14, 2022 March 1, 2032 3.21% 4,500 4,500 January 21, 2022 March 1, 2032 3.21% 20,000 20,000 Total SBA Debentures $ 175,000 $ 175,000 (1) Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.
Schedule of Debt Issuance Costs, Net of Accumulated Amortization	Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 SBA Debentures $ 4,237 $ 4,677 July 2024 Notes — 172 February 2025 Notes 48 134 June 2025 Notes 121 243 June 2025 3-Year Notes 113 229 March 2026 A Notes 134 205 March 2026 B Notes 146 224 September 2026 Notes 1,925 2,661 January 2027 Notes 3,068 4,065 2031 Asset-Backed Notes 1,015 1,456 2033 Notes 984 1,065 MUFG Bank Facility (1) 2,220 3,540 SMBC Facility (1) 1,235 1,775 Total $ 15,246 $ 20,446 (1)
Components of Interest Expense, Related Fees and Cash Paid for Interest Expense for Debt	For the three and nine months ended September 30, 2024, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,149 $ 147 $ — $ 1,296 $ 2,300 $ 3,424 $ 439 $ — $ 3,863 $ 4,575 July 2024 Notes 202 24 — 226 2,504 2,706 172 — 2,878 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 755 40 — 795 — 2,263 121 — 2,384 1,508 June 2025 3-Year Notes 750 38 — 788 — 2,250 116 — 2,366 1,500 March 2026 A Notes 563 24 — 587 1,125 1,688 71 — 1,759 2,250 March 2026 B Notes 568 25 — 593 1,138 1,706 77 — 1,783 2,276 September 2026 Notes 2,174 205 — 2,379 4,266 6,523 612 — 7,135 8,531 January 2027 Notes 3,080 208 — 3,288 5,906 9,236 622 — 9,858 11,812 2031 Asset-Backed Notes 1,903 100 — 2,003 1,856 5,710 300 — 6,010 5,568 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 MUFG Bank Facility 4,105 443 329 4,877 3,875 8,181 1,328 1,572 11,081 7,596 SMBC Facility 3,961 180 174 4,315 4,020 9,989 540 599 11,128 9,582 Total $ 20,370 $ 1,490 $ 503 $ 22,363 $ 28,685 $ 57,156 $ 4,565 $ 2,171 $ 63,892 $ 64,221 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2024 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2024 of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the three and nine months ended September 30, 2023, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,150 $ 146 $ — $ 1,296 $ 2,300 $ 3,412 $ 436 $ — $ 3,848 $ 4,562 July 2024 Notes 1,252 74 — 1,326 2,505 3,756 222 — 3,978 5,009 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 June 2025 3-Year Notes 750 39 — 789 — 2,250 117 — 2,367 1,500 March 2026 A Notes 563 24 — 587 1,125 1,688 71 — 1,759 2,250 March 2026 B Notes 569 26 — 595 1,138 1,706 78 — 1,784 2,275 September 2026 Notes 2,174 203 — 2,377 4,266 6,523 611 — 7,134 8,532 January 2027 Notes 3,079 207 — 3,286 5,906 9,236 621 — 9,857 11,812 2031 Asset-Backed Notes 1,902 101 — 2,003 1,857 5,709 301 — 6,010 5,570 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 MUFG Bank Facility 1,247 443 709 2,399 1,240 4,323 1,327 2,017 7,667 4,673 SMBC Facility 1,828 180 276 2,284 1,715 5,891 513 715 7,119 5,703 Total $ 16,428 $ 1,539 $ 985 $ 18,952 $ 23,747 $ 50,237 $ 4,585 $ 2,732 $ 57,554 $ 57,410 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2023 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2023, of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively.
Summary of SBIC Investments	The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 3,306,724 92.9 % $ 2,987,577 92.0 % Unsecured Debt 73,854 2.1 % 69,722 2.2 % Preferred Stock 47,342 1.3 % 53,038 1.6 % Common Stock 95,693 2.7 % 99,132 3.1 % Warrants 30,023 0.8 % 33,969 1.0 % Investment Funds & Vehicles 6,877 0.2 % 4,608 0.1 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2024 and December 31, 2023 is shown as follows: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of United States $ 3,219,874 90.4 % $ 2,861,615 88.1 % United Kingdom 174,566 4.9 % 222,136 6.9 % Israel 77,767 2.2 % 52,868 1.6 % Netherlands 59,562 1.7 % 89,995 2.8 % Canada 16,441 0.5 % 15,730 0.5 % Ireland 4,513 0.1 % — 0.0 % Denmark 4,176 0.1 % 4,173 0.1 % Singapore 1,999 0.1 % — 0.0 % Germany 1,219 0.0 % 1,144 0.0 % Other 396 0.0 % 385 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,125,617 31.6 % $ 1,257,699 38.7 % Software 1,018,236 28.6 % 764,985 23.6 % Healthcare Services, Other 574,750 16.1 % 300,079 9.3 % Consumer & Business Services 355,831 10.0 % 525,973 16.2 % Diversified Financial Services 112,709 3.2 % 114,722 3.5 % Electronics & Computer Hardware 96,125 2.7 % 20,324 0.6 % Information Services 81,266 2.3 % 126,605 3.9 % Medical Devices & Equipment 56,153 1.6 % 22,096 0.7 % Space Technologies 46,082 1.3 % — 0.0 % Biotechnology Tools 35,311 1.0 % 48,381 1.5 % Sustainable and Renewable Technology 27,858 0.8 % 9,581 0.3 % Communications & Networking 26,465 0.7 % 29,400 0.9 % Manufacturing Technology 2,096 0.1 % 11,006 0.3 % Consumer & Business Products 1,285 0.0 % 2,589 0.1 % Semiconductors 655 0.0 % 1,205 0.0 % Media/Content/Info 55 0.0 % 12,704 0.4 % Drug Delivery 19 0.0 % 21 0.0 % Surgical Devices — 0.0 % 676 0.0 % Total $ 3,560,513 100.0 % $ 3,248,046 100.0 % The following table summarizes information related to our SBICs as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description HC IV SBIC V HC IV SBIC V Number of investments held 28 1 25 — Fair value of investments (in millions) $ 352.4 $ 11.2 $ 331.5 $ — Percentage of fair value of investments based on the Company's total investment portfolio 9.9 % 0.3 % 10.2 % 0.0 % Tangible assets (in millions) $ 369.7 $ 13.3 $ 341.8 $ — Percentage of tangible assets based on the Company's total assets 10.1 % 0.4 % 10.0 % 0.0 %

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Taxable Income And Taxable Net Realized Gains (Losses)	Taxable income and taxable net realized gains (losses) for the three and nine months ended September 30, 2024 and 2023 appears as follows: (in millions, except per share data) Three Months Ended September 30, Nine Months Ended September 30, Description 2024 2023 2024 2023 Taxable income $ 75.8 $ 72.7 $ 230.0 $ 197.7 Taxable income per share $ 0.47 $ 0.50 $ 1.44 $ 1.40 Taxable net realized gains (losses) $ 8.7 $ 6.8 $ 18.1 $ 34.2 Taxable net realized gains (losses) per share $ 0.05 $ 0.04 $ 0.11 $ 0.24 Weighted average shares outstanding 161.0 146.9 159.7 141.2
Schedule of Aggregate Unrealized Appreciation And Depreciation of Investment Over Federal Income Tax	The aggregate gross unrealized appreciation of the Company’s investments over cost for U.S. federal income tax purposes appears as follows: (in millions) September 30, 2024 December 31, 2023 Aggregate Gross Unrealized Appreciation $ 121.3 $ 118.3 Aggregate Gross Unrealized Depreciation 169.9 115.9 Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes (48.6) 2.4 Aggregate cost of securities for U.S. federal income tax purposes (in billions) 3.6 3.2

Stockholders' Equity and Dist_2

Stockholders' Equity and Distributions (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Common Stock Shares Issued and Sold	The Company issued and sold the following shares of common stock during the nine months ended September 30, 2024 and 2023: (in millions, except per share data) Nine Months Ended September 30, Number of Shares Issued Gross Proceeds Underwriting Fees/Offering Expenses Net Proceeds Average Price/Share 2024 3.7 $ 67.3 $ 1.0 $ 66.3 $ 17.83 2023 16.2 $ 243.6 $ 5.3 $ 238.3 $ 14.69
Schedule of Dividends Declared	The following table summarizes the Company’s distributions declared during the nine months ended September 30, 2024 and year ended December 31, 2023: (in thousands, except per share data) Distribution Type Declared Date Record Date Payment Date Per Share Amount Total Amount Base February 9, 2023 March 2, 2023 March 9, 2023 $ 0.39 $ 53,749 Supplemental February 9, 2023 March 2, 2023 March 9, 2023 $ 0.08 $ 11,025 Base April 27, 2023 May 16, 2023 May 23, 2023 $ 0.39 $ 55,910 Supplemental April 27, 2023 May 16, 2023 May 23, 2023 $ 0.08 $ 11,469 Base July 28, 2023 August 18, 2023 August 25, 2023 $ 0.40 $ 60,445 Supplemental July 28, 2023 August 18, 2023 August 25, 2023 $ 0.08 $ 12,089 Base October 26, 2023 November 15, 2023 November 22, 2023 $ 0.40 $ 61,345 Supplemental October 26, 2023 November 15, 2023 November 22, 2023 $ 0.08 $ 12,269 Total distributions declared during the year ended December 31, 2023 $ 1.90 $ 278,301 Base February 8, 2024 February 28, 2024 March 6, 2024 $ 0.40 $ 63,359 Supplemental February 8, 2024 February 28, 2024 March 6, 2024 $ 0.08 $ 12,672 Base April 25, 2024 May 14, 2024 May 21, 2024 $ 0.40 $ 64,912 Supplemental April 25, 2024 May 14, 2024 May 21, 2024 $ 0.08 $ 12,982 Base July 25, 2024 August 13, 2024 August 20, 2024 $ 0.40 $ 64,953 Supplemental July 25, 2024 August 13, 2024 August 20, 2024 $ 0.08 $ 12,990 Total distributions declared during the nine months ended September 30, 2024 $ 1.44 $ 231,868

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Unvested Restricted Stock Equity	The activities for the Company's unvested restricted stock equity awards for each of the nine months ended September 30, 2024, and 2023, are summarized below: Nine Months Ended September 30, 2024 2023 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 1,880,409 $ 14.52 958,985 $ 16.35 Granted 835,481 $ 17.48 1,314,268 $ 13.83 Vested (687,360) $ 14.46 (526,292) $ 16.18 Forfeited (38,128) $ 15.45 (11,572) $ 15.42 Unvested Shares End of Period 1,990,402 $ 12.70 1,735,389 $ 14.50

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator Net increase (decrease) in net assets resulting from operations $ 68,711 $ 27,967 $ 201,527 $ 217,306 Less: Total distributions declared (77,943) (72,534) (231,868) (204,687) Total Earnings (loss), net of total distributions (9,232) (44,567) (30,341) 12,619 Earnings (loss), net of distributions attributable to common shares (9,232) (44,567) (30,341) 12,486 Add: Distributions declared attributable to common shares 77,263 71,860 229,650 202,556 Numerator for basic and diluted change in net assets per common share $ 68,031 $ 27,293 $ 199,309 $ 215,042 Denominator Basic weighted average common shares outstanding 161,019 146,899 159,742 141,223 Common shares issuable 496 211 511 903 Weighted average common shares outstanding assuming dilution 161,515 147,110 160,253 142,126 Change in net assets per common share: Basic $ 0.42 $ 0.19 $ 1.25 $ 1.52 Diluted $ 0.42 $ 0.19 $ 1.24 $ 1.51
Schedule of Number of Anti-diluted Shares as Calculated Based on Weighted Average Closing Price of Common Stock	The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2024, and 2023, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three Months Ended September 30, Nine Months Ended September 30, Anti-dilutive Securities 2024 2023 2024 2023 Unvested common stock options 832 347 1,212 1,782 Restricted stock units — — — 5,810 Unvested restricted stock awards 152 395 398 40,034

Financial Highlights (Tables)

Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2024
Investment Company, Financial Highlights [Abstract]
Schedule of Financial Highlights	Following is a schedule of financial highlights for the nine months ended September 30, 2024 and 2023: (in thousands, except per share data and ratios) Nine Months Ended September 30, 2024 2023 Per share data: (1) Net asset value at beginning of period $ 11.43 $ 10.53 Net investment income 1.53 1.54 Net realized gain (loss) 0.01 0.04 Net unrealized appreciation (depreciation) (0.28) (0.04) Total from investment operations 1.26 1.54 Net increase (decrease) in net assets from capital share transactions (1) 0.10 0.25 Distributions of net investment income (6) (1.45) (1.45) Stock-based compensation expense included in net investment income and other movements (2) 0.06 0.06 Net asset value at end of period $ 11.40 $ 10.93 Ratios and supplemental data: Per share market value at end of period $ 19.64 $ 16.42 Total return (3) 26.84 % 36.09 % Shares outstanding at end of period 162,505 151,179 Weighted average number of common shares outstanding 159,742 141,223 Net assets at end of period $ 1,851,810 $ 1,652,057 Ratio of total expense to average net assets (4) 9.18 % 10.38 % Ratio of net investment income before investment gains and losses to average net assets (4) 17.67 % 18.85 % Portfolio turnover rate (5) 20.06 % 22.20 % Weighted average debt outstanding $ 1,696,442 $ 1,601,552 Weighted average debt per common share $ 10.62 $ 11.34 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, the expense is offset by a corresponding increase in paid-in capital. Additionally, adjusts for other items attributed to the difference between certain per share data based on the weighted-average basic shares outstanding and those calculated using the shares outstanding as of a period end or transaction date. (3) The total return for the nine months ended September 30, 2024, and 2023 equals to the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the nine months ended September 30, 2024, and 2023 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Unfunded Contractual Commitments and Unencumbered Unfunded Commitments	As of September 30, 2024, and December 31, 2023, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2024 December 31, 2023 Debt Investments: Earnix Ltd. $ 41,250 $ — Arcus Biosciences, Inc. 37,500 — Shield AI, Inc. 37,500 — Thumbtack, Inc. 30,000 40,000 Armis, Inc. 25,000 — Checkr Group, Inc. 23,625 23,625 Skydio, Inc. 22,500 22,500 Pindrop Security, Inc. 19,375 — Braeburn Pharmaceuticals 17,500 — Coronet Cyber Security Ltd. 17,000 — Phathom Pharmaceuticals, Inc. 15,300 6,120 Akero Therapeutics, Inc. 15,000 15,000 Main Street Rural, Inc. 14,000 10,500 Harness, Inc. 11,550 — Marathon Health, LLC 10,000 — Viridian Therapeutics 10,000 — Suzy, Inc. 8,000 12,000 WellBe Senior Medical, LLC 8,000 — Geron Corporation 7,800 — Semperis Technologies Inc. 7,500 — Elation Health, Inc. 7,500 7,500 Curana Health Holdings, LLC 7,500 — ATAI Life Sciences N.V. 7,000 — Behavox Limited 7,000 — Dragos 6,500 13,000 Leapwork ApS 6,345 3,900 enGene, Inc. 5,250 — Babel Street 4,367 3,375 Heron Therapeutics, Inc. 4,000 4,000 AlphaSense Inc. 4,000 — Saama Technologies, LLC 3,875 3,875 Allvue Systems, LLC 3,590 3,590 Sight Sciences, Inc. 3,500 — LogRhythm, Inc. 3,142 — Recover Together, Inc. 2,500 — Dronedeploy, Inc. 3,125 6,250 Riviera Partners LLC 3,000 3,000 Zappi, Inc. 2,571 2,571 Loftware, Inc. 2,277 2,277 (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2024 December 31, 2023 Debt Investments: Streamline Healthcare Solutions $ 2,200 $ 2,200 New Relic, Inc. 2,176 2,176 Sumo Logic, Inc. 2,000 2,000 Ceros, Inc. 1,707 1,707 ThreatConnect, Inc. 1,600 1,600 LogicSource 1,209 1,209 3GTMS, LLC 1,155 1,182 Zimperium, Inc. 1,088 3,727 Flight Schedule Pro, LLC 1,080 639 Ikon Science Limited 1,050 1,050 LinenMaster, LLC 1,000 1,000 Fortified Health Security 840 840 Omeda Holdings, LLC 731 731 Dispatch Technologies, Inc. 688 625 Constructor.io Corporation 625 625 ShadowDragon, LLC 333 333 Cybermaxx Intermediate Holdings, Inc. 12 390 Automation Anywhere, Inc. — 29,400 Tarsus Pharmaceuticals, Inc. — 20,625 Kura Oncology, Inc. — 19,250 Tipalti Solutions Ltd. — 10,500 Next Insurance, Inc. — 10,000 Senseonics Holdings, Inc. — 8,750 Modern Life, Inc. — 6,500 Brain Corporation — 5,000 Cutover, Inc. — 2,650 Plentific Ltd — 2,625 Altumint, Inc. — 2,500 Yipit, LLC — 2,250 Dashlane, Inc. — 2,137 Annex Cloud — 1,750 Agilence, Inc. — 800 Enmark Systems, Inc. — 457 Alchemer LLC — 445 Cytracom Holdings LLC — 72 Total Unfunded Debt Commitments: 484,936 330,828 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 1,757 1,757 Forbion Growth Opportunities Fund II C.V. 2,277 2,748 Total Unfunded Commitments in Investment Funds & Vehicles: 4,034 4,505 Total Unfunded Commitments $ 488,970 $ 335,333 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $152.2 million and $127.7 million of unfunded commitments as of September 30, 2024, and December 31, 2023, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds. The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) September 30, 2024 December 31, 2023 Expiring during: 2024 $ 162,870 $ 291,896 2025 236,470 3,004 2026 32,202 7,537 2027 15,071 14,078 2028 6,164 6,547 2029 27,983 3,590 2030 4,176 4,176 Total Unfunded Debt Commitments 484,936 330,828 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 1,757 1,757 2032 2,277 2,748 Total Unfunded Commitments in Investment Funds & Vehicles 4,034 4,505 Total Unfunded Commitments $ 488,970 $ 335,333
Schedule of Contractual Obligations	The following tables provide the Company’s contractual obligations as of September 30, 2024 and December 31, 2023: As of September 30, 2024: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,751,000 $ 170,000 $ 1,216,000 $ — $ 365,000 Lease and License Obligations (4) 24,528 3,206 6,551 5,560 9,211 Total $ 1,775,528 $ 173,206 $ 1,222,551 $ 5,560 $ 374,211 As of December 31, 2023: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,570,000 $ 105,000 $ 689,000 $ 411,000 $ 365,000 Lease and License Obligations (4) 26,741 2,539 6,629 6,248 11,325 Total $ 1,596,741 $ 107,539 $ 695,629 $ 417,248 $ 376,325 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $175.0 million in principal outstanding under the SBA Debentures, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of September 30, 2024. There was also $201.0 million outstanding under the SMBC Facility and $240.0 million outstanding under the MUFG Bank Facility as of September 30, 2024. (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $175.0 million in principal outstanding under the SBA Debentures, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of December 31, 2023. There was also $94.0 million outstanding under the SMBC Facility and $61.0 million outstanding under the MUFG Bank Facility as of December 31, 2023.
Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases	The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2024, and 2023: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Total operating lease cost $ 762 $ 691 $ 2,091 $ 1,995 Cash paid for amounts included in the measurement of lease liabilities $ 371 $ 495 $ 1,268 $ 2,231 As of September 30, 2024 As of December 31, 2023 Weighted-average remaining lease term (in years) 8.06 8.68 Weighted-average discount rate 6.85 % 6.79 %
Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability	The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2024: (in thousands) As of September 30, 2024 2024 $ 598 2025 3,088 2026 3,179 2027 3,452 Thereafter 14,090 Total lease payments 24,407 Less: imputed interest & other items (5,927) Total operating lease liability $ 18,480

Related Party Disclosures (Tabl

Related Party Disclosures (Tables)	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The assigned investment activities for the nine months ended September 30, 2024 and 2023, are summarized below: (in millions) Nine Months Ended September 30, 2024 2023 Investment commitments assigned to or directly committed by the Adviser Funds $ 422.1 $ 491.4 Investment fundings assigned to, directly originated or funded by the Adviser Funds $ 277.1 $ 294.4 Amounts received by the Company from the Adviser Funds relating to assigned investments $ 6.0 $ 12.1

CONSOLIDATED SCHEDULE OF INVE_4

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES (Tables)	9 Months Ended
	Sep. 30, 2024
Investments in and Advances to Affiliates [Abstract]
Schedule of Investments in and Advances to Affiliates	(in thousands) Investment (1) Amount of Interest, Dividends, and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of September 30, 2024 Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC (8) Preferred Stock $ — $ — $ 260 $ — $ — $ 58 $ 318 Common Stock — — 2 — — (1) 1 Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) (5) Unsecured Debt 4,034 — 34,478 1,155 — — 35,633 Member Units — — 28,034 — — (6,365) 21,669 Hercules Adviser LLC (6) Unsecured Debt 5,457 — 12,000 — — — 12,000 Member Units — — 28,713 — — 2,720 31,433 Total Majority Owned Control Investments $ 9,491 $ — $ 103,487 $ 1,155 $ — $ (3,588) $ 101,054 Other Control Investments Tectura Corporation (7) Senior Debt $ 518 $ — $ 8,250 $ — $ — $ — $ 8,250 Preferred Stock — — 3,263 — — 524 3,787 Common Stock — — 4 — — 2 6 Total Other Control Investments $ 518 $ — $ 11,517 $ — $ — $ 526 $ 12,043 Total Control Investments $ 10,009 $ — $ 115,004 $ 1,155 $ — $ (3,062) $ 113,097 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (6) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. (8) As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES For the Nine Months Ended September 30, 2023 (unaudited) (in thousands) Investment (1) Amount of Interest and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of September 30, 2023 Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC (8) Preferred Stock $ — $ — $ 313 $ — $ — $ (68) $ 245 Common Stock — — 6 — — (4) 2 Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC) (5) Unsecured Debt 2,359 — 21,700 9,872 — 2,867 34,439 Member Units — — 15,244 4,500 — 1,809 21,553 Hercules Adviser LLC (6) Unsecured Debt 455 — 12,000 — — — 12,000 Member Units — — 19,153 — — 9,515 28,668 Total Majority Owned Control Investments $ 2,814 $ — $ 68,416 $ 14,372 $ — $ 14,119 $ 96,907 Other Control Investments Tectura Corporation (7) Senior Debt $ 516 $ — $ 8,042 $ — $ — $ (1,799) $ 6,243 Preferred Stock — — — — — — — Common Stock — — — — — — — Total Other Control Investments $ 516 $ — $ 8,042 $ — $ — $ (1,799) $ 6,243 Total Control Investments $ 3,330 $ — $ 76,458 $ 14,372 $ — $ 12,320 $ 103,150 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (6) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to "Note 1" for additional disclosure. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. (8) As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of September 30, 2024 (unaudited) (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal or Shares Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 318 Medical Devices & Equipment Common Stock 180,000 — 1 Total Coronado Aesthetics, LLC $ 250 $ 319 Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) (3) Diversified Financial Services Unsecured Debt September 2026 FIXED 3.45%, PIK Interest 8.05% $ 26,033 25,774 25,774 Diversified Financial Services Unsecured Debt September 2026 FIXED 11.95% $ 10,000 9,859 9,859 Diversified Financial Services Member Units 1 34,006 21,669 Total Gibraltar Acquisition, LLC $ 69,639 $ 57,302 Hercules Adviser LLC (4) Diversified Financial Services Unsecured Debt June 2025 FIXED 5.00% $ 12,000 12,000 12,000 Diversified Financial Services Member Units 1 35 31,433 Total Hercules Adviser LLC $ 12,035 $ 43,433 Total Majority Owned Control Investments (5.46%)* $ 81,924 $ 101,054 Other Control Investments Tectura Corporation Consumer & Business Services Senior Secured Debt January 2027 FIXED 8.25% $ 8,250 $ 8,250 $ 8,250 Consumer & Business Services Common Stock 414,994,863 900 6 Consumer & Business Services Preferred Series BB Equity 1,000,000 — 15 Consumer & Business Services Preferred Series C Equity 3,235,298 13,263 3,772 Total Tectura Corporation $ 22,413 $ 12,043 Total Other Control Investments (0.65%)* $ 22,413 $ 12,043 Total Control Investments (6.11%)* $ 104,337 $ 113,097 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. (3) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (4) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of and for the year ended December 31, 2023 (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal or Shares Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 260 Medical Devices & Equipment Common Stock 180,000 — 2 Total Coronado Aesthetics, LLC $ 250 $ 262 Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC) (3) Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.50% $ 25,000 24,663 24,663 Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.95% $ 10,000 9,815 9,815 Diversified Financial Services Member Units 1 34,006 28,034 Total Gibraltar Acquisition, LLC $ 68,484 $ 62,512 Hercules Adviser LLC (4) Diversified Financial Services Unsecured Debt June 2025 Interest rate FIXED 5.00% $ 12,000 12,000 12,000 Diversified Financial Services Member Units 1 35 28,713 Total Hercules Adviser LLC $ 12,035 $ 40,713 Total Majority Owned Control Investments (5.74%)* $ 80,769 $ 103,487 Other Control Investments Tectura Corporation Consumer & Business Services Senior Secured Debt July 2024 Interest rate FIXED 8.25% $ 8,250 $ 8,250 $ 8,250 Consumer & Business Services Common Stock 414,994,863 900 4 Consumer & Business Services Preferred Series BB Equity 1,000,000 — 12 Consumer & Business Services Preferred Series C Equity 3,235,298 13,263 3,251 Total Tectura Corporation $ 22,413 $ 11,517 Total Other Control Investments (0.64%)* $ 22,413 $ 11,517 Total Control Investments (6.38%)* $ 103,182 $ 115,004 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. (3) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (4) Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

Description of Business (Detail

Description of Business (Details)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment company, regulated status	true

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accounting Policies [Abstract]
Investment company, accounting and reporting under Topic 946			true
Percentage of asset investments subject to internal valuation (approximately)	97.40%		97.40%
Cash and cash equivalents, held in foreign currency	$ 102,000		$ 102,000		$ 804,000
Cash and cash equivalents, held in foreign currency, cost basis	102,000		102,000		$ 842,000
Other comprehensive income	$ 0	$ 0	$ 0	$ 0

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Investments Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 3,553,636	$ 3,243,438
Senior Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	3,306,724	2,987,577
Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	73,854	69,722
Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,342	53,038
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	95,693	99,132
Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	30,023	33,969
Investment Funds & Vehicles measured at Net Asset Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	6,877	4,608
Total Investments, at fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	3,560,513	3,248,046
Derivative Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	(1,168)	(766)
Total Investments including cash and cash equivalents and derivative instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	3,559,345	3,303,280
Accounts payable and accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other liabilities	(1,770)
Escrow and Other Investment Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other assets	158	10,888
Money Market Fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		56,000
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	49,018	57,342
Quoted Prices in Active Markets for Identical Assets (Level 1) | Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	49,018	57,342
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		56,000
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	10,647	11,881
Significant Other Observable Inputs (Level 2) | Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	10,647	11,881
Significant Other Observable Inputs (Level 2) | Money Market Fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	3,493,971	3,174,215
Significant Unobservable Inputs (Level 3) | Senior Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	3,306,724	2,987,577
Significant Unobservable Inputs (Level 3) | Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	73,854	69,722
Significant Unobservable Inputs (Level 3) | Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,342	53,038
Significant Unobservable Inputs (Level 3) | Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	46,675	41,790
Significant Unobservable Inputs (Level 3) | Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	19,376	22,088
Significant Unobservable Inputs (Level 3) | Accounts payable and accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other liabilities	(1,770)
Significant Unobservable Inputs (Level 3) | Escrow and Other Investment Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other assets	$ 158	10,888
Significant Unobservable Inputs (Level 3) | Money Market Fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Significant Unobservable Inputs (Level 3) - Recurring - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 3,185,103	$ 2,882,285
Net realized gains (losses)	(11,561)	(12,204)
Net change in unrealized appreciation (depreciation)	(39,187)	(3,562)
Purchases	1,111,555	1,025,931
Sales	(21,326)	(1,909)
Repayments	(732,225)	(695,856)
Gross Transfers into Level 3	2,323	0
Gross Transfers out of Level 3	2,323	0
Ending balance	3,492,359	3,194,685
Accounts payable and accrued liabilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
Gross Transfers into Level 3	(1,770)
Ending balance	(1,770)
Preferred Stock
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	53,038	41,488
Net realized gains (losses)	(711)	(3,441)
Net change in unrealized appreciation (depreciation)	(9,013)	1,392
Purchases	1,597	2,851
Gross Transfers into Level 3	2,431
Ending balance	47,342	42,290
Common Stock
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	41,790	25,059
Net realized gains (losses)	(1,351)
Net change in unrealized appreciation (depreciation)	474	10,684
Purchases	4,100	4,500
Sales	0	(594)
Gross Transfers into Level 3	1,662
Ending balance	46,675	39,649
Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	22,088	19,419
Net realized gains (losses)	(464)	(3,443)
Net change in unrealized appreciation (depreciation)	(2,367)	1,539
Purchases	2,948	3,711
Sales	(2,829)	(1,108)
Ending balance	19,376	20,118
Senior Secured Debt
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,987,577	2,741,388
Net realized gains (losses)	(9,120)	(5,400)
Net change in unrealized appreciation (depreciation)	(34,978)	(22,135)
Purchases	1,099,563	1,003,953
Repayments	(732,225)	(695,856)
Gross Transfers out of Level 3	4,093
Ending balance	3,306,724	3,021,950
Unsecured Debt
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	69,722	54,056
Net change in unrealized appreciation (depreciation)	828	4,958
Purchases	3,304	10,916
Ending balance	73,854	69,930
Escrow and Other Investment Receivables
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	10,888
Net realized gains (losses)	85
Net change in unrealized appreciation (depreciation)	5,869
Purchases	43
Sales	(18,497)
Gross Transfers out of Level 3	1,770
Ending balance	$ 158
Escrow Receivable
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		875
Net realized gains (losses)		80
Sales		(207)
Ending balance		$ 748

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Schedule of Equity Investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Total net change in unrealized appreciation (depreciation)	$ (13,894)	$ (46,240)	$ (44,982)	$ (6,277)
Significant Unobservable Inputs (Level 3) | Debt Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Total net change in unrealized appreciation (depreciation)			(32,300)	(16,900)
Significant Unobservable Inputs (Level 3) | Preferred Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Total net change in unrealized appreciation (depreciation)			(9,200)	(2,000)
Significant Unobservable Inputs (Level 3) | Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Total net change in unrealized appreciation (depreciation)			(300)	10,700
Significant Unobservable Inputs (Level 3) | Warrant Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Total net change in unrealized appreciation (depreciation)			$ (800)	$ (900)

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Liquidation | Accounts payable and accrued liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ (1,770)
Liquidation | Minimum | Probability weighting of alternative outcomes | Accounts payable and accrued liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1000
Liquidation | Maximum | Probability weighting of alternative outcomes | Accounts payable and accrued liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.5000
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Accounts payable and accrued liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3897
Total Level Three Debt Investments and Other Investment Receivables (Payables)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 3,378,808	$ 3,066,947
Debt Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	3,380,578	3,057,299
Debt Investments | Debt Investments originated within 6 months
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	240,443	431,512
Debt Investments | Imminent Payoffs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	70,171	54,430
Debt Investments | Debt Investments Maturing in Less than One Year
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	72,911	62,220
Debt Investments | Debt Investments in Wholly-Owned Subsidiaries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	47,633
Equity and Warrant Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	113,393	116,916
Equity Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 43,990	$ 52,094
Equity Investments | Market Comparable Companies | Minimum | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Equity Investments | Market Comparable Companies | Minimum | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.4	0.3
Equity Investments | Market Comparable Companies | Minimum | Tangible Book Value Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	1.6	1.8
Equity Investments | Market Comparable Companies | Minimum | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1348	0.0711
Equity Investments | Market Comparable Companies | Maximum | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Equity Investments | Market Comparable Companies | Maximum | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	14.8	20.1
Equity Investments | Market Comparable Companies | Maximum | Tangible Book Value Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	1.6	1.8
Equity Investments | Market Comparable Companies | Maximum | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.9282	0.9272
Equity Investments | Market Comparable Companies | Weighted Average | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Equity Investments | Market Comparable Companies | Weighted Average | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	13.4	7.2
Equity Investments | Market Comparable Companies | Weighted Average | Tangible Book Value Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	1.6	1.8
Equity Investments | Market Comparable Companies | Weighted Average | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3618	0.3157
Equity Investments | Market Adjusted OPM Backsolve
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 13,781	$ 11,096
Equity Investments | Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.8375)	(0.8614)
Equity Investments | Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3035	0.3269
Equity Investments | Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.0848)	0.0747
Equity Investments | Discounted Cash Flow
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 33,234	$ 28,713
Equity Investments | Discounted Cash Flow | Minimum | Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1152	0.1988
Equity Investments | Discounted Cash Flow | Maximum | Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3340	0.3197
Equity Investments | Discounted Cash Flow | Weighted Average | Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3114	0.3051
Equity Investments | Other
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 3,012	$ 2,925
Warrants | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 15,466	$ 19,014
Warrants | Market Comparable Companies | Minimum | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Warrants | Market Comparable Companies | Minimum | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.9	0.9
Warrants | Market Comparable Companies | Minimum | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1293	0.0621
Warrants | Market Comparable Companies | Maximum | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Warrants | Market Comparable Companies | Maximum | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	11.9	10.2
Warrants | Market Comparable Companies | Maximum | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3396	0.3312
Warrants | Market Comparable Companies | Weighted Average | EBITDA Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		12.3
Warrants | Market Comparable Companies | Weighted Average | Revenue Multiple
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	4.1	4.2
Warrants | Market Comparable Companies | Weighted Average | Discount for Lack of Marketability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.2463	0.2170
Warrants | Market Adjusted OPM Backsolve
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 3,910	$ 3,074
Warrants | Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.6204)	(0.7067)
Warrants | Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.3035	0.3486
Warrants | Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.0140)	0.1317
Warrants | Other
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 0
Pharmaceuticals | Debt Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 990,349	$ 971,775
Pharmaceuticals | Debt Investments | Market Comparable Companies | Minimum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0990	0.1091
Pharmaceuticals | Debt Investments | Market Comparable Companies | Minimum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.0200)	(0.0100)
Pharmaceuticals | Debt Investments | Market Comparable Companies | Maximum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1655	0.2143
Pharmaceuticals | Debt Investments | Market Comparable Companies | Maximum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0400	0.0350
Pharmaceuticals | Debt Investments | Market Comparable Companies | Weighted Average | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1274	0.1346
Pharmaceuticals | Debt Investments | Market Comparable Companies | Weighted Average | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0008	0.0004
Pharmaceuticals | Debt Investments | Liquidation
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 8,455
Pharmaceuticals | Debt Investments | Liquidation | Minimum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.1000
Pharmaceuticals | Debt Investments | Liquidation | Maximum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.5000
Pharmaceuticals | Debt Investments | Liquidation | Weighted Average | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.4183
Technology | Debt Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 1,202,375	$ 1,181,823
Technology | Debt Investments | Market Comparable Companies | Minimum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1008	0.1130
Technology | Debt Investments | Market Comparable Companies | Minimum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.0075)	(0.0100)
Technology | Debt Investments | Market Comparable Companies | Maximum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1919	0.2074
Technology | Debt Investments | Market Comparable Companies | Maximum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0300	0.0500
Technology | Debt Investments | Market Comparable Companies | Weighted Average | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1326	0.1503
Technology | Debt Investments | Market Comparable Companies | Weighted Average | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0033	0.0047
Technology | Debt Investments | Liquidation
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 52,586	$ 0
Technology | Debt Investments | Liquidation | Minimum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0500	1
Technology | Debt Investments | Liquidation | Maximum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	1	1
Technology | Debt Investments | Liquidation | Weighted Average | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.5786	1
Technology | Debt Investments | Convertible Note Analysis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 25,745	$ 23,244
Technology | Debt Investments | Convertible Note Analysis | Minimum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0100	0.0100
Technology | Debt Investments | Convertible Note Analysis | Maximum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.7000	0.5000
Technology | Debt Investments | Convertible Note Analysis | Weighted Average | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.5064	0.3932
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 20,957	$ 1,678
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Minimum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1213	0.1075
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Minimum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0025	0.0075
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Maximum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1566	0.1075
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Maximum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0300	0.0075
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Weighted Average | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1543	0.1075
Sustainable and Renewable Technology | Debt Investments | Market Comparable Companies | Weighted Average | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0043	0.0075
Medical Devices | Debt Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 55,413
Medical Devices | Debt Investments | Market Comparable Companies | Minimum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1223
Medical Devices | Debt Investments | Market Comparable Companies | Minimum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0
Medical Devices | Debt Investments | Market Comparable Companies | Maximum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1319
Medical Devices | Debt Investments | Market Comparable Companies | Maximum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0050
Medical Devices | Debt Investments | Market Comparable Companies | Weighted Average | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1265
Medical Devices | Debt Investments | Market Comparable Companies | Weighted Average | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0028
Lower Middle Market | Debt Investments | Market Comparable Companies
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	$ 601,995	$ 322,162
Lower Middle Market | Debt Investments | Market Comparable Companies | Minimum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0866	0.1254
Lower Middle Market | Debt Investments | Market Comparable Companies | Minimum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	(0.0025)	(0.0075)
Lower Middle Market | Debt Investments | Market Comparable Companies | Maximum | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1968	0.2015
Lower Middle Market | Debt Investments | Market Comparable Companies | Maximum | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0325	0.0225
Lower Middle Market | Debt Investments | Market Comparable Companies | Weighted Average | Hypothetical Market Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.1461	0.1413
Lower Middle Market | Debt Investments | Market Comparable Companies | Weighted Average | Premium/(Discount)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input	0.0084	0.0056
Other Investment Receivable | Other Investment Receivables | Liquidation
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 9,648
Other Investment Receivable | Other Investment Receivables | Liquidation | Minimum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.1000
Other Investment Receivable | Other Investment Receivables | Liquidation | Maximum | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.5000
Other Investment Receivable | Other Investment Receivables | Liquidation | Weighted Average | Probability weighting of alternative outcomes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investment company, investment owned, measurement input		0.4183

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Narrative (Details) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
2033 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current price per par value (in dollars per share)	$ 25.63	$ 25.25
2033 Notes | Underwriting
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current price per par value (in dollars per share)	25	25
2031 Asset-Backed Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current price per par value (in dollars per share)	$ 0.970	$ 0.950

Fair Value of Financial Instr_8

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy of Outstanding Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	$ 1,739,209	$ 1,554,869
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	1,739,209	1,554,869
Carrying Value | SBA Debentures
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	170,763	170,323
Carrying Value | July 2024 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value		104,828
Carrying Value | February 2025 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	49,952	49,866
Carrying Value | June 2025 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	69,879	69,757
Carrying Value | June 2025 3-Year Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	49,887	49,771
Carrying Value | March 2026 A Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	49,866	49,795
Carrying Value | March 2026 B Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	49,854	49,776
Carrying Value | September 2026 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	323,075	322,339
Carrying Value | January 2027 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	346,932	345,935
Carrying Value | 2031 Asset-Backed Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	148,985	148,544
Carrying Value | 2033 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	39,016	38,935
Carrying Value | MUFG Bank Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	240,000	61,000
Carrying Value | SMBC Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value	201,000	94,000
Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	1,680,028	1,450,995
Fair Value | Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	186,508	182,900
Fair Value | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	1,493,520	1,268,095
Fair Value | SBA Debentures
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	155,728	142,011
Fair Value | SBA Debentures | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	155,728	142,011
Fair Value | July 2024 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value		105,755
Fair Value | July 2024 Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value		105,755
Fair Value | February 2025 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	49,902	49,144
Fair Value | February 2025 Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	49,902	49,144
Fair Value | June 2025 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	69,890	67,198
Fair Value | June 2025 Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	69,890	67,198
Fair Value | June 2025 3-Year Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	50,560	48,983
Fair Value | June 2025 3-Year Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	50,560	48,983
Fair Value | March 2026 A Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	48,691	47,702
Fair Value | March 2026 A Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	48,691	47,702
Fair Value | March 2026 B Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	48,726	47,759
Fair Value | March 2026 B Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	48,726	47,759
Fair Value | September 2026 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	301,311	288,711
Fair Value | September 2026 Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	301,311	288,711
Fair Value | January 2027 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	327,712	315,832
Fair Value | January 2027 Notes | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	327,712	315,832
Fair Value | 2031 Asset-Backed Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	145,500	142,500
Fair Value | 2031 Asset-Backed Notes | Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	145,500	142,500
Fair Value | 2033 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	41,008	40,400
Fair Value | 2033 Notes | Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	41,008	40,400
Fair Value | MUFG Bank Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	240,000	61,000
Fair Value | MUFG Bank Facility | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	240,000	61,000
Fair Value | SMBC Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	201,000	94,000
Fair Value | SMBC Facility | Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate Fair Value	$ 201,000	$ 94,000

Investments - Schedule of Reali

Investments - Schedule of Realized Gains and Losses and Changes in Unrealized Appreciation and Depreciation on Control and Affiliate investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	$ 3,560,513		$ 3,560,513		$ 3,248,046
Interest & Dividend Income	119,050	$ 110,339	352,358	$ 319,222
Fee Income	6,198	6,405	19,449	18,843
Net Change in Unrealized Appreciation (Depreciation)	(13,894)	(46,240)	(44,982)	(6,277)
Control investments
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	113,097	103,150	113,097	103,150	$ 115,004	$ 76,458
Interest & Dividend Income	3,487	1,099	9,901	3,270
Fee Income	36	22	108	60
Net Change in Unrealized Appreciation (Depreciation)	1,273	(1,099)	(3,062)	12,320
Realized Gain (Loss)	0	0	0	0
Control investments | Coronado Aesthetics, LLC
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	319	247	319	247
Interest & Dividend Income	0	0	0	0
Fee Income	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	133	(50)	57	(72)
Realized Gain (Loss)	0	0	0	0
Control investments | Gibraltar Business Capital, LLC
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	57,302	55,992	57,302	55,992
Interest & Dividend Income	1,359	772	3,926	2,299
Fee Income	36	22	108	60
Net Change in Unrealized Appreciation (Depreciation)	(74)	(1,726)	(6,365)	4,676
Realized Gain (Loss)	0	0	0	0
Control investments | Hercules Adviser LLC
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	43,433	40,668	43,433	40,668
Interest & Dividend Income	1,954	153	5,457	455
Fee Income	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	705	1,507	2,720	9,515
Realized Gain (Loss)	0	0	0	0
Control investments | Tectura Corporation
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	12,043	6,243	12,043	6,243
Interest & Dividend Income	174	174	518	516
Fee Income	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	509	(830)	526	(1,799)
Realized Gain (Loss)	$ 0	$ 0	$ 0	$ 0

Investments - Schedule of Fair

Investments - Schedule of Fair Value Portfolio of Investments by Asset Class (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,560,513	$ 3,248,046
Investment Type Concentration Risk | Total Investments Benchmark
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,560,513	$ 3,248,046
Percentage of Total Portfolio	100%	100%
Investment Type Concentration Risk | Total Investments Benchmark | Senior Secured Debt
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,306,724	$ 2,987,577
Percentage of Total Portfolio	92.90%	92%
Investment Type Concentration Risk | Total Investments Benchmark | Unsecured Debt
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 73,854	$ 69,722
Percentage of Total Portfolio	2.10%	2.20%
Investment Type Concentration Risk | Total Investments Benchmark | Preferred Stock
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 47,342	$ 53,038
Percentage of Total Portfolio	1.30%	1.60%
Investment Type Concentration Risk | Total Investments Benchmark | Common Stock
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 95,693	$ 99,132
Percentage of Total Portfolio	2.70%	3.10%
Investment Type Concentration Risk | Total Investments Benchmark | Warrants
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 30,023	$ 33,969
Percentage of Total Portfolio	0.80%	1%
Investment Type Concentration Risk | Total Investments Benchmark | Investment Funds & Vehicles
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 6,877	$ 4,608
Percentage of Total Portfolio	0.20%	0.10%

Investments - Schedule of Fai_2

Investments - Schedule of Fair Value Portfolio of Investments by Geographic Location (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,560,513	$ 3,248,046
Geographic Concentration Risk | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,560,513	$ 3,248,046
Percentage of Total Portfolio	100%	100%
Geographic Concentration Risk | United States | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,219,874	$ 2,861,615
Percentage of Total Portfolio	90.40%	88.10%
Geographic Concentration Risk | United Kingdom | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 174,566	$ 222,136
Percentage of Total Portfolio	4.90%	6.90%
Geographic Concentration Risk | Israel | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 77,767	$ 52,868
Percentage of Total Portfolio	2.20%	1.60%
Geographic Concentration Risk | Netherlands | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 59,562	$ 89,995
Percentage of Total Portfolio	1.70%	2.80%
Geographic Concentration Risk | Canada | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 16,441	$ 15,730
Percentage of Total Portfolio	0.50%	0.50%
Geographic Concentration Risk | Ireland | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 4,513	$ 0
Percentage of Total Portfolio	0.10%	0%
Geographic Concentration Risk | Denmark | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 4,176	$ 4,173
Percentage of Total Portfolio	0.10%	0.10%
Geographic Concentration Risk | SINGAPORE | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 1,999	$ 0
Percentage of Total Portfolio	0.10%	0%
Geographic Concentration Risk | Germany | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 1,219	$ 1,144
Percentage of Total Portfolio	0%	0%
Geographic Concentration Risk | Other | Total Investments Benchmark, Geographical
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 396	$ 385
Percentage of Total Portfolio	0%	0%

Investments - Schedule of Fai_3

Investments - Schedule of Fair Value Portfolio by Industry Sector (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,560,513	$ 3,248,046
Industry Sector Concentration Risk | Total Industry Sectors
Schedule Of Investments [Line Items]
Investments at Fair Value	3,560,513	3,248,046
Industry Sector Concentration Risk | Drug Discovery & Development
Schedule Of Investments [Line Items]
Investments at Fair Value	1,125,617	1,257,699
Industry Sector Concentration Risk | Software
Schedule Of Investments [Line Items]
Investments at Fair Value	1,018,236	764,985
Industry Sector Concentration Risk | Healthcare Services, Other
Schedule Of Investments [Line Items]
Investments at Fair Value	574,750	300,079
Industry Sector Concentration Risk | Consumer & Business Services
Schedule Of Investments [Line Items]
Investments at Fair Value	355,831	525,973
Industry Sector Concentration Risk | Diversified Financial Services
Schedule Of Investments [Line Items]
Investments at Fair Value	112,709	114,722
Industry Sector Concentration Risk | Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Investments at Fair Value	96,125	20,324
Industry Sector Concentration Risk | Information Services
Schedule Of Investments [Line Items]
Investments at Fair Value	81,266	126,605
Industry Sector Concentration Risk | Medical Devices & Equipment
Schedule Of Investments [Line Items]
Investments at Fair Value	56,153	22,096
Industry Sector Concentration Risk | Space Technologies
Schedule Of Investments [Line Items]
Investments at Fair Value	46,082	0
Industry Sector Concentration Risk | Biotechnology Tools
Schedule Of Investments [Line Items]
Investments at Fair Value	35,311	48,381
Industry Sector Concentration Risk | Sustainable and Renewable Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	27,858	9,581
Industry Sector Concentration Risk | Communications & Networking
Schedule Of Investments [Line Items]
Investments at Fair Value	26,465	29,400
Industry Sector Concentration Risk | Manufacturing Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	2,096	11,006
Industry Sector Concentration Risk | Consumer & Business Products
Schedule Of Investments [Line Items]
Investments at Fair Value	1,285	2,589
Industry Sector Concentration Risk | Semiconductors
Schedule Of Investments [Line Items]
Investments at Fair Value	655	1,205
Industry Sector Concentration Risk | Media/Content/Info
Schedule Of Investments [Line Items]
Investments at Fair Value	55	12,704
Industry Sector Concentration Risk | Drug Delivery
Schedule Of Investments [Line Items]
Investments at Fair Value	19	21
Industry Sector Concentration Risk | Surgical Devices
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 0	$ 676
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Total Industry Sectors
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	100%	100%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Drug Discovery & Development
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	31.60%	38.70%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Software
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	28.60%	23.60%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Healthcare Services, Other
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	16.10%	9.30%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Consumer & Business Services
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	10%	16.20%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Diversified Financial Services
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	3.20%	3.50%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	2.70%	0.60%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Information Services
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	2.30%	3.90%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Medical Devices & Equipment
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	1.60%	0.70%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Space Technologies
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	1.30%	0%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Biotechnology Tools
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	1%	1.50%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Sustainable and Renewable Technology
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0.80%	0.30%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Communications & Networking
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0.70%	0.90%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Manufacturing Technology
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0.10%	0.30%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Consumer & Business Products
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0%	0.10%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Semiconductors
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0%	0%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Media/Content/Info
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0%	0.40%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Drug Delivery
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0%	0%
Industry Sector Concentration Risk | Industry Sub Sector Investments Benchmark | Surgical Devices
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	0%	0%

Investments - Narrative (Detail

Investments - Narrative (Details)	Sep. 30, 2024 Firm equityInvestment	Dec. 31, 2023 Firm equityInvestment
Schedule Of Investments [Line Items]
Percentage of fair value investment in portfolio companies	30.60%	29.70%
Count greater five percent fair value equity | equityInvestment	4	5
Percentage of equity investments held in portfolio companies	52.90%	56.50%
Concentrations of Credit Risk
Schedule Of Investments [Line Items]
Number of portfolio companies | Firm	5	5

Investments - Schedule of Inves

Investments - Schedule of Investment Collateral (Details) - Total Debt Investments Benchmark - Collateral Type Concentration Risk	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	100%	100%
Senior Secured First Lien
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	89.50%	88.80%
Second lien
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	8.30%	8.90%
Unsecured
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	2.20%	2.30%
All assets including intellectual property | Senior Secured First Lien
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	63.10%	52.30%
All assets with negative pledge on intellectual property | Senior Secured First Lien
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	16.10%	24%
“Last-out” with security interest in all of the assets | Senior Secured First Lien
Schedule Of Investments [Line Items]
Percentage of Total Portfolio	10.30%	12.50%

Investments - Schedule of Deriv

Investments - Schedule of Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Summary of Investment Holdings [Line Items]
Total	$ (1,356)	$ 784	$ (1,251)	$ 230
Foreign currency forward contract
Summary of Investment Holdings [Line Items]
Total	1,168		1,168		$ 766
Net realized gain (loss) - Non-control / Non-affiliate investments	0	0	(849)	0
Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments	(1,356)	$ 784	(402)	$ 230
Foreign currency forward contract | Other assets
Summary of Investment Holdings [Line Items]
Foreign currency forward contract	0		0		0
Foreign currency forward contract | Accounts payable and accrued liabilities
Summary of Investment Holdings [Line Items]
Foreign currency forward contract	$ 1,168		$ 1,168		$ 766

Investments - Schedule of Inv_2

Investments - Schedule of Investment Interest Income and Fee Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule Of Investments [Line Items]
Total interest and dividend income	$ 119,050	$ 110,339	$ 352,358	$ 319,222
Total fee income	6,198	6,405	19,449	18,843
Contractual interest income
Schedule Of Investments [Line Items]
Total interest and dividend income	90,288	89,747	268,441	258,685
Exit fee interest income
Schedule Of Investments [Line Items]
Total interest and dividend income	12,047	10,904	34,519	34,340
PIK interest income
Schedule Of Investments [Line Items]
Total interest and dividend income	12,706	6,652	37,870	17,999
Dividend income
Schedule Of Investments [Line Items]
Total interest and dividend income	2,100	0	5,800	0
Other Interest Income
Schedule Of Investments [Line Items]
Total interest and dividend income	1,909	3,036	5,728	8,198
Recurring fee income
Schedule Of Investments [Line Items]
Total fee income	2,423	2,243	7,081	6,418
Fee income - expired commitments
Schedule Of Investments [Line Items]
Total fee income	413	300	1,790	651
Accelerated fee income - early repayments
Schedule Of Investments [Line Items]
Total fee income	$ 3,362	$ 3,862	$ 10,578	$ 11,774

Investments - Schedule of Unamo

Investments - Schedule of Unamortized Capitalized Fee Income (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	$ 46.4	$ 42.3
Offset against debt investment cost
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	36.7	32.9
Deferred obligation contingent on funding or other milestone
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	$ 9.7	$ 9.4

Investments - Schedule of Loan

Investments - Schedule of Loan Exit Fees Receivable (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	$ 40.4	$ 40.2
Included within debt investment cost
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	37	35.9
Deferred receivable related to expired commitments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	$ 3.4	$ 4.3

Debt - Schedule of Available an

Debt - Schedule of Available and Outstanding Debt (Details) - USD ($) $ in Thousands		Sep. 30, 2024	Jul. 09, 2024	Dec. 31, 2023	Jan. 31, 2023	Jun. 23, 2022	Jun. 22, 2022	Jan. 20, 2022	Sep. 16, 2021	Mar. 04, 2021	Nov. 04, 2020	Oct. 27, 2020	Jun. 03, 2020	Feb. 05, 2020	Jul. 16, 2019	Sep. 24, 2018
Debt Instrument [Line Items]
Total Available		$ 2,285,000		$ 2,215,000
Principal		1,751,000		1,570,000
Carrying value		1,739,209		1,554,869
SMBC LC Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		175,000		175,000	$ 175,000
SBA Debentures
Debt Instrument [Line Items]
Total Available	[1]	350,000		175,000
Principal	[1]	175,000		175,000
Carrying value	[1]	170,763		170,323
Maximum borrowing capacity		350,000
SBA Debentures | HC IV
Debt Instrument [Line Items]
Total Available		175,000		175,000
Maximum borrowing capacity		175,000		175,000								$ 175,000
SBA Debentures | Hercules SBIC V, L.P.
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 175,000
July 2024 Notes
Debt Instrument [Line Items]
Total Available		0		105,000											$ 105,000
Principal		0		105,000
Carrying value		0		104,828
February 2025 Notes
Debt Instrument [Line Items]
Total Available		50,000		50,000										$ 50,000
Principal		50,000		50,000
Carrying value		49,952		49,866
June 2025 Notes
Debt Instrument [Line Items]
Total Available		70,000		70,000									$ 70,000
Principal		70,000		70,000
Carrying value		69,879		69,757
June 2025 3-Year Notes
Debt Instrument [Line Items]
Total Available		50,000		50,000		$ 50,000
Principal		50,000		50,000
Carrying value		49,887		49,771
March 2026 A Notes
Debt Instrument [Line Items]
Total Available		50,000		50,000							$ 50,000
Principal		50,000		50,000
Carrying value		49,866		49,795
March 2026 B Notes
Debt Instrument [Line Items]
Total Available		50,000		50,000						$ 50,000
Principal		50,000		50,000
Carrying value		49,854		49,776
September 2026 Notes
Debt Instrument [Line Items]
Total Available		325,000		325,000					$ 325,000
Principal		325,000		325,000
Carrying value		323,075		322,339
January 2027 Notes
Debt Instrument [Line Items]
Total Available		350,000		350,000				$ 350,000
Principal		350,000		350,000
Carrying value		346,932		345,935
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Total Available		150,000		150,000			$ 150,000
Principal		150,000		150,000
Carrying value		148,985		148,544
2033 Notes
Debt Instrument [Line Items]
Total Available		40,000		40,000												$ 40,000
Principal		40,000		40,000
Carrying value		39,016		38,935
MUFG Bank Facility
Debt Instrument [Line Items]
Total Available		400,000		400,000
Principal		240,000		61,000
Carrying value		240,000		61,000
SMBC Facility
Debt Instrument [Line Items]
Total Available	[2]	400,000		400,000
Principal	[2]	201,000		94,000
Carrying value	[2]	$ 201,000		$ 94,000
[1] As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV. “Total Available” includes $175.0 million of available commitment through the letter of credit facility as of September 30, 2024 and December 31, 2023.

Debt - Schedule of Debt Issuanc

Debt - Schedule of Debt Issuance Costs, Net of accumulated Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Debt issuance costs	$ 11,791	$ 15,131
Debt Issuance Costs, Net and Other Assets
Debt Instrument [Line Items]
Debt issuance costs	15,246	20,446
SBA Debentures
Debt Instrument [Line Items]
Debt issuance costs	4,237	4,677
July 2024 Notes
Debt Instrument [Line Items]
Debt issuance costs	0	172
February 2025 Notes
Debt Instrument [Line Items]
Debt issuance costs	48	134
June 2025 Notes
Debt Instrument [Line Items]
Debt issuance costs	121	243
June 2025 3-Year Notes
Debt Instrument [Line Items]
Debt issuance costs	113	229
March 2026 A Notes
Debt Instrument [Line Items]
Debt issuance costs	134	205
March 2026 B Notes
Debt Instrument [Line Items]
Debt issuance costs	146	224
September 2026 Notes
Debt Instrument [Line Items]
Debt issuance costs	1,925	2,661
January 2027 Notes
Debt Instrument [Line Items]
Debt issuance costs	3,068	4,065
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Debt issuance costs	1,015	1,456
2033 Notes
Debt Instrument [Line Items]
Debt issuance costs	984	1,065
MUFG Bank Facility
Debt Instrument [Line Items]
Debt issuance costs	2,220	3,540
SMBC Facility
Debt Instrument [Line Items]
Debt issuance costs	$ 1,235	$ 1,775

Debt - Components of Interest E

Debt - Components of Interest Expense, Related Fees and Cash Paid for Interest Expense for Debt (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Interest expense	$ 20,370	$ 16,428	$ 57,156	$ 50,237
Amortization of debt issuance cost (loan fees)	1,490	1,539	4,565	4,585
Unused facility and other fees (loan fees)	503	985	2,171	2,732
Total interest expense and fees	22,363	18,952	63,892	57,554
Cash paid for interest expense	28,685	23,747	64,221	57,410
SBA Debentures
Debt Instrument [Line Items]
Interest expense	1,149	1,150	3,424	3,412
Amortization of debt issuance cost (loan fees)	147	146	439	436
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	1,296	1,296	3,863	3,848
Cash paid for interest expense	2,300	2,300	4,575	4,562
July 2024 Notes
Debt Instrument [Line Items]
Interest expense	202	1,252	2,706	3,756
Amortization of debt issuance cost (loan fees)	24	74	172	222
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	226	1,326	2,878	3,978
Cash paid for interest expense	2,504	2,505	5,008	5,009
February 2025 Notes
Debt Instrument [Line Items]
Interest expense	535	535	1,605	1,605
Amortization of debt issuance cost (loan fees)	29	29	86	86
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	564	564	1,691	1,691
Cash paid for interest expense	1,070	1,070	2,140	2,140
June 2025 Notes
Debt Instrument [Line Items]
Interest expense	755	754	2,263	2,263
Amortization of debt issuance cost (loan fees)	40	40	121	121
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	795	794	2,384	2,384
Cash paid for interest expense	0	0	1,508	1,509
June 2025 3-Year Notes
Debt Instrument [Line Items]
Interest expense	750	750	2,250	2,250
Amortization of debt issuance cost (loan fees)	38	39	116	117
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	788	789	2,366	2,367
Cash paid for interest expense	0	0	1,500	1,500
March 2026 A Notes
Debt Instrument [Line Items]
Interest expense	563	563	1,688	1,688
Amortization of debt issuance cost (loan fees)	24	24	71	71
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	587	587	1,759	1,759
Cash paid for interest expense	1,125	1,125	2,250	2,250
March 2026 B Notes
Debt Instrument [Line Items]
Interest expense	568	569	1,706	1,706
Amortization of debt issuance cost (loan fees)	25	26	77	78
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	593	595	1,783	1,784
Cash paid for interest expense	1,138	1,138	2,276	2,275
September 2026 Notes
Debt Instrument [Line Items]
Interest expense	2,174	2,174	6,523	6,523
Amortization of debt issuance cost (loan fees)	205	203	612	611
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	2,379	2,377	7,135	7,134
Cash paid for interest expense	4,266	4,266	8,531	8,532
Amortization of original issue discounts	42	42	125	125
January 2027 Notes
Debt Instrument [Line Items]
Interest expense	3,080	3,079	9,236	9,236
Amortization of debt issuance cost (loan fees)	208	207	622	621
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	3,288	3,286	9,858	9,857
Cash paid for interest expense	5,906	5,906	11,812	11,812
Amortization of original issue discounts	126	126	377	377
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Interest expense	1,903	1,902	5,710	5,709
Amortization of debt issuance cost (loan fees)	100	101	300	301
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	2,003	2,003	6,010	6,010
Cash paid for interest expense	1,856	1,857	5,568	5,570
Amortization of original issue discounts	47	47	141	141
2033 Notes
Debt Instrument [Line Items]
Interest expense	625	625	1,875	1,875
Amortization of debt issuance cost (loan fees)	27	27	81	81
Unused facility and other fees (loan fees)	0	0	0	0
Total interest expense and fees	652	652	1,956	1,956
Cash paid for interest expense	625	625	1,875	1,875
MUFG Bank Facility
Debt Instrument [Line Items]
Interest expense	4,105	1,247	8,181	4,323
Amortization of debt issuance cost (loan fees)	443	443	1,328	1,327
Unused facility and other fees (loan fees)	329	709	1,572	2,017
Total interest expense and fees	4,877	2,399	11,081	7,667
Cash paid for interest expense	3,875	1,240	7,596	4,673
SMBC Facility
Debt Instrument [Line Items]
Interest expense	3,961	1,828	9,989	5,891
Amortization of debt issuance cost (loan fees)	180	180	540	513
Unused facility and other fees (loan fees)	174	276	599	715
Total interest expense and fees	4,315	2,284	11,128	7,119
Cash paid for interest expense	$ 4,020	$ 1,715	$ 9,582	$ 5,703

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Jul. 16, 2024 USD ($)

Jul. 09, 2024 USD ($)

Oct. 27, 2020 USD ($)

Sep. 30, 2024 USD ($) creditFacility

Sep. 30, 2023 USD ($)

Sep. 30, 2024 USD ($) creditFacility

Sep. 30, 2023 USD ($)

Dec. 31, 2023 USD ($) creditFacility

Jan. 31, 2023 USD ($)

Jun. 23, 2022 USD ($)

Jun. 22, 2022 USD ($)

Jan. 20, 2022 USD ($)

Sep. 16, 2021 USD ($)

Mar. 04, 2021 USD ($)

Nov. 04, 2020 USD ($)

Jun. 03, 2020 USD ($)

Feb. 05, 2020 USD ($)

Jul. 16, 2019 USD ($)

Sep. 24, 2018 USD ($)

Debt Instrument [Line Items]

Weighted average cost of debt

5.10%

4.80%

5%

4.80%

Total Available

$ 2,285,000

$ 2,285,000

$ 2,215,000

Repayments of debt

758,000

$ 478,000

Restricted cash

$ 5,113

$ 5,252

$ 5,113

$ 5,252

$ 17,114

Number of available credit facilities | creditFacility

2

2

2

Credit Facility

Debt Instrument [Line Items]

Line of credit interest rate

7.79%

7.41%

Debt average amount outstanding

$ 311,000

$ 192,300

MUFG Bank Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 400,000

$ 400,000

Line of credit facility, description

funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions.

Debt instrument, variable interest rate, type [Extensible enumeration]

One Month Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]

Interest rate plus applicable margin adjustment

2.75%

Line of credit facility, covenant terms

these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV.

MUFG Bank Facility | Maximum

Debt Instrument [Line Items]

Maximum borrowing capacity

600,000

$ 600,000

SMBC Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

225,000

$ 225,000

Line of credit facility, description

Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026

Line of credit facility, unused capacity, commitment fee percentage

0.375%

SMBC Facility | Minimum

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

0.875%

SMBC Facility | Maximum

Debt Instrument [Line Items]

Maximum borrowing capacity

500,000

$ 500,000

Interest rate plus applicable margin adjustment

2%

SMBC LC Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

175,000

$ 175,000

175,000

$ 175,000

SMBC LC Facility | Maximum

Debt Instrument [Line Items]

Maximum borrowing capacity

400,000

400,000

VIE

Debt Instrument [Line Items]

Restricted cash

5,113

5,113

17,114

SBA Debentures

Debt Instrument [Line Items]

Maximum borrowing capacity

350,000

350,000

Total Available

[1]

350,000

$ 350,000

175,000

SBA Debentures | HC IV

Debt Instrument [Line Items]

Debt instrument, license description

HC IV received its license to operate as an SBIC on October 27, 2020. The license has a 10-year term

License term

10 years

Maximum borrowing capacity

$ 175,000

175,000

$ 175,000

175,000

Total Available

$ 175,000

$ 175,000

175,000

SBA Debentures | Hercules SBIC V, L.P.

Debt Instrument [Line Items]

Debt instrument, license description

On July 9, 2024, SBIC V received its license to operate as an SBIC

License term

10 years

Maximum borrowing capacity

$ 175,000

Debt instrument, interest rate

4.509%

4.509%

July 2024 Notes

Debt Instrument [Line Items]

Total Available

$ 0

$ 0

105,000

$ 105,000

Debt instrument, interest rate

4.77%

Debt retired

Jul. 16, 2024

Debt instrument, redemption, description

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the July 2024 Notes is due semiannually

Debt instrument, collateral

The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

Repayments of debt

$ 105,000

Repayment of accrued interest

$ 2,500

February 2025 Notes

Debt Instrument [Line Items]

Total Available

50,000

$ 50,000

50,000

$ 50,000

Debt instrument, interest rate

4.28%

Debt retired

Feb. 05, 2025

Debt instrument, redemption, description

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the February 2025 Notes is due semiannually

Debt instrument, collateral

The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 Notes

Debt Instrument [Line Items]

Total Available

70,000

$ 70,000

70,000

$ 70,000

Debt instrument, interest rate

4.31%

Debt retired

Jun. 03, 2025

Debt instrument, redemption, description

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the June 2025 Notes is due semiannually.

Debt instrument, collateral

The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 3-Year Notes

Debt Instrument [Line Items]

Total Available

50,000

$ 50,000

50,000

$ 50,000

Debt instrument, interest rate

6%

Debt retired

Jun. 23, 2025

Debt instrument, redemption, description

On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.00% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the June 2025 3-Year Notes is due semiannually.

Debt instrument, collateral

The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 A Notes

Debt Instrument [Line Items]

Total Available

50,000

$ 50,000

50,000

$ 50,000

Debt instrument, interest rate

4.50%

Debt retired

Mar. 04, 2026

Debt instrument, redemption, description

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.50% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the March 2026 A Notes is due semiannually

Debt instrument, collateral

The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 B Notes

Debt Instrument [Line Items]

Total Available

50,000

$ 50,000

50,000

$ 50,000

Debt instrument, interest rate

4.55%

Debt retired

Mar. 04, 2026

Debt instrument, redemption, description

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering

Debt instrument, payment terms, description

Interest on the March 2026 B Notes is due semiannually

Debt instrument, collateral

The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

September 2026 Notes

Debt Instrument [Line Items]

Total Available

325,000

$ 325,000

325,000

$ 325,000

Debt instrument, interest rate

2.625%

Debt retired

Sep. 16, 2026

Debt instrument, redemption, description

On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021.

Debt instrument, payment terms, description

Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year.

Debt instrument, collateral

The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

January 2027 Notes

Debt Instrument [Line Items]

Total Available

350,000

$ 350,000

350,000

$ 350,000

Debt instrument, interest rate

3.375%

Debt retired

Jan. 20, 2027

Debt instrument, redemption, description

The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.

Debt instrument, payment terms, description

Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year.

Debt instrument, collateral

The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

2031 Asset-Backed Notes

Debt Instrument [Line Items]

Total Available

150,000

$ 150,000

150,000

$ 150,000

Debt instrument, interest rate

4.95%

Debt retired

Jul. 20, 2031

Debt instrument, payment terms, description

Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.

2031 Asset-Backed Notes | VIE

Debt Instrument [Line Items]

Restricted cash

5,100

$ 5,100

17,100

2033 Notes

Debt Instrument [Line Items]

Total Available

$ 40,000

$ 40,000

$ 40,000

$ 40,000

Debt instrument, interest rate

6.25%

Debt retired

Oct. 30, 2033

Debt instrument, redemption, description

The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023.

Debt instrument, payment terms, description

Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year

Debt instrument, collateral

The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

[1] As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV.

Debt - Schedule of SBA Debentur

Debt - Schedule of SBA Debentures Outstanding Principal Balances (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Outstanding principal balances		$ 1,751,000	$ 1,570,000
SBA Debentures Issued on March 26, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Mar. 26, 2021
Maturity Date		Sep. 01, 2031
Interest rate		1.58%
Outstanding principal balances		$ 37,500	37,500
SBA Debentures Issued on June 25, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Jun. 25, 2021
Maturity Date		Sep. 01, 2031
Interest rate		1.58%
Outstanding principal balances		$ 16,200	16,200
SBA Debentures Issued on July 28, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Jul. 28, 2021
Maturity Date		Sep. 01, 2031
Interest rate		1.58%
Outstanding principal balances		$ 5,400	5,400
SBA Debentures Issued on August 20, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Aug. 20, 2021
Maturity Date		Sep. 01, 2031
Interest rate		1.58%
Outstanding principal balances		$ 5,400	5,400
SBA Debentures Issued on October 21, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Oct. 21, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 14,000	14,000
SBA Debentures Issued on November 1, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Nov. 01, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 21,000	21,000
SBA Debentures Issued on November 15, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Nov. 15, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 5,200	5,200
SBA Debentures Issued on November 30, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Nov. 30, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 20,800	20,800
SBA Debentures Issued on December 20, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Dec. 20, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 10,000	10,000
SBA Debentures Issued on December 23, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Dec. 23, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 10,000	10,000
SBA Debentures Issued on December 28, 2021
Debt Instrument [Line Items]
Issuance/pooling date		Dec. 28, 2021
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 5,000	5,000
SBA Debentures Issued on January 14, 2022
Debt Instrument [Line Items]
Issuance/pooling date		Jan. 14, 2022
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 4,500	4,500
SBA Debentures Issued on January 21, 2022
Debt Instrument [Line Items]
Issuance/pooling date		Jan. 21, 2022
Maturity Date		Mar. 01, 2032
Interest rate		3.21%
Outstanding principal balances		$ 20,000	20,000
SBA Debentures
Debt Instrument [Line Items]
Outstanding principal balances	[1]	$ 175,000	$ 175,000
[1] As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV.

Debt - Summary of SBIC Investme

Debt - Summary of SBIC Investments (Details) $ in Thousands	Sep. 30, 2024 USD ($) Firm	Dec. 31, 2023 USD ($) Firm
Schedule Of Investments [Line Items]
Fair value of investments (in millions)	$ 3,560,513	$ 3,248,046
HC IV
Schedule Of Investments [Line Items]
Investments held by number of companies | Firm	28	25
Fair value of investments (in millions)	$ 352,400	$ 331,500
Percentage of fair value of investments based on the Company's total investment portfolio	9.90%	10.20%
Tangible assets (in millions)	$ 369,700	$ 341,800
Percentage of tangible assets based on the Company's total assets	10.10%	10%
Hercules SBIC V, L.P.
Schedule Of Investments [Line Items]
Investments held by number of companies | Firm	1	0
Fair value of investments (in millions)	$ 11,200	$ 0
Percentage of fair value of investments based on the Company's total investment portfolio	0.30%	0%
Tangible assets (in millions)	$ 13,300	$ 0
Percentage of tangible assets based on the Company's total assets	0.40%	0%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Valuation Allowance [Line Items]
Income tax, including excise tax, paid	$ 0	$ 100,000	$ 5,185,000	$ 5,205,000
Taxes payable	$ 5,300,000	$ 5,300,000	$ 5,300,000	$ 5,300,000
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Valuation Allowance [Line Items]
Adjustments to additional paid in capital, other					$ 800,000

Income Taxes - Taxable income a

Income Taxes - Taxable income and Taxable Net Realized Gains Losses (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Taxable income	$ 75.8	$ 72.7	$ 230	$ 197.7
Taxable income, per share (in dollars per share)	$ 0.47	$ 0.50	$ 1.44	$ 1.40
Taxable net realized gains (losses)	$ 8.7	$ 6.8	$ 18.1	$ 34.2
Taxable net realized gains, per share (in dollars per share)	$ 0.05	$ 0.04	$ 0.11	$ 0.24
Weighted average shares outstanding (in shares)	161,019	146,899	159,742	141,223

Income Taxes - Schedule of Aggr

Income Taxes - Schedule of Aggregate Unrealized Appreciation of Company investment Federal Income Tax (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Aggregate Gross Unrealized Appreciation	$ 121.3	$ 118.3
Aggregate Gross Unrealized Depreciation	169.9	115.9
Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes	(48.6)	2.4
Aggregate cost of securities for U.S. federal income tax purposes (in billions)	$ 3,600	$ 3,200

Stockholders' Equity and Dist_3

Stockholders' Equity and Distributions - Narrative (Details) - $ / shares		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 07, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	May 05, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Common stock, shares outstanding (in shares)		162,505,000		162,505,000		157,758,000
Per share amount (in dollars per share)		$ 0.48	$ 0.48	$ 1.44	$ 1.42	$ 1.90
Stock issued during period, shares, dividend reinvestment plan (in shares)				342,129	197,592
Spillover amount per share
Class Of Stock [Line Items]
Undistributed taxable earnings (in dollars per share)		$ 0.94		$ 0.94
Common Stock
Class Of Stock [Line Items]
Common stock, shares issued (in shares)		162,505,144		162,505,144		157,758,072
Common stock, shares outstanding (in shares)		162,505,144	151,179,000	162,505,144	151,179,000	157,758,072	162,428,000	144,641,000		133,045,000
Equity distribution agreement, shares sold (in shares)	6,500,000
Equity distribution agreement remaining available shares (in shares)		13,600,000		13,600,000
Stock issued during period, shares, dividend reinvestment plan (in shares)		136,000	65,000	341,000	198,000
Common Stock | 2023 Equity Distribution Agreement
Class Of Stock [Line Items]
Equity distribution agreement available shares (in shares)									25,000,000

Stockholders' Equity and Dist_4

Stockholders' Equity and Distributions - Schedule of Common Stock Shares Issued and Sold (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Class Of Stock [Line Items]
Number of shares issued (in shares)			3.7	16.2
Proceeds from issuance of shares	$ (88)	$ 107,562	$ 66,284	$ 238,310
Average price/share (in dollars per share)	$ 17.83	$ 14.69	$ 17.83	$ 14.69
Common - Gross Proceeds
Class Of Stock [Line Items]
Proceeds from issuance of shares			$ 67,300	$ 243,600
Common - Offering Expenses
Class Of Stock [Line Items]
Proceeds from issuance of shares			$ 1,000	$ 5,300

Stockholders' Equity and Dist_5

Stockholders' Equity and Distributions - Schedule of Dividends Declared (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended							9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Dividends Payable [Line Items]
Per share amount (in dollars per share)	$ 0.48				$ 0.48			$ 1.44	$ 1.42	$ 1.90
Total Amount	$ 77,943				$ 72,534			$ 231,868	$ 204,687	$ 278,301
Base Dividend Q1 2023
Dividends Payable [Line Items]
Distribution Type							Base
Declared Date							Feb. 09, 2023
Record Date							Mar. 02, 2023
Payment Date							Mar. 09, 2023
Per share amount (in dollars per share)							$ 0.39
Total Amount							$ 53,749
Supplemental Dividend Q1 2023
Dividends Payable [Line Items]
Distribution Type							Supplemental
Declared Date							Feb. 09, 2023
Record Date							Mar. 02, 2023
Payment Date							Mar. 09, 2023
Per share amount (in dollars per share)							$ 0.08
Total Amount							$ 11,025
Base Dividend Q2 2023
Dividends Payable [Line Items]
Distribution Type						Base
Declared Date						Apr. 27, 2023
Record Date						May 16, 2023
Payment Date						May 23, 2023
Per share amount (in dollars per share)						$ 0.39
Total Amount						$ 55,910
Supplemental Dividend Q2 2023
Dividends Payable [Line Items]
Distribution Type						Supplemental
Declared Date						Apr. 27, 2023
Record Date						May 16, 2023
Payment Date						May 23, 2023
Per share amount (in dollars per share)						$ 0.08
Total Amount						$ 11,469
Base Dividend Q3 2023
Dividends Payable [Line Items]
Distribution Type					Base
Declared Date					Jul. 28, 2023
Record Date					Aug. 18, 2023
Payment Date					Aug. 25, 2023
Per share amount (in dollars per share)					$ 0.40
Total Amount					$ 60,445
Supplemental Dividend Q3 2023
Dividends Payable [Line Items]
Distribution Type					Supplemental
Declared Date					Jul. 28, 2023
Record Date					Aug. 18, 2023
Payment Date					Aug. 25, 2023
Per share amount (in dollars per share)					$ 0.08
Total Amount					$ 12,089
Base Dividend Q4 2023
Dividends Payable [Line Items]
Distribution Type				Base
Declared Date				Oct. 26, 2023
Record Date				Nov. 15, 2023
Payment Date				Nov. 22, 2023
Per share amount (in dollars per share)				$ 0.40
Total Amount				$ 61,345
Supplemental Dividend Q4 2023
Dividends Payable [Line Items]
Distribution Type				Supplemental
Declared Date				Oct. 26, 2023
Record Date				Nov. 15, 2023
Payment Date				Nov. 22, 2023
Per share amount (in dollars per share)				$ 0.08
Total Amount				$ 12,269
Base Dividend Q1 2024
Dividends Payable [Line Items]
Distribution Type			Base
Declared Date			Feb. 08, 2024
Record Date			Feb. 28, 2024
Payment Date			Mar. 06, 2024
Per share amount (in dollars per share)			$ 0.40
Total Amount			$ 63,359
Supplemental Dividend Q1 2024
Dividends Payable [Line Items]
Distribution Type			Supplemental
Declared Date			Feb. 08, 2024
Record Date			Feb. 28, 2024
Payment Date			Mar. 06, 2024
Per share amount (in dollars per share)			$ 0.08
Total Amount			$ 12,672
Base Dividend Q2 2024
Dividends Payable [Line Items]
Distribution Type		Base
Declared Date		Apr. 25, 2024
Record Date		May 14, 2024
Payment Date		May 21, 2024
Per share amount (in dollars per share)		$ 0.40
Total Amount		$ 64,912
Supplemental Dividend Q2 2024
Dividends Payable [Line Items]
Distribution Type		Supplemental
Declared Date		Apr. 25, 2024
Record Date		May 14, 2024
Payment Date		May 21, 2024
Per share amount (in dollars per share)		$ 0.08
Total Amount		$ 12,982
Base Dividend Q3 2024
Dividends Payable [Line Items]
Distribution Type	Base
Declared Date	Jul. 25, 2024
Record Date	Aug. 13, 2024
Payment Date	Aug. 20, 2024
Per share amount (in dollars per share)	$ 0.40
Total Amount	$ 64,953
Supplemental Dividend Q3 2024
Dividends Payable [Line Items]
Distribution Type	Supplemental
Declared Date	Jul. 25, 2024
Record Date	Aug. 13, 2024
Payment Date	Aug. 20, 2024
Per share amount (in dollars per share)	$ 0.08
Total Amount	$ 12,990

Equity Incentive Plans - Narrat

Equity Incentive Plans - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 28, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 3,200,000	$ 3,300,000	$ 9,700,000	$ 9,800,000
Unrecognized compensation costs	$ 20,000,000	$ 21,300,000	$ 20,000,000	$ 21,300,000
Total unrecognized compensation costs expected to be recognized, period			2 years 3 months 18 days	2 years 9 months 18 days
Performance award shares vested (in shares)			687,360	526,292
Unvested performance awards (in shares)	1,990,402	1,735,389	1,990,402	1,735,389	1,880,409	958,985
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentages			0%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentages			200%
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			$ 98,000	$ 73,000
Service vesting awards granted			134,000	134,000
Service-Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards granted			$ 14,700,000	$ 18,300,000
Service-Vesting Awards | Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentages			33.33%
Service vesting awards			one year
Service-Vesting Awards | Share-Based Payment Arrangement, Tranche Two and Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards			2 years
Service-Vesting Awards | Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentages			33.33%
Service-Vesting Awards | Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentages			33.33%
Service-Vesting Awards | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			7 years
Performance Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards			The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted.
Vesting period			4 years
Performance award shares vested (in shares)			0	0
Unvested performance awards (in shares)	0	0	0	0
Performance Vesting Awards | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Disposal period after vesting			1 year
Performance DEUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance award shares vested (in shares)			0	54,858
Distribution equivalent units (“DEUs”) were issued with a grant date fair value				$ 700,000
Liability Classified Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			$ 500,000	1,100,000
Unrecognized compensation costs		$ 900,000		$ 900,000
Total unrecognized compensation costs expected to be recognized, period				7 months 6 days
Vesting period			4 years
Liability award vested			$ 3,100,000	$ 0
Accounts payable and accrued liabilities		$ 2,200,000		$ 2,200,000
Other Liability Classified Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			3 years
2018 Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized (in shares)	18,700,000		18,700,000				9,261,229
Director Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized (in shares)	300,000		300,000				300,000

Equity Incentive Plans - Unvest

Equity Incentive Plans - Unvested Restricted Stock Equity Awards (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Shares
Unvested shares beginning of period (in shares)	1,880,409	958,985
Granted (in shares)	835,481	1,314,268
Vested (in shares)	(687,360)	(526,292)
Forfeited (in shares)	(38,128)	(11,572)
Unvested shares end of period (in shares)	1,990,402	1,735,389
Weighted Average Grant Date Fair Value per Share
Unvested shares beginning of period (in dollars per share)	$ 14.52	$ 16.35
Granted (in dollars per share)	17.48	13.83
Vested (in dollars per share)	14.46	16.18
Forfeited (in dollars per share)	15.45	15.42
Unvested shares end of period (in dollars per share)	$ 12.70	$ 14.50

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Numerator
Net increase (decrease) in net assets resulting from operations	$ 68,711	$ 27,967	$ 201,527	$ 217,306
Distributions declared	77,943	72,534	231,868	204,687	$ 278,301
Numerator for basic change in net assets per common share	68,031	27,293	199,309	215,042
Numerator for diluted change in net assets per common share	68,031	27,293	199,309	215,042
Total Earnings (loss), net of total distributions	$ (9,232)	$ (44,567)	$ (30,341)	$ 12,619
Denominator
Basic weighted average common shares outstanding (in shares)	161,019	146,899	159,742	141,223
Common shares issuable (in shares)	496	211	511	903
Weighted average common shares outstanding assuming dilution (in shares)	161,515	147,110	160,253	142,126
Change in net assets per common share:
Basic (in dollars per share)	$ 0.42	$ 0.19	$ 1.25	$ 1.52
Diluted (in dollars per share)	$ 0.42	$ 0.19	$ 1.24	$ 1.51
Common Stock
Numerator
Distributions declared	$ 77,263	$ 71,860	$ 229,650	$ 202,556
Earnings (loss), net of distributions attributable to common shares	$ (9,232)	$ (44,567)	$ (30,341)	$ 12,486

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Number of Anti-diluted Shares as Calculated Based on Weighted Average Closing Price of Common Stock (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Unvested common stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	832	347	1,212	1,782
Restricted stock units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	0	0	5,810
Unvested restricted stock awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	152	395	398	40,034

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) shares in Thousands	Oct. 28, 2024 shares	Oct. 27, 2024 shares	Sep. 30, 2024 votePerShare $ / shares shares	Dec. 31, 2023 $ / shares shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares authorized (in shares)			200,000	200,000
Common stock, par value (in dollars per share) | $ / shares			$ 0.001	$ 0.001
Common stock voting rights, number of votes per share | votePerShare			1
Subsequent Event
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares authorized (in shares)	300,000	200,000

Financial Highlights (Details)

Financial Highlights (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Per share data
Net asset value at beginning of period (in dollars per share)			$ 11.43	$ 10.53
Total from investment operations (in dollars per share)			1.26	1.54
Net increase (decrease) in net assets from capital share transactions (in dollars per share)			0.10	0.25
Distributions of net investment income (in dollars per share)			(1.45)	(1.45)
Stock-based compensation expense included in net investment income and other movements (in dollars per share)			0.06	0.06
Net asset value at ending of period (in dollars per share)	$ 11.40	$ 10.93	11.40	10.93
Ratios and supplemental data:
Per share market value at end of period (in dollars per share)	$ 19.64	$ 16.42	$ 19.64	$ 16.42
Total return			26.84%	36.09%
Shares outstanding at end of period (in shares)	162,505	151,179	162,505	151,179
Weighted average shares outstanding (in shares)	161,019	146,899	159,742	141,223
Net assets at end of period	$ 1,851,810	$ 1,652,057	$ 1,851,810	$ 1,652,057	$ 1,856,545	$ 1,802,706	$ 1,585,510	$ 1,401,459
Ratio of total expense to average net assets			9.18%	10.38%
Ratio of net investment income before investment gains and losses to average net assets			17.67%	18.85%
Portfolio turnover rate			20.06%	22.20%
Weighted average debt outstanding			$ 1,696,442	$ 1,601,552
Weighted average debt per common share (in dollars per share)			$ 10.62	$ 11.34
Net Investment Income
Per share data
Net gain (loss) (in dollars per share)			1.53	1.54
Net realized gain (loss)
Per share data
Net gain (loss) (in dollars per share)			0.01	0.04
Net unrealized appreciation (depreciation)
Per share data
Net gain (loss) (in dollars per share)			$ (0.28)	$ (0.04)

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Unfunded debt commitments	$ 488,970		$ 488,970		$ 335,333
Rent expense	$ 800	$ 900	$ 2,700	$ 2,500

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Unfunded commitments	$ 488,970	$ 335,333
Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	484,936	330,828
Investment Funds & Vehicles
Loss Contingencies [Line Items]
Unfunded commitments	4,034	4,505
Adviser Funds
Loss Contingencies [Line Items]
Unfunded commitments	152,200	127,700
Earnix Ltd. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	41,250	0
Arcus Biosciences, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	37,500	0
Shield AI, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	37,500	0
Thumbtack, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	30,000	40,000
Armis, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	25,000	0
Checkr Group, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	23,625	23,625
Skydio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	22,500	22,500
Pindrop Security, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	19,375	0
Braeburn Pharmaceuticals | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	17,500	0
Coronet Cyber Security Ltd. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	17,000	0
Phathom Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	15,300	6,120
Akero Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	15,000	15,000
Main Street Rural, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	14,000	10,500
Harness, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	11,550	0
Marathon Health, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	10,000	0
Viridian Therapeutics | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	10,000	0
Suzy, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	8,000	12,000
WellBe Senior Medical, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	8,000	0
Geron Corporation | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,800	0
Semperis Technologies Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,500	0
Elation Health, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,500	7,500
Curana Health Holdings, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,500	0
ATAI Life Sciences N.V. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,000	0
Behavox Limited | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	7,000	0
Dragos | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	6,500	13,000
Leapwork ApS | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	6,345	3,900
enGene, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	5,250	0
Babel Street | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	4,367	3,375
Heron Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	4,000	4,000
AlphaSense Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	4,000	0
Saama Technologies, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,875	3,875
Allvue Systems, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,590	3,590
Sight Sciences, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,500	0
LogRhythm, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,142	0
Recover Together, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,500	0
Dronedeploy, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,125	6,250
Riviera Partners LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	3,000	3,000
Zappi, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,571	2,571
Loftware, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,277	2,277
Streamline Healthcare Solutions | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,200	2,200
New Relic, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,176	2,176
Sumo Logic, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	2,000	2,000
Ceros, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,707	1,707
ThreatConnect, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,600	1,600
LogicSource | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,209	1,209
3GTMS, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,155	1,182
Zimperium, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,088	3,727
Flight Schedule Pro, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,080	639
Ikon Science Limited | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,050	1,050
LinenMaster, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	1,000	1,000
Fortified Health Security | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	840	840
Omeda Holdings, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	731	731
Dispatch Technologies, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	688	625
Constructor.io Corporation | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	625	625
ShadowDragon, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	333	333
Cybermaxx Intermediate Holdings, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	12	390
Automation Anywhere, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	29,400
Tarsus Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	20,625
Kura Oncology, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	19,250
Tipalti Solutions Ltd. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	10,500
Next Insurance, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	10,000
Senseonics Holdings, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	8,750
Modern Life, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	6,500
Brain Corporation | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	5,000
Cutover, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	2,650
Plentific Ltd | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	2,625
Altumint, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	2,500
Yipit, LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	2,250
Dashlane, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	2,137
Annex Cloud | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	1,750
Agilence, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	800
Enmark Systems, Inc. | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	457
Alchemer LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	445
Cytracom Holdings LLC | Debt Investments
Loss Contingencies [Line Items]
Unfunded commitments	0	72
Forbion Growth Opportunities Fund I C.V. | Investment Funds & Vehicles
Loss Contingencies [Line Items]
Unfunded commitments	1,757	1,757
Forbion Growth Opportunities Fund II C.V. | Investment Funds & Vehicles
Loss Contingencies [Line Items]
Unfunded commitments	$ 2,277	$ 2,748

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Unencumbered Unfunded Commitments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments And Contingencies [Line Items]
Total Unfunded Debt Commitments	$ 488,970	$ 335,333
Debt Investments
Commitments And Contingencies [Line Items]
2024	162,870	291,896
2025	236,470	3,004
2026	32,202	7,537
2027	15,071	14,078
2028	6,164	6,547
2029	27,983	3,590
2030	4,176	4,176
Total Unfunded Debt Commitments	484,936	330,828
Investment Funds & Vehicles
Commitments And Contingencies [Line Items]
2030	1,757	1,757
2032	2,277	2,748
Total Unfunded Debt Commitments	$ 4,034	$ 4,505

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Contractual Obligations (Details) - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Debt
Total		$ 1,739,209	$ 1,554,869
Lease and License Obligations
Total		24,407
Lease and license obligations, less than 1 year		3,088
Contractual Obligations, Total
Total		1,775,528	1,596,741
Less than 1 year		173,206	107,539
1 - 3 years		1,222,551	695,629
3 - 5 years		5,560	417,248
After 5 years		374,211	376,325
Principal		1,751,000	1,570,000
SMBC Facility
Contractual Obligations, Total
Principal		201,000	94,000
MUFG Bank Facility
Contractual Obligations, Total
Principal		240,000	61,000
SBA Debentures
Debt
Total	[1]	170,763	170,323
Contractual Obligations, Total
Principal	[1]	175,000	175,000
July 2024 Notes
Debt
Total		0	104,828
Contractual Obligations, Total
Principal		0	105,000
February 2025 Notes
Debt
Total		49,952	49,866
Contractual Obligations, Total
Principal		50,000	50,000
June 2025 Notes
Debt
Total		69,879	69,757
Contractual Obligations, Total
Principal		70,000	70,000
June 2025 3-Year Notes
Debt
Total		49,887	49,771
Contractual Obligations, Total
Principal		50,000	50,000
March 2026 A Notes
Debt
Total		49,866	49,795
Contractual Obligations, Total
Principal		50,000	50,000
March 2026 B Notes
Debt
Total		49,854	49,776
Contractual Obligations, Total
Principal		50,000	50,000
2031 Asset-Backed Notes
Debt
Total		148,985	148,544
Contractual Obligations, Total
Principal		150,000	150,000
2033 Notes
Debt
Total		39,016	38,935
Contractual Obligations, Total
Principal		40,000	40,000
September 2026 Notes
Debt
Total		323,075	322,339
Contractual Obligations, Total
Principal		325,000	325,000
January 2027 Notes
Debt
Total		346,932	345,935
Contractual Obligations, Total
Principal		350,000	350,000
Debt Investments
Debt
Total		1,751,000	1,570,000
Debt, less than 1 year		170,000	105,000
Debt, 1-3 years		1,216,000	689,000
Debt, 3-5 years		0	411,000
Debt, after 5 years		365,000	365,000
Lease and License Obligations
Lease and License Obligations
Total		24,528	26,741
Lease and license obligations, less than 1 year		3,206	2,539
Lease and license obligations, 1-3 years		6,551	6,629
Lease and license obligations, 3-5 years		5,560	6,248
Lease and license obligations, after 5 years		$ 9,211	$ 11,325
[1] As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV.

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Total operating lease cost	$ 762	$ 691	$ 2,091	$ 1,995
Cash paid for amounts included in the measurement of lease liabilities	$ 371	$ 495	$ 1,268	$ 2,231
Weighted-average remaining lease term (in years)	8 years 21 days		8 years 21 days		8 years 8 months 4 days
Weighted-average discount rate	6.85%		6.85%		6.79%

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
2024	$ 598
2025	3,088
2026	3,179
2027	3,452
Thereafter	14,090
Total	24,407
Less: imputed interest & other items	(5,927)
Operating lease liability	$ 18,480	$ 5,195

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Distributions paid			$ 225,591,000	$ 201,751,000
Adviser Subsidiary
Related Party Transaction [Line Items]
Distributions paid	$ 1,800,000	$ 0	5,000,000	0
Amounts received by the Company from the Adviser Funds relating to assigned investments	2,200,000	$ 2,400,000	7,900,000	$ 7,500,000
Receivable from related party	$ 100,000		$ 100,000		$ 100,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - Adviser Funds - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Investment commitments assigned to or directly committed by the Adviser Funds	$ 422.1	$ 491.4
Investment fundings assigned to, directly originated or funded by the Adviser Funds	277.1	294.4
Amounts received by the Company from the Adviser Funds relating to assigned investments	$ 6	$ 12.1

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares shares in Thousands

3 Months Ended

12 Months Ended

Aug. 13, 2024

May 14, 2024

Mar. 06, 2024

Feb. 08, 2024

Dec. 31, 2024

Sep. 30, 2024

Jun. 30, 2024

Mar. 31, 2024

Dec. 31, 2024

Oct. 28, 2024

Oct. 27, 2024

Oct. 24, 2024

Dec. 31, 2023

Subsequent Event [Line Items]

Common stock, shares authorized (in shares)

200,000

200,000

Subsequent Event

Subsequent Event [Line Items]

Common stock, shares authorized (in shares)

300,000

200,000

Base Dividend Q4 2024 | Subsequent Event

Subsequent Event [Line Items]

Cash distribution, per share (in dollars per share)

$ 0.40

Supplemental Dividend 2024

Subsequent Event [Line Items]

Supplemental dividends amount to be paid (in dollars per share)

$ 0.32

Supplemental Dividend 2024 | Subsequent Event

Subsequent Event [Line Items]

Supplemental dividends amount to be paid (in dollars per share)

$ 0.32

Supplemental Dividend Q4 2024 | Subsequent Event

Subsequent Event [Line Items]

Cash distribution, per share (in dollars per share)

$ 0.08

Supplemental dividends amount to be paid each quarter (in dollars per share)

$ 0.08

Supplemental Dividend Q1 2024

Subsequent Event [Line Items]

Supplemental dividends amount to be paid each quarter (in dollars per share)

$ 0.08

Dividends paid

$ 0.08

Supplemental Dividend Q2 2024

Subsequent Event [Line Items]

Supplemental dividends amount to be paid each quarter (in dollars per share)

$ 0.08

Dividends paid

$ 0.08

Supplemental Dividend Q3 2024

Subsequent Event [Line Items]

Supplemental dividends amount to be paid each quarter (in dollars per share)

$ 0.08

Dividends paid

$ 0.08

CONSOLIDATED SCHEDULE OF INVE_5

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES - Summary of Schedule of Investment Gain/(Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income	$ 125,248	$ 116,744	$ 371,807	$ 338,065
Investments, fair value, beginning balance			3,248,046
Net Change in Unrealized Appreciation (Depreciation)	(13,894)	(46,240)	(44,982)	(6,277)
Investments, fair value, ending balance	3,560,513		3,560,513
Control investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			10,009	3,330
Realized Gain (Loss)	0	0	0	0
Investments, fair value, beginning balance			115,004	76,458
Gross Additions			1,155	14,372
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)	1,273	(1,099)	(3,062)	12,320
Investments, fair value, ending balance	113,097	103,150	113,097	103,150
Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			9,491	2,814
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			103,487	68,416
Gross Additions			1,155	14,372
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			(3,588)	14,119
Investments, fair value, ending balance	101,054	96,907	101,054	96,907
Control investments | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			518	516
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			11,517	8,042
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			526	(1,799)
Investments, fair value, ending balance	12,043	6,243	12,043	6,243
Coronado Aesthetics, LLC | Control investments
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	133	(50)	57	(72)
Investments, fair value, ending balance	319	247	319	247
Gibraltar Business Capital, LLC | Control investments
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	(74)	(1,726)	(6,365)	4,676
Investments, fair value, ending balance	57,302	55,992	57,302	55,992
Hercules Adviser LLC | Control investments
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	705	1,507	2,720	9,515
Investments, fair value, ending balance	43,433	40,668	43,433	40,668
Tectura Corporation | Control investments
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	0	0	0	0
Net Change in Unrealized Appreciation (Depreciation)	509	(830)	526	(1,799)
Investments, fair value, ending balance	12,043	6,243	12,043	6,243
Preferred Stock | Coronado Aesthetics, LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0	0
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			260	313
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			58	(68)
Investments, fair value, ending balance	318	245	318	245
Preferred Stock | Gibraltar Business Capital, LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income				0
Realized Gain (Loss)				0
Investments, fair value, beginning balance				15,244
Gross Additions				4,500
Gross Reductions				0
Net Change in Unrealized Appreciation (Depreciation)				1,809
Investments, fair value, ending balance		21,553		21,553
Preferred Stock | Tectura Corporation | Control investments | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0	0
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			3,263	0
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			524	0
Investments, fair value, ending balance	3,787	0	3,787	0
Common Stock | Coronado Aesthetics, LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0	0
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			2	6
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			(1)	(4)
Investments, fair value, ending balance	1	2	1	2
Common Stock | Tectura Corporation | Control investments | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0	0
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			4	0
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			2	0
Investments, fair value, ending balance	6	0	6	0
Member Units | Gibraltar Business Capital, LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0
Realized Gain (Loss)			0
Investments, fair value, beginning balance			28,034
Gross Additions			0
Gross Reductions			0
Net Change in Unrealized Appreciation (Depreciation)			(6,365)
Investments, fair value, ending balance	21,669		21,669
Member Units | Hercules Adviser LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			0	0
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			28,713	19,153
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			2,720	9,515
Investments, fair value, ending balance	31,433	28,668	31,433	28,668
Unsecured Debt | Gibraltar Business Capital, LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			4,034	2,359
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			34,478	21,700
Gross Additions			1,155	9,872
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			0	2,867
Investments, fair value, ending balance	35,633	34,439	35,633	34,439
Unsecured Debt | Hercules Adviser LLC | Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			5,457	455
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			12,000	12,000
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			0	0
Investments, fair value, ending balance	12,000	12,000	12,000	12,000
Senior Secured Debt | Tectura Corporation | Control investments | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Amount of Interest and Fees Credited to Income			518	516
Realized Gain (Loss)			0	0
Investments, fair value, beginning balance			8,250	8,042
Gross Additions			0	0
Gross Reductions			0	0
Net Change in Unrealized Appreciation (Depreciation)			0	(1,799)
Investments, fair value, ending balance	$ 8,250	$ 6,243	$ 8,250	$ 6,243

CONSOLIDATED SCHEDULE OF INVE_6

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES - Summary of Schedule of Investment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Investments in and Advances to Affiliates [Line Items]
Investment cost	$ 3,609,986	$ 3,247,033
Investments, at fair value:	$ 3,560,513	$ 3,248,046
Control investments
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	6.11%	6.38%
Investment cost	$ 104,337	$ 103,182
Investments, at fair value:	$ 113,097	$ 115,004	$ 103,150	$ 76,458
Control investments | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	5.46%	5.74%
Investment cost	$ 81,924	$ 80,769
Investments, at fair value:	$ 101,054	$ 103,487	96,907	68,416
Control investments | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	0.65%	0.64%
Investment cost	$ 22,413	$ 22,413
Investments, at fair value:	12,043	11,517	6,243	8,042
Control investments | Coronado Aesthetics, LLC
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	319		247
Control investments | Coronado Aesthetics, LLC | Majority Owned Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	318	260	245	313
Control investments | Coronado Aesthetics, LLC | Majority Owned Control Investments | Common Stock
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	1	2	2	6
Control investments | Coronado Aesthetics, LLC | Medical Devices & Equipment | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost	250	250
Investments, at fair value:	$ 319	$ 262
Control investments | Coronado Aesthetics, LLC | Medical Devices & Equipment | Majority Owned Control Investments | Common Stock
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	180,000	180,000
Investment cost	$ 0	$ 0
Investments, at fair value:	$ 1	$ 2
Control investments | Coronado Aesthetics, LLC | Medical Devices & Equipment | Preferred Series A | Majority Owned Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	5,000,000	5,000,000
Investment cost	$ 250	$ 250
Investments, at fair value:	318	260
Control investments | Gibraltar Business Capital, LLC
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	57,302		55,992
Control investments | Gibraltar Business Capital, LLC | Majority Owned Control Investments | Unsecured Debt
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	35,633	34,478	34,439	21,700
Control investments | Gibraltar Business Capital, LLC | Majority Owned Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:			21,553	15,244
Control investments | Gibraltar Business Capital, LLC | Majority Owned Control Investments | Member Units
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	21,669	28,034
Control investments | Gibraltar Business Capital, LLC | Diversified Financial Services | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost	69,639	68,484
Investments, at fair value:	$ 57,302	$ 62,512
Control investments | Gibraltar Business Capital, LLC | Diversified Financial Services | Majority Owned Control Investments | Unsecured Debt One
Investments in and Advances to Affiliates [Line Items]
Maturity Date	2026-09	2026-09
Interest rate and floor, fixed	3.45%	11.50%
Investment, interest rate, paid in kind	8.05%
Principal amount	$ 26,033	$ 25,000
Investment cost	25,774	24,663
Investments, at fair value:	$ 25,774	$ 24,663
Control investments | Gibraltar Business Capital, LLC | Diversified Financial Services | Majority Owned Control Investments | Unsecured Debt Two
Investments in and Advances to Affiliates [Line Items]
Maturity Date	2026-09	2026-09
Interest rate and floor, fixed	11.95%	11.95%
Principal amount	$ 10,000	$ 10,000
Investment cost	9,859	9,815
Investments, at fair value:	$ 9,859	$ 9,815
Control investments | Gibraltar Business Capital, LLC | Diversified Financial Services | Majority Owned Control Investments | Member Units
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	1	1
Investment cost	$ 34,006	$ 34,006
Investments, at fair value:	21,669	28,034
Control investments | Hercules Adviser LLC
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	43,433		40,668
Control investments | Hercules Adviser LLC | Majority Owned Control Investments | Unsecured Debt
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	12,000	12,000	12,000	12,000
Control investments | Hercules Adviser LLC | Majority Owned Control Investments | Member Units
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	31,433	28,713	28,668	19,153
Control investments | Hercules Adviser LLC | Diversified Financial Services | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost	12,035	12,035
Investments, at fair value:	$ 43,433	$ 40,713
Control investments | Hercules Adviser LLC | Diversified Financial Services | Majority Owned Control Investments | Unsecured Debt
Investments in and Advances to Affiliates [Line Items]
Maturity Date	2025-06	2025-06
Interest rate and floor, fixed	5%	5%
Principal amount	$ 12,000	$ 12,000
Investment cost	12,000	12,000
Investments, at fair value:	$ 12,000	$ 12,000
Control investments | Hercules Adviser LLC | Diversified Financial Services | Majority Owned Control Investments | Member Units
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	1	1
Investment cost	$ 35	$ 35
Investments, at fair value:	31,433	28,713
Control investments | Tectura Corporation
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	12,043		6,243
Control investments | Tectura Corporation | Other Control Investments | Senior Secured Debt
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	8,250	8,250	6,243	8,042
Control investments | Tectura Corporation | Other Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	3,787	3,263	0	0
Control investments | Tectura Corporation | Other Control Investments | Common Stock
Investments in and Advances to Affiliates [Line Items]
Investments, at fair value:	6	4	$ 0	$ 0
Control investments | Tectura Corporation | Consumer & Business Services | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost	22,413	22,413
Investments, at fair value:	$ 12,043	$ 11,517
Control investments | Tectura Corporation | Consumer & Business Services | Other Control Investments | Senior Secured Debt
Investments in and Advances to Affiliates [Line Items]
Maturity Date	2027-01	2024-07
Interest rate and floor, fixed	8.25%	8.25%
Principal amount	$ 8,250	$ 8,250
Investment cost	8,250	8,250
Investments, at fair value:	$ 8,250	$ 8,250
Control investments | Tectura Corporation | Consumer & Business Services | Other Control Investments | Common Stock
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	414,994,863	414,994,863
Investment cost	$ 900	$ 900
Investments, at fair value:	$ 6	$ 4
Control investments | Tectura Corporation | Consumer & Business Services | Preferred Series BB | Other Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	1,000,000	1,000,000
Investment cost	$ 0	$ 0
Investments, at fair value:	$ 15	$ 12
Control investments | Tectura Corporation | Consumer & Business Services | Series C Preferred Stock | Other Control Investments | Preferred Stock
Investments in and Advances to Affiliates [Line Items]
Shares (in shares)	3,235,298	3,235,298
Investment cost	$ 13,263	$ 13,263
Investments, at fair value:	$ 3,772	$ 3,251